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National Healthcare Safety Network (NHSN) Overview 
The NHSN is a secure, Internet-based surveillance system that expands and integrates patient and 
healthcare personnel safety surveillance systems managed by the Division of Healthcare Quality 
Promotion (DHQP) at the Centers for Disease Control and Prevention.  In addition, facilities that 
participate in certain reporting programs operated by the Centers for Medicare and Medicaid Services 
(CMS) can do so through use of NHSN.  Furthermore, some U.S. states use NHSN as a means for 
healthcare facilities to submit data on healthcare-associated infections (HAIs) and transfusion-related 
adverse events mandated through their specific state legislation.   
NHSN enables healthcare facilities to collect and use data about HAIs, adherence to clinical practices 
known to prevent HAIs, the incidence or prevalence of multidrug-resistant organisms within their 
organizations, trends and coverage of healthcare personnel safety and vaccination, and adverse events 
related to the transfusion of blood and blood products.   
The NHSN includes five components: Patient Safety, Healthcare Personnel Safety, Biovigilance, 
Dialysis, and Long-term Care Facility (Figure 1).  
Figure 1: NHSN Components 
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The Patient Safety Component includes four modules that focus on events associated with medical 
devices, surgical procedures, antimicrobial agents used during healthcare, and multidrug resistant 
organisms. 
 Device-associated Module:
o Bloodstream Infection (CLABSI – Central line-associated bloodstream infection)
o Central line insertion practices (CLIP) adherence
o Urinary Tract Infection (CAUTI – Catheter-associated urinary tract infection)
o Ventilator-associated events (VAE) (adult locations only)
o Pneumonia (VAP – Ventilator-associated pneumonia) - in pediatric locations (in-plan* or
off-plan*), or NICU and adult locations (off-plan* only)
 Procedure-associated Module:
o Surgical site infection (SSI)
 Antimicrobial Use and Resistance Module (AUR)
 Multidrug-Resistant Organism and Clostridium difficile Infection (MDRO/CDI) Module
*Note: “In-plan” surveillance means that the facility has committed to following the NHSN surveillance 
protocol, in its entirety, for that particular event, as shown in the facility’s NHSN monthly reporting 
plan. “Off-plan” surveillance is surveillance that is done because a facility has decided to track a 
particular event for internal use. Data that are entered into NHSN “off-plan” are not included in NSHN 
annual reports or other NHSN publications. A facility makes no commitment to follow the NHSN 
protocol for “off-plan” events. Further, “off-plan” data cannot be uploaded into NHSN via Clinical 
Document Architecture (CDA) and must be manually entered. Instructions and standardized surveillance 
methods and definitions for each module of the Patient Safety Component are provided in this manual 
and on the NHSN website (www.cdc.gov/nhsn).  Modules may be used singly or simultaneously.
The NHSN Long-term Care Facility Component provides long-term care facilities (LTCFs) with 
standardized surveillance methods and definitions for three modules: (1) Multidrug resistant organism 
(MDRO) and Clostridium difficile Infection (CDI) laboratory-identified (LabID) Events; (2) Urinary 
Tract Infections (UTI); and (3) Prevention Process Measures. The component is ideal for use by nursing 
homes, skilled nursing facilities, chronic care facilities, and assisted living and residential care facilities. 
LTCF surveillance protocols, training materials, data collection forms, instructions, and other supporting 
materials are provided on the Long-term Care Facility Component website: 
https://www.cdc.gov/nhsn/ltc/index.html. 
Outpatient hemodialysis centers have several surveillance options tailored to their patients and setting in 
the Dialysis Component. The component consists of 3 modules: 1) Dialysis Event; (2) Prevention 
Process Measures; and (3) Dialysis Patient Influenza Vaccination.  Facilities that treat hemodialysis 
outpatients should refer to the Dialysis Component instructions and standardized surveillance methods 
and definitions at www.cdc.gov/nhsn/dialysis/index.html.  
There are two modules in the Healthcare Personnel Safety (HPS) Component of NHSN: the 
Healthcare Personnel Exposure Module and the Healthcare Personnel Vaccination Module.  These 
modules may be used separately or simultaneously.  Instructions and standardized surveillance methods 
and definitions for each module are provided in the NHSN Manual: HPS Component Protocol 
https://www.cdc.gov/nhsn/pdfs/hps-manual/vaccination/hps-flu-vaccine-protocol.pdf  
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The NHSN Biovigilance Component, Hemovigilance Module facilitates national surveillance of 
transfusion-related recipient adverse events. The Hemovigilance Module is designed for transfusion 
service staff to collect data on annual facility and transfusion service characteristics, individual reports 
on adverse transfusion reactions, errors or accidents associated with adverse reactions, and monthly 
counts of transfused or discarded components. The Hemovigilance Module surveillance protocol, 
training materials, data collection forms, instructions, and other supporting materials are provided on the 
Hemovigilance Module website: www.cdc.gov/nhsn/acute-care-hospital/bio-hemo/index.html. 
Surveillance Techniques 
Some of the options in the following modules require active, patient-based, prospective surveillance of 
events and their corresponding denominator data by a trained Infection Preventionist (IP).  This means 
that the IP shall seek out infections during a patient’s stay by screening a variety of data sources, such as 
laboratory, pharmacy, admission/discharge/transfer, radiology/imaging, and pathology databases, as 
well as patient charts, including history and physical exam notes, nurses’/physicians’ notes, temperature 
charts, etc.  Others may be trained to screen data sources for these infections, but the IP must make the 
final determination.  Laboratory-based surveillance should not be used alone, unless all possible criteria 
for identifying an infection are solely determined by laboratory evidence (for example, LabID event 
detection in the MDRO/CDI Module).  Retrospective chart reviews should be used only when patients 
are discharged before all information can be gathered.  NHSN forms should be used to collect all 
required data, using the NHSN definitions of each data field.  To minimize the IP’s data collection 
burden, others may be trained to collect the denominator data and process of care data (for example, 
central line insertion practices). 
Procedure-Associated Module 
 
Surgical site infection (SSI) monitoring is offered through this module.  SSI surveillance requires active, 
patient-based, prospective surveillance techniques (see Surveillance Techniques above).  To minimize 
IPs’ workload of collecting denominator data, operating room data may be downloaded (see file 
specifications at: http://www.cdc.gov/nhsn/PDFs/ImportingProcedureData_current.pdf) 
 
Both pre-discharge and post-discharge surveillance methods should be used to detect SSIs.  Surveillance 
may include both inpatient and outpatient operative procedures.  These methods include 1) direct 
examination of patients’ wounds during hospitalization, or follow-up visits to either surgery clinics or 
physicians’ offices, 2) review of medical records or surgery clinic patient records, 3) surgeon surveys by 
mail or telephone, and 4) patient surveys by mail or telephone (though patients may have a difficult time 
assessing their infections).  Any combination of these methods is acceptable for use; however, CDC 
criteria for SSI must be applied.   
 
Device-Associated Module 
 
Medical instrumentation increases the risk of development of an HAI and most patients admitted for 
health care are exposed to some kind of medical device in the course of their treatment.  Such devices 
include, but are not limited to, vascular and urinary catheters, and ventilators.  NHSN enables facilities 
to monitor infectious complications associated with the use of these devices and also to monitor 
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processes related to their use which might increase infection risk.  Specifically, surveillance of central 
line-associated bloodstream infection (CLABSI), catheter-associated urinary tract infection (CAUTI), 
ventilator-associated events (VAE), and/or ventilator-associated pneumonia (VAP) is possible using the 
NHSN.  See Dialysis Component for detailed instructions for Dialysis Event (DE) surveillance of 
hemodialysis outpatients (www.cdc.gov/nhsn/dialysis/index.html). In addition, central line insertion 
practices (CLIP) can be monitored to inform facilities of the appropriateness of their processes and how 
they may relate to HAI development.   
 
Device-associated denominator data should be collected at the same time each day, or by weekly 
sampling methods for CLABSI and CAUTI surveillance (see the CLABSI and CAUTI protocols for 
guidance).  When denominator data are available from electronic databases (for example, ventilator days 
from respiratory therapy), these sources may be used as long as the counts are not substantially different 
(+/- 5%) from manually-collected counts that have been validated for a minimum of three months.  See 
the respective device-associated event protocols for detailed surveillance instructions. 
 
Antimicrobial Use and Resistance (AUR) Module 
 
The use of antimicrobial agents has a direct effect on antimicrobial resistance patterns of pathogens.  
The observed increase in multidrug resistance is in part due to inappropriate prescription of, as well as 
incomplete completion of courses of antibiotics.   
 
The AUR Module allows facilities to collect information on the amount of antimicrobials that are used 
for patient care within their systems, as well as to collect data on the prevalence of drug-resistant 
organisms in their inpatient and outpatient areas. Electronic capture and reporting of microbiology and 
pharmacy data are the only available options for reporting data into this module.  
 
See the Antimicrobial Use and Resistance protocol for detailed surveillance instructions. 
 
Multidrug-resistant Organism and Clostridium difficile Infection (MDRO/CDI) Module 
 
The NHSN MDRO/CDI Module offers a means for facilities to meet criteria and metrics that are 
outlined in several organizational guidelines to control and measure the spread of MDROs and CDI 
within their healthcare system.  The module has two separate and independent reporting options, 
Laboratory-identified (LabID) Event and Infection Surveillance that may be tailored to meet the needs 
of participating NHSN facilities.   
 
In addition, the following process measures are available: (1) adherence to hand hygiene; (2) adherence 
to contact precautions when caring for patients infected or colonized with an MDRO or C. difficile; and 
(3) adherence to active surveillance testing (AST) of MRSA and/or VRE. Active surveillance testing 
outcome measures is also available in locations where AST adherence is being performed, and enables 
facilities to use the results of AST to monitor the incidence and prevalence of positive MRSA and/or 
VRE cultures. See the MDRO/CDI protocol for detailed surveillance instructions. 
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Identifying Healthcare-associated Infections (HAI) for NHSN Surveillance 
To standardize the classification of an infection as present on admission (POA) or a 
healthcare-associated infection (HAI), the following objective surveillance definitions and 
guidance are used for NHSN surveillance:  
• 7-day Infection Window Period (IWP)
• Date of Event (DOE)
• POA
• HAI
• 14-day Repeat Infection Timeframe (RIT)
• Secondary BSI Attribution Period (SBAP)
• Pathogen Assignment Guidance
• Location of  Attribution (LOA) 
The intention of this approach is to align criteria and definitions and decrease subjectivity 
while maintaining epidemiologic standardization and clinical relevance. A variety of 
scenarios to include repeat infections of the same type, concurrent infections of differing 
types, and pathogen assignment in multi-pathogen infections are addressed. See Appendix 
Flow Diagram for NHSN Event Determination.  
General Instructions 
1. The guidance found in this Chapter is not applicable when performing SSI, VAE or
LabID surveillance. Infection window period, Date of Event, POA, HAI, and RIT,
Secondary BSI Attribution Period definitions as defined in this chapter do not apply
to SSI, VAE, or LabID Events (Table 1).
Please refer to Chapters 9, 10 and 12 respectively for guidance specific to these event
determinations (Table 1).
2. Organisms belonging to the following genera are typically causes of community-
associated infections and are rarely or are not known to be causes of healthcare-
associated infections. They are excluded, and cannot be used to meet any NHSN
definition:  Blastomyces, Histoplasma, Coccidioides, Paracoccidioides, Cryptococcus
and Pneumocystis.  Additionally refer to individual event protocols for pathogen
exclusions specific to the event being reported, for example, BSI, UTI, PNEU,
ENDO, GIT, and IAB.
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If the date of specimen collection is on or after the date of documentation of 
evidence of consent AND the patient is being supported for organ donation purposes, 
an event identified using the specimen culture result or microbiologic non-culture 
based diagnostic test result should not be reported as an HAI. The patient should, 
however, still be included in device and patient day denominator data collection.  
3. Hospice patients are not excluded from NHSN surveillance.
4. Identification of organisms from specimens collected during post-mortem
examination (autopsy) are only eligible for use in meeting the CNS/IC (Intracranial)
infection definition and the PNEU infection definition using lung tissue specimen
obtained by transthoracic or transbronchial biopsy immediately post-mortem. For all
other NHSN definitions autopsy specimens/reports are not eligible for use.
5. Infections occurring in newborns with date of event on hospital day 1 or day 2 are
considered POA. Those with date of event on day 3 or later are HAI. This includes
infections acquired transplacentally (for example but not limited to  herpes simplex,
toxoplasmosis, rubella, cytomegalovirus, or syphilis) or as a result from passage
through the birth canal. Exception: See guidance about non-reporting of CLABSIs
with Group B Streptococcus during a neonate’s first 6 days of life found in the
Comments and Reporting Instuctions section of the Bloodstream Infection Event
(Central Line-Associated Bloodstream Infection and Non-central line-associated
Bloodstream Infection) protocol.
6. Reactivation of a latent infection (for example but not limited to herpes zoster
[shingles], herpes simplex, syphilis, or tuberculosis) is not considered to be an HAI.
Table 1: Exceptions to application of Chapter 2 
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Observation Patients in Inpatient Locations:  
For purposes of NHSN surveillance, if an observation patient is admitted to an inpatient 
location, the patient must be included in all surveillance events designated in the monthly 
reporting plan and included in patient and device day counts. The patient is being housed, 
monitored, and cared for in an inpatient location and therefore is at risk for acquisition of an 
HAI. 
Infection Window Period:   
 
The Infection Window Period (IWP) is defined as the 7-days during which all site-specific 
infection criteria must be met. It includes the collection date of the first positive diagnostic 
test that is used as an element to meet the site-specific infection criterion, the 3 calendar 
days before and the 3 calendar days after (Table 2). For purposes of defining the Infection 
Window Period the following examples are considered diagnostic tests: 
 
  laboratory specimen collection 
  imaging test  
  procedure or exam  
 
Table 2: Infection Window Period 
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3 days 
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Date of first positive diagnostic test that is used as an 
element of the site-specific criterion  
OR 
In the absence of a diagnostic test, use the date of the 
first documented localized sign or symptom that is used 
as an element of the site-specific criterion  
 
 
3 days 
after 
 
 
 
 
It is important to use the first diagnostic test that creates an infection window period 
during which all elements of the criterion can be found. See example below. 
 
Example  
When meeting PNEU definition using the PNU2 criterion, identification of an eligible 
organism from blood or from a site-specific specimen, and an imaging test may be available.  
Both the organism identification and the imaging test are diagnostic tests.  Use the first 
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diagnostic test for which all elements of the PNU2 criterion occur within the infection 
window period.  
 
In this example below, Option 1 uses the imaging test (not the blood culture) to set the 
infection window period. This is the first diagnostic test that creates an infection window 
period in which all elements of PNU2 criterion occur. 
 
Option 1: Correct diagnostic test 
selection 
 
Hospital 
Day 
Infection Window 
Period 
-2  
-1  
1  
2 POA New onset cough 
3  Imaging test: Infiltrate 
4 Fever > 38.0 C 
5 Fever > 38.0 C 
6 Blood culture: A. baumannii  
7 Rales, Fever > 38.0 C 
8 Cough, Rales 
9  
10  
11  
12  
13  
14  
15  
16  
17  
Option 2: Incorrect diagnostic test 
selection  
 
 
 
Hospital 
Day 
Infection Window 
Period 
-2  
-1  
1  
2 New onset cough 
3 HAI Imaging test: Infiltrate 
4 Fever > 38.0 C 
5 Fever > 38.0 C 
6 Blood culture: A. baumannii  
7 Rales, Fever > 38.0 C 
8 Cough, Rales 
9  
10  
11  
12  
13  
14  
15  
16  
17  
 
Infection Window Period Special Considerations  
 
1. Infection criteria that do not include a diagnostic test: 
 
For site-specific infection criteria that do not include a diagnostic test, the date of 
the first documented localized sign or symptom that is used as an element of the site-
specific infection criterion is used to define the infection window period for example, 
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diarrhea, site-specific pain, purulent drainage. Note that a non-specific sign or 
symptom for example, fever is not considered to be localized and therefore is not to 
be used to define the infection window period. 
For example, when meeting EMET using criterion 2, there is no diagnostic test as a 
part of this criterion. The date of the first documented localized sign or symptom, 
purulent drainage or pain or tenderness that is used as an element to meet EMET 
criterion 2 is to be used to set the infection window period. Fever is not a localized 
sign. 
  
 
 
2. More than one criterion can be met: 
When more than one criterion of a site-specific infection definition is met, 
identify the infection window period that results in the earliest date of event. 
 
Example   
A patient has purulent drainage noted at a superficial wound site on hospital day 2. It 
is documented on day 3 that the wound site is painful and swelling is present.  S. 
aureus is identified from a wound specimen with collection date on day 4. SKIN 
definition can be met using criterion 2a with pain, swelling and positive culture from 
the site-specific specimen (diagnostic test) and also met using criterion 1 with 
purulent drainage (sign). Using the sign of infection, purulent drainage, to set the 
infection window period results in Criterion 1 being met and provides the earliest date 
of event. 
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SKIN Criterion 1  
Correct Determination 
SKIN Criterion 2a 
 
 
Hospital 
Day 
Infection Window 
Period 
-2  
-1  
1  
2 POA Purulent Drainage from 
wound  
(SKIN Criterion 1) 
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
 
Hospital 
Day 
Infection Window 
Period 
-2  
-1  
1  
2  
3 HAI Pain, Swelling  
(SKIN Criterion 2a) 
4 Drainage culture: S. 
aureus 
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
 
 
 
3. Endocarditis: 
When meeting the Endocarditis (ENDO) definition, the Infection Window Period 
(IWP) is defined as the 21 days during which all site-specific infection criteria 
must be met. It includes the date the first positive diagnostic test that is used as an 
element of the ENDO infection criterion was obtained, the 10 calendars days 
before and the 10 calendar days after. The IWP is lengthened for ENDO to 
accommodate the extended diagnostic timeframe that is frequently required to 
reach a clinical determination of endocarditis. 
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Date of Event (Event Date): 
 
The Date of Event (DOE) is the date the first element used to meet an NHSN site-specific 
infection criterion occurs for the first time within the seven-day infection window period 
(Table 3 and Table 4).  
 
An infection is considered Present on Admission (POA) if the date of event of the 
NHSN site-specific infection criterion occurs during the POA time period, which is 
defined as the day of admission to an inpatient location (calendar day 1), the 2 days 
before admission, and the calendar day after admission. For purposes of NHSN 
surveillance and determination of the Repeat Infection Timeframe (as defined below) 
if the date of event is determined to be either of the two days prior to inpatient 
admission, then the date of event will be hospital day 1.  
 
An infection is considered a Healthcare-associated Infection (HAI) if the date of 
event of the NHSN site-specific infection criterion occurs on or after the 3rd calendar 
day of admission to an inpatient location where day of admission is calendar day 1. 
 
Note:  
Accurate determination of DOE is critical because DOE is used to determine: 
 if an event is HAI or POA  
 location of attribution  
 device association 
 day 1 of the Repeat Infection Timeframe  
 
Table 3: Date of Event and Classification Determination 
 
Hospital Day 
 
Date of Event 
Assignment for RIT 
Classification 
2 days before admit Hospital Day 1 
POA 
1 day before admit Hospital Day 1 
1 Hospital Day 1 
2 Hospital Day 2 
3 Hospital Day 3 
HAI 4 Hospital Day 4 
5 Hospital Day 5 
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Table 4: Infection Window Period and Date of Event (Patient age < 65) 
 
Note the date of event is the date the first element used to meet the site-specific infection 
criterion occurs for the first time in the infection window period. In the first example, it is 
day 2, the date the fever occurs for the first time in the infection window period and this 
results in a POA determination. In the second example it is day 4, the date of the diagnostic 
test, which is the first element in the infection window period and this results in an HAI 
determination. Date of event may be, but is not always, the date of the diagnostic test which 
is used to set the infection window period. 
  
Example 1  
 
 
HOSPITAL 
DAY 
INFECTION 
WINDOW PERIOD 
1  
2 Date of Event  Fever > 38.0 C 
3 Fever > 38.0 C 
4 Urine culture: 
>100,000 CFU/ ml         
E. coli 
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15    
16  
17  
18  
 SUTI-POA 
Date of Event = 2  
Pathogen = E. coli  
Example 2 
 
 
HOSPITAL 
DAY 
INFECTION 
WINDOW PERIOD 
1  
2  
3  
4 Date of Event Urine culture: 
>100,000 CFU/ml       
E. coli 
5 Fever > 38.0 C 
6 Fever > 38.0 C 
7  
8  
9  
10  
11  
12  
13  
14  
15    
16  
17  
18  
 SUTI-HAI 
Date of Event = 4 
Pathogen = E. coli  
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Notes: 
 Acceptable documentation includes patient-reported signs or symptoms documented in 
the medical record by a healthcare professional.  Information communicated verbally 
from facility to facility, or information found in another facility’s medical record cannot 
be used unless also documented in the current facility’s medical record (with the 
exception of post –discharge SSI surveillance.) For example, the following would be 
eligible for use if documented in the current facilities medical record:  
o patients states measured fever > 38.0° C or >100.4° F 
o nursing home documents fever prior to arrival to the hospital and in the POA 
timeframe 
o patient complains of dysuria  
 
 Physician diagnosis can be accepted as evidence of an infection only when physician 
diagnosis is an element of the specific infection definition.  For example, physician 
diagnosis is not an element of any UTI criteria; therefore, physician diagnosis of a UTI 
may not be used to satisfy POA status of a UTI. 
Repeat Infection Timeframe: 
 
The Repeat Infection Timeframe (RIT) is a 14-day timeframe during which no new 
infections of the same type are reported.  
 
 The RIT applies to both POA and HAI determinations.  
  The date of event is Day 1 of the 14-day RIT. 
 If criteria for the same type of infection are met and the date of event is within the 
14-day RIT, another new event is not identified for purposes of tracking or reporting, 
however, additional pathogens recovered during the RIT from the same type of 
infection are added to the event. Note the original date of event is maintained as is the 
original 14-day RIT. Additionally, device association determination location of 
attribution are not to be amended. See examples in Table 5 and Table 6 below. 
 The RIT will apply at the level of specific type of infection with the exception of BSI, 
UTI, and PNEU where the RIT will apply at the major type of infection. 
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Specific Type Example: 
 
Patients will have no more than one SKIN infection reported in a SKIN RIT, 
but may have overlapping or simultaneous SKIN RIT and DECU RIT  
 
Major Type Examples: 
 Patients will have no more than one BSI reported in a BSI RIT (LCBI 
1, LCBI 2, MBI-LCBI 1,MBI-LCBI 2, MBI-LCBI 3) 
 Patients will have no more than one PNEU reported in a PNEU RIT 
(PNU1, PNU2, and PNU3). 
 Patients will have no more than one UTI reported in a UTI RIT  
(SUTI, ABUTI, USI) 
 
 The RIT applies during a patient’s single admission, including the day of discharge 
and the day after, in keeping with the Transfer Rule.  An RIT does not carry over 
from one admission to another even if readmission is to the same facility.  
 
 The RIT for Endocarditis (ENDO) is extended to include the remainder of the 
patient’s current admission.   
 
In the example below (Table 5), the Date of Event is hospital day 4. The 14-day RIT is 
hospital day 4 through day 17. On hospital day 12, within the RIT, a urine culture with > 
100,000 CFU/ml S. aureus is identified. The urine pathogen identified from the hospital day 
12 culture is added to the originally identified infection on hospital day 4.  Determination of 
a new infection or continuation of ongoing infection is not required. The original date of 
event and the RIT are maintained. 
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Table 5: Repeat Infection Timeframe 
 
 
In the example below (Table 6) a non-catheter associated UTI is identified with date of event 
on day 4. This sets an RIT day 4 -17. On day 5 a Foley catheter is inserted. On day 8, within 
the RIT, a urine culture with > 100,000 CFU/ml E.coli is identified. The E.coli is added to 
the originally identified day 4 event. The device association does not change and the date of 
event and RIT are maintained. 
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Table 6.  Repeat Infection Timeframe and Interim Device Insertion 
 
 
 
 
Notes: 
 A patient may have negative cultures during the RIT without impact on the RIT. 
 Do not change the device-association determination during the RIT.   
 Do not change location of attribution determination during the RIT. 
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Secondary BSI Attribution Period  
 
(Refer to Appendix B, Secondary Bloodstream Infection (BSI) Guide of the BSI Event 
Protocol) The Secondary BSI Attribution Period*(SBAP) is the period in which a blood 
specimen must be collected for a secondary bloodstream infection to be attributed to a 
primary site infection. This period includes the Infection Window Period combined with the 
Repeat Infection Timeframe (RIT). It is 14-17 days in length depending upon the date of 
event.  
 
For purposes of NHSN, in order for a bloodstream infection to be determined 
secondary to another site of infection the following requirements must be met: ‡  
 
An NHSN site-specific definition must be met; either one of the CDC/NHSN Surveillance 
Definitions for Specific Types of Infections (defined in (Chapter 17), or UTI, PNEU or SSI 
definition. 
 
 AND 
 
 One of the following scenarios must be met: 
 
Scenario 1:  At least one organism from the blood specimen matches an organism 
identified from the site-specific infection that is used as an element to meet the NHSN 
site-specific infection criterion and the blood specimen is collected in the secondary 
BSI attribution period.(infection window period + repeat infection timeframe). 
 
OR  
 
Scenario 2: An organism identified in the blood specimen is an element that is used 
to meet the NHSN site-specific infection criterion, and therefore is collected during 
the site-specific infection window period. 
 
*Notes:  
 
 When meeting the Endocarditis (ENDO) definition, the secondary BSI attribution 
period includes the 21-day infection window period and all subsequent days of the 
patient’s current admission.  
 
o As a result of this lengthy ENDO secondary BSI attribution period, secondary 
BSI pathogen assignment for ENDO, is limited to organism(s) identified in 
blood specimen that match the organism(s) used to meet the ENDO definition.  
For example, if the ENDO definition was met using a site-specific specimen 
(cardiac vegetation) or using a blood specimen where S. aureus was the 
identified organism and subsequently a blood specimen collected during the 
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ENDO secondary BSI attribution period is positive for S. aureus and E.coli, 
while the S. aureus can be assigned to the ENDO event, it cannot be assumed 
the E.coli can be assigned as a secondary BSI pathogen. The blood organism 
(E.coli) does not match the organism (S. aureus) used to meet the ENDO 
definition.  If the blood specimen can be used to meet an ENDO definition 
criterion both organisms can be assigned. Otherwise, the E.coli will need to be 
investigated as a separate BSI and be identified as a secondary BSI to another 
site-specific infection or determined to be a primary BSI.  
 
‡Exception: 
Necrotizing enterocolitis (NEC) criteria include neither a site-specific specimen nor organism 
identified from blood specimen, however an exception for assigning a BSI secondary to NEC 
is provided.   
 
A BSI is considered secondary to NEC if the patient meets one of the two NEC 
criteria AND an organism identified from blood specimen collected during the 
secondary BSI attribution period is an LCBI pathogen, or the same common 
commensal which is identified from two or more blood specimens drawn on separate 
occasions collected on the same or consecutive days. 
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Secondary BSI Attribution Period Tables: 
 
In the example below (Table 7), the Date of Event is hospital day 4. The 14-day RIT is 
hospital day 4 through day 17. The Secondary BSI Attribution Period is the Infection 
Window Period combined with the Repeat Infection Timeframe (RIT), 17 days in this 
example. The blood culture collected on hospital day 10 has a matching pathogen to the site 
specific culture used to meet SUTI definition, and therefore, a secondary BSI is identified.  
 
 
Table 7: Secondary BSI Attribution Period 
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In the example below (Table 8), the Date of Event is hospital day 4. The 14-day RIT is 
hospital day 4 through day 17. The secondary BSI Attribution Period is 17 days in length. 
The blood culture collected on hospital day 5 is used as an element to meet the PNU2 
infection definition and therefore a secondary BSI is identified.  
 
Table 8: Secondary BSI Attribution Period 
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Pathogen Assignment Guidance: 
 
The following provides guidance for reporting pathogens associated with site-specific 
infections that are identified during the RIT or during the secondary BSI attribution period.  
 
 Additional eligible pathogens recovered during the RIT from the same type of infection 
are added to the event. 
 Report all site-specific pathogens before secondary BSI pathogens.  
o SUTIs can only have two organisms entered according to NHSN application 
rules.  However, if yes is selected for the secondary BSI field, the third pathogen 
field will become available for data entry. 
 If at least one BSI pathogen with a collection date in the secondary BSI attribution period 
matches organism from a specimen (either a site-specific specimen or a blood specimen) 
that was used to meet a site-specific infection criterion, additional eligible BSI pathogens 
are also considered secondary to the event. 
 BSI pathogens may be assigned to more than one infection source at the same time in the 
following scenarios. 
1) Secondary BSI pathogen assigned to two different site-specific infections (see 
Example 1) 
OR 
Secondary BSI pathogen assigned to a site-specific infection and assigned as 
pathogen to a primary BSI event (see Example 2). 
Example 1:  
 
K. pneumoniae is identified in a blood culture during the RIT of a SUTI with K. 
pneumoniae. The patient is also recovering from COLO surgery performed at your 
facility in the past week and now has: 
o Fever > 38.0° C, 
o Abdominal pain, and 
o CT showing abdominal abscess 
These three elements, when combined with a positive blood culture, meet IAB criterion 
3b.   If a facility includes both UTI and SSI (for COLO) in their monthly reporting 
plan, a UTI and SSI will be reported, both with a secondary BSI and with pathogen 
K. pneumoniae. 
 
Note: As per the SSI protocol, the SSI-IAB does not have an Infection Window Period or 
RIT. The secondary BSI attribution period is 17 days in duration including the date of 
event, 3 days prior and 13 days after the date of event.   
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Example 1(Cont.)  
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Example 2:   
On day 4 of hospital admission, S. aureus is identified in a blood culture 
meeting the HAI, LCBI 1 criterion. On day 8 the patient has a fever > 38.0° C 
and E. coli is identified in a urine culture meeting the SUTI definition. On 
hospital day 13, a blood culture positive for E.coli is identified. Because the 
blood culture occurs within both the LCBI RIT and the SUTI secondary 
BSI attribution period, the pathogen, E.coli is assigned to both events.  
 
 
 Pathogens excluded from specific infection definitions (for example, yeast in UTI, or 
Enterococcus spp. in PNEU) are also excluded as pathogens for BSIs secondary to that 
type of infection (specifically, they cannot be added to one of these infections as a 
pathogen).  The excluded organism must be accounted for as either: 
1) A primary bloodstream infection (BSI/CLABSI) (see Example 3) 
OR 
 
2) A secondary BSI attributed to another primary infection (for example, to an IAB 
or SINU), in accordance with Appendix B, Secondary BSI Guide of the BSI 
Event protocol (see Example 4) 
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Example 3:   
A SUTI with Enterococcus faecalis is identified and a subsequent blood culture 
with yeast and E. faecalis is collected during the SUTI secondary BSI attribution 
period.  A BSI secondary to SUTI is identified.  E. faecalis is already 
documented as a pathogen, but the yeast will not be reported as a secondary 
BSI pathogen, because yeasts are excluded as organisms in the UTI 
definition. In this example, no other primary source of infection for which the 
yeast BSI can be assigned as secondary is identified. Therefore a primary BSI 
with yeast only is identified. 
 
Note: The Enterococcus faecalis is not assigned as a pathogen for the primary 
BSI because if an excluded organism had not been identified, a primary BSI 
would not have been reported.  
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Example 4:  
A PNU2 with Acinetobacter baumannii cultured from blood is identified. 
Note: the positive chest imaging result is the diagnostic test that is used to 
define the infection window period.  A subsequent blood culture with 
Enterococcus faecalis and A. baumannii is collected during the secondary BSI 
attribution period of this PNU2 event.  Enterococcus faecalis will not be 
reported as a pathogen for the PNU2, because Enterococcus spp. are 
excluded as organisms in the PNEU definition.  Another primary source of 
infection, SUTI, is found and Enterococcus faecalis is assigned as a secondary 
BSI pathogen.  
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 Determination of a secondary BSI to a primary site of infection does not set an RIT for 
all subsequent BSIs. If a blood culture occurs during a site specific infection’s secondary 
BSI attribution period and it cannot be used as an element to meet the infection definition 
or does not have at least one matching pathogen to the site-specific infection culture used 
to meet the site-specific infection criterion the BSI must be evaluated as a new BSI event 
(see Example 5) 
Example 5: 
A SUTI with Enterococcus faecalis is identified and a blood culture with E. 
faecalis collected on hospital day 11 within the SUTI secondary BSI 
attribution period is also identified. On hospital day 15 (also within the SUTI 
RIT and secondary BSI attribution period), a blood culture growing 
Staphylococcus aureus is identified. Because the blood growing S. aureus 
does not have at least one pathogen that matches the urine culture used to 
meet the SUTI criterion the BSI cannot be attributed as secondary to the 
SUTI. The BSI will need to be investigated as a new BSI event and either 
assigned as a secondary BSI to another primary site of infection or determined 
to be a primary BSI.  
 
Note: The secondary BSI attribution period for a primary site of infection does 
not establish a repeat infection timeframe for all subsequent BSIs.  
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When identifying a BSI which appears to fall within a BSI-RIT, it is important to verify the 
initial BSI was indeed a primary BSI and not a secondary BSI to site-specific event. Only 
primary BSIs create a BSI RIT, therefore, incorrectly establishing a BSI-RIT for a secondary 
BSI event can result in the inaccurate assignment of a BSI pathogen(s) and the identification 
of a true CLABSI event will likely be missed (see Example 6).  
Example 6: 
  
Initially a BSI was identified as POA and therefore not further investigated.   Upon 
identification of a subsequent BSI it cannot be assumed that the POA BSI set a BSI 
RIT.  Instead, it must be verified that the initial BSI was indeed a primary BSI and 
not a secondary BSI to a site-specific infection. In the example below, upon further 
review the initial BSI was actually determined to be a secondary BSI to a SKIN 
infection. The SKIN Secondary BSI Attribution Period does not capture all 
subsequent BSIs. In this example it can only account for BSIs that have at least one 
matching pathogen to the site-specific specimen (wound drainage) used to meet 
SKIN. The BSI on hospital day 9 does not match and it also was determined not to be 
secondary to another site-specific infection and therefore a CLABSI is identified. 
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Location of Attribution (LOA): 
 
The inpatient location where the patient was assigned on the date of event is the location of 
attribution (see Date of Event definition). Non-bedded patient locations, (for example 
Operating Room (OR) or Interventional Radiology (IR) are not eligible for assignment of 
location of attribution for HAI events. Location of attribution must be assigned to a location 
where denominator data (for example, patient days, device days) can be collected.  
Exception to Location of Attribution: 
 
Transfer Rule: If the date of event is on the date of transfer or discharge, or the next day, the 
infection is attributed to the transferring/discharging location. This is called the Transfer 
Rule. If the patient was in multiple locations within the transfer rule time frame, attribute the 
infection to the first location in which the patient was housed the day before the infection’s 
date of event. Receiving locations or facilities should share information about such HAIs 
with the transferring location or facility to enable accurate reporting. See examples below. 
 
 
Location Example: 
 
Date Patient 
Location 
Location of 
Attribution 
3/22 Unit A  
3/23 Unit A 
Unit B 
 
3/24 
Date of Event 
Unit B Unit A 
3/25 Unit B  
 
Facility Example: 
 
Date Patient 
Location 
Location of 
Attribution 
3/22 Facility 1  
3/23 Facility 1 
Facility 2 
 
3/24 
Date of Event 
Facility 2 Facility 1 
3/25 Facility 2  
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Multiple Transfers Example: 
In instances where a patient has been transferred to more than one location on the 
date of an infection, or the day before, attribute the infection to the first location in 
which the patient was housed the day before the infection’s date of event. 
 
Date Patient 
Location 
Location of 
Attribution 
3/22 Unit A  
3/23 Unit A 
Unit B 
Unit C 
 
3/24 
Date of Event 
Unit C 
Unit D 
Unit A 
3/25 Unit D  
 
 
Note: The complete set of CDC/NHSN HAI site-specific infection criteria, and the 
comments and reporting instructions integral to the correct application of the criteria, can be 
found in Chapter 17, CDC/NHSN Surveillance Definitions for Specific Types of Infections, 
PNEU (Chapter 6), UTI (Chapter 7) and SSI (Chapter 9) . 
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APPENDIX:  Flow Diagram for NHSN Event Determination 
Is the diagnostic test 
a positive urine 
culture?
Yes No
Using the patient’s 
age and Foley 
catheter status  
decide which 
elements of the UTI 
definition are 
eligible for use. Do 
all elements 
required to meet 
the NHSN definition 
occur within the 
Infection Window 
Period (IWP)? 
Do all elements 
required to meet 
the NHSN definition 
occur within the 
Infection Window 
Period (IWP)? 
No
Yes
No
Yes
Determine 
the Date of Event 
(DOE)
Is the DOE during 
the  Healthcare-
associated Infection  
(HAI) or Present on 
Admission (POA) 
timeframe?
POAHAI
Determine if the 
infection is device-
associated
Determine the 
location of 
attribution
Determine the 14- 
day Repeat Infection 
Timeframe (RIT)
If not a primary 
bloodstream 
infection (BSI), 
determine the 
Secondary BSI 
Attribution Period 
(SBAP)
STOP
Not an NHSN event
Identify the diagnostic test, 
or in the absence of a diagnostic test, 
the localized sign/symptom that will 
determine the Infection Window 
Period (IWP)
STOP
 Not an NHSN event
Refer to the NHSN Patient Safety Component Manual, 
Chapter 2 for detailed guidance.
Is there a 
Repeat 
Infection 
Timeframe 
(RIT) in place  
for the same 
event type?
Yes
STOP
 No new event is 
found, add eligible 
pathogens to the 
original event
No
Is there a
 UTI Repeat 
Infection 
Timeframe 
(RIT)  in place?
Yes
STOP 
No new event is 
found, add eligible 
pathogens to the 
original UTI
No
 
 January 2018 3 -1 
 
Monthly Reporting Plan and Annual Surveys  
Patient Safety Monthly Reporting Plan and Annual Surveys 
 
Monthly Reporting Plan 
The Patient Safety Monthly Reporting Plan form (CDC 57.106) is used by NHSN 
facilities to inform CDC which Patient Safety modules are used during a given month.  
This allows CDC to select the data that should be included in the aggregate data analysis 
used for creating national benchmarks. Data entered into NHSN may represent either “in-
plan” or “off-plan” surveillance.  Each participating facility must identify and enter a 
monthly plan to indicate the module(s) used, if any, and the events, locations and/or 
procedures that will be monitored in-plan. The modules and locations selected for the 
month represent in-plan surveillance and indicate that the NHSN surveillance protocols 
will be used in their entirety, for that surveillance.   
• Only in-plan data are submitted to The Centers for Medicare and Medicaid 
Services (CMS) in accordance with CMS’s Quality Reporting Programs and 
included in NHSN annual reports or other NHSN publications.  
• “Off-plan” surveillance is surveillance that is done because a facility has decided 
to track a particular event for internal use. A facility makes no commitment to 
follow the NHSN protocol for “off-plan” events and such data are not included in 
CMS Quality Reporting Programs, NHSN annual reports or other NHSN 
publications. 
There must be a plan completed for every month that data are entered into NHSN 
although a facility may choose “No NHSN Patient Safety Modules Followed this Month” 
as an option. The reporting plan should take into account reporting requirements (for 
example, local, state, or CMS mandates) when applicable to the facility.  The monthly 
reporting plan is the first step in indicating the data that should be submitted to CMS as 
part of the CMS Quality Reporting Programs.  
 
Instructions for completing the Patient Safety Monthly Reporting Plan form can be found 
in the Table of Instructions. 
 
Annual Facility Survey 
 
One or more annual facility surveys must be completed upon enrollment into NHSN, 
activation of an NHSN component, and/or identification of select CMS-certified units. 
Thereafter, at the beginning of each year, a new facility survey(s) must be completed to 
reflect data from the prior calendar year. For example, at the beginning of 2018, an acute 
care hospital completes a 2017Annual Hospital Survey containing data from 2017. 
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Monthly Reporting Plan and Annual Surveys  
In the Patient Safety Component there are separate surveys for the following types of 
facilities: 
• Hospital (includes general, acute care hospitals; critical access hospitals; surgical; 
oncology; orthopedic; pediatric; women’s; women’s and children’s; military; 
psychiatric; and Veterans Affairs): Patient Safety Component – Annual Hospital 
Survey (57.103) 
• Long-term Acute Care (LTAC) Hospital: Patient Safety Component – Annual 
Facility Survey for LTAC (57.150) 
• Inpatient Rehabilitation Facility (includes free-standing facilities and CMS-
certified inpatient rehabilitation units located within a hospital): Patient Safety 
Component – Annual Facility Survey for IRF (57.151) 
 
Instructions for completing the Annual Survey form can be found in the Table of 
Instructions.  A link to the Table of Instructions form is included on each of the annual 
survey forms.  
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Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and 
Non-central Line Associated Bloodstream Infection) 
 
Table of Contents 
Bloodstream infection event (Central line and non-central line-associated BSI: Introduction 
and settings. 3 
Key Terms and Abbreviations (universal)  3 
Definitions specific to BSI / CLABSI surveillance: 3-5 
Devices that are Not Central Lines  6 
Table 1: Laboratory Confirmed Bloodstream Infection Definitions:  
LCBI 1, LCBI 2, LCBI 3 7-9 
Table 2: Mucosal Barrier Injury LCBI (MB-LCBI) Combined table 10 
Comments and Reporting Instructions  11-14 
Blood specimen collection 14 
Making Determinations about Device Day Counts and Device Association: Examples for 
Table 3 15 
Table 3: Associating the Use of Central Lines to BSI Events (CLABSI) 16 
Rationale for Table 3  17 
Pathogen Exclusions and Reporting Considerations 17-18 
Table 4: Reporting Speciated and Unspeciated Organisms from Blood Specimens 18 
Table 5: Examples Illustrating the MBI-LCBI Criteria for Neutropenia: (Rationale) 19 
Monthly Summary Data (numerator data, reporting instruction, denominator data, collection 
methods)         20-22 
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Data Analysis  23 
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Introduction: Although a 46% decrease in CLABSIs has occurred in hospitals across the U.S. from 
2008-2013, an estimated 30,100 central line-associated bloodstream infections (CLABSI) still occur in 
intensive care units and wards of U.S. acute care facilities each year.1 CLABSIs are serious infections 
typically causing a prolongation of hospital stay and increased cost and risk of mortality.   
  
CLABSI can be prevented through proper insertion techniques and management of the central line. 
These techniques are addressed in the CDC’s Healthcare Infection Control Practices Advisory 
Committee (CDC/HICPAC) Guidelines for the Prevention of Intravascular Catheter-Related Infections, 
2011.2  
Settings: Surveillance may occur in any inpatient location where denominator data can be 
collected, which can include critical/intensive care units (ICU), specialty care areas (SCA), neonatal 
units including neonatal intensive care units (NICUs), step down units, wards, and long term care units. 
A complete listing of inpatient locations and instructions for mapping can be found in the CDC 
Locations and Descriptions chapter. 
Note: CLABSI surveillance after patient discharge from a facility is not required. However, if 
discovered, any CLABSI with a date of event (DOE) on the day of or the day after discharge is 
attributed to the discharging location and should be communicated to that facility to encourage 
appropriate NHSN reporting of CLABSIs. (See Transfer Rule, Chapter 2). Do not collect or report 
additional central line days after discharge. 
 
Key Terms and Abbreviations  
 
Refer to the NHSN Patient Safety Manual, Chapter 2 Identifying Healthcare Associated Infections in 
NHSN and Chapter 16 NHSN Key Terms for definitions of the following universal concepts for 
conducting HAI surveillance.  
I. Date of event (DOE) 
II. Healthcare associated infection (HAI) 
III. Infection window period (IWP) 
IV. Present on admission (POA) 
V. Repeat infection timeframe (RIT) 
VI. Secondary BSI attribution period (SBAP) 
VII. Location of Attribution (LOA) 
VIII. Transfer rule  
Definitions Specific to BSI / CLABSI Surveillance: 
Primary bloodstream infection (BSI): A Laboratory Confirmed Bloodstream Infection (LCBI) that is 
not secondary to an infection at another body site (see Appendix B. Secondary BSI Guide and 
CDC/NHSN Surveillance Definitions for Specific Types of Infection [Ch-17], UTI [Ch-7], Pneumonia 
(Ch-6), and SSI (Ch-9). 
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LCBI Hierarchy; Types of LCBIs (see Table 1 and Table 2):   
 
 
Secondary BSI: A BSI that is thought to be seeded from a site-specific infection at another body site 
(see Appendix B. Secondary BSI Guide and CDC/NHSN Surveillance Definitions for Specific Types of 
Infection [Ch-17], UTI [Ch-7], Pneumonia (Ch-6), and SSI (Ch-9). 
Secondary BSI Attribution Period (SBAP): the period in which a blood specimen must be collected for a 
secondary BSI to be attributed to a primary site of infection. This period includes the Infection Window 
Period (IWP) combined with the Repeat Infection Timeframe (RIT). It is 14-17 days in length depending 
upon the date of event (see Ch. 2 page 2-13). 
Infusion: The administration of any solution through the lumen of a catheter into a blood vessel. 
Infusions include continuous infusion (for example, nutritional fluids or medications), intermittent 
infusion (for example, IV flush), IV antimicrobial administration, and blood transfusion or hemodialysis 
treatment.  
Access: The performance of any of the following activities during the current inpatient admission: 
 Line placement 
 Use of (entering the line with a needle or needless device) any central line for: 
o Infusion 
o Withdrawal of blood 
 Use for hemodynamic monitoring. 
 
Notes: 
1. If a patient is admitted to a an inpatient location with a central line (CL) already in place, and it 
is the patient’s only CL, the day of first access in an inpatient location begins the device day 
count as CL Day 1. Note: simply “de-accessing” a central line (for example, removal of port 
needle but port remains in body) does not result in the patient’s removal from CLABSI 
surveillance nor from including the central line in central line day counts. 
 
BSIs
LCBI 1
MBI-LCBI 1
LCBI 2
MBI-LCBI 2
LCBI 3
MBI-LCBI 3
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2. An inpatient location, for making determinations about central line access, includes but is not 
limited to, any department or unit within the facility that provides service to inpatients [for 
example, inpatient Dialysis, Operating Room (OR), Interventional Radiology, Gastroenterology 
Lab (GI), Cardiac Catheterization lab (CC), wards, ICUs, etc.].  
 
3. Include any inpatient receiving dialysis in CLABSI surveillance conducted in the patient’s 
assigned inpatient location, regardless of whether or not the patient only has one CL and dialysis 
staff are the only providers to access it during dialysis treatment.  
Examples: CLABSIs in the following examples will be attributed to Unit A  
 Patient on Unit A receives onsite dialysis by contracted dialysis staff  
 Dialysis staff travels to Unit A to provide dialysis to Unit A patient  
 Patient in Unit A for inpatient care is transported to dialysis unit within the facility for 
dialysis 
Because CLABSI events cannot be attributed to a non-bedded location, such events must be 
attributed to the inpatient location housing the patient. 
Central line (CL): An intravascular catheter that terminates at, close to the heart, OR in one of the great 
vessels that is used for infusion, withdrawal of blood, or hemodynamic monitoring. Consider the 
following great vessels when making determinations about CLABSI events and counting CL device 
days:  
 Aorta 
 Pulmonary artery 
 Superior vena cava 
 Inferior vena cava 
 Brachiocephalic veins 
 Internal jugular veins 
 Subclavian veins 
 External iliac veins 
 Common iliac veins 
 Femoral veins 
 In neonates, the umbilical artery/vein. 
Notes:  
1. Neither the type of device nor the insertion site are used to determine if a device is considered a 
central line for NHNS reporting purposes. 
2. At times, a CL may migrate from its original central location after confirmation of proper 
placement. NHSN does not require ongoing verification of proper line placement. Therefore, 
once a line has been designated a CL it continues to be a CL, regardless of migration, until 
removed from the body or patient discharge, whichever comes first. CL days are included in 
device-day counts for any CLABSI surveillance conducted in that location.  
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3. An introducer is an intravascular catheter, and depending on the location of the tip and its use,
may be considered a CL.
4. A non-lumened intravascular catheter that terminates at or close to the heart or in a great vessel
that is not used for infusion, withdrawal of blood or hemodynamic monitoring is not  considered
a CL for NHSN reporting purposes (for example, non-lumened pacemaker wires. Please note:
there are some pacemaker wires that do have lumens, which may be considered a central line).
Types of Central Lines for NHSN reporting purposes: 
1. Permanent central line: Includes:
a. Tunneled catheters, including tunneled dialysis catheters
b. Implanted catheters (including ports)
2. Temporary central line: A non-tunneled, non-implanted catheter
3. Umbilical catheter: A vascular catheter inserted through the umbilical artery or vein in a neonate.
All umbilical catheters are central lines.
Eligible Central Line: A CL that has been in place for more than two consecutive calendar days (on 
or after CL day 3), following the first access of the central line, in an inpatient location, during the 
current admission. Such lines are eligible for CLABSI events and remain eligible for CLABSI events 
until the day after removal from the body or patient discharge, whichever comes first. See Table 3 for 
examples 
Central line-associated BSI (CLABSI): A laboratory confirmed bloodstream infection where an 
eligible BSI organism is identified and an eligible central line is present on the LCBI DOE or the day 
before. 
Eligible BSI Organism: Any organism that is eligible for use to meet LCBI or MBI-LCBI criteria. In 
other words, an organism that is not an excluded pathogen for use in meeting LCBI or MBI-LCBI 
criteria. These organisms may or may not be included on the NHSN organism list. Please contact NHSN 
for guidance regarding organisms that are not included on the NHSN organism list 
Devices Not Considered CLs for NHSN Reporting Purposes: 
• Arterial catheters
• Arteriovenous fistula
• Arteriovenous graft
• Atrial catheters (also known as transthoracic intra-cardiac catheters, those 
catheters inserted directly into the right or left atrium via the heart wall)
• Extracorporeal membrane oxygenation (ECMO)
• Hemodialysis reliable outflow (HERO) dialysis catheter
• Intra-aortic balloon pump (IABP) devices
• Non-accessed central line (not accessed nor inserted during the hospitalization)
• Peripheral IV or Midlines
• Ventricular Assist Device (VAD) 
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Table 1: Laboratory-Confirmed Bloodstream Infection Criteria:  
Must meet one of the following LCBI criteria:  
Criterion Comments and reporting instructions that follow the site-specific criteria provide 
further explanation and are integral to the correct application of the criteria. 
 
Once an LCBI determination is made, proceed to the MBI-LCBI definitions and  
determine if the corresponding MBI-LCBI criteria are also met 
 (for example, after meeting LCBI 2, investigate for potential MBI-LCBI 2)  
 
LCBI 1 
If LCBI 1 
criteria        
is met, 
consider 
MBI-LCBI 1 
Patient of any age has a recognized pathogen, which is an organism not included on the 
NHSN common commensal list, identified from one or more blood specimens obtained 
by a culture or non-culture based microbiologic testing method (excluding organisms 
identified by testing on sera) 
AND 
Organism(s) identified in blood is not related to an infection at another site 
(See Appendix B: Secondary BSI Guide). 
Notes:  
1. If a patient meets both LCBI 1 and LCBI 2 criteria, report LCBI 1 with the 
recognized pathogen entered as pathogen #1 and the common commensal as 
pathogen #2. 
2.  No additional elements (in other words, no sign or symptom such as fever) are 
needed to meet LCBI 1 criteria; therefore, the LCBI 1 DOE will always be the 
collection date of the first positive blood specimen used to set the BSI IWP. 
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LCBI 2       
If LCBI 2 
criteria     
is met, 
consider 
MBI-LCBI 2 
Patient of any age has at least one of the following signs or symptoms: 
fever (>38.0oC), chills, or hypotension 
AND 
Organism(s) identified in blood is not related to an infection at another site 
(See Appendix B: Secondary BSI Guide). 
AND 
The same NHSN common commensal is identified by a culture or non-culture based 
microbiologic testing method, from two or more blood specimens collected on separate 
occasions (see Blood Specimen Collection). 
Common Commensal organisms include, but not are not limited to, diphtheroids 
(Corynebacterium spp. not C. diphtheria), Bacillus spp. (not B. anthracis), 
Propionibacterium spp., coagulase-negative staphylococci (including S. epidermidis), 
viridans group streptococci, Aerococcus spp. Micrococcus spp. and Rhodococcus spp.  
For a full list of common commensals, see the Common Commensal tab of the NHSN 
Organisms List. 
Notes: 
1. Criterion elements must occur within the 7-day IWP (as defined in Chapter 2)
which includes the collection date of the positive blood specimen, the 3 calendar
days before and the 3 calendar days after.
2. The two matching common commensal specimens represent a single element for
use in meeting LCBI 2 criteria and the collection date of the first specimen is used
to determine the BSI IWP.
3. At least one element (specifically, a sign or symptom of fever, chills or
hypotension) is required to meet LCBI 2 criteria; the LCBI 2 DOE will always be
the date the first element occurs for the first time during the BSI IWP, whether that
be a sign or symptom or the positive blood specimen.
6/1 Fever > 38.0 °C LCBI 2 DOE = 6/1 
6/2 No LCBI element 
6/3 No LCBI element 
Single 
element 
6/4 S. epidermidis(1 of 2) Date of 1st diagnostic test = 6/4 
6/5 S. epidermidis(2 of 2)
6/6 No LCBI element 
6/7 No LCBI element 
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LCBI 3 
If LCBI 3 
criteria is 
met, 
consider 
MBI-LCBI 3  
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient ≤ 1 year of age has at least one of the following signs or symptoms:  
fever (>38.0oC), hypothermia (<36.0oC), apnea, or bradycardia 
 
AND 
 
Organism(s) identified in blood is not related to an infection at another site 
(See Appendix B: Secondary BSI Guide). 
 
AND 
 
The same NHSN common commensal is identified by a culture or non-culture based 
microbiologic testing method, from two or more blood specimens collected on separate 
occasions (see Blood Specimen Collection). 
Common Commensal organisms include, but not are not limited to, diphtheroids 
(Corynebacterium spp. not C. diphtheria), Bacillus spp. (not B. anthracis), 
Propionibacterium spp., coagulase-negative staphylococci (including S. epidermidis), 
viridans group streptococci, Aerococcus spp. Micrococcus spp, and Rhodococcus spp. 
For a full list of common commensals, see the Common Commensal tab of the NHSN 
organisms list. 
Notes:  
1. Criterion elements must occur within the 7-day IWP (as defined in Chapter 2) 
which includes the collection date of the positive blood specimen, the 3 calendar 
days before and the 3 calendar days after. 
2. The two matching common commensal specimens represent a single element for 
use in meeting LCBI 2 criteria and the date of the first is used to determine the BSI 
IWP.    
3. At least one element (specifically, a sign or symptom of fever, hypothermia, apnea 
or bradycardia) is required to meet LCBI 3 criteria; the LCBI 3 DOE will always be 
the date the first element occurs for the first time during the BSI IWP whether that 
be a sign or symptom or the positive blood specimen. 
 6/1 No LCBI element  
 6/2 No LCBI element  
Single 
element 
6/3 S. epidermidis (1 of 2) Date of 1st diagnostic test = 6/3 
LCBI DOE = 6/3 
6/4 S. epidermidis (1 of 2)  
 6/5 Apnea documented  
 6/6 No LCBI element  
 6/7 No LCBI element  
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Table 2: Mucosal  Barrier Injury Laboratory-Confirmed Bloodstream Infection (MBI-LCBI) 
Must meet one of the following MBI-LCBI criteria 
An MBI-LCBI is a subset of the LCBI criteria; therefore, a BSI event must fully meet an LCBI 
criterion before evaluating for the corresponding MBI-LCBI criteria.  
The MBI-LCBI DOE will always be the date the prerequisite LCBI criteria was met. 
Abnormal ANC and WBC values reflect risk factors for acquiring an MBI-LCBI, not 
symptoms of infection and therefore are not used in DOE determinations. 
MBI-LCBI 1 MBI-LCBI 2 MBI-LCBI 3 
 Patient of any age fully meets 
LCBI 1 criteria 
Patient of any age fully meets 
LCBI 2 criteria 
Patient <1 year of age fully 
meets LCBI 3 criteria 
with at least one blood 
specimen  
with at least two blood specimens 
 identified by culture or non-culture based microbiologic testing method 
with ONLY intestinal 
organisms from the NHSN 
MBI organism list* 
with ONLY viridans group streptococci & no other organisms 
AND 
Patient meets at least one of the following: 
1. Is an allogeneic hematopoietic stem cell transplant recipient within the past year with one of the
following documented during same hospitalization as positive blood specimen:
a. Grade III or IV gastrointestinal graft versus host disease [GI GVHD]
b. ≥1-liter diarrhea in a 24-hour period (or ≥20 mL/kg in a 24-hour period for patients <18
years of age) with onset on or within the 7 calendar days before the date the positive blood
specimen was collected.
2. Is neutropenic, defined as at least two separate days with ANC† and/or WBC values <500
cells/mm3 collected within a 7-day time period which includes the collection date of the positive
blood specimen, the 3 calendar days before and the 3 calendar days after (See Table 6).
Note: 
1. If a patient meets both MBI-LCBI 1 and MBI-LCBI 2 criteria (specifically has Viridans Group
Streptococcus plus only other MBI organisms in the blood specimen), report organisms as MBI-
LCBI 1 with the recognized pathogen as pathogen #1 and the common commensal as pathogen
#2.
2. Any combination of ANC and/or WBC values can be used to meet neutropenic criteria provided
they are collected on separate days within the 7-day period that includes the date of the positive
blood specimen, the 3 calendar days before and the 3 calendar days after.
*A partial list of MBI-LCBI organisms is provided in Appendix A.
See MBI organism tab on the NHSN organism list for the full list of MBI organisms. 
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†
 Formula for calculating ANC if not provided by your laboratory: 
 
 The ANC is not always reported directly in the chart 
 The WBC in the chart is usually reported in terms of thousand cell/mm3 
ANC = Absolute Segs + Absolute Bands 
OR 
ANC = WBC x %Segs + %Bands / 100 
 
Example:  
WBC: 2 k/mm3 Segs: 20% Bands: 20% ANC = 2000 x (20+20)/100 = 800 cells/mm3 
 
Comments and Reporting Instructions: 
 Scenarios where “central line” data field should be marked “no” regardless of presence of CL: 
a. A  BSI meeting LCBI criteria that is accompanied by documentation of observed or suspected 
patient injection into the vascular access line, within the BSI IWP, will be considered an LCBI 
but not a CLABSI for NHSN reporting purposes. This exclusion is very specific to 
“INJECTION”. Manipulating or tampering with the line (such as biting, picking at, sucking on, 
etc.) DOES NOT meet the intent of this exclusion. The documentation must state specifically 
that the patient was “observed injecting…” or “suspected of injecting…” the device. Insinuations 
or describing events that suggest such behavior DO NOT meet the intent of this exclusion. If 
entering into NHSN, answer “No” to the risk factor field “Central line?” Device days should be 
included in summary denominator counts. A subsequent positive blood specimen collected after 
the BSI RIT must be investigated and meet the exclusion criteria again in a new BSI IWP in 
order to determine it is not central line associated. 
b. NHSN is phasing in additional reporting options over the next 3 years that will offer additional 
exclusions from central line association much like the above noted patient injection exclusion. 
The first step in this process, effective for 2018 reporting, is the addition of two optional fields: 
extracorporeal life support, (ECMO) and ventricular assist device (VAD). These fields will be 
optional when first introduced before becoming required for reporting in 2020.  
Use of these reporting options require a positive blood specimen meeting LCBI criteria 
accompanied by the presence of: 
 
• Extracorporeal life support, (ECMO) 
                OR 
• Ventricular assist device (VAD) 
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That has been in place for more than 2 days on the BSI DOE, and is still in place on the DOE or 
the day before. Such cases are considered LCBIs but are not central line associated (not a CLABSI) 
for NHSN reporting purposes. Report such events, however, mark the “Central Line” risk factor 
field “No”.  Marking the appropriate device field, ECMO or VAD, “Yes” is also optional.
BSI Event Form screenshot: 
Note: 
The “Any hemodialysis question” grouped with the others for consistency, is not new. Continued 
use, as desired, to identify trends related to dialysis is optional but does not affect central line 
association. 
c. Also added to the protocol (not included on the BSI event form) are reporting instructions for 
marking the “central line” data field “No” if there is a diagnosis during the current admission, of 
Epidermolysis bullosa (EB) or Munchausen Syndrome by Proxy (MSBP). Again, if a CL has 
been in place for more than 2 days on a BSI DOE, these events are considered LCBIs but are 
NOT considered central line associated. Optional fields for EB and MSBP will be added to the 
BSI event form for use in 2019 and will also become required fields in 2020.
d. Occasionally, a patient with both a central line and another vascular access device will have pus 
at the other access site.  If a specimen of the pus which identifies an organism(s) that matches at 
least one organism found in the blood is collected in the LCBI IWP, the BSI will not be 
considered central line associated When this occurs, enter “No” in the risk factor field for central 
line on the NHSN BSI event form if reporting. Device days however, should be included in the 
summary denominator count. Vascular access devices included in this exception are limited to:
• Arterial catheters
• Arteriovenous fistulae
• Arteriovenous grafts
• Atrial catheters (also known as transthoracic intra-cardiac catheters, those catheters 
inserted directly into the right or left atrium via the heart wall)
• Hemodialysis reliable outflow (HERO) dialysis catheters
• Intra-aortic balloon pump (IABP) devices
• Non-accessed CL (those neither inserted nor used during current admission)
• Peripheral IV or Midlines 
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e. Group B Streptococcus identified from blood, with a date of event during the first 6 days of life,
will not be reported as a CLABSI. A BSI RIT will be set but no central line association is made.
If reported to NHSN, the data field “Central Line” should be marked “No”.
Note: Meeting LCBI criteria in all of the situations noted above result in setting a BSI RIT and any 
associated central line days should be included in device counts for denominator summary data.   
 Do not report a BSI that has a DOE that occurs within a BSI RIT. However, add additional
organisms identified that are eligible for BSI events to the initial BSI event. See RIT guidance in
Chapter 2, Identifying Healthcare associated Infections or Chapter 16, Key Terms.
 Only primary BSIs create a 14-day BSI RIT:
Primary BSI example: Patient has a positive blood specimen identifying S. aureus on hospital 
day 6, which is not secondary to another site-specific source of infection. A subsequent positive 
blood specimen is collected on hospital day 12 that identifies Pseudomonas aeruginosa. Because 
this occurs in the BSI RIT, no new BSI event is identified or reported and Pseudomonas is added 
to the initial BSI event.  
 Secondary BSIs do not create a 14-day BSI RIT:
Secondary BSI example: A SUTI with Enterococcus faecalis is identified and E. faecalis is also 
collected from a blood specimen on hospital day 11 within the SUTI secondary BSI attribution 
period. This BSI is secondary to the SUTI. Only a SUTI RIT is set, not a BSI RIT. On hospital 
day 15 (also within the SUTI RIT and secondary BSI attribution period), a blood culture which 
grows Staphylococcus aureus is collected. Because the blood growing S. aureus does not have at 
least one pathogen that matches the urine culture used to meet the SUTI criterion the BSI cannot 
be attributed as secondary to the SUTI. There is no BSI RIT in effect, therefore the BSI will need 
to be investigated as a new BSI event and either assigned as a secondary BSI to another primary 
site of infection or determined to be a primary BSI.  
Note: The secondary BSI attribution period of a primary source of infection is not a “catch 
all” for subsequent BSIs.  
 There is no expectation that positive blood specimens collected during the present on admission
(POA) timeframe be investigated. If identified, they are not reported to NHSN. However, if a
subsequent positive blood specimen is collected within 14 days of a positive blood specimen
collected during the POA timeframe, it is imperative that a determination be made for the original
blood specimen in order to make the correct determination about the subsequent blood specimen.
Example 1: A patient has a positive blood specimen with E. coli that is POA 6/1. On 6/10, a 
subsequent positive blood specimen with K. pneumonia is collected. The 6/1 blood specimen is 
investigated and if determined to be a primary BSI, it sets a 14-day BSI RIT (6/1-6/14). 
Therefore, the 6/10 specimen is not a new BSI event and K. pneumonia is added to the POA BSI 
event if reported. 
4-14
January 2018 
Device-associated Module 
BSI 
Example 2: A patient has a positive blood specimen that identifies S. aureus present on 
admission 6/1.  On 6/10, a subsequent positive blood specimen with K. pneumonia is collected. 
To make the correct determination about the second blood specimen, the initial POA BSI event 
must be investigated to determine if it is primary or secondary to another site. In reviewing the 
chart, a right elbow culture from 5/31, also positive for S. aureus, plus the symptoms needed to 
meet JNT criteria 3c were documented making the 6/1 BSI secondary to JNT. The POA primary 
JNT infection creates a 14-day JNT RIT (6/1-6/14), during which no new JNT infections are 
reported. Because the subsequent blood specimen does not contain at least one matching 
pathogen to the specimen used to meet the JNT criteria, the positive blood with K. pneumonia 
cannot be attributed to the original JNT event and must be investigated as a primary or secondary 
BSI.  
Purulent phlebitis confirmed with a positive semi quantitative culture of a catheter tip, but with 
either a negative or no blood culture is considered a CVS-VASC, not an LCBI, SST-SKIN, or an 
SST-ST infection.  
Blood Specimen Collection 
1. In LCBI criteria 2 and 3, the phrase “two or more blood specimens drawn on separate occasions”
means:
a. blood from at least two separate blood draws was collected on the same or consecutive
calendar days, and
b. two separate site preparations (decontamination steps) were performed during specimen
collection.
This will reduce misidentification of contaminated blood specimens as LCBIs. For example, aseptic 
technique indicates that separate site decontaminations would be performed for blood specimens 
drawn from different sites (in other words; different venipunctures, a combination of venipuncture 
and lumen withdrawal, or different lumens of the same central line), or at different times.  
Specimens collected in this manner would therefore be considered “separate occasions”.  
2. Specimen Collection Considerations: Blood specimens drawn through central lines can have a higher
rate of contamination than blood specimens collected through peripheral venipuncture. 3, 4 However,
all positive blood specimens, regardless of the site from which they are drawn or the purpose for
which they are collected, must be included when conducting in-plan CLABSI surveillance (for
example, weekly blood cultures performed in hematology and oncology locations).
3. Catheter tip cultures cannot be used in place of blood specimens for meeting LCBI criteria.
4. In  MBI-LCBI 1, 2 and 3, “No other organisms” means there is no identification of a non-MBI-LCBI
pathogen (such as S. aureus) or 2 matching common commensals (such as coagulase-negative
staphylococci) collected from the blood on separate occasions that would otherwise meet LCBI
criteria.  If this occurs, the infection does not meet MBI-LCBI criteria.
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5. When a blood specimen positive for an organism not included on the NHSN MBI organism list is 
collected during the BSI RIT of an MBI-LCBI, the initial MBI-LCBI event is edited to an LCBI and 
the identified non-MBI organism is added.  
 
Making Determinations about Device Day Counts and Device Association (See Table 3 examples) 
1. If a patient is admitted or transferred into an inpatient facility with an existing CL in place and it is 
the patient’s only CL, the first day of access, as an in-patient, is considered CL Day 1 (see Table 3 
Patient A & B). 
 
2. If an eligible central line is removed or the patient is discharged, the BSI DOE must be the day of or 
the day after device removal/patient discharge in order to meet CLABSI criteria (see Table 3 Patient 
B, C and D).  
 
3. If an accessed CL is removed and a new CL is inserted before a full calendar day without a CL has 
passed (new line inserted the same day or the day after other is removed), device day count 
continues uninterrupted and the device becomes an eligible central line on CL day 3 (see Table 3 
Patient C). If instead, after removal, at least one full calendar day (not to be interpreted as 24 hours) 
passes with no CL in place, device day count starts over (CL day 1) when a new line is placed and it 
will become an eligible CL on CL day 3 (see Table 3 Patient D).  
 
4. Non-use of or de-accessing a CL, for any period of time, after access as an inpatient (for example, 
removal of the port needle but the port remains in body) does not exclude the CL from device day 
counts nor does it keep it from becoming an eligible CL (eligible for a CLABSI event) on CL day 3 
(see Table 3 Patient E)
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Table 3: Associating the Use of Central Lines to BSI Events (CLABSI): This table provides examples that illustrate: 
 Device association as determined by the presence of an eligible CL on the BSI DOE or the day before. 
 CLABSI event eligibility based on the presence of an eligible CL on or after CL Day 3. 
Date 31-Mar 1-Apr 2-Apr 3-Apr 4-Apr 5-Apr 6-Apr 
Patient A:        
CL Status 
CL in CL in CL in CL in CL in  CL in CL in 
Accessed No  No  Yes Yes No. De-accessed No No  
Eligible for 
CLABSI event 
No No No No Yes-eligible CL Yes-eligible CL Yes-eligible CL 
     CL Day 1 CL Day 2 CL Day 3 CL Day 4 CL Day 5 
Patient B:         
CL Status 
CL in CL in CL in CL in CL in / CL out  No device No device 
Accessed No  No  Yes Yes Removed              -  - 
Eligible for 
CLABSI event 
No No No No Yes-eligible CL Yes-eligible CL No 
 -  - CL Day 1 CL Day 2 CL Day 3  - - 
Patient C:         
CL Status  
CL in CL in CL in/ CL out CL in CL in CL in/ CL out No device 
Accessed Yes Yes Removed Placed Yes Removed -  
Eligible for 
CLABSI event 
Yes Yes Yes Yes Yes Yes Yes 
 CL Day 3 CL Day 4 CL Day 5 CL Day 6 CL Day 7 CL Day 8 -  
Patient D:         
CL Status  
CL in CL in CL in/ CL out No device CL in CL in CL in  
Accessed Yes Yes Removed - Placed Yes Yes 
Eligible for 
CLABSI event 
Yes-eligible CL Yes-eligible CL Yes-eligible CL Yes-eligible CL No No Yes-eligible CL 
 CL Day 3 CL Day 4 CL Day 5   CL Day 1 CL Day 2 CL Day 3 
Patient E:         
CL Status  
No device CL in CL in CL in CL in CL in CL in  
Accessed - Placed Yes Yes Yes Yes Yes 
Eligible for 
CLABSI event 
- No No Yes-eligible CL Yes-eligible CL Yes-eligible CL Yes-eligible CL 
 -  CL Day 1 CL Day 2 CL Day 3 CL Day 4 CL Day 5 CL Day 6 
BOLD = change in status 
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Rationale for Table 3: The goal of NHSN HAI surveillance is to identify risks to the patient that are the 
result of device use in general; therefore, NHSN will not require a BSI to be associated with a specific 
device when more than one line is present. In the examples above, 
1. Patient A becomes eligible for a CLABSI on 4/4 because an accessed CL had been in place for 
some portion of > 2 consecutive calendar days making it an eligible CL on 4/4 (CL day 3).  The 
central line remains eligible for a CLABSI until it is removed or the patient is discharged, whichever 
comes first. 
 
2. Patient B, eligible for a CLABSI on 4/4 (CL Day 3) through 4/5. An accessed CL had been in place 
> 2 consecutive calendar days making it an eligible CL on 4/4 (CL day 3). A BSI DOE on the day of 
or the day after device removal or patient discharge is considered device-associated (CLABSI).  
 
3. Patient C, eligible for a CLABSI on 3/31 (CL Day 3) through 4/6 because an accessed CL had been 
in place > 2 consecutive calendar days. A BSI DOE occurring on the day of or the day after device 
removal or patient discharge is considered a device-associated infection (CLABSI). The patient 
remains eligible for a CLABSI event through 4/6 because a full calendar day did not pass without a 
CL in place, therefore, device counts continue uninterrupted. 
 
4. Patient D, eligible for a CLABSI 3/31 (CL Day 3) through 4/3. An accessed CL had been in place > 
2 consecutive calendar days, however, a full calendar day passed (4/3) with no CL in place, 
therefore, device day counts start over @CL day 1 when a new line is placed. After 4/3, the patient 
will not be eligible for a CLABSI event again until 4/6 when the new CL becomes an eligible CL 
(CL day 3). 
 
5. Patient E, eligible for a CLABSI on 4/3 (CL Day 3) through 4/6 because line placement is 
considered first access which begins device day counts regardless of whether the line is being 
actively used or not and an accessed CL had been in place > 2 consecutive calendar days. 
 
 
 
Pathogen Exclusions and Reporting Considerations:  
 
1. The term “recognized pathogen” in LCBI 1 criteria refers to any organism that is not included on the 
NHSN common commensal list (see NHSN Master Organism List for the complete list of common 
commensals used for NHSN reporting purposes). Exceptions: 
a. Organisms belonging to the following genera are excluded as LCBI pathogens: Campylobacter, 
Salmonella, Shigella, Listeria, Vibrio and Yersinia as well as C. difficile, Enterohemorrhagic 
E.coli, and Enteropathogenic E. coli.  These organisms are eligible for use in secondary BSI 
determinations but will not be reported as the sole pathogen in a primary BSI.   
b. Organisms belonging to the following genera cannot be used to meet any NHSN definition:  
Blastomyces, Histoplasma, Coccidioides, Paracoccidioides, Cryptococcus and Pneumocystis. 
These organisms are excluded because they typically cause community-associated infections and 
are rarely known to cause healthcare-associated infections. 
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2. Business rules written into the pathogen fields of the NHSN application prevent entry of a common 
commensal as pathogen #1 when attempting to report both a recognized pathogen and commensal 
identified in an LCBI 1 or MBI-LCBI 1. In order to save the event successfully, enter the recognized 
pathogen first as pathogen # 1 and the common commensal as pathogen #2. 
3. For LCBI criteria 2 and 3, if the common commensal is identified to the species level for one blood 
specimen, and a companion blood specimen is identified with only a descriptive name, which is 
complementary to the companion culture (in other words, to the genus level), then it is assumed the 
organisms are the same.  An organism identified to the species level should be reported along with 
the antibiogram, if available (see Table 4). Colony morphology and antibiogram comparisons should 
not be used to determine the ‘sameness’ of organisms because laboratory testing capabilities and 
protocols vary between facilities. To reduce reporting variabilities due to differences in laboratory 
practice only genus and species identification should be used and they should only be reported once. 
If antibiograms are available and the sensitivities differ for the same organisms in separate 
specimens, always report the more resistant panel.  
4. A common commensal identified in a single blood specimen is considered a contaminant.  It will not 
be used to meet LCBI 2 or 3 criteria nor will it prevent a case from meeting MBI-LCBI criteria when 
the organism requirements call for ”only” a specific organism or type of organism (for example, 
“only intestinal organisms from the MBI list”). 
 
Table 4: Reporting Speciated and Unspeciated Organisms Identified from Blood Specimens 
 
Culture Report Companion Culture Report Report as… 
Coagulase-positive staphylococci S. aureus S. aureus 
S. epidermidis Coagulase-negative staphylococci S. epidermidis 
Enterococcus spp. E. faecium E. faecium 
Bacillus spp. (not anthracis) B. cereus B. cereus 
S. salivarius Strep viridans S. salivarius 
 
Note: When identification to the species level is not provided, the genus of the organism will be 
reported to NHSN. When identification to the genus level is not provided, report the organism as 
available on the NHSN all organism list (for example, Gram-positive bacilli). 
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Table 5: Examples Illustrating the MBI-LCBI Criteria for Neutropenia 
ND = not done; *Day the positive blood specimen was collected 
Rationale for Table 5: 
Patient A meets MBI-LCBI 1 criteria with neutropenia: Positive blood specimen with intestinal 
organism (Candida spp.) and neutropenia*. In this case, the WBC values on Day 1 = 400, and Day -1 = 
320 are used. 
Patient B meets MBI-LCBI 2 criteria with neutropenia: At least two positive blood specimens with 
viridans group streptococci, fever >38°C and neutropenia*. In this case, the ANC values on day -1 = 
110 and Day -2 = 120 are used. 
Note:  Any two of Days -2, -1, 2, 3, and 4 could be used to meet this requirement since WBC and/or 
ANC values of <500cells/mm3 were present on those days. 
Patient C meets MBI-LCBI 1 criteria with neutropenia: Positive blood specimen with intestinal 
organism (Candida spp.) and neutropenia*. In this case, WBC values on Day 1 = 600 and Day 2 = 230 
are used. 
*Neutropenia is defined as: 2 separate days of ANC or WBC <500 cells/mm3 occurring on the collection
date of the positive blood specimen (Day 1) or during the 3 days before or the 3 days after Day 1
Day 
-7
Day 
-6
Day 
-5
Day 
-4
Day 
-3
Day 
-2
Day 
-1
Day 
1* 
Day 
2 
Day 
3 
Day 
4 
Pt. 
A 
WBC 100 800 400 300 ND ND 320 400 
+ BC* w/
Candida
spp. x1
ND 550 600 
Pt. 
B 
ANC ND 410 130 ND ND 120 110 ND 
+BC* w/
viridans
strep x2 and
fever >38°C
110 300 320 
Pt. 
C 
WBC 100 800 400 300 ND ND ND 600 
+ BC* w/
Candida
spp. x1
230 ND 400 
--
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Monthly Summary Data 
 
Numerator Data:  The Primary Bloodstream Infection (BSI) form (CDC 57.108) is used to collect and 
report each CLABSI that is identified during the month selected for surveillance. For CLABSI 
surveillance, all LCBI and MBI-LCBI that are identified as central-line associated must be included.   
The Instructions for Completion of Primary Bloodstream Infection (BSI) form contains brief instructions 
for collection and entry of each data element on the form.  The Primary BSI form includes patient 
demographic information and whether a central line was present, and, if so, the type of central line the 
patient had if appropriate to the location; these data will be used to calculate line-specific infection rates.  
Additional data include the specific criteria met for identifying the primary BSI, whether the patient 
died, organisms identified from blood specimens, and the organisms’ antimicrobial susceptibilities.  
 
Reporting Instruction: 
During the month of surveillance, if no CLABSI events are identified, the “Report No Events” box must 
be checked on the appropriate denominator summary screen, (for example, Denominators for Intensive 
Care Unit [ICU]/other locations [not NICU or SCA], etc.   
 
Denominator Data: Device days and patient days are used for denominator reporting.  Device-day 
denominator data that are collected differ according to the patient location. The following methods can 
be used for the collection of denominator data: 
Table 6: Denominator Data Collection Methods 
Data Collection 
Method 
Details 
Manual, Daily Denominator data (patient days and device days) should be collected at the 
same time, every day, for each location performing surveillance to ensure 
that differing collection methods don’t inadvertently result in device days 
being > patient days.   
 For locations other than specialty care areas/oncology (SCA/ONC) and 
NICUs, the number of patients with  at least one central line, of any 
type, is collected daily, at the same time each day during the month and 
is recorded on the Denominators for Intensive Care Unit (ICU)/Other 
Locations (Not NICU or SCA/ONC) form (CDC 57.118).  Only the 
totals for the month are entered into NHSN 
Note: Only one central line per patient is counted per calendar day 
regardless of how many central lines the patient may have.  
 For specialty care areas/oncology, the number of patients with at least 
one central line are separated into those with permanent central lines 
and those with temporary central lines. The number of patients with at 
least one central line, of either or both type(s), is collected daily, at the 
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Data Collection 
Method 
Details 
same time each day during the month and is recorded on the 
Denominators for Specialty Care Area (SCA)/Oncology (ONC) form 
(CDC 57.117).  Only the totals for the month are entered into NHSN. 
Temporary and permanent lines are reported separately in this location 
because permanent lines are more commonly used in this patient 
population and may be associated with a lower BSI rate when 
compared to temporary central lines.   
Notes:  
1. Only one central line per patient is counted per calendar day 
regardless of how many central lines the patient may have.  
2. If a patient has both a temporary and a permanent central line, only 
report the temporary line because it is associated with a higher risk 
of bloodstream infection. 
The Instructions for Completion of Denominators for Intensive Care 
Unit (ICU)/Other Locations (Not NICU and SCA/ONC) and 
Instructions for Completion of Denominators for Specialty Care Areas 
(SCA)/Oncology (ONC) contain brief instructions for collection and 
entry of each data element on the form.  
 In NICUs, the number of patients with at least one central line is 
stratified by birth weight in five categories because the risk of BSI 
varies by birth weight. These data are reported on the Denominators for 
Neonatal Intensive Care Unit (NICU) form (CDC 57.116). 
Note:  Report only birth weight when entering BSI denominator data. 
The infant’s weight at the time of BSI identification is not used and 
should not be reported. For example, a neonate weighs 1006 grams at 
birth but remains in the NICU for two months and has a body weight of 
1650 grams when a CLABSI develops; enter the birth weight of 1006 
grams on the BSI form.  
The Instructions for Completion of Denominators for Neonatal 
Intensive Care Unit (NICU) form contains brief instructions for 
collection and entry of each data element on the forms.   
 
Manual, sampled 
once/week 
(collected at the 
same time on the 
same designated 
day, once per week) 
 To reduce staff time spent collecting surveillance data, once weekly 
sampling of denominator data to generate estimated central line days, 
may be used as an alternative to daily collection in non-oncology ICUs 
and wards (see Notes below). Sampling may not be used in SCA/ONC 
locations or NICUs.  During the month, the number of patients in the 
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Data Collection 
Method 
Details 
location (patient-days) and the number of patients with at least one 
central line of any type (central line days) is collected on a designated 
day each week (for example, every Tuesday), and at the same time 
each day.  
 
 Evaluations of this method have repeatedly shown that use of Saturday 
or Sunday generate the least accurate estimates of denominator data, 
therefore, weekend days should not be selected as the designated 
denominator data collection day.6-8  If the designated day is missed, 
collect the denominator data on the next available weekday.   
 
 The following must be collected and entered into NHSN:  
1. The monthly total for patient-days, collected daily 
2. The sampled total for patient-days 
3. The sampled total central line-days 
 
When these data are entered, the NHSN application will calculate       
an estimate of central line-days.   
 
Notes:  
 
1. To ensure the accuracy of estimated denominator data obtained by 
sampling, only ICU and ward location types with an average of 75 
or more central line-days per month are eligible to use this method. 
A review of each location’s central line denominator data for the 
past twelve months in NHSN will help determine which locations 
are eligible.  
 
2. The accuracy of estimated denominator data generated by sampling 
can be heavily influenced by incorrect or missing data. Careful 
implementation of data collection following the guidance in this 
protocol is essential to avoid erroneous fluctuations in rates or 
SIRs. 
 
Electronic For any location, denominator data from electronic sources (in other 
words, central line days from electronic charting may be used only after a 
validation of a minimum 3 months proves the data to be within 5% (+/-) of 
the manually collected once-a-day counts.  
Perform the validation of electronic counts separately for each location 
conducting CLABSI surveillance. 
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Data Analyses: The standardized infection ratio (SIR) is calculated by dividing the number of observed 
events by the number of predicted events. The number of predicted events is calculated using 
probabilities estimated from negative binomial models constructed from 2015 NHSN data, which 
represents a standard population. Beginning with 2015 data, SIRs are calculated for CLABSI (excluding 
MBI-LCBI events). 
 
Note: The SIR will be calculated only if the number of predicted events (numPred) is ≥1 to help enforce 
a minimum precision criterion. 
 
While SIRs can be calculated for single locations, the measure also allows you to summarize your data 
across multiple locations, adjusting for differences in the incidence of infection among the location 
types. For example, you can obtain one CLABSI SIR adjusting for all locations reported. Similarly, you 
can obtain one CLABSI SIR for all ICUs in your facility.  
 
The SUR, or Standardized Utilization Ratio, is a risk adjusted summarized measure for device use. 
Similar to the SIRs, the SUR can be calculated for single locations as well as be summarized across 
multiple locations.  
 
The CLABSI rate per 1000 central line days is calculated by dividing the number of CLABSIs by the 
number of central line days and multiplying the result by 1000.  The Central Line Utilization Ratio is 
calculated by dividing the number of central line days by the number of patient days.  These calculations 
will be performed separately for different types of ICUs, specialty care areas, oncology units, and other 
locations in the institution.  Separate rates and ratios will also be calculated for different types of central 
lines in specialty care areas/oncology locations and for birth weight categories in NICUs. 
 
Descriptive analysis output options of numerator and denominator data, such as line listings, frequency 
tables, and bar and pie charts are available in the NHSN application. CLABSI SIRs, rates, and run charts 
are also available. Guides on using NHSN analysis features are available from: 
https://www.cdc.gov/nhsn/ps-analysis-resources/reference-guides.html.  
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Table 7:  CLABSI Measures Available in NHSN   
 
Measure Calculation Application 
CLABSI SIR  
(Excluding MBI-
LCBIs) 
The number of Observed CLABSIs  
The number of Predicted CLABSIs  
Both location 
specific and 
summarized measure 
MBI-LCBI SIR  
(ACH Only) 
The number of Observed MBI-LCBIs 
The number of Predicted MBI-LCBIs 
Both location 
specific and 
summarized measure 
CLABSI Rates 
The number of CLABSIs for a location  x 1000 
The number of Central Line Days for that location 
Location specific 
measure only 
MBI-LCBI Rates 
The number MBI-LCBIs for a location  x 1000 
The number of Central Line Days for that location 
Location specific 
measure only 
Central Line SUR 
The number of Observed Central Line Days 
The number of Predicted Central Line Days 
Both location 
specific and 
summarized measure 
DUR 
The Central Line Days for a location 
The Patient Days for that location 
Location specific 
measure only 
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Appendix A:  Partial List of Criterion 1 MBI-LCBI Eligible Enterobacteriaceae Genera 
Abiotrophia  Escherichia (E) Pantoea (+E) 
Alistipes  Eubacterium   Parabacteroides   
Alloscardovia  Ewingella (E) Peptostreptococcus 
Anaerobiospirillum  Faecalibacterium   Pichia   
Anaerococcus  Filifactor   Porphyromonas   
Anaerorhabdus  Finegoldia   Prevotella 
Arcobacter   Flavonifractor   Proteus (E) 
Atopobium   Fusobacterium Providencia (E) 
Averyella (+E) Gemella   Pseudoflavonifractor   
Bacteroides Geotrichum   Pseudoramibacter   
Bifidobacterium   Granulicatella   Rahnella (E) 
Bilophila   Hafnia (E) Raoultella (+E) 
Blautia   Helcococcus   Rothia   
Buttiauxella (E) Helicobacter   Ruminococcus   
Campylobacter   Klebsiella (E) Saccharomyces   
Candida Kluyvera (E) Sarcina   
Capnocytophaga   Kluyveromyces   Serratia (E) 
CDC Enteric Group 58 
(+E) Lactobacillus   Shigella (E) 
Cedecea (E) Leclercia (E) Slackia   
Citrobacter (E) Leminorella (E) 
Streptococcus (VGS 
subset) 
Clostridium Leptotrichia   Tannerella   
Collinsella   Leuconostoc   Tatumella (E) 
Cronobacter (+E) Megamonas   Tetragenococcus   
Dialister   Megasphaera   Tissierella   
Dichelobacter   Mitsuokella   Trabulsiella (E) 
Edwardsiella (E) Moellerella (E) Veillonella 
Eggerthella   Mogibacterium   Weissella   
Eggerthia   Morganella (E) Yersinia (E) 
Enterobacter (E) Obesumbacterium (+E) Yokenella (E) 
Enterococcus Odoribacter     
E = Family Enterobacteriaceae  
 
Note: See complete list of MBI Pathogens including species by selecting the MBI Organisms tab at the 
bottom of the NHSN Organism List  
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Appendix B: Secondary BSI Guide (not applicable to Ventilator-associated Events [VAE]) 
The purpose of using the CDC/NHSN infection criteria is to identify and consistently categorize 
infections that are healthcare-associated into major and site-specific infection types. LCBI criteria 
include the caveat that the organism(s) identified from the blood cannot be related to infection at another 
site (in other words, it must be a primary BSI). One must be sure that there is no other CDC/NHSN 
defined primary site-specific infection that may have seeded the bloodstream secondarily; otherwise the 
bloodstream infection may be misclassified as a primary BSI and erroneously associated with the use of 
a central line, specifically called a CLABSI. For locations performing in-plan VAE surveillance, refer to 
Figure B2 in this appendix, as well as the VAE chapter for specific guidance on assigning a secondary 
BSI to a VAE. When conducting BSI surveillance the PNEU definitions (as well as UTI, SSI and all 
definitions found in Chapter 17) are available for attributing a secondary BSI for any patient in any 
location. For example, a ventilated patient in an adult location where VAE surveillance is being 
conducted can have a secondary BSI assigned to VAE or PNEU. A ventilated patient in a neonatal 
location where in-plan PedVAP surveillance is not an option can have a secondary BSI assigned to 
PNEU.   
 
Secondary BSI Scenarios: For purposes of NHSN reporting, in order for a bloodstream infection to be 
determined secondary to another site of infection the following requirements must be met:*  
 
An NHSN site-specific definition must be met; either one of the CDC/NHSN Surveillance 
Definitions for Specific Types of Infections (defined in Chapter 17), or UTI, PNEU or SSI 
definitions.  
 
     AND  
 
One of the following scenarios must be met:  
 
Scenario 1: At least one organism from the blood specimen matches an organism identified from the 
site-specific infection that is used as an element to meet the NHSN site-specific infection criterion AND 
the blood specimen is collected during the secondary BSI attribution period (infection window period + 
repeat infection timeframe)†.  
 
OR 
Scenario 2: An organism identified in the blood specimen is an element that is used to meet the NHSN 
site-specific infection criterion, and therefore is collected during the site-specific infection window 
period.  
Exception Notes:  
1. *The necrotizing enterocolitis (NEC) definition does not include criteria for a matching site-specific 
specimen nor an organism identified from a blood specimen that can be used as an element to meet 
the NEC criteria, however an * exception for assigning a BSI secondary to NEC is provided.  
 A BSI is considered secondary to NEC if the patient meets one of the two NEC criteria AND an 
organism identified from a blood specimen, collected during the secondary BSI attribution 
period, is an LCBI pathogen, or the same common commensal identified from two or more blood 
specimens drawn on separate occasions that are on the same or consecutive days. 
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2. † The ENDO criteria have different rules for infection window period, RIT, pathogen assignment 
and secondary BSI attribution period.  (See ENDO criteria in Ch. 17). 
 Below are examples with guidance on how to distinguish between the primary or secondary nature 
of a BSI.  The definition of “matching organisms”, important notes and reporting instructions are 
also provided. See Figure B1: Secondary BSI Guide for algorithmic display of the following 
instructions. 
Scenario 1: An organism identified from the site-specific infection is used as an element to meet the 
site-specific infection criterion, AND the blood specimen contains at least one matching organism to 
that site-specific specimen.  The positive blood specimen must be collected during the site-specific 
infection’s secondary BSI attribution period. (For your convenience, a list of infection criteria that 
include a blood specimen with at least one matching pathogen to the site-specific specimen that was 
used as an element to meet the definition are included in Table B1). 
 
a. Example: Patient meets NHSN criteria for a symptomatic urinary tract infection (suprapubic 
tenderness and >105 CFU/ml of E. coli) and blood specimen collected during the SUTI 
secondary BSI attribution period is positive for E. coli. This is a SUTI with a secondary BSI 
and the reported organism is E. coli. 
 
b. Example: Patient meets NHSN criteria for a symptomatic urinary tract infection (suprapubic 
tenderness and >105 CFU/ml of E. coli) and blood specimen collected during the SUTI 
secondary BSI attribution period grows E. coli and P. aeruginosa. This is a SUTI with a 
secondary BSI and the reported organisms are E. coli and P. aeruginosa, since both site and 
blood specimens are positive for at least one matching pathogen. 
 
c. Example: Patient meets NHSN criteria for a symptomatic urinary tract infection (suprapubic 
tenderness and >105 CFU/ml of E. coli) and a single blood specimen collected during the 
SUTI secondary BSI attribution period E. coli and S. epidermidis. This is a SUTI with a 
secondary BSI and the reported organism is only E. coli, since the single common 
commensal S. epidermidis positive blood specimen by itself does not meet BSI criteria. 
 
Scenario 2: An organism identified from a blood specimen is an element used to meet the site-
specific infection criterion, and is collected during the site-specific infection window period. (For 
your convenience, a list of infection criteria that include positive blood culture as an element are 
included in Table B1). 
 
a. Example: Patient becomes febrile and complains of nausea and abdominal pain. CT scan 
done that day shows fluid collection suggestive of infection. Blood specimen collected that 
day results in identification of Bacteroides fragilis. Because the patient meets IAB criterion 
3b, using the identification of an organisms from the blood specimen as an element (fever, 
nausea or abdominal pain, positive blood specimen and CT scan showing infection in 
abdominal cavity), the BSI is considered secondary to IAB.   
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b. Example: Patient is febrile, has a new onset of cough and has positive chest imaging test 
indicating the presence of an infiltrate. Blood specimens collected identify Pseudomonas 
aeruginosa. Because the patient can meet PNU2 definition using the identification of 
organisms from a blood specimen as one of the elements of the infection criterion 
(specifically, infiltrate on chest imaging test, fever, new onset of cough and organism 
identified from blood specimen ), the BSI is considered secondary to PNEU.  
 
Note:  In situations where an NHSN infection definition can be met using more than one 
criterion of the infection definition, it is possible that identification of an organism from the 
blood and site-specific specimens may not match and a BSI may still be considered a secondary 
BSI. Consider the following: 
 
a. Example: During the SSI surveillance period, a postoperative patient becomes febrile and 
complains of nausea and abdominal pain. CT scan done that day shows fluid collection 
suggestive of infection. Culture results show Escherichia coli from the T-tube drainage 
specimen and the blood specimen grows Bacteroides fragilis. Although the organisms in the 
blood culture and site-specific culture do not match for at least one organism, the blood 
culture is considered secondary to IAB.  This is because the patient meets organ/space SSI 
IAB criterion 3b, using the identification of organism in a blood specimen as an element 
(fever, nausea or abdominal pain, organism identified from a blood specimen and CT scan 
showing infection in abdominal cavity).  This patient also meets IAB criterion 3a using the 
positive site culture plus fever, and nausea or abdominal pain even though the organism 
involved is different from that used for IAB criterion 3b. In this case, the BSI is considered 
secondary to the organ/space SSI IAB and both organisms would be listed as IAB infection 
pathogens.  
 
b. Example: Patient is febrile, has a new onset of cough and has positive chest imaging test 
indicating the presence of an infiltrate. Blood and bronchoalveolar lavage (BAL) specimens 
are collected. Results identify Klebsiella pneumoniae > 104 CFU/ml from the BAL and 
Pseudomonas aeruginosa from the blood. Although the organisms in the blood specimen 
and site-specific specimen do not match for at least one organism, because the patient can 
meet PNU2 definition using either the identification of organism from  blood specimen or 
BAL specimen as one of the elements of the infection criterion (i.e. infiltrate on chest 
imaging test, fever, new onset of cough and organism identified from blood specimen or 
identified from BAL specimen), the blood is considered a secondary BSI to PNEU and both 
organisms would be listed as PNEU pathogens.  
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Note: If no matching organism is identified from the blood and the site-specific specimen, 
which is used to meet the site-specific infection definition, and the organism identified from the 
blood specimen cannot be used to meet the site-specific infection criteria, secondary BSI 
attribution cannot be assigned. The BSI would be primary in nature.  
 
a. Example: Patient has pustules on their abdomen with tenderness and swelling.  Purulent 
material is obtained from the pustules and is positive for Streptococccus Group B. A blood 
specimen collected the same day identifies methicillin resistant Staphylococcus aureus. 
Because the organisms from the site and blood specimens do not match, and there is no site-
specific criterion for SKIN that includes organisms identified from blood specimen, both a 
site-specific infection, SKIN (criteria 1 and 2a) and a primary BSI would be reported. 
 
b. Example: A patient has an abscess in the soft tissue around a percutaneous endoscopic 
gastrostomy (PEG) tube, identified by CT scan, and there is also purulent drainage from that 
site.  No site-specific specimen was collected, but a blood specimen is positive for 
Staphylococcus aureus. No other sites of infection are identified. Because no culture of the 
site was collected, and the patient therefore cannot meet ST criterion 1, and because there is 
no ST criterion which uses identification of organism from blood specimen as an element, 
this patient has a ST infection with unknown pathogen (criterion 2), and a primary BSI with 
the pathogen Staphylococcus aureus for NHSN reporting purposes. 
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Table B1: Secondary BSI Guide: List of all NHSN primary site-specific definitions available for 
making secondary BSI determinations using Scenario 1 or Scenario 2 
Scenario 1 Scenario 2 
A positive blood specimen must contain at least one 
eligible matching organism to the site-specific 
specimen 
Positive blood specimen must be an element of the 
site-specific definition 
And the blood specimen is collected in the site-
specific secondary BSI attribution period 
And blood specimen is collected in the site-specific 
infection window period 
And an eligible organism identified from the site-
specific specimen is used as an element to meet the 
site-specific definition  
And an eligible organism identified in a blood 
specimen is used as an element to meet the site-
specific definition  
Site Criterion 
ABUTI ABUTI 
BONE 1 
BRST 1 
CARD 1 
CIRC 2 or 3 
CONJ 1 
DECU 1 
DISC 1 
EAR 1, 3, 5 or 7,  
EMET 1 
ENDO 1  
EYE 1 
GE 2a 
GIT  2a, 2b (only yeast) 
IAB 1 or 3a 
IC 1  
JNT 1 
LUNG 1 
MED 1 
MEN 1 
ORAL 1 or 3a 
OREP 1 
PJI 1 
PNEU 2 or 3 
SA 1 
SINU 1 
SSI SI, DI or OS 
SKIN 2a 
ST 1 
UMB 1a 
UR 1a or 3a 
USI 1 
SUTI 1a, 1b or 2 
VASC only as SSI 1 
VCUF 3 
 
Site Criterion 
BONE 3a 
BURN 1 
DISC 3a 
ENDO 
4a, 4b, 5a or 5b 
(specific 
organisms) 
6e or 7e plus other 
criteria as listed 
GIT 1b or 2c 
IAB 2b or 3b 
JNT 3c 
MEN 2c or 3c 
OREP 3a 
PNEU 2 or 3 
SA 3a 
UMB 1b 
USI 3b or 4b 
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Secondary BSI Reporting Instructions: 
 
 For reporting secondary BSI for possible VAP (PVAP), see Figure B2 and Chapter 10.  
 
 Do not report secondary bloodstream infection for vascular (VASC) infections, Ventilator-
Associated Conditions (VAC), or Infection-related Ventilator-Associated Complications 
(IVAC), pneumonia 1 (PNEU 1).  
 
 When a BSI is suspected to be secondary to a lower, respiratory tract infection the BSI can be 
determined to be secondary to VAE or PNEU definitions. (See Figure B2).  
 
 Site-specific organism exclusions apply to secondary BSI attribution as well. 
 
A matching organism is defined as one of the following:  
 1.  If genus and species are identified in both specimens, they must be the same.  
a. Example: An intraabdominal specimen is used as an element to meet IAB definition and is 
growing Enterobacter cloacae. A blood specimen with a collection date in the IAB 
secondary BSI attribution period is reported to be growing Enterobacter cloacae. These are 
considered matching organisms.  
b. Example: An intraabdominal specimen is used as an element to meet IAB definition and is 
growing Enterobacter aerogenes. A blood specimen with a collection date in the IAB 
secondary BSI attribution period is reported to be growing Enterobacter cloacae. These are 
NOT considered matching organisms as the species are different.  
 
2. If one organism is less definitively identified than the other, the lesser identified organism must be 
identified at least to the genus level and at that level the organisms must be the same. 
a. Example: A surgical wound growing Pseudomonas species is used to meet deep incisional 
SSI criteria and a blood specimen growing Pseudomonas aeruginosa is collected in the SSI 
secondary BSI attribution period. The organisms are considered matching at the genus level 
and therefore the BSI is secondary to the SSI. 
b. Example: PCR identifying Enterococcus faecalis in CSF meets the MEN definition. A 
subsequent blood culture collected in the MEN secondary BSI attribution period is identified 
as Enterococcus species. The organisms are considered to be matching and therefore the BSI 
is secondary to MEN.   
 
3. There are two exceptions to the definition:  
a. Infections meeting LCBI 2 criteria with Staphylococcus or Streptococcus 
Example (Staphylococcus): A patient has a fever and a previous chest tube site is 
reddened, swollen and a culture is collected from the soft tissue.  A culture of the chest 
tube site is positive for Staphylococcus species. SST/ST definition is met. The next day, 
two blood culture sets are collected.  Both are positive for coagulase negative 
Staphylococcus.  The organisms are NOT considered matching, because Staphylococcus 
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species could represent a coagulase negative or a coagulase positive Staphylococcus. 
Therefore, the BSI would not be considered secondary to SST/ST.   
Example (Streptococcus):  A patient has a fever and a previous chest tube is red and 
swollen and a culture is collected from the soft tissue. The chest tube site culture is 
reported positive for Streptococcus species. SST/ST definition is met. The next day 2 
blood culture sets are collected.  The blood cultures are both positive for Streptococcus, 
viridans group.  The organisms are NOT considered matching, because Streptococcus 
species could represent a Streptococcus, viridans group or non- Streptococcus, viridans 
group. Therefore, the BSI would not be considered secondary to SST/ST.  
b. In cases where an organism is identified only as “yeast” or “yeast not otherwise specified”, 
the organism can be considered a match to other yeasts, when collected during the required 
timeframe, whether more fully identified or not.  
Example: A culture of tissue from the ulcer margin of a decubiti reported positive for 
yeast is used as an element to meet the DECU definition. A blood specimen collected in 
the secondary BSI attribution period of the DECU is reported as Candida albicans. In 
this example the two organisms are considered matching organisms as the organisms are 
complementary (i.e., Candida is a type of yeast) and because yeasts isolated from non-
sterile sites are commonly not identified to the genus or genus and species level.  
Note: This exception is limited to yeast. It does not apply to identification of organisms 
as Gram positive cocci, Gram negative rods, etc. 
 
Example: A culture of tissue from ulcer margin of a decubiti reported positive for Gram 
negative rod is used as an element to meet DECU definition. A blood specimen collected 
in the secondary BSI attribution period of the DECU is reported as E.coli. In this example 
the two organisms are NOT considered matching organisms.  
Notes: 
1. Antibiograms of the blood and potential primary site isolates do not have to match. 
 
2. If the blood specimen by itself does not meet BSI criteria (for example, only one blood specimen 
positive for a common commensal), that specimen may not be used to meet secondary BSI criteria 
(see Scenario 1c). 
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Pathogen Assignment  
 
 Additional pathogens identified from secondary BSIs, should be added to the pathogens reported for 
the primary infection type.  The Secondary BSI data collection field should be checked yes.  
 A secondary BSI pathogen may be assigned to two different primary sites of infection (for example, 
UTI and an IAB infection). In example 1 below, two primary sites of infection have been identified 
and a blood culture is collected within both the SUTI and the IAB secondary BSI attribution period. 
The blood culture pathogen matches the pathogens for both primary sites of infection (SUTI and 
IAB). Therefore, the pathogen is reported for both primary sites of infection as a secondary 
bloodstream infection.  
 If at least one BSI pathogen with a collection date in the secondary BSI attribution period matches 
an organism from a specimen that was used to meet a site-specific infection criterion (either a site-
specific specimen or a blood specimen) the BSI is considered secondary to the event. However, if no 
matching pathogen is identified, the subsequent BSI pathogen must be evaluated and deemed 
primary or secondary to another site-specific infection. For example: A patient with a primary 
UTI with E. coli and a secondary BSI with E. coli has a subsequent positive blood specimen with 
yeast. Yeast is an excluded pathogen for meeting UTI criteria; therefore, the subsequent blood must 
be evaluated as primary or secondary to another site-specific infection.
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Example 1: Pathogen Assignment  
 
 
 
 
Pathogens excluded from specific infection definitions (e.g., yeast in UTI, or Enterococcus spp. for 
PNEU) are also excluded as pathogens for BSIs secondary to that type of infection (i.e., they cannot be 
added on to one of these infections as a pathogen).  In example 2 below, the excluded organism must be 
accounted for as either 1) a primary bloodstream infection (BSI/CLABSI) or, 2) a secondary 
bloodstream infection attributed to another primary infection (e.g., IAB, SINU). A blood culture with 
yeast and E. faecalis is collected during the SUTI RIT.  A BSI secondary to SUTI is identified.  E. 
faecalis is already documented as a pathogen, but the yeast will not be reported as a secondary BSI 
pathogen, because yeasts are excluded as organisms in the UTI definition.  Because no other primary 
source of infection for which the yeast BSI can be assigned as secondary is found, a primary BSI with 
yeast is identified. 
 
Note: The Enterococcus faecalis is not reported as a pathogen for the primary BSI because if an 
excluded organism had not been identified, a primary BSI would not have been reported. 
Hospital 
Day (HD) 
UTI 
SBAP  
UTI
RIT 
UTI Infection 
Window Period 
IAB Infection 
Window Period 
IAB 
RIT 
IAB 
SBAP 
1       
2       
3       
4  1 Urine culture: 
>100,000 cfu/ml     
K. pneumoniae 
   
5  2 Fever > 38.0 C    
6  3     
7  4     
8  5  Fever >38.0 C, 
Abdominal pain  
  
9  6  CT Scan : 
Abdominal 
abscess 
  
10  7 Blood culture:         
K. pneumoniae    
Blood culture:         
K. pneumoniae 
  
11  8     
12  9     
13  10     
14  11     
15  12     
16  13     
17  14     
18       
19       
20       
21       
22       
23       
   SUTI & 
Secondary BSI 
DOE = HD 4 
Pathogen: K. 
pneumoniae 
IAB & 
Secondary BSI 
DOE = HD  8 
Pathogen: K. 
pneumoniae 
  
Secondary BSI Attribution 
Period (SBAP)           
(Infection Window Period + RIT) 
 
Infection Window Period 
(First positive diagnostic test, 3 days 
before and 3 days after) 
 
Repeat Infection Timeframe   
(RIT)                                          
(DOE = day 1) 
 
Date of Event (DOE)       
Date the first element occurs for the first 
time within the infection window period 
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Example 2: Pathogen Assignment (continued)  
 
 Hospital 
Day (HD) 
UTI 
SBAP  
UTI 
RIT 
UTI Infection 
Window Period 
BSI Infection 
Window  Period 
BSI 
RIT 
1      
2      
3  1 Dysuria   
4  2 Urine culture:         
> 100,000 cfu/ml   
E. faecalis  
  
5  3    
6  4    
7  5    
8  6    
9  7    
10  8    
11  9 Blood culture: 
E.faecalis / Yeast 
Blood culture:       
E. faecalis / Yeast 
1 
12  10   2 
13  11   3 
14  12   4 
15  13   5 
16  14   6 
17     7 
18     8 
19     9 
20     10 
21     11 
22     12 
23     13 
24     14 
25      
   UTI & Secondary 
BSI  
DOE = HD 3 
Pathogen: E. 
faecalis 
Primary BSI 
DOE  = HD 11 
Pathogen: Yeast 
 
Infection Window Period          
(First positive diagnostic test, 3 days 
before and 3 days after) 
 
Repeat Infection Timeframe   
(RIT)                                           
(date of event = day 1) 
 
Secondary BSI Attribution 
Period (SBAP) 
 (Infection Window Period + RIT) 
 
Date of Event (DOE)       
Date the first element occurs for the first 
time within the infection window period 
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Figure B1:  Secondary BSI Guide for eligible organisms*‡  
(Not applicable to Ventilator-associated Events [VAE], See Figure B2)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
*Exception: The necrotizing enterocolitis (NEC) definition does not include criteria for a matching 
site-specific specimen nor an organism identified from a blood specimen, however an exception for 
assigning a BSI secondary to NEC is provided.  A BSI is considered secondary to NEC if the patient 
meets one of the two NEC criteria AND an organism identified from a blood specimen, collected 
during the secondary BSI attribution period, is an LCBI pathogen or the same common commensal 
is identified from 2 or more blood specimens drawn on separate occasions but on the same or 
consecutive days. 
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Figure B2:  VAE Guidance for Secondary BSI Determination 
 
 
 
*Secondary BSIs may be reported for possible VAP (PVAP) events, provided that at least one organism 
identified from the blood specimen matches an organism identified from an appropriate respiratory tract 
specimen (including respiratory secretions, pleural fluid and lung tissue). The respiratory tract specimen 
must have been collected on or after the 3rd day of mechanical ventilation and within 2 calendar days 
before or after the day of onset of worsening oxygenation to be considered as a criterion for meeting the 
PVAP definitions. In addition, the blood  specimen must have been collected during the 14-day event 
period, where day 1 is the day of onset of worsening oxygenation. 
 
 In cases where PVAP is met with only the histopathology criterion and no culture or non-culture 
based test is performed on an eligible respiratory specimen, and there is also a positive blood 
specimen, a secondary BSI to VAE is not reported.  
 In cases where a culture or non-culture based test of respiratory secretions, pleural fluid or lung 
tissue is performed and does not identify an organism that matches an organism identified  from 
blood, a secondary BSI to VAE is not reported. 
 
Note: Candida species or yeast not otherwise specified, coagulase-negative Staphylococcus species, and 
Enterococcus species identified from blood cannot be deemed secondary to a PVAP, unless the 
organism was also identified from pleural fluid or lung tissue.  
Positive blood specimen.  
Lower respiratory tract infection suspected as 
source.
PVAP
SI secondary to 
PVAP per VAE 
surveillance 
protocol *
BSI NOT             
secondary to PVAP
Determine if BSI is 
secondary to another 
site-specific infection
Refer to Figure B1
VAC, IVAC  
or
No VAE
Determine if BSI is 
secondary to another 
site-specific infection
Refer to Figure B1
B
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Central Line Insertion Practices (CLIP) Adherence Monitoring 
 
Introduction:  Central line-associated bloodstream infections (CLABSIs) may be prevented 
through proper placement and management of the central line.  The CDC’s Healthcare 
Infection Control Practices Advisory Committee (CDC/HICPAC) Guidelines for the 
Prevention of Intravascular Catheter-Related Infections, 20111  recommend evidence-based 
central line insertion practices known to reduce the risk of subsequent central line-associated 
bloodstream infection. These include hand hygiene by inserters, use of maximal sterile 
barriers during insertion, proper use of a skin antiseptic prior to insertion, and time to allow 
the skin antiseptic to dry before catheter insertion. 
 
Several centers have found it useful to monitor adherence to evidence-based central line 
insertion practices as a method for identifying quality improvement opportunities and 
strategically targeting interventions. Feedback of adherence data has been a component of 
multifaceted interventions that have successfully reduced CLABSI rates.   
 
Participation in NHSN CLIP surveillance enables participating facilities and CDC to:  
• Monitor central line insertion practices in individual patient care units and facilities 
and provide aggregate adherence data for all participating facilities; facilities have the 
option of recording inserter-specific adherence data 
• Facilitate quality improvement by identifying specific gaps in adherence to 
recommended prevention practices, thereby helping to target intervention strategies 
for reducing CLABSI rates  
 
Participating facilities may perform surveillance for insertion practices during the following:  
• a month when concurrent CLABSI surveillance is being conducted 
• a month when no CLABSI surveillance is being conducted 
 
If participating facilities wish to identify associations between insertion practices 
and outcomes (specifically, CLABSI), surveillance for insertion practices and CLABSI must 
be done concurrently. 
 
Settings: Surveillance may occur in any type of patient care location where central lines are 
inserted.  
  
Numerator and Denominator Data: The Central Line Insertion Practices Adherence 
Monitoring Form (CDC 57.125) is used to collect and report central line insertion practices 
for every central line insertion attempt occurring during the month in the unit(s) selected for 
surveillance.  If an insertion attempt is unsuccessful, report a new CLIP event only if a new 
site preparation was performed.  The Table of Instructions for Completion of the Central Line 
Insertion Practices Adherence Monitoring Form contains directions for collection and entry 
of each data element on the form.  The form can be completed at or near the time of 
insertion, either by the inserter or an observer present at the insertion (for example, a nurse 
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assisting with the catheter insertion), or the form can be completed from documentation in 
the patient chart (only if all elements of the monitoring form have been incorporated into 
standard central-line insertion procedure notes). The form includes information pertaining to 
demographics of the patient, information pertaining to the inserter, information on maximal 
sterile barriers used, the reason for central line insertion, whether the insertion was 
successful, skin antisepsis, hand hygiene practice before insertion, type of central line 
including whether it was antimicrobial coated, insertion site and, if placed because of 
suspected existing central line infection, the use of a guide wire. Elements of some of these 
data will be used to calculate adherence to recommended insertion practices.   
 
Data Analyses:   Adherence rates for specific insertion practices will be calculated by 
dividing the number of bundle- compliant central line insertions (numerator) by the total 
number of central line insertions (denominator) and multiplying the result by 100.  Such 
calculations can also be done for a bundle of practices that have been shown to reduce the 
incidence of CLABSI (specifically, NHSN CLIP Bundle).  In NHSN for CLIP insertions 
dated January 1, 2016 and forward, adherence to the bundle requires a “Yes” to all of the 
following: 
• Hand hygiene performed 
• Appropriate skin prep* 
o Chlorhexidine gluconate (CHG) for patients ≥60 days old unless there is a 
documented contraindication to CHG 
o Povidone iodine, alcohol, CHG, or other specified for children <60 days old  
• Skin prep agent has completely dried before insertion 
• All 5 maximal sterile barriers used 
o Sterile gloves 
o Sterile gown 
o Cap 
o Mask worn 
o Large sterile drape (a large sterile drape covers the patient’s entire body) 
 
Note: These calculations are performed separately for different types of locations in the 
institution. Participants have the option of calculating inserter-specific adherence rates. 
 
*The Food and Drug Administration (FDA) has labeled CHG to be used with care in 
premature infants and infants < 2 months of age.  
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Pneumonia (Ventilator-associated [VAP] and non-ventilator-associated 
Pneumonia [PNEU]) Event 
 
Introduction:  In 2011, an estimated 157,000 healthcare-associated pneumonias 
occurred in acute care hospitals in U.S.; 39% of these pneumonias were ventilator-
associated (VAP).1 Patients receiving invasive mechanical ventilation are at risk for 
numerous complications, including pneumonia. Ventilator-associated pneumonia (VAP) 
and other healthcare-associated pneumonias are important, common healthcare-
associated infections, but national surveillance for VAP has long been a challenge 
because of the lack of objective, reliable definitions. Due to these challenges, in January 
2013 the National Healthcare Safety Network (NHSN) replaced surveillance for 
ventilator-associated pneumonia (VAP) in adult inpatient locations with surveillance for 
ventilator-associated events (VAE).2 Based on discussions with an expert working group 
in 2012-2013, NHSN also discontinued in-plan VAP surveillance in neonatal locations. 
As of January 2014, in-plan VAP surveillance is only available in pediatric inpatient 
locations.  
 
Settings:  Surveillance may occur in any inpatient pediatric location where denominator 
data can be collected, such as critical/intensive care units (pedICUs), specialty care areas 
(SCA), step-down units, wards, and long term care units. In-plan surveillance for 
ventilator-associated pneumonia (pedVAP) using the criteria found in this chapter is 
restricted to patients of any age in pediatric locations (excludes neonatal locations).  In-
plan surveillance conducted for mechanically-ventilated patients in adult locations 
(regardless of age) will use the Ventilator-Associated Event (VAE) protocol (see VAE 
chapter). The PNEU definitions are still available for those units seeking to conduct off-
plan PNEU surveillance for mechanically-ventilated adult, pediatric and neonatal patients 
and non-ventilated adults, pediatric or neonatal patients. A complete listing of inpatient 
locations and instructions for mapping can be found in the CDC Locations and 
Descriptions chapter.  
 
Note: If you are following pedVAP in your monthly reporting plan it is not required to 
monitor for VAPs after the patient is discharged from the facility. However, if 
discovered, any VAPs with event date on the day of discharge or day after discharge 
should be reported to NHSN (see Transfer Rule below).  No additional ventilator days are 
reported. 
Definitions:  
Present on Admission (POA): Infections that are POA, as defined in Chapter 2, are not 
considered HAIs and therefore are never reported to NHSN.   
 
Note: POA reporting exception for PNEU/VAP:  One eligible chest imaging test is 
acceptable to satisfy the imaging parameter for PNEU/VAP-POA determinations 
regardless of whether the patient has underlying pulmonary or cardiac disease.  
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Healthcare-associated infections (HAI): All NHSN site-specific infections must first meet 
the HAI definition as defined in Chapter 2 before a site-specific infection can be reported 
to NHSN. 
Note: For patients with underlying pulmonary or cardiac disease who are required to 
have serial imaging test results, to satisfy the PNEU/VAP definitions, the second imaging 
test must occur within seven days of the first but is not required to occur within the 
Infection Window Period. The date of the first CXR will be utilized when determining if 
the PNEU/VAP criteria are met within the infection window period.  All other elements 
of PNEU/VAP definition must be present within the infection window period.  
Pneumonia (PNEU) is identified by using a combination of imaging, clinical and 
laboratory criteria. The following pages detail the various criteria that may be used for 
meeting the surveillance definition of healthcare-associated pneumonia (Tables 1-4 and 
Figures 1 and 2), general comments applicable to all site-specific criteria, and reporting 
instructions. Table 5 shows threshold values for cultured specimens used in the 
surveillance diagnosis of pneumonia.   
Date of event:  For a PNEU/VAP the date of event is the date when the first element used 
to meet the PNEU infection criterion occurred for the first time within the 7-day Infection 
Window Period.  
Ventilator: any device used to support, assist or control respiration (inclusive of the 
weaning period) through the application of positive pressure to the airway when delivered 
via an artificial airway, specifically an oral/nasal endotracheal or tracheostomy tube. 
Note: Ventilation and lung expansion devices that deliver positive pressure to the airway 
(for example: CPAP, Bipap, bi-level, IPPB and PEEP) via non-invasive means (for 
example: nasal prongs, nasal mask, full face mask, total mask, etc.) are not considered 
ventilators unless positive pressure is delivered via an artificial airway (oral/nasal 
endotracheal or tracheostomy tube). 
Ventilator-associated pneumonia (VAP): A pneumonia where the patient is on 
mechanical ventilation for >2 calendar days on the date of event, with day of ventilator 
placement being Day 1, * 
AND 
the ventilator was in place on the date of event or the day before. 
*If the ventilator was in place prior to inpatient admission, the ventilator day count 
begins with the admission date to the first inpatient location.
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General Comments Applicable to All Pneumonia Specific Site Criteria: 
 Physician’s diagnosis of pneumonia alone is not an acceptable criterion for POA
(present on admission) or HAI (healthcare-associated) pneumonia.
 Although specific criteria are included for infants and children and
immunocompromised patients, all patients may meet any of the other pneumonia
site-specific criteria.
 Pneumonia due to gross aspiration (for example, in the setting of intubation in the
field, emergency department, or operating room) that meets the PNEU/VAP
definition with a date of event during the HAI timeframe is considered healthcare-
associated (HAI).
 Multiple episodes of healthcare-associated pneumonia may occur in critically ill
patients with lengthy hospital stays. When determining whether to report multiple
episodes of healthcare-associated pneumonia in a single patient, follow the Repeat
Infection Timeframe (RIT) guidance found in Chapter 2.
 Excluded organisms that cannot be used to meet the PNEU/VAP definition are as
follows:
1. “Normal respiratory flora,” “normal oral flora,” “mixed respiratory flora,”
“mixed oral flora,” “altered oral flora” or other similar results indicating
isolation of commensal flora of the oral cavity or upper respiratory tract
2. The following organisms unless identified from lung tissue or pleural fluid
specimens:
i. Candida species* or yeast not otherwise specified
ii. coagulase-negative Staphylococcus species
iii. Enterococcus species
Note: Candida species* or yeast not otherwise specified, coagulase-
negative Staphylococcus species, and Enterococcus species identified 
from blood cannot be deemed secondary to a PNU2 or PNU3, unless the 
organism was also identified from a pleural fluid or lung tissue specimen 
*Candida species identified from sputum, tracheal aspirate, endotracheal
aspirate, broncho-alveolar lavage (BAL) specimens or protected specimen
brushing combined with a matching organism identified from a blood
specimen can be used to satisfy the PNU3 definition.
3. Additionally, because organisms belonging to the following genera are
typically causes of community-associated infections and are rarely or are
not known to be causes of healthcare-associated infections, they are also
excluded, and cannot be used to meet any NHSN definition:  Blastomyces,
Histoplasma, Coccidioides, Paracoccidioides, Cryptococcus and
Pneumocystis.
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 Abbreviations used in the PNEU laboratory criteria:
BAL–bronchoalveolar lavage 
EIA–enzyme immunoassay 
IFA–immunofluorescent antibody 
LRT–lower respiratory tract 
PMN–polymorphonuclear leukocyte 
RIA–radioimmunoassay 
Reporting Instructions: 
 There is a hierarchy of specific categories within the major site pneumonia.  If the
patient meets criteria for more than one specific site during the infection window
period or the RIT, report only one:
o If a patient meets criteria for both PNU1 and PNU2, report PNU2.
o If a patient meets criteria for both PNU2 and PNU3, report PNU3.
o If a patient meets criteria for both PNU1 and PNU3, report PNU3.
 Pathogens and secondary bloodstream infections can only be reported for PNU2 and
PNU3 specific events.
 Report concurrent LUNG and PNEU with at least one matching organism(s) as
PNEU.
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Table 1:  Specific Site Algorithms for Clinically Defined Pneumonia (PNU1) 
Imaging Test 
Evidence 
Signs/Symptoms/Laboratory 
Two or more serial chest 
imaging test results with 
at least one of the 
following1,2,14: 
New and persistent 
or  
Progressive and 
persistent  
 Infiltrate
 Consolidation
 Cavitation
 Pneumatoceles, in
infants ≤1 year old
Note: In patients 
without underlying 
pulmonary or cardiac 
disease (for example: 
respiratory distress 
syndrome, 
bronchopulmonary 
dysplasia, pulmonary 
edema, or chronic 
obstructive pulmonary 
disease), one definitive 
imaging test result is 
acceptable.1 
For ANY PATIENT, at least one of the following: 
 Fever (>38.0°C or >100.4°F)
 Leukopenia (≤4000 WBC/mm3) or leukocytosis (>12,000 WBC/mm3)
 For adults >70 years old, altered mental status with no other recognized cause
And at least two of the following: 
 New onset of purulent sputum3  or change in character of sputum4, or increased
respiratory secretions, or increased suctioning requirements
 New onset or worsening cough, or dyspnea, or tachypnea5
 Rales6 or bronchial breath sounds
 Worsening gas exchange (for example: O2 desaturations (for example:  PaO2/FiO2
<240)7, increased oxygen requirements, or increased ventilator demand)
ALTERNATE CRITERIA, for infants <1 year old: 
Worsening gas exchange  (for example:2 desaturations [for example pulse oximetry 
<94%], increased oxygen requirements, or increased ventilator demand) 
And at least three of the following: 
 Temperature instability
 Leukopenia (≤4000 WBC/mm3) or leukocytosis (>15,000 WBC/mm3) and left shift
(>10% band forms)
 New onset of purulent sputum3  or change in character of sputum4, or increased
respiratory secretions or increased suctioning requirements
 Apnea, tachypnea5 , nasal flaring with retraction of chest wall or nasal flaring with
grunting
 Wheezing, rales6, or rhonchi
 Cough
 Bradycardia (<100 beats/min) or tachycardia (>170 beats/min)
ALTERNATE CRITERIA, for child >1 year old or ≤12 years old, at least three of the 
following: 
 Fever (>38. 0°C or >100. 4°F) or hypothermia (<36. 0°C or <96. 8°F)
 Leukopenia (≤4000 WBC/mm3) or leukocytosis (≥15,000 WBC/mm3)
 New onset of purulent sputum3  or change in character of sputum4, or increased
respiratory secretions, or increased suctioning requirements
 New onset or worsening cough, or dyspnea, apnea, or tachypnea5.
 Rales6 or bronchial breath sounds
 Worsening gas exchange (for example: O2 desaturations [for example pulse
oximetry <94%], increased oxygen requirements, or increased ventilator demand)
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Table 2:  Specific Site Algorithms for Pneumonia with Common Bacterial or Filamentous 
Fungal Pathogens and Specific Laboratory Findings (PNU2) 
Imaging Test 
Evidence 
Signs/Symptoms Laboratory 
Two or more serial chest 
imaging test results with at 
least one of the 
following1,2,14: 
New and persistent  
or  
Progressive and persistent 
 Infiltrate
 Consolidation
 Cavitation
 Pneumatoceles, in
infants ≤1 year old
Note: In patients without 
underlying pulmonary or 
cardiac disease (for 
example: respiratory 
distress syndrome, 
bronchopulmonary 
dysplasia, pulmonary 
edema, or chronic 
obstructive pulmonary 
disease), one definitive 
chest imaging test result is 
acceptable.1 
At least one of the following: 
 Fever (>38.0°C or >100.4°F)
 Leukopenia (≤4000 WBC/mm3)
or leukocytosis (>12,000
WBC/mm3)
 For adults >70 years old, altered
mental status with no other
recognized cause
And at least one of the following: 
 New onset of purulent sputum3 or
change in character of sputum4, or
increased respiratory secretions,
or increased suctioning
requirements
 New onset or worsening cough, or
dyspnea or tachypnea5
 Rales6 or bronchial breath sounds
 Worsening gas exchange (for
example:  O2 desaturations [for
example:  PaO2/FiO2 <240]7,
increased oxygen requirements, or
increased ventilator demand)
At least one of the following: 
• Organism identified from blood8,13
• Organism identified from pleural fluid9,13
• Positive quantitative culture or 
corresponding semi-quantitative culture 
result9 from minimally-contaminated LRT 
specimen (specifically, BAL, protected 
specimen brushing or endotracheal 
aspirate)
• ≥5% BAL-obtained cells contain 
intracellular bacteria on direct 
microscopic exam (for example: Gram’s 
stain)
• Positive quantitative culture or 
corresponding semi-quantitative culture 
result9  of lung tissue
• Histopathologic exam shows at least one 
of the following evidences of pneumonia:
o Abscess formation or foci of 
consolidation with intense PMN 
accumulation in bronchioles and 
alveoli
o Evidence of lung parenchyma 
invasion by fungal hyphae or 
pseudohyphae 
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Table 3:  Specific Site Algorithms for Viral, Legionella, and other Bacterial Pneumonias 
with Definitive Laboratory Findings (PNU2) 
Imaging Test 
Evidence 
Signs/Symptoms Laboratory 
Two or more serial chest 
imaging test results with 
at least one of the 
following1,2,14: 
New and persistent  
or  
Progressive and persistent 
 Infiltrate
 Consolidation
 Cavitation
 Pneumatoceles, in
infants ≤1 year old
Note: In patients without 
underlying pulmonary or 
cardiac disease (for 
example: respiratory 
distress syndrome, 
bronchopulmonary 
dysplasia, pulmonary 
edema, or chronic 
obstructive pulmonary 
disease), one definitive 
chest imaging test result 
is acceptable.1 
At least one of the following: 
 Fever (>38.0°C or >100.4°F)
 Leukopenia (≤4000 WBC/mm3) or
leukocytosis (>12,000 WBC/mm3)
 For adults >70 years old, altered
mental status with no other
recognized cause
And at least one of the following: 
 New onset of purulent sputum3 or
change in character of sputum4, or
increased respiratory secretions, or
increased suctioning requirements
 New onset or worsening cough or
dyspnea, or  tachypnea5
 Rales6 or bronchial breath sounds
 Worsening gas exchange (for
example:  O2 desaturations [for
example:  PaO2/FiO2 <240]7,
increased oxygen requirements, or
increased ventilator demand)
At least one of the following: 
 Virus, Bordetella, Legionella,
Chlamydia or Mycoplasma identified
from respiratory secretions or tissue
by a culture or non-culture based
microbiologic testing method which
is performed for purposes of clinical
diagnosis or treatment (for example:
not Active Surveillance
Culture/Testing (ASC/AST).
 Fourfold rise in paired sera (IgG) for
pathogen (for example: influenza
viruses, Chlamydia)
 Fourfold rise in Legionella
pneumophila serogroup 1 antibody titer
to ≥1:128 in paired acute and
convalescent sera by indirect IFA.
 Detection of L. pneumophila serogroup
1 antigens in urine by RIA or EIA
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Table 4: Specific Site Algorithm for Pneumonia in Immunocompromised Patients 
(PNU3) 
Imaging Test 
Evidence 
Signs/Symptoms Laboratory 
 
Two or more serial chest 
imaging test results with 
at least one of the 
following1,2,14: 
 
New and persistent  
or  
Progressive and 
persistent  
 
 Infiltrate 
 
 Consolidation 
 
 Cavitation 
 
 Pneumatoceles, in 
infants ≤1 year old  
 
Note: In patients 
without underlying 
pulmonary or cardiac 
disease (for example:  
respiratory distress 
syndrome, 
bronchopulmonary 
dysplasia, pulmonary 
edema, or chronic 
obstructive pulmonary 
disease), one definitive 
chest imaging test result 
is acceptable.1 
 
Patient who is 
immunocompromised (see 
definition in footnote 10 ) has at 
least one of the following: 
 
 Fever (>38.0°C or >100.4°F) 
 
 For adults >70 years old, altered 
mental status with no other 
recognized cause 
 
 New onset of purulent sputum3, 
or change in character of 
sputum4, or increased respiratory 
secretions, or increased 
suctioning requirements 
 
 New onset or worsening cough, 
or  dyspnea, or tachypnea5 
 
 Rales6 or bronchial breath sounds 
 
 Worsening gas exchange (for 
example:  O2 desaturations [for 
example:  PaO2/FiO2 <240]7, 
increased oxygen requirements, 
or increased ventilator demand)  
 
 Hemoptysis 
 
 Pleuritic chest pain 
 
 
At least one of the following: 
 
 Identification of matching Candida spp. 
from blood and one of the following: 
sputum, endotracheal aspirate, BAL or 
protected specimen brushing.11,12,13 
 
 Evidence of fungi from minimally-
contaminated LRT specimen (specifically 
BAL, protected specimen brushing or 
endotracheal aspirate) from one of the 
following: 
 
 Direct microscopic exam 
 Positive culture of fungi 
 Non-culture diagnostic laboratory test   
 
OR  
 
Any of the following from:  
 
LABORATORY CRITERIA DEFINED 
UNDER PNU2 
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Figure 1: Pneumonia Flow Diagram for Patients of Any Age 
Facility ID#_______________Event #______________________ Event Date __/__/____ 
Patient with underlying diseases1,2,14  
has 2 or more imaging test results with 
one of the following:
New & persistent OR
Progressive & persistent
q Infiltrate
q Consolidation
q Cavitation
q Pneumatoceles, in ≤ 1 y.o
At least one of the following:
q Fever (>38.0°C/100.4°F)
q Leukopenia (≤ 4,000 WBC/mm3) or leukocytosis (≥12,000 
WBC/mm3)
q Altered mental status with no other cause, in ≥70 y.o.
At least two of the following:
q New onset of purulent 
sputum3, or change in 
character of sputum, or ↑ 
respiratory secretions, or 
↑ suctioning 
requirements4
q New onset or worsening 
cough, or dyspnea, or 
tachypnea5
q Rales 6 or bronchial breath 
sounds
q Worsening gas exchange 
(e.g., O2 desats [e.g., 
PaO2/FiO2 < 240]7, ↑ O2 
req, or ↑ ventilation 
demand)
At least one of the following: 
q New onset of purulent 
sputum3, or change in 
character of sputum, or 
↑ respiratory 
secretions, or 
↑suctioning 
requirements4
q New onset or worsening 
cough, or dyspnea, or 
tachypnea5
q Rales 6 or bronchial 
breath sounds
q Worsening gas 
exchange (e.g., O2 
desats [e.g., PaO2/FiO2  
< 240]7, ↑ O2 req, or         
↑ ventilation demand
Patient without underlying diseases 1,2,14 
has 1 or more imaging test results with one 
of the following:
New & persistent OR 
Progressive & persistent
q Infiltrate
q Consolidation
q Cavitation
q Pneumatoceles, in ≤ 1 y.o.
At least one of the following in an 
immunocompromised patient 10 : 
q Fever (>38.0°C/100.4°F)
q Altered mental status with no 
other cause, in ≥70 y.o.
q New onset of purulent sputum3, or 
change in character of sputum, or 
↑ respiratory secretions, or             
↑ suctioning requirements4
q New onset or worsening cough, or 
dyspnea, or tachypnea5
q Rales 6 or bronchial breath 
sounds
q Worsening gas exchange (e.g.,   
O2 desats [e.g., PaO2/FiO2 < 240]7,       
↑ O2 req, or ↑ ventilation demand)
q Hemoptysis
q Pleuritic chest pain
At least one of the following:
q Identification of matching 
Candida spp.from blood and 
one of the following: sputum, 
endotracheal aspirate, BAL or 
protected specimen brushing 
11,12,13
q Evidence of fungi from 
minimally contaminated LRT 
specimen (specifically: BAL, 
protected specimen brushing 
or endotracheal aspirate) 
from one of the following:
 Direct microscopic 
exam
 Positive culture of fungi
 Non-culture diagnostic  
laboratory test
At least one of the following:
q Virus, Bordetella, Legionella, 
Chlamydia or Mycoplasma 
identified from respiratory 
secretions or tissue  by a 
culture or non-culture based 
microbiologic testing method 
which is performed for 
purposes of clinical diagnosis 
or treatment (e.g., not Active 
Surveillance Culture/Testing 
(ASC/AST).
q 4-fold rise in paired sera (IgG) 
for pathogen (e.g., Influenza 
viruses, Chlamydia)
q 4-fold rise in L. pneumophila 
antibody titer to ≥1:128 in 
paired acute and convalescent 
sera by indirect IFA
q Detection of Legionella 
pneumophila serogroup 1 
antigens in urine by RIA or EIA
PNU3PNU2PNU1
At least one of the following:
q Organism identified from  
blood 8,13
q Organism identified from 
pleural fluid13
q Positive quantitative culture or 
corresponding semi-
quantitative result9 from 
minimally-contaminated LRT 
specimen (e.g., BAL, protected 
specimen brushing, or 
endotracheal aspirate)
q ≥5% BAL-obtained cells 
contain intracellular bacteria 
on direct microscopic exam
q Positive quantitative culture or 
corresponding semi-
quantitative result9 of lung 
parenchyma
q Histopathologic exam shows at 
least one of the following:
               • Abscess formation or 
foci of consolidation with  
intense PMN 
accumulation in 
bronchioles and alveoli
               • Evidence of lung 
parenchyma invasion by 
fungal hyphae or 
pseudohyphae
L
A
B
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Immunocompromised
 Immunocompromised
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Figure 2: Pneumonia Flow Diagram, Alternative Criteria for Infants and Children 
 
Facility ID#_______________Event #______________________ Event Date __/__/____ 
 
S
IG
N
S
 &
 S
Y
M
P
T
O
M
S
IM
A
G
IN
G
ALTERNATE CRITERIA for Infants                    
<1 year old
q Worsening gas exchange  (e.g., O2 
desaturations [e.g., pulse oximetry 
<94%], increased oxygen 
requirements, or increased ventilator 
demand)
AND THREE of the following:
q Temperature instability
q Leukopenia (≤4000 WBC/mm3) or 
leukocytosis (>15,000 WBC/mm3) and 
left shift (>10% band forms)
q New onset of purulent sputum3 or 
change in character of sputum4, or 
increasd respiratory secretions or 
increased suctioning requirements.
q Apnea, tachypnea5, nasal flaring with 
retraction of chest wall or grunting 
q Wheezing, rales 6 or rhonchi
q Cough
q Bradycardia (<100 beats/min) or 
tachycardia (>170 beats/min) 
 
ALTERNATE CRITERIA for Children                    
> 1 or ≤ 12 years old 
At least THREE of the following:
q Fever (>38. 0°C or >100. 4°F) or 
hypothermia (<36. 0°C or <96. 8°F)
q Leukopenia (≤4000 WBC/mm3) or 
leukocytosis (>15,000 WBC/mm3)
q New onset of purulent sputum3, or 
change in character of sputum4, or 
increased respiratory secretions, or 
increased suctioning requirements4
q New onset or worsening cough, or 
dyspnea, or tachypnea5
q Rales 6 or bronchial breath sounds
q Worsening gas exchange (e.g., O2 
desats [e.g., PaO2/FiO2 < 240]7, ↑ O2 
req, or ↑ ventilation demand)
PNU1
Patient with underlying diseases1,2,14  has 2 or 
more imaging test results with one of the following:
New & persistent 
OR
Progressive & persistent
q Infiltrate
q Consolidation
q Cavitation
q Pneumatoceles, in ≤ 1 y.o
Patient without underlying diseases 1,2,14 has 1 or more 
imaging test results with one of the following:
New & persistent 
OR 
Progressive & persistent
q Infiltrate
q Consolidation
q Cavitation
q Pneumatoceles, in ≤ 1 y.o.
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Footnotes to Algorithms and Flow Diagrams:  
1. Occasionally, in non-ventilated patients, the diagnosis of healthcare-associated pneumonia may be quite 
clear on the basis of symptoms, signs, and a single definitive chest imaging test result. However, in patients 
with pulmonary or cardiac disease (for example: interstitial lung disease or congestive heart failure), the 
diagnosis of pneumonia may be particularly difficult. Other non-infectious conditions (pulmonary edema 
from decompensated congestive heart failure) may simulate the presentation of pneumonia. In these more 
difficult cases, serial chest imaging test results must be examined to help separate infectious from non-
infectious pulmonary processes. To help confirm difficult cases, it may be useful to review multiple imaging 
test results spanning over several calendar days. Pneumonia may have rapid onset and progression, but does 
not resolve quickly. Imaging test evidence of pneumonia will persist. Rapid imaging resolution suggests that 
the patient does not have pneumonia, but rather a non-infectious process such as atelectasis or congestive 
heart failure. 
2. Note that there are many ways of describing the imaging appearance of pneumonia. Examples include, but 
are not limited to, “air-space disease”, “focal opacification”, “patchy areas of increased density”. Although 
perhaps not specifically delineated as pneumonia by the radiologist, in the appropriate clinical setting these 
alternative descriptive wordings should be seriously considered as potentially positive findings.  
3. Purulent sputum is defined as secretions from the lungs, bronchi, or trachea that contain >25 neutrophils 
and <10 squamous epithelial cells per low power field (x100).  Refer to the table below if your laboratory 
reports these data semi-quantitatively or uses a different format for reporting Gram stain or direct examination 
results (for example:  “many WBCs” or “few squamous epithelial cells”).  This laboratory confirmation is 
required since written clinical descriptions of purulence are highly variable. 
 
How do I use the purulent respiratory 
secretions criterion if … 
Instruction 
My laboratory reports counts of “white blood 
cells” or “polymorphonuclear leukocytes” or 
“leukocytes” rather than counts of 
“neutrophils”? 
Assume that counts of cells identified by these other 
descriptors (for example “white blood cells”) are 
equivalent to counts of neutrophils, unless the 
laboratory tells you this is not the case. 
My laboratory reports semi-quantitative 
results (not quantitative results) for numbers 
of neutrophils and squamous epithelial cells? 
Check with the laboratory to get information about 
what quantitative ranges the semi-quantitative reports 
correspond to. 
My laboratory cannot provide additional 
information on how its semi-quantitative 
reporting corresponds to quantitative 
reporting ranges for neutrophils and 
squamous epithelial cells? 
Use the following direct examination results to meet 
the purulent respiratory secretions criterion: heavy, 4+, 
or ≥25 neutrophils per low power field (lpf) [x100], 
AND rare, occasional, few, 1+ or 2+, or ≤10 squamous 
epithelial cells per lpf [x100] [19]. 
My laboratory reports only the numbers of 
neutrophils present, without reporting the 
number of squamous epithelial cells? 
In this situation, the purulent secretions criterion may 
be met using the specified quantitative and semi-
quantitative thresholds for neutrophils alone 
(specifically heavy, 4+, or ≥25 neutrophils per lpf 
[x100]). 
My laboratory uses different reporting 
thresholds for neutrophils and squamous 
epithelial cells (for example:  maximum 
report of ≥ 20 neutrophils per low power field 
[x100], or minimum report of ≤ 15 squamous 
epithelial cells per low power field [x100])? 
In this situation, the purulent secretions criterion may 
be met using the laboratory’s specified maximum 
quantitative threshold for neutrophils, and/or minimum 
quantitative threshold for squamous epithelial cells. 
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4. Change in character of sputum refers to the color, consistency, odor and quantity.  
5. In adults, tachypnea is defined as respiration rate >25 breaths per minute. Tachypnea is defined as >75 
breaths per minute in premature infants born at <37 weeks gestation and until the 40th week; >60 breaths per 
minute in patients <2 months old; >50 breaths per minute in patients 2-12 months old; and >30 breaths per 
minute in children >1 year old. 
6. Rales may be described as “crackles”. 
7. This measure of arterial oxygenation is defined as the ratio of the arterial tension (PaO2) to the inspiratory 
fraction of oxygen (FiO2).        
8. Coagulase-negative Staphylococcus species, Enterococcus species and Candida species or yeast not 
otherwise specified that are identified from blood cannot be deemed secondary to a PNEU, unless the 
organism was also identified from pleural fluid (where specimen was obtained during thoracentesis or initial 
placement of chest tube and NOT from an indwelling chest tube) or lung tissue. Identification of matching 
Candida spp. from blood and sputum, endotracheal aspirate, BAL or protected specimen brushing can be used 
to satisfy PNU3 definition for immunocompromised patients. 
9.  Refer to threshold values for cultured specimens with growth of eligible pathogens. (Table 5).  
Notes: 
 A specimen that is not obtained through an artificial airway (specifically endotracheal tube or 
tracheostomy) is not considered minimally contaminated and is not eligible for use in meeting the 
laboratory criteria for PNU2.  Sputum is not a minimally-contaminated specimen.  
 Because they are an indication of commensal flora of the oral cavity or upper respiratory tract, the 
following organisms can only be used to meet PNEU definitions when identified from pleural fluid 
obtained during thoracentesis or initial placement of chest tube (not from an indwelling chest tube) or 
lung tissue:  
o Coagulase-negative Staphylococcus species  
o Enterococcus species  
o Candida species or yeast not otherwise specified. Exception: identification of matching 
Candida spp. from blood and sputum, endotracheal aspirate, BAL or protected specimen 
brushing can be used to satisfy PNU3 definition for immunocompromised patients. 
10. Immunocompromised patients include only: 
 those with neutropenia defined as absolute neutrophil count or total white blood cell count (WBC) 
<500/mm3 
 those with leukemia, lymphoma or who are HIV positive with CD4 count <200 
 those who have undergone splenectomy 
 those who have a history of solid organ or hematopoietic stem cell transplant  
 those on cytotoxic chemotherapy  
 those on steroids (excluding inhaled steroids) daily for >2 weeks. 
My laboratory processes respiratory 
specimens such as bronchoalveolar lavage 
fluid using a centrifugation procedure (for 
example, “cytospin”), and there is no 
quantitation or semi-quantitation of 
neutrophils or white blood cells in the direct 
examination report? 
In this situation, a report indicating the presence of 
white blood cells, without quantitation, is sufficient to 
meet the purulent secretions criterion. 
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11. Blood specimen and sputum, endotracheal aspirate, BAL or protected specimen brushing specimens must 
have a collection date that occurs within the Infection Window Period.   
12. Semi-quantitative or non-quantitative cultures of sputum obtained by deep cough, induction, 
aspiration, or lavage are acceptable.   
13. Identification of organism by a culture or non-culture based microbiologic testing method 
which is performed for purposes of clinical diagnosis or treatment (for example:  not Active 
Surveillance Culture/Testing (ASC/AST). 
14. If the imaging test result, is non-definitive for pneumonia, check to see if subsequent imaging 
tests are definitive. For example, if a chest imaging test result states infiltrate vs. atelectasis and a 
subsequent imaging test result is definitive for infiltrate—the initial imaging test would be 
eligible for use. In the absence of finding an imaging result that clarifies a non-definitive finding, 
if there is clinical correlation (documentation that imaging is interpreted as evidence of 
pneumonia and treatment for pneumonia) then the non-definitive imaging test is eligible for use. 
Unless you have a subsequent imaging test result that is definitive for pneumonia or clinical 
correlation, the imaging requirement of the PNEU definitions is not met. 
 
Table 5:  Threshold values for cultured specimens used in the diagnosis of pneumonia  
Specimen collection/technique Values
*  
 
Lung tissue† >104 CFU/g tissue  
  
Bronchoscopically (B) obtained specimens  
Bronchoalveolar lavage (B-BAL) >104 CFU/ml  
Protected BAL (B-PBAL) >104 CFU/ml 
Protected specimen brushing (B-PSB) >103 CFU/ml 
  
Nonbronchoscopically (NB) obtained (blind)specimens  
NB-BAL ≥104 CFU/ml  
NB-PSB >103 CFU/ml  
Endotracheal aspirate (ETA)  ≥ 105 CFU/ml  
CFU = colony forming units  
g = gram  
ml = milliliter  
 
* Consult with your laboratory to determine if reported semi-quantitative results match 
the quantitative thresholds. In the absence of additional information available from your 
laboratory, a semi-quantitative result of “moderate” or “heavy” growth, or 2+, 3+ or 4+ 
growth is considered to correspond. 
†Open-lung biopsy specimens and immediate post-mortem specimens obtained by 
transthoracic or transbronchial biopsy  
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Numerator Data:  The Pneumonia (PNEU) form (CDC 57.111) is used to collect and 
report each VAP that is identified during the month selected for surveillance. The 
Instructions for Completion of Pneumonia (PNEU) form contains brief instructions for 
collection and entry of each data element on the form. The pneumonia form includes 
patient demographic information and information on whether or not mechanically-
assisted ventilation was present. Additional data include the specific criteria met for 
identifying pneumonia, whether the patient developed a secondary bloodstream infection, 
whether the patient died, the organisms identified from culture or non-culture based 
microbiologic testing methods, and the organisms’ antimicrobial susceptibilities.  
 
Reporting Instruction: If no VAPs are identified during the month of surveillance, the 
“Report No Events” box must be checked on the appropriate denominator summary 
screen, for example:  Denominators for Intensive Care Unit (ICU)/Other Locations (Not 
NICU or SCA/ONC), etc.   
 
Denominator Data: Device days and patient days are used for denominators (see Key 
Terms chapter). Ventilator days, which are the number of patients managed with a 
ventilatory device, are collected daily, at the same time each day, according to the chosen 
location using the appropriate form (CDC 57.116, 57.117, and 57.118). These daily 
counts are summed and only the total for the month is entered into NHSN. Ventilator 
days and patient days are collected for each of the locations where VAP is monitored. 
When denominator data are available from electronic sources (for example: ventilator 
days from respiratory therapy), these sources may be used as long as the counts are not 
substantially different (+/- 5%) from manually-collected counts, validated for a minimum 
of three months.  
 
Data Analyses: The VAP rate per 1000 ventilator days is calculated by dividing the 
number of VAPs by the number of ventilator days and multiplying the result by 1000.  
The Ventilator Utilization Ratio is calculated by dividing the number of ventilator days 
by the number of patient days.  These calculations will be performed separately for the 
different types of ICUs, SCAs, and other locations in the institution.   
 
Descriptive analysis options of numerator and denominator data are available in the 
NHSN application, such as line listings, frequency tables, and bar and pie charts. VAP 
rates and run charts are also available. Guides on using NHSN analysis features are 
available from: www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html.  
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Urinary Tract Infection (Catheter-Associated Urinary Tract Infection 
[CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) and 
Other Urinary System Infection [USI]) Events  
 
Introduction: Urinary tract infections (UTIs) are the fourth most common type of 
healthcare-associated infection, with an estimated 93,300 UTIs in acute care hospitals in 
2011. UTIs additionally account for more than 12% of infections reported by acute care 
hospitals1.  Virtually all healthcare-associated UTIs are caused by instrumentation of the 
urinary tract.  
 
Approximately 12%-16% of adult hospital inpatients will have an indwelling urinary catheter 
at some time during their hospitalization, and each day the indwelling urinary catheter 
remains, a patient has a 3%-7% increased risk of acquiring a catheter-associated urinary tract 
infection (CAUTI).2-3 
 
CAUTI can lead to such complications as prostatitis, epididymitis, and orchitis in males, and 
cystitis, pyelonephritis, gram-negative bacteremia, endocarditis, vertebral osteomyelitis, 
septic arthritis, endophthalmitis, and meningitis in patients. Complications associated with 
CAUTI cause discomfort to the patient, prolonged hospital stay, and increased cost and 
mortality4. It has been estimated that each year, more than 13,000 deaths are associated with 
UTIs.5     
  
Prevention of CAUTI is discussed in the CDC/HICPAC document, Guideline for Prevention 
of Catheter-associated Urinary Tract Infection.6 
 
Settings:  Surveillance may occur in any inpatient location(s) where denominator data can be 
collected, such as critical intensive care units (ICU), specialty care areas (SCA), step- down 
units, wards, inpatient rehabilitation locations, and long term acute care locations. Neonatal 
ICUs may participate, but only off plan (not as a part of their monthly reporting plan). A 
complete listing of inpatient locations and instructions for mapping are located in the CDC 
Locations and Descriptions chapter.   
 
Note:  Surveillance for CAUTI after the patient is discharged from the facility is not 
required. However, if discovered, any CAUTI with a date of event (DOE) on the day of 
discharge or the next day is attributable to the discharging location and should be included in 
any CAUTIs reported to NHSN for that location (see Transfer Rule  Chapter 2).  No 
additional indwelling catheter days are reported. 
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Refer to the NHSN Patient Safety Manual, Chapter 2 Identifying Healthcare Associated 
Infections in NHSN and Chapter 16 NHSN Key Terms for definitions of the following 
universal concepts for conducting HAI surveillance. 
  
I. Date of event (DOE) 
II. Healthcare associated infection (HAI) 
III. Infection window period (IWP) 
IV. Present on admission (POA) 
V. Repeat infection timeframe (RIT) 
VI. Secondary BSI attribution period (SBAP) 
VII. Location of Attribution (LOA) 
VIII. Transfer rule  
Definitions:  
 
Urinary tract infections (UTI) are defined using Symptomatic Urinary Tract Infection (SUTI) 
criteria, Asymptomatic Bacteremic UTI (ABUTI), and Urinary System Infection (USI) 
criteria.  (See Table 1 and 2 and Figure2). 
 
Note: UTI is a primary site of infection and cannot be considered secondary to another site of 
infection. 
 
Indwelling catheter: A drainage tube that is inserted into the urinary bladder through the 
urethra, is left in place, and is connected to a drainage bag (including leg bags). These 
devices are also called Foley catheters. Condom or straight in-and-out catheters are not 
included nor are nephrostomy tubes, ileoconduits, or suprapubic catheters unless a Foley 
catheter is also present. Indwelling urethral catheters that are used for intermittent or 
continuous irrigation are included in CAUTI surveillance.  
 
Catheter-associated UTI (CAUTI): A UTI where an indwelling urinary catheter (IUC) was in 
place for >2 calendar days on the date of event, with day of device placement being Day 1*, 
AND 
an indwelling urinary catheter was in place on the date of event or the day before. If an 
indwelling urinary catheter was in place for > 2 calendar days and then removed, the date of 
event for the UTI must be the day of discontinuation or the next day for the UTI to be 
catheter-associated.  
 
*If the IUC was in place prior to inpatient admission, the catheter day count that determines 
device –association begins with the admission date to the first inpatient location. This allows 
for consistency with device denominator count (see Table 3 Denominator Data Collection 
Methods) 
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Example of Associating Catheter Use to UTI: 
A patient in an inpatient unit has a Foley catheter inserted and the following day is the date of 
event for a UTI. Because the catheter has not been in place >2 calendar days on the date of 
event, this is not a CAUTI. However, depending on the date of admission, this may be a 
healthcare-associated UTI. Please refer to SUTI 1b: Non-CAUTI. 
Notes: 
 SUTI 1b and USI cannot be catheter-associated.
 SUTI 1b cannot be met in a patient > 65 years of age with fever >380 C as the only
element within the Infection Window Period
Indwelling urinary catheters that are removed and reinserted: If, after indwelling urinary 
catheter removal, the patient is without an indwelling urinary catheter for at least 1 full 
calendar day (NOT to be read as 24 hours), then the urinary catheter day count will start 
anew. If instead, a new indwelling urinary catheter is inserted before a full calendar day has 
passed, the urinary catheter device day count, to determine eligibility for a CAUTI, will 
continue uninterrupted.  
Figure 1: Associating Catheter Use to UTI 
Rationale: NHSN surveillance for infection is not aimed at a specific device. Instead 
surveillance is aimed at identifying risk to the patient that is the result of device use in 
general.  
Notes: 
 In the examples above, Patient A is eligible for a CAUTI beginning on March 31,
through April 6th, since a Foley was in place for some portion of each calendar day
until April 6th.  A UTI with date of event on April 6th would be a CAUTI since the
catheter had been in place greater than 2 days and was removed the day before the
date of event.
March 31  
(Hospital day 3) 
April 1 April 2 April 3 April 4 April 5 April 6 
Patient A Foley 
Day 3 
Foley 
Day 4 
Foley 
removed 
(Foley 
Day 5) 
Foley 
replaced 
(Foley 
Day 6) 
Foley 
Day 7 
Foley 
removed 
Day 8 
No 
Foley 
Patient B Foley 
Day 3 
Foley 
Day 4 
Foley 
removed 
(Foley 
Day 5) 
No 
Foley 
Foley 
replaced 
(Foley 
Day 1) 
Foley 
Day 2 
Foley 
Day 3 
-
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 Patient B is eligible for a CAUTI on March 31 (Foley Day 3) through April 3.  The 
catheter had been in place > 2 days and an HAI occurring on the day of device 
discontinuation or the following calendar day is considered a device-associated 
infection.   
 If the patient did not have a CAUTI by April 3, the patient is not eligible for a CAUTI 
until April 6, when the second indwelling urinary catheter had been in place for 
greater than 2 days.  
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Criterion Urinary Tract Infection (UTI) 
 Symptomatic UTI (SUTI) 
Must meet at least one of the following criteria: 
 
SUTI 1a 
 
Catheter-
associated 
Urinary 
Tract 
Infection 
(CAUTI) 
in any age 
patient 
Patient must meet 1, 2, and 3 below: 
 
1. Patient had an indwelling urinary catheter that had been in place for > 2 days 
on the date of event AND was either: 
 Present for any portion of the calendar day on the date of event†,  
OR 
 Removed the day before the date of event‡ 
 
 
2. Patient has at least one of the following signs or symptoms:  
 fever (>38.0°C): To use fever in a patient > 65 years of age, the indwelling urinary 
catheter needs to be in place > 2 calendar days on date of event. 
 suprapubic tenderness* 
 costovertebral angle pain or tenderness* 
 urinary urgency ^ 
 urinary frequency ^ 
 dysuria ^ 
 
3. Patient has a urine culture with no more than two species of organisms 
identified, at least one of which is a bacterium of ≥105 CFU/ml (See 
Comments). All elements of the SUTI criterion must occur during the IWP 
(See IWP Definition Chapter 2 Identifying HAIs in NHSN). 
 
† When entering event into NHSN choose “INPLACE” for Risk Factor for Urinary 
Catheter  
‡ When entering event into NHSN choose “REMOVE” for Risk Factor for Urinary 
Catheter  
*With no other recognized cause (see Comments) 
^ These symptoms cannot be used when catheter is in place.  An indwelling urinary 
catheter in place could cause patient complaints of “frequency” “urgency” or 
“dysuria”. 
 
Note:    
 Fever is a non-specific symptom of infection and cannot be excluded from UTI 
determination because it is clinically deemed due to another recognized cause. 
 
 
Table 1. Urinary Tract Infection Criteria  
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SUTI 1b 
 
Non-
Catheter-
associated 
Urinary 
Tract 
Infection 
(Non-
CAUTI) 
in any age 
patient 
 
Patient must meet 1, 2, and 3 below: 
 
1. One of the following is true:  
 Patient has/had an indwelling urinary catheter but it has/had not been in 
place >2 calendar days on the date of event† 
OR 
 Patient did not have a urinary catheter in place on the date of event nor 
the day before the date of event † 
 
2. Patient has at least one of the following signs or symptoms:  
• fever (>38°C) in a patient that is ≤ 65 years of age 
• suprapubic tenderness* 
• costovertebral angle pain or tenderness* 
• urinary frequency ^ 
• urinary urgency ^ 
• dysuria ^ 
 
3.  Patient has a urine culture with no more than two species of organisms 
identified, at least one of which is a bacterium of ≥105 CFU/ml. (See 
Comments) All elements of the SUTI criterion must occur during the  IWP 
(See IWP Definition Chapter 2 Identifying HAIs in NHSN).  
 
† When entering event into NHSN choose “NEITHER” for Risk Factor for Urinary 
Catheter  
*With no other recognized cause (see Comments)  
^These symptoms cannot be used when catheter is in place.   An indwelling urinary 
catheter in place could cause patient complaints of “frequency” “urgency” or 
“dysuria”. 
 
Note:    
 Fever is a non-specific symptom of infection and cannot be excluded from 
UTI determination because it is clinically deemed due to another recognized 
cause. 
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SUTI 2 
  
CAUTI or 
Non-
CAUTI in 
patients 1 
year of age 
or less 
Patient must meet 1, 2, and 3 below: 
 
1. Patient is ≤1 year of age (with‡ or without an indwelling urinary catheter) 
 
2. Patient has at least one of the following signs or symptoms:  
• fever (>38.0°C) 
• hypothermia (<36.0°C) 
• apnea* 
• bradycardia* 
• lethargy* 
• vomiting* 
•    suprapubic tenderness*  
 
3.  Patient has a urine culture with no more than two species of organisms 
identified, at least one of which is a bacterium of ≥105 CFU/ml. (See 
Comments) All elements of the SUTI criterion must occur during the IWP 
(See IWP Definition Chapter 2 Identifying HAIs in NHSN).  
 
‡ If patient had an indwelling urinary catheter in place for >2 calendar days, and 
catheter was in place on the date of event or the previous day the CAUTI criterion 
is met.  If no such indwelling urinary catheter was in place, UTI (non-catheter 
associated) criterion is met. 
   
*With no other recognized cause (See  Comments) 
 
Note: Fever and hypothermia are non-specific symptoms of infection and cannot 
be excluded from UTI determination because they are clinically deemed due to 
another recognized cause. 
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Comments  “Mixed flora” is not available in the pathogen list within NSHN. Therefore, it 
cannot be reported as a pathogen to meet the NHSN UTI criteria. Additionally, 
“mixed flora” represent at least two species of organisms. Therefore, an additional 
organism recovered from the same culture would represent >2 species of 
microorganisms. Such a specimen also cannot be used to meet the UTI criteria.  
 
The following excluded organisms cannot be used to meet the UTI definition:  
 Candida species or yeast not otherwise specified  
 mold 
 dimorphic fungi or  
 parasites  
An acceptable urine specimen may include these organisms as long as one 
bacterium of greater than or equal to 100,000 CFU/ml is also present.  
Additionally, these non-bacterial organisms identified from blood cannot be 
deemed secondary to a UTI since they are excluded as organisms in the UTI 
definition. 
 Suprapubic tenderness whether elicited by palpation (tenderness-sign) or 
provided as a subjective complaint of suprapubic pain (pain-symptom), 
documentation of either found in the medical record is acceptable as a part of 
SUTI criterion if documented in the medical record during the Infection 
Window Period. 
 Lower abdominal pain or bladder or pelvic discomfort are examples of 
symptoms that can be used as suprapubic tenderness. Generalized “abdominal 
pain” in the medical record is not to be interpreted as suprapubic tenderness as 
there are many causes of abdominal pain and this symptom is too general. 
 Left or right lower back or flank pain are examples of symptoms that can be 
used as costovertebral angle pain or tenderness. Generalized "low back pain" is 
not to be interpreted as costovertebral pain.  
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Asymptomatic Bacteremic Urinary Tract 
Catheter –
associated 
ABUTI or 
Non-
catheter 
associated 
ABUTI in 
any age 
patient 
Patient must meet 1, 2, and 3 below: 
1. Patient with* or without an indwelling urinary catheter has no signs or
symptoms of SUTI 1 or 2 according to age (Note: Patients > 65 years of age
with a non-catheter-associated ABUTI may have a fever and still meet the
ABUTI criterion)
2. Patient has a urine culture with no more than two species of organisms
identified, at least one of which is a bacterium of ≥105 CFU/ml  (see
Comment section below)
3. Patient has organism identified** from blood specimen with at least one
matching bacterium to the bacterium identified in the urine specimen, OR
meets LCBI criterion 2 (without fever) and matching common
commensal(s) in the urine. All elements of the ABUTI criterion must occur
during the IWP (See IWP Definition Chapter 2 Identifying HAIs in NHSN).
*Patient had an indwelling urinary catheter in place for >2 calendar days on the
date of event, and the indwelling urinary catheter was in place on the date of event
or the day before. Catheter - associated ABUTI is reportable if the location is in
the facility’s reporting plan.
** Organisms identified by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or treatment (for 
example, not Active Surveillance Culture/Testing (ASC/AST). 
Comments A urine specimen with “Mixed flora” cannot be used to meet the urine criterion. 
Additionally, the following excluded organisms cannot be used to meet the UTI 
definition:  
 Candida species or yeast not otherwise specified
 mold
 dimorphic fungi or
 parasites
An acceptable urine specimen may include these excluded organisms as long as 
one bacterium of greater than or equal to 100,000 CFU/ml is also present.  
Additionally, these non-bacterial organisms identified from blood cannot be 
deemed secondary to a UTI since they are excluded as organisms in the UTI 
definition 
Table 2. Urinary System Infection Criteria  
 
 
January 2018  7-10 
Device-associated Module 
 UTI 
 
Criterion Urinary System Infection (USI) (kidney, ureter, bladder, urethra, or 
perinephric space) 
Other infections of the urinary system must meet at least one of the following 
criteria: 
 1. Patient has organisms identified** from fluid (excluding urine) or 
tissue from affected site 
2. Patient has an abscess or other evidence of infection on gross 
anatomical exam, during invasive procedure, or on histopathologic exam 
3. Patient has at least one of the following signs or symptoms: 
 fever (>38.0°C) 
 localized pain or tenderness*  
 
And at least one of the following: 
a) purulent drainage from affected site 
b) organisms identified** from blood and imaging test evidence 
of infection (e.g., ultrasound, CT scan, magnetic resonance 
imaging [MRI], or radiolabel scan [gallium, technetium]) 
which if equivocal is supported by clinical correlation (i.e., 
physician documentation of antimicrobial treatment for 
urinary system infection). 
 
4.  Patient <1 year of age has at least one of the following signs or 
symptoms:  
• fever (>38.0°C)  
• hypothermia (<36.0°C)  
• apnea* 
• bradycardia* 
• lethargy* 
• vomiting* 
 
And at least one of the following: 
a) purulent drainage from affected site 
b) organisms identified** from blood and imaging test evidence 
of infection, (for example , ultrasound, CT scans, magnetic 
resonance imaging [MRI], or radiolabel scan [gallium, 
technetium]) 
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* With no other recognized cause 
** Organisms identified by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or 
treatment (e.g., not Active Surveillance Culture/Testing (ASC/AST). 
Notes:   
 Fever and hypothermia are non-specific symptoms of infection and cannot 
be excluded from USI determination because they are clinically deemed due 
to another recognized cause. 
 All elements of the USI criterion must occur during the IWP (See IWP 
Definition Chapter 2 Identifying HAIs in NHSN). 
Comments  Report infections following circumcision in newborns as SST-CIRC. 
 If patient meets USI criteria and they also meet UTI criteria, report UTI 
only, unless the USI is a surgical site organ/space infection, in which case, 
only USI should be reported. 
 For NHSN reporting purposes, Urinary System Infection (USI) cannot be 
catheter associated, therefore, USI will only present as specific event type if 
urinary catheter status is marked “Neither”.    
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Figure 2: Identifying SUTI and ABUTI Flowchart 
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Monthly Summary Data 
Numerator Data: The Urinary Tract Infection (UTI) form (CDC 57.114) is used to collect 
and report each CAUTI that is identified during the month selected for surveillance.  The 
Instructions for Completion of Urinary Tract Infection form include brief instructions for 
collection and entry of each data element on the form.  USIs are never included in CAUTI 
data and are reported separately on the HAI Custom Event Form.  The UTI form includes 
patient demographic information and information on whether or not an indwelling urinary 
catheter was present.  Additional data include the specific criteria met for identifying the 
UTI, whether the patient developed a secondary bloodstream infection, whether the patient 
died, and the organisms isolated from cultures and their antimicrobial susceptibilities.  
Reporting Instructions: 
If no CAUTIs are identified during the month of surveillance, the ” Report No Events” box 
must be checked on the appropriate denominator summary screen, (for example , 
Denominators for Intensive Care Unit (ICU)/Other Locations (Not NICU or SCA/ONC).   
Denominator Data: Device days and patient days are used for denominators (See Key 
Terms chapter).The method of collecting device-day denominator data may differ depending 
on the location of patients being monitored. The following methods may be used:     
Table 3: Denominator Data Collection Methods 
Denominator Data 
Collection Method 
Details 
Manual, Daily 
(specifically, collected 
at the same time every 
day of the month) 
Denominator data (patient days and device days) should be collected 
at the same time, every day, for each location performing 
surveillance to ensure that differing collection methods don’t 
inadvertently result in device days being > patient days.   
The Instructions for Completion of Denominators for Intensive Care 
Unit (ICU)/Other Locations (Not NICU and SCA/ONC) and 
Instructions for Completion of Denominators for Specialty Care 
Areas (SCA)/Oncology (ONC) contain brief instructions for 
collection and entry of each data element on the form.  
Indwelling urinary catheter days, which are the number of patients 
with an indwelling urinary catheter device, are collected daily, at the 
same time each day, according to the chosen location using the 
appropriate form (CDC 57.117 and 57.118). These daily counts are 
summed and only the total for the month is entered into NHSN.  
Indwelling urinary catheter days and patient days are collected 
separately for each of the locations monitored. 
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Denominator Data 
Collection Method 
Details 
Manual, sampled 
once/week (collected at 
the same time on the 
same designated day, 
once per week) 
To reduce staff time spent collecting surveillance data, once weekly 
sampling of denominator data to generate estimated urinary catheter 
days may be used as an alternative to daily collection in non-
oncology ICUs and wards (see Notes below). Sampling may not be 
used in SCA/ONC locations or NICUs.  During the month, the 
number of patients in the location (patient-days) and the number of 
patients with an indwelling urinary catheter (urinary catheter-days) is 
collected on a designated day each week (for example, every 
Tuesday), at the same time during the month.  
 
Evaluations of this method have repeatedly shown that use of 
Saturday or Sunday generate the least accurate estimates of 
denominator data, and, therefore, these days should not be selected as 
the designated day.7-9 If the day designated for the collection of 
sampled data is missed, collect the data on the next available day 
instead.   
 
The following must be collected and entered into NHSN:  
1. The monthly total for patient-days, based on collection daily 
2. The sampled total for patient-days 
3. The sampled total urinary catheter-days 
 
When these data are entered, the NHSN application will calculate an 
estimate of urinary catheter-days.   
 
Notes:  
• To ensure the accuracy of estimated denominator data 
obtained by sampling, only ICU and ward location types with 
an average of 75 or more urinary catheter-days per month are 
eligible to use this method. A review of each location’s 
urinary catheter denominator data for the past 12 months in 
NHSN will help determine which locations are eligible.  
• The accuracy of estimated denominator data generated by 
sampling can be heavily influenced by incorrect or missing 
data. Careful implementation of data collection following the 
guidance in this protocol is essential to avoid erroneous 
fluctuations in rates or Standardized Infection Ratios (SIRs). 
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Denominator Data 
Collection Method 
Details 
Electronic For any location, denominator data from electronic sources (for 
example , urinary catheter days from electronic charting), may be 
used  after validation of a minimum 3 months proves the data to be 
within 5% (+/-)  of the manually-collected, once a day counts  
 
Perform the validation of electronic counts separately for each 
location conducting CAUTI surveillance. 
 
 
Data Analyses:  The Standardized Infection Ratio (SIR) is calculated by dividing the 
number of observed infections by the number of predicted infections. The number of 
predicted infections is calculated using probabilities from negative binomial regression 
models constructed from 2015 NHSN data, which represents a standard population. 
 
Notes:  
The SIR will be calculated only if the number of predicted CAUTIs (numPred) is ≥1 to help 
enforce a minimum precision criterion. 
 
While the CAUTI SIR can be calculated for single locations, the measure also allows you to 
summarize your data by multiple locations, adjusting for differences in the incidence of 
infection among the location types. For example, you will be able to obtain one CAUTI SIR 
adjusting for all locations reported. Similarly, you can obtain one CAUTI SIR for all ICUs in 
your facility.  
 
The SUR, or Standardized Utilization Ratio, is a risk-adjusted summary measure for device 
use. Similar to the SIR, the SUR can be calculated for single locations as well as be 
summarized across multiple locations 
 
The CAUTI rate per 1000 urinary catheter days is calculated by dividing the number of 
CAUTIs by the number of catheter days and multiplying the result by 1000.  The Urinary 
Catheter Utilization Ratio is calculated by dividing the number of urinary catheter days by 
the number of patient days. These calculations will be performed separately for the different 
types of ICUs, specialty care areas, and other locations in the institution, except for neonatal 
locations.  
 
Descriptive analysis output options of numerator and denominator data, such as line listings, 
frequency tables, and bar and pie charts are available in the NHSN application. SIRs, SURs 
and CAUTI rates and run charts are also available. Guides on using NHSN analysis features 
are available at:  www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html.  
Table 3. CAUTI Measures Available in NHSN 
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Measure Calculation Application 
CAUTI SIR 
The number of Observed CAUTIs  
The number of Predicted CAUTIs  
Both location 
specific and 
summarized 
measure 
CAUTI Rates 
The number of CAUTIs for a location               x 1000 
The number of Urinary Catheter Days for a location 
Location specific 
measure only 
Urinary Catheter 
SUR 
The number of Observed Urinary Catheter Days 
The number of Predicted Urinary Catheter Days 
Both location 
specific and 
summarized 
measure 
DUR 
The Urinary Catheter Days for a location 
The Patient Days for that location 
Location specific 
measure only 
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Surgical Site Infection (SSI) Event 
 
Introduction: In 2010, an estimated 16 million operative procedures were performed in acute 
care hospitals in the United States1. A recent prevalence study found that SSIs were the most 
common healthcare-associated infection, accounting for 31% of all HAIs among hospitalized 
patients2. The CDC healthcare-associated infection (HAI) prevalence survey found that there 
were an estimated 157,500 surgical site infections associated with inpatient surgeries in 20113.  
NHSN data included 16,147 SSIs following 849,659 operative procedures in all groups 
reported, for an overall SSI rate of 1.9% between 2006-20084. A 19% decrease in SSI related 
to 10 select procedures was reported between 2008 and 20135. 
 
While advances have been made in infection control practices, including improved operating 
room ventilation, sterilization methods, barriers, surgical technique, and availability of 
antimicrobial prophylaxis, SSIs remain a substantial cause of morbidity, prolonged 
hospitalization, and death. SSI is associated with a mortality rate of 3%, and 75% of SSI-
associated deaths are directly attributable to the SSI6.  
 
Surveillance of SSI with feedback of appropriate data to surgeons has been shown to be an 
important component of strategies to reduce SSI risk7-10. A successful surveillance program 
includes the use of epidemiologically-sound infection definitions and effective surveillance 
methods, stratification of SSI rates according to risk factors associated with SSI development, 
and data feedback8,9. A new CDC and Healthcare Infection Control Practices Advisory 
Committee guideline for the Prevention of Surgical Site Infection has been published in 2017 
and has replaced the previous Guideline for Prevention of Surgical Site Infection, 199910. 
 
Settings: Surveillance of surgical patients will occur in any inpatient and/or outpatient setting 
where the selected NHSN operative procedure(s) are performed. 
 
Requirements: Perform surveillance for SSI following at least one NHSN operative 
procedure category (ICD-10-PCS and CPT Mapping) as indicated in the Patient Safety 
Monthly Reporting Plan (CDC 57.106). Collect SSI (numerator) and operative procedure 
category (denominator) data on all procedures included in the selected procedure categories for 
at least one month to meet NHSN requirements, or as otherwise specified by mandates and 
other reporting requirements. A procedure must meet the NHSN definition of an operative 
procedure in order to be included in the surveillance. All procedures included in the NHSN 
monthly surveillance plan are followed for superficial, deep, and organ/space SSIs. SSI events 
where PATOS = Yes are reported to NHSN.  
 
SSI monitoring requires active, patient-based, prospective surveillance. Post-discharge and 
ante-discharge surveillance methods should be used to detect SSIs following inpatient 
surgeries and post-discharge surveillance for outpatient operative procedures.  
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For example, these methods include:  
 Review of medical records or surgery clinic patient records  
o Admission, readmission, ED, and OR logs 
o Patient charts for signs and symptoms of SSI 
o Lab, X-ray, other diagnostic test reports 
o Nurses and physician notes 
 Visit the ICU and wards – talk to primary care staff 
 Surgeon surveys by mail or telephone  
 Patient surveys by mail or telephone (though patients may have a difficult time 
assessing their infections). 
 
Any combination of these methods is acceptable for use; however, CDC criteria for SSI must 
be used. To minimize Infection Preventionists’ (IPs) workload of collecting denominator data, 
operating room data may be downloaded.  
(See file specifications at: https://www.cdc.gov/nhsn/pdfs/ps-analysis-
resources/ImportingProcedureData.pdf). 
 
An SSI will be associated with a particular NHSN operative procedure and the facility in 
which that procedure was performed. 
 
The International Classification of Diseases, 10th Revision Clinical Modifications (ICD-10-
CM/PCS) codes, which are defined by the ICD-10 Coordination and Maintenance Committee 
of the National Center for Health Statistics and the Centers for Medicare and Medicaid 
Services (CMS), are developed as a tool for classification of morbidity data. Their wide use 
enables the grouping of surgery types for the purpose of determining SSI rates. The ICD-10-
PCS mapping is located on the NHSN website in the SSI Protocol under “Supporting 
Materials”. Mapping is also provided for Current Procedural Terminology (CPT) codes to 
NHSN operative procedure categories to assist users in determining the correct NHSN code to 
report for facilities using CPT codes. The CPT NHSN operative procedure mapping is also 
found in the “Supporting Materials” section of the SSI Protocol on the NHSN website. The 
ICD-10-PCS and the CPT mapping documents include a general definition for each NHSN 
operative procedure category as well as a description for each individual operative procedure 
code.  
 
Notes: 
 The Infection Window Period, Present on Admission (POA), Hospital Associated 
Infection and Repeat Infection Timeframe definitions should not be applied to the SSI 
protocol. For more POA and PATOS details see numerator reporting instructions #2 
and #3. 
 ICD-10-PCS and CPT code fields remain optional fields in 2017.  
 The former NHSN Category “OTH - other” is not mapped to ICD-10-PCS and CPT 
codes. Any infections associated with procedures not included in one of the mapped 
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NHSN Operative Procedure Categories are not considered an NHSN surgical site 
infection, although it may be a healthcare-associated infection. 
 
Definition of an NHSN Operative Procedure 
 
An NHSN Operative Procedure is a procedure: 
 that is included in the ICD-10-PCS or CPT NHSN operative procedure code mapping 
And 
 takes place during an operation where at least one incision (including laparoscopic 
approach and cranial Burr holes) is made through the skin or mucous membrane, or 
reoperation via an incision that was left open during a prior operative procedure  
And 
 takes place in an operating room (OR), defined as a patient care area that met the 
Facilities Guidelines Institute’s (FGI) or American Institute of Architects’ (AIA) 
criteria for an operating room when it was constructed or renovated11. This may include 
an operating room, C-section room, interventional radiology room, or a cardiac 
catheterization lab. 
 
Exclusions: Otherwise eligible procedures that are assigned an ASA score of 6 are not eligible 
for NHSN SSI surveillance. 
 
Note: Incisional closure method is NOT a part of the NHSN operative procedure definition; all 
otherwise eligible procedures are included, regardless of closure type. Therefore both 
primarily closed procedures and those that are not closed primarily should be entered into the 
denominator data for procedures in the facility’s monthly reporting plan. Any SSIs attributable 
to either primarily closed or non-primarily closed procedures should be reported. 
 
NHSN Operative Procedure Category Mappings to ICD-10-PCS and CPT Codes: 
 
ICD-10-PCS and CPT Code mappings to NHSN operative procedures categories can be found 
in the “Supporting Materials” section of the SSI Protocol on the NHSN website. 
Denominator for Procedure Definitions: 
ASA physical status: Assessment by the anesthesiologist of the patient’s preoperative physical 
condition using the American Society of Anesthesiologists’ (ASA) Classification of Physical 
Status12,13. Patient is assigned one of the following: 
1. A normally healthy patient 
2. A patient with mild systemic disease 
3. A patient with severe systemic disease  
4. A patient with severe systemic disease that is a constant threat to life 
5. A moribund patient who is not expected to survive without the operation. 
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Note: Do NOT report procedures with an ASA physical status of 6 (a declared brain-dead 
patient whose organs are being removed for donor purposes) to NHSN. 
 
Date of event (DOE): For an SSI, the date of event is the date when the first element used to 
meet the SSI infection criterion occurs for the first time during the SSI surveillance period.  
The date of event must fall within the SSI surveillance period to meet SSI criteria. The type of 
SSI (superficial incisional, deep incisional, or organ/space) reported should reflect the deepest 
tissue layer involved in the infection during the surveillance period. The date of event should 
be the date that the patient met criteria for the deepest level of infection. Synonym: infection 
date.   
 
All symptoms required to meet an SSI criteria usually occur within a 7-10 day timeframe with 
no more than 2-3 days between elements. The elements must be relational to each other, 
meaning you should ensure the elements all associate to the SSI and this can only happen if 
elements occur in a relatively tight timeframe. Each case differs based on the individual 
elements occurring and the type of SSI.  
 
Diabetes: The NHSN SSI surveillance definition of diabetes indicates that the patient has a 
diagnosis of diabetes requiring management with insulin or a non-insulin anti-diabetic agent. 
This includes patients with “insulin resistance” who are on management with anti-diabetic 
agents. This also includes patients with a diagnosis of diabetes who are noncompliant with 
their diabetes medications. 
 
The ICD-10-CM diagnosis codes that reflect the diagnosis of diabetes are also acceptable for 
use to answer YES to the diabetes field question on the denominator for procedure entry if 
they are documented during the admission where the procedure is performed.  These codes are 
found on the NHSN website in the SSI section under “Supporting Materials”. The NHSN 
definition excludes patients with no diagnosis of diabetes. The definition also excludes patients 
who receive insulin for perioperative control of hyperglycemia but have no diagnosis of 
diabetes.  
 
Duration of operative procedure: The interval in hours and minutes between the 
Procedure/Surgery Start Time, and the Procedure/Surgery Finish Time, as defined by the 
Association of Anesthesia Clinical Directors (AACD)14: 
 Procedure/Surgery Start Time (PST): Time when the procedure is begun (for example, 
incision for a surgical procedure). 
 Procedure/Surgery Finish (PF): Time when all instrument and sponge counts are 
completed and verified as correct, all postoperative radiologic studies to be done in the 
OR are completed, all dressings and drains are secured, and the physicians/surgeons 
have completed all procedure-related activities on the patient. 
 
Emergency operative procedure: A procedure that is documented per the facilities protocol to 
be an Emergency or Urgent procedure.   
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General anesthesia: The administration of drugs or gases that enter the general circulation and 
affect the central nervous system to render the patient pain free, amnesic, unconscious, and 
often paralyzed with relaxed muscles. This does not include conscious sedation. 
 
Height: The patient’s most recent height documented in the medical record in feet (ft.) and 
inches (in.), or meters (m). 
 
NHSN Inpatient Operative Procedure: An NHSN operative procedure performed on a patient 
whose date of admission to the healthcare facility and the date of discharge are different 
calendar days. 
  
NHSN Outpatient Operative Procedure: An NHSN operative procedure performed on a patient 
whose date of admission to the healthcare facility and date of discharge are the same calendar 
day.  
 
Non-primary Closure is defined as closure of the surgical wound in a way which leaves the  
skin level completely open following the surgery. Closure of any portion of the skin represents 
primary closure (see below).  For surgeries with non-primary closure, the deep tissue layers 
may be closed by some means (with the skin level left open), or the deep and superficial layers 
may both be left completely open. An example of a surgery with non-primary closure would 
be a laparotomy in which the incision was closed to the level of the deep tissue layers, 
sometimes called “fascial layers” or “deep fascia,” but the skin level was left open. Another 
example would be an “open abdomen” case in which the abdomen is left completely open after 
the surgery. Wounds with non-primary closure may or may not be described as "packed” with 
gauze or other material, and may or may not be covered with plastic, “wound vacs,” or other 
synthetic devices or materials. 
 
Primary Closure is defined as closure of the skin level during the original surgery, regardless 
of the presence of wires, wicks, drains, or other devices or objects extruding through the 
incision. This category includes surgeries where the skin is closed by some means. Thus, if 
any portion of the incision is closed at the skin level, by any manner, a designation of primary 
closure should be assigned to the surgery.  
 
Note: If a procedure has multiple incision/laparoscopic trocar sites and any of the incisions are 
closed primarily then the procedure technique is recorded as primary closed.  
 
Scope: An instrument used to visualize the interior of a body cavity or organ. In the context of 
an NHSN operative procedure, use of a scope involves creation of several small incisions to 
perform or assist in the performance of an operation rather than use of a traditional larger 
incision (specifically, open approach). Robotic assistance is considered equivalent to use of a 
scope for NHSN SSI surveillance. See also Instructions for Completion of Denominator for 
Procedure Form and both Numerator Data and Denominator Data reporting instructions in this 
chapter. 
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ICD-10-PCS codes can be helpful in answering this scope question. The fifth character 
indicates the approach to reach the procedure site. A value of zero (0) as the fifth character 
represents an open approach and a value of four (4) as the fifth character represents a 
percutaneous endoscopic approach. If the fifth character of the ICD-10-PCS code is a four (4) 
then the field for scope can be YES.  
 
Secondary BSI Attribution Period for SSI: The secondary BSI attribution period for SSI is a 
17-day period that includes the date of event, 3 days prior, and 13 days after. For detailed 
instructions on determining whether identification of an organisms from a blood specimen 
represents a secondary BSI, refer to the Secondary BSI Guide (Appendix B of the BSI Event 
Protocol).  
 
Trauma: Blunt or penetrating injury occurring prior to the start of the procedure. 
Note: Complex trauma cases may require multiple trips to the OR during the same admission 
to repair the initial trauma. In such cases, trauma = yes.  
 
Weight: The patient’s most recent weight documented in the medical record in pounds (lbs.) or 
kilograms (kg) prior to or otherwise closest to the procedure. 
 
Wound class: An assessment of the degree of contamination of a surgical wound at the time of 
the operation. Wound class should be assigned by a person involved in the surgical procedure 
(for example, surgeon, circulating nurse, etc.). The wound class system used in NHSN is an 
adaptation of the American College of Surgeons wound classification schema.  
 
Based on feedback from external experts in the field of surgery, there are a group of NHSN 
procedures that can never be recorded as clean. These surgical procedure categories are APPY, 
BILI, CHOL, COLO, REC, SB, and VHYS. Therefore, for these procedures in the application 
clean is not an option on the drop down menu. 
 
All other surgical procedure categories can be entered as clean procedures within the NHSN 
application. For example CSEC, HYST, or OVRY can be a clean wound class if documented 
as such. 
 
Wounds are divided into four classes:  
 
1. Clean: An uninfected operative wound in which no inflammation is encountered and 
the respiratory, alimentary, genital, or uninfected urinary tracts are not entered. In 
addition, clean wounds are primarily closed and, if necessary, drained with closed 
drainage. Operative incisional wounds that follow nonpenetrating (blunt) trauma 
should be included in this category if they meet the criteria.  
 
Note: The clean wound classification level will not be available for denominator data 
entry for the following NHSN operative procedure categories: APPY, BILI, CHOL, 
COLO, REC, SB, and VHYS  
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2. Clean-Contaminated: Operative wounds in which the respiratory, alimentary, genital,
or urinary tracts are entered under controlled conditions and without unusual
contamination. Specifically, operations involving the biliary tract, appendix, vagina,
and oropharynx are included in this category, provided no evidence of infection or
major break in technique is encountered.
3. Contaminated: Open, fresh, accidental wounds. In addition, operations with major
breaks in sterile technique (for example, open cardiac massage) or gross spillage from
the gastrointestinal tract, and incisions in which acute, nonpurulent inflammation is
encountered, including necrotic tissue without evidence of purulent drainage (for
example, dry gangrene), are included in this category.
4. Dirty or Infected: Includes old traumatic wounds with retained devitalized tissue and
those that involve existing clinical infection or perforated viscera. This definition
suggests that the organisms causing postoperative infection were present in the
operative field before the operation.
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Table 1. Surgical Site Infection Criteria 
Criterion Surgical Site Infection (SSI) 
Superficial incisional SSI 
Must meet the following criteria: 
Date of event for infection occurs within 30 days after any NHSN 
operative procedure (where day 1 = the procedure date) 
AND 
involves only skin and subcutaneous tissue of the incision 
AND 
patient has at least one of the following: 
a. purulent drainage from the superficial incision.
b. organisms identified from an aseptically-obtained specimen
from the superficial incision or subcutaneous tissue by a culture or
non-culture based microbiologic testing method which is
performed for purposes of clinical diagnosis or treatment (for
example, not Active Surveillance Culture/Testing (ASC/AST).
c. superficial incision that is deliberately opened by a surgeon,
attending physician** or other designee and culture or non-culture
based testing is not performed.
    AND 
patient has at least one of the following signs or symptoms: pain or 
tenderness; localized swelling; erythema; or heat.  
d. diagnosis of a superficial incisional SSI by the surgeon or
attending physician** or other designee.
www.cdc.gov/nhsn/xls/icd10-pcs-pcm-nhsn-opc.xlsx 
www.cdc.gov/nhsn/xls/cpt-pcm-nhsn.xlsx 
** The term attending physician for the purposes of application of the 
NHSN SSI criteria may be interpreted to mean the surgeon(s), infectious 
disease, other physician on the case, emergency physician or physician’s 
designee (nurse practitioner or physician’s assistant). 
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Comments There are two specific types of superficial incisional SSIs: 
1. Superficial Incisional Primary (SIP) – a superficial incisional SSI
that is identified in the primary incision in a patient that has had an
operation with one or more incisions (for example, C-section
incision or chest incision for CBGB)
2. Superficial Incisional Secondary (SIS) – a superficial incisional
SSI that is identified in the secondary incision in a patient that has
had an operation with more than one incision (for example, donor
site incision for CBGB)
Reporting 
Instructions 
for 
Superficial 
SSI 
The following do not qualify as criteria for meeting the NHSN 
definition of superficial SSI: 
 Diagnosis/treatment of cellulitis (redness/warmth/swelling), by itself,
does not meet criterion “d” for superficial incisional SSI. Conversely,
an incision that is draining or that has organisms identified by culture
or non-culture based testing is not considered a cellulitis.
 A stitch abscess alone (minimal inflammation and discharge confined
to the points of suture penetration).
 A localized stab wound or pin site infection- Such an infection might
be considered either a skin (SKIN) or soft tissue (ST) infection,
depending on its depth, but not an SSI
Note: A laparoscopic trocar site for an NHSN operative procedure is
not considered a stab wound.
 Circumcision is not an NHSN operative procedure. An infected
circumcision site in newborns is classified as CIRC and is not an SSI
 An infected burn wound is classified as BURN and is not an SSI.
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Deep incisional SSI 
Must meet the following criteria: 
The date of event for infection occurs within 30 or 90 days after the 
NHSN operative procedure (where day 1 = the procedure date) according 
to the list in Table 2 
AND 
involves deep soft tissues of the incision (for example, fascial and muscle 
layers) 
AND 
patient has at least one of the following: 
a. purulent drainage from the deep incision.
b. a deep incision that spontaneously dehisces, or is deliberately
opened or aspirated by a surgeon, attending physician** or other
designee
          AND  
organism is identified by a culture or non-culture based 
microbiologic testing method which is performed for purposes of 
clinical diagnosis or treatment (for example, not Active 
Surveillance Culture/Testing (ASC/AST) or culture or non-culture 
based microbiologic testing method is not performed     
     AND 
patient has at least one of the following signs or symptoms: fever 
(>38°C); localized pain or tenderness. A culture or non-culture 
based test that has a negative finding does not meet this criterion. 
c. an abscess or other evidence of infection involving the deep
incision that is detected on gross anatomical or histopathologic
exam, or imaging test.
** The term attending physician for the purposes of application of the 
NHSN SSI criteria may be interpreted to mean the surgeon(s), infectious 
disease, other physician on the case, emergency physician or physician’s 
designee (nurse practitioner or physician’s assistant). 
Comments There are two specific types of deep incisional SSIs: 
1. Deep Incisional Primary (DIP) – a deep incisional SSI that is
identified in a primary incision in a patient that has had an
operation with one or more incisions (for example, C-section
incision or chest incision for CBGB)
2. Deep Incisional Secondary (DIS) – a deep incisional SSI that is
identified in the secondary incision in a patient that has had an
operation with more than one incision (for example, donor site
incision for CBGB)
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Organ/Space SSI 
Must meet the following criteria: 
Date of event for infection occurs within 30 or 90 days after the NHSN 
operative procedure (where day 1 = the procedure date) according to the 
list in Table 2 
AND 
infection involves any part of the body deeper than the fascial/muscle  
layers, that is opened or manipulated during the operative procedure 
AND 
patient has at least one of the following: 
a. purulent drainage from a drain that is placed into the organ/space
(for example, closed suction drainage system, open drain, T-tube
drain, CT guided drainage)
b. organisms are identified from fluid or tissue in the organ/space by
a culture or non-culture based microbiologic testing method which
is performed for purposes of clinical diagnosis or treatment (for
example, not Active Surveillance Culture/Testing (ASC/AST).
c. an abscess or other evidence of infection involving the
organ/space that is detected on gross anatomical or histopathologic
exam, or imaging test evidence suggestive of infection.
AND 
meets at least one criterion for a specific organ/space infection site listed 
in Table 3. These criteria are found in the Surveillance Definitions for 
Specific Types of Infections chapter. 
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Table 2. Surveillance Periods for SSI  Following Selected NHSN Operative Procedure 
Categories. Day 1 = the date of the procedure. 
30-day Surveillance
Code Operative Procedure Code Operative Procedure 
AAA Abdominal aortic aneurysm repair LAM Laminectomy 
AMP Limb amputation LTP Liver transplant 
APPY Appendix surgery NECK Neck surgery 
AVSD Shunt for dialysis NEPH Kidney surgery 
BILI Bile duct, liver or pancreatic surgery OVRY Ovarian surgery 
CEA Carotid endarterectomy PRST Prostate surgery 
CHOL Gallbladder surgery REC Rectal surgery 
COLO Colon surgery SB Small bowel surgery 
CSEC Cesarean section SPLE Spleen surgery 
GAST Gastric surgery THOR Thoracic surgery 
HTP Heart transplant THYR Thyroid and/or parathyroid 
surgery 
HYST Abdominal hysterectomy VHYS Vaginal hysterectomy 
KTP Kidney transplant XLAP Exploratory Laparotomy 
90-day Surveillance
Code Operative Procedure 
BRST Breast surgery 
CARD Cardiac surgery 
CBGB Coronary artery bypass graft with both chest and donor site incisions 
CBGC Coronary artery bypass graft with chest incision only 
CRAN Craniotomy 
FUSN Spinal fusion 
FX Open reduction of fracture 
HER Herniorrhaphy 
HPRO Hip prosthesis 
KPRO Knee prosthesis 
PACE Pacemaker surgery 
PVBY Peripheral vascular bypass surgery 
VSHN Ventricular shunt 
Note: Superficial incisional SSIs are only followed for a 30-day period for all procedure types. 
Secondary incisional SSIs are only followed for a 30-day period regardless of the surveillance 
period for the primary site. 
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Table 3. Specific Sites of an Organ/Space SSI. 
(Criteria for these sites can be found in the Surveillance Definitions for Specific Types of 
Infections chapter). 
Note: Appendix  contains a list of all NHSN operative procedure groups and the site specific 
SSIs that that may be attributable for each group.  
Numerator Data: All patients having any of the procedures included in the selected NHSN 
operative procedure category(s) are monitored for SSI. The Surgical Site Infection (SSI) form 
is completed for each SSI. If no SSI events are identified during the surveillance month, check 
the “Report No Events” field in the Missing PA Events tab of the Incomplete/Missing List. 
The Instructions for Completion of the Surgical Site Infection form include brief instructions 
for collection and entry of each data element on the form. The SSI form includes patient 
demographic information and information about the operative procedure, including the date 
and type of procedure. Information about the SSI includes the date of SSI, specific criteria met 
for identifying the SSI, when/how the SSI was detected, whether the patient developed a 
secondary bloodstream infection, whether the patient died, the organism(s) identified and the 
organisms’ antimicrobial susceptibilities. 
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SSI Event Reporting Instructions: 
1. Excluded organisms: Well-known community associated organisms (organisms
belonging to the following genera: Blastomyces, Histoplasma, Coccidioides,
Paracoccidioides, Cryptococcus and Pneumocystis) and/or organisms associated with
latent infections (for example, herpes zoster [shingles], herpes simplex, syphilis, or
tuberculosis) are excluded from meeting SSI criteria.
2. Attributing SSI to an NHSN procedure when there is evidence of infection at the
time of the primary surgery: The Present on Admission (POA) definition does not
apply to the SSI protocol. If evidence of infection is present at the time of the
procedure and the patient meets the NHSN SSI criteria during the SSI surveillance
period, an SSI  is attributed to the procedure (see PATOS below). A high wound class
is not an exclusion for a patient later meeting criteria for an SSI, but in most cases is
included as a risk factor for SSI in risk modeling.
3. Infection present at time of surgery (PATOS): PATOS denotes that there is
evidence of an infection or abscess at the start of or during the index surgical procedure
(in other words, it is present preoperatively). PATOS is a YES/NO field on the SSI
Event form. The evidence of infection or abscess must be noted/documented
intraoperatively in an operative note or report of surgery. Only select PATOS = YES if
it applies to the depth of SSI that is being attributed to the procedures (for example, if a
patient has evidence of an intraabdominal infection at the time of surgery and then later
returns with an organ/space SSI the PATOS field would be selected as a YES. If the
patient returned with a superficial or deep incisional SSI the PATOS field would be
selected as a NO). The patient does not have to meet the NHSN definition of an SSI at
the time of the primary procedure but there must be notation that there is evidence of
an infection or abscess present at the time of surgery.  PATOS is not necessarily
diagnosis driven.
 The use of the ending “itis” in an operative note/report does not necessarily
meet PATOS, as it may only reflect inflammation which is not infectious in
nature (for example, diverticulitis, peritonitis, and appendicitis)
 Identification of an organism alone using culture or non-culture based
microbiologic testing method or on a pathology report from a surgical specimen
does not = PATOS (specifically, a positive culture/path report without surgical
documentation of infection is not PATOS = yes).
 The following verbiage alone without specific mention of infection does not
meet the PATOS definition: colon perforation, necrosis, gangrene, fecal
spillage, nicked bowel during procedure, or a note of inflammation.
 Fresh trauma resulting in a contaminated case does not necessarily meet the
PATOS requirement. For example, a fresh gunshot wound to the abdomen will
be a trauma case with a high wound class but there would not have been time
for infection to develop.
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 PATOS can be met when an abscess is noted, there is mention of infection in
the OR note, purulence or pus is noted, or “feculent peritonitis” is noted, etc.
An infected appendix that has ruptured will meet PATOS =Yes, if the patient
has a subsequent intraabdominal organ space SSI.
Example: 
1. Patient admitted with an acute abdomen. Sent to OR for an XLAP where there is a
finding of an abscess due to ruptured appendix and an APPY is performed. Patient
returns two weeks later and meets criteria for an organ/space IAB SSI. The
PATOS field would be selected as YES on the SSI event since an abscess was
noted at the time of surgery in the same level as the subsequent SSI.
2. Patient is admitted with a ruptured diverticulum. In the OR note the surgeon
documents that there are multiple abscesses in the intraabdominal cavity. Patient
returns three weeks later and meets criteria for a superficial SSI. The PATOS field
would be selected as NO since there was no documentation of evidence of
infection or abscess of the superficial area at the time of the procedure.
3. During an unplanned cesarean section (CSEC) the surgeon nicks the bowel and
there is contamination of the intraabdominal cavity. One week later the patient
returns and meets criteria for an organ/space OREP (other reproductive) SSI. The
PATOS field would be selected as NO since there was no documentation of
evidence of infection or abscess at the time of the CSEC. The colon nick was a
complication but there was no infection present at the time of surgery.
4. Patient undergoes a foot amputation (AMP) due to “dry-gangrene” of the foot from
chronic ischemia.  There is no evidence of infection at the time of surgery.   The
word gangrene is not sufficient to qualify for infection.  The patient returns two
weeks later and has a superficial SSI. The PATOS field would be selected as NO
since there was no documentation of evidence of infection or abscess at the time of
AMP-amputation
Note: For more information about PATOS see: PATOS-Infection 
4. Multiple tissue levels are involved in the infection: The type of SSI (superficial
incisional, deep incisional, or organ/space) reported should reflect the deepest tissue
layer involved in the infection during the surveillance period. The date of event should
be the date that the patient met criteria for the deepest level of infection:
 Report infection that involves the organ/space as an organ/space SSI, whether
or not it also involves the superficial or deep incision sites.
 Report infection that involves the superficial and deep incisional sites as a deep
incisional SSI.
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 If an SSI started as a deep incisional SSI  on day 10 of the SSI surveillance 
period and then a week later, (day 17 of the SSI surveillance period) meets 
criteria for an organ space  SSI the date of event would be the date of the organ 
space  SSI. 
 
5. Reporting of SSI after a non-primary closure: If a patient develops an SSI after a 
non-primary closure it should be attributed to that procedure if it meets criteria for an 
SSI within the appropriate surveillance period. 
 
6. Attributing SSI to a NHSN procedure when several are performed on different 
dates: If a patient has several NHSN operative procedures performed on different dates 
prior to an infection, attribute the SSI to the operative procedure that was performed 
most closely in time prior to the infection date, unless there is evidence that the 
infection was associated with a different operation.  
 
Note: For multiple NHSN operative procedures performed within a 24 hour period, see    
Denominator Reporting Instruction #9. 
 
7. Attributing SSI to NHSN procedures that involve multiple primary incision sites: 
If multiple primary incision sites of the same NHSN operative procedure become 
infected, only report as a single SSI, and assign the type of SSI (superficial incisional, 
deep incisional, or organ/space) that represents the deepest tissue level involved at any 
of the infected sites. For example:  
 If one laparoscopic incision meets criteria for a superficial incisional SSI and 
another meets criteria for a deep incisional SSI, only report one deep incisional 
SSI.  
 If one or more laparoscopic incision sites meet criteria for superficial incisional 
SSI but the patient also has an organ/space SSI related to the laparoscopic 
procedure, only report one organ/space SSI. 
 If an operative procedure is limited to a single breast and involves multiple 
incisions in that breast that become infected, only report a single SSI.  
 In a colostomy formation or reversal (take down) procedure, the stoma and 
other abdominal incision sites are considered primary incisions.  If both the 
stoma and another abdominal incision site develop superficial incisional SSI, 
report only as one SSI (SIP). 
 
8. Attributing SSI to NHSN procedures that have secondary incision sites: Certain 
procedures can involve secondary incisions (specifically the following, BRST, CBGB, 
CEA, FUSN, PVBY, REC, and VSHN). The surveillance period for all secondary sites 
is 30 days, regardless of the required deep incisional or organ/space SSI surveillance 
period for the primary incision site(s) (Table 2). Procedures meeting this designation 
are reported as only one operative procedure. For example: 
 A saphenous vein harvest incision site in a CBGB procedure is considered the 
secondary incision. One CBGB procedure is reported, the saphenous vein 
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harvest site is monitored for 30 days after surgery for SSI, and the chest 
incision is monitored for 90 days. If the patient has a superficial infection of the 
leg site and a deep incisional SSI of the chest site two SSIs are reported. 
 A tissue harvest site (for example, Transverse Rectus Abdominis
Myocutaneous [TRAM] flap) in a BRST procedure is considered the secondary
incision site. One BRST procedure is reported, and if the secondary incision
gets infected, report as either SIS or DIS as appropriate.
9. SSI detected at another facility: It is required that if an SSI is detected at a facility
other than the one in which the operation was performed, the IP of the index facility
will be provided with enough detail so the infection can be reported to NHSN. When
reporting the SSI, the index facility should indicate that Detected = RO – (Readmission
to facility other than where procedure was performed).
10. SSI Attribution after Multiple types of NHSN procedures are performed during a
single trip to the OR: If more than one NHSN operative procedure category was
performed through a single incision/laparoscopic sites during a single trip to the
operating room, attribute the SSI to the procedure that is thought to be associated with
the infection. If it is not clear, as is often the case when the infection is an incisional
SSI, use the NHSN Principal Operative Procedure Category Selection Lists (Table 4) to
select the operative procedure to which the SSI should be attributed. For example, if a
patient develops SSI after a single trip to the OR in which both a COLO and SB were
performed, and the source of the SSI is not apparent, assign the SSI to the COLO
procedure.
11. SSI following invasive manipulation/accession of the operative site: An SSI will not
be attributed if the following 3 criteria are ALL met:
• during the post-operative period the surgical site is without evidence of
infection and,
• an invasive manipulation/accession of the site is performed for diagnostic or
therapeutic purposes (for example, needle aspiration, accession of ventricular
shunts, accession of breast expanders) and,
• an infection subsequently develops in a tissue level which was entered during
the manipulation/accession.
Tissue levels that are BELOW the deepest entered level will be eligible for SSI.  For 
example, a superficial debridement following a COLO procedure, where the 
muscle/fascia and organ/space was not entered, a subsequent organ/space SSI 
following the debridment may be an SSI attributable to the index COLO procedure.  
This reporting instruction does NOT apply to closed manipulation (for example, closed 
reduction of a dislocated hip after an orthopedic procedure). Invasive manipulation 
does not include wound packing, or changing of wound packing materials as part of 
postoperative care.  
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12. Reporting instructions for post-operative infection scenarios: An SSI that
otherwise meets the NHSN definitions should be reported to NHSN without regard to
post-operative accidents, falls, inappropriate showering or bathing practices, or other
occurrences that may or may not be attributable to patients’ intentional or unintentional
postoperative actions. SSI should also be reported regardless of the presence of certain
skin conditions (for example, dermatitis, blister, impetigo) that occur near an incision,
and regardless of the possible occurrence of a “seeding” event from an unrelated
procedure (for example, dental work). This instruction concerning various
postoperative circumstances is necessary to reduce subjectivity and data collection
burden.
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Table 4. NHSN Principal Operative Procedure Category Selection Lists 
(The categories with the highest risk of SSI are listed before those with lower risks). 
Denominator Data: For all patients having any of the procedures included in the NHSN 
Operative Procedure category(s) for which SSI surveillance is being performed during the 
month, complete the Denominator for Procedure form. The data are collected individually for 
each operative procedure performed during the month specified on the Patient Safety Monthly 
Reporting Plan. The Instructions for Completion of the Denominator for Procedure Form 
include brief instructions for collection and entry of each data element on the form.  
Priority Code Abdominal  Operations 
1 LTP Liver transplant 
2 COLO Colon surgery 
3 BILI Bile duct, liver or pancreatic surgery 
4 SB Small bowel surgery 
5 REC Rectal surgery 
6 KTP Kidney transplant 
7 GAST Gastric surgery 
8 AAA Abdominal aortic aneurysm repair 
9 HYST Abdominal hysterectomy 
10 CSEC Cesarean section 
11 XLAP Laparotomy 
12 APPY Appendix surgery 
13 HER Herniorrhaphy 
14 NEPH Kidney surgery 
15 VHYS Vaginal Hysterectomy 
16 SPLE Spleen surgery 
17 CHOL Gall bladder surgery 
18 OVRY Ovarian surgery 
Priority Code Thoracic Operations 
1 HTP Heart transplant 
2 CBGB Coronary artery bypass graft with donor incision(s) 
3 CBGC Coronary artery bypass graft, chest incision only 
4 CARD Cardiac surgery 
5 THOR Thoracic surgery 
Priority Code Neurosurgical (Brain/Spine) Operations 
1 VSHN Ventricular shunt 
2 CRAN Craniotomy 
3 FUSN Spinal fusion 
4 LAM Laminectomy 
Priority Code Neck Operations 
1 NECK Neck surgery 
2 THYR Thyroid and or parathyroid surgery 
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Denominator Reporting Instructions: 
 
1. Closure type: Incisional closure type does not exclude a procedure from SSI surveillance.  
All otherwise eligible procedures are included in the denominator reporting, regardless of 
closure type. The closure technique is entered for each denominator for procedure. If a 
procedure has multiple incision sites and any of the incisions are closed primarily then the 
procedure is entered as a primary closure. 
 
Note: If a patient returns to the OR within 24 hours of the end of the first procedure, assign 
the surgical wound closure that applies when the patient leaves the OR from the first 
operative procedure. 
 
2. Wound class: A high wound class is not an exclusion for denominator reporting. If the 
procedure meets the definition of an NHSN operative procedure it should be reported in 
the denominator data regardless of wound class. NHSN will use the wound class for risk 
adjustment, as appropriate. 
 
3. Different operative procedure categories performed during same trip to the OR: If 
procedures in more than one NHSN operative procedure category are performed during the 
same trip to the operating room through the same or different incisions, a Denominator for 
Procedure form is reported for each NHSN operative procedure category being monitored. 
For example, if a CARD and CBGC are done through the same incision, a Denominator 
for Procedure form is reported for each. In another example, if following a motor vehicle 
accident, a patient has an open reduction of fracture (FX) and splenectomy (SPLE) 
performed during the same trip to the operating room and both procedure categories are 
being monitored, complete a Denominator for Procedure form for each.  
EXCEPTION: If a patient has both a CBGC and CBGB during the same trip to the 
operating room, report only as a CBGB. Only report as a CBGC if there is only a chest 
incision. CBGB and CBGC are never reported for the same patient for the same trip to the 
operating room. 
 
4. Duration of the procedure when more than one category of NHSN operative 
procedure is performed through the same incision: If more than one NHSN operative 
procedure category is performed through the same incision during the same trip to the 
operating room, record the combined duration of all procedures, which is the time from 
procedure/surgery start time to procedure/surgery finish time. For example, if a CBGC and 
a CARD are performed on a patient during the same trip to the operating room, the time 
from start time to finish time is reported for both operative procedures. 
 
5. Duration of Operative procedures if patient has two different NHSN operative 
procedures performed via separate incisions on the same trip to the OR; try to 
determine the correct duration for each separate procedure (if this is documented), 
otherwise, take the time for both procedures and split it evenly between the two.   
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6. Same operative procedure category but different ICD-10-PCS or CPT codes during
same trip to the OR: If procedures of different ICD-10-PCS or CPT codes from the same
NHSN operative procedure category are performed through the same incision/laparoscopic
sites, record only one procedure for that category. For example, a facility is performing
surveillance for CARD procedures. A patient undergoes a replacement of both the mitral
and tricuspid valves during the same trip to the operating room. Complete one CARD
Denominator for Procedure form because both procedures are in the same operative
procedure category [CARD].
7. For revision HPRO and KPRO procedures: If total or partial revision HPRO or KPRO
is performed, determine if any of the ICD-10-PCS/CM diagnosis or procedure codes
indicating infection (see link below) were coded for that joint in the 90 days prior to and
including the index HPRO or KPRO revision. If any of the specified codes are recorded,
indicate on the denominator form that the revision was associated with ‘prior infection at
index joint’ = YES. Note that the ‘prior infection at index joint’ variable only applies to
revision HPRO and KPRO. The cases designated ‘prior infection at index joint’ = yes
should be validated before the procedure is submitted to NHSN. This validation is
necessary to ensure the code is aligned with the index joint revision. The ICD-10-PCS/CM
code mapping guidance is found on the NHSN website in the SSI section under
“Supporting Materials.”
8. Same NHSN operative procedure via separate incisions: For operative procedures that
can be performed via separate incisions during same trip to operating room (specifically
the following, AMP, BRST, CEA, FUSN, FX, HER, HPRO, KPRO, LAM, NEPH,
OVRY, PVBY), separate Denominator for Procedure forms are completed. To document
the duration of the procedures, indicate the procedure/surgery start time to
procedure/surgery finish time for each procedure separately or, alternatively, take the total
time for the procedures and split it evenly between procedures.
Notes: 
 A COLO procedure with a colostomy formation is entered as one COLO procedure.
 Laparoscopic hernia repairs are considered one procedure, regardless of the number of
hernias that are repaired in that trip to the OR. In most cases there will be only one
incision time documented for this procedure. If more than one time is documented,
total the durations. Open (specifically, non-laparoscopic) hernia repairs are reported as
one procedure for each hernia repaired via a separate incision, (specifically, if two
incisions are made to repair two defects), then two procedures will be reported. It is
anticipated that separate incision times will be recorded for these procedures. If not,
take the total time for both procedures and split it evenly between the two.
9. More than one operative procedure through same incision within 24 hours: If a
patient goes to the operating room more than once during the same admission and another
procedure is performed through the same incision and if the start time of the second
procedure is within 24 hours of the finish time of the original operative incision, report
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only one Denominator for Procedure form for the original procedure, combining the 
durations for both procedures based on the procedure start times and finish times for both 
procedures. For example, a patient has a CBGB lasting 4 hours. He returns to the OR six 
hours later for another NHSN operative procedure via the same incision (for example, 
CARD). The second operation has duration of 1.5 hours. Record the operative procedure 
as one CBGB and the duration of operation as 5 hour 30 minutes. If the wound class has 
changed, report the higher wound class. If the ASA class has changed, report the higher 
ASA class. Do not report the CARD procedure in your denominator data.   
Note: When the patient returns to the OR within 24 hours of the end of the first procedure 
assign the surgical wound closure technique that applies when the patient leaves the OR 
from the first operative procedure. 
10. Patient expires in the OR: If a patient expires in the operating room, do not complete a
Denominator for Procedure form. This operative procedure is excluded from the
denominator.
11. HYST or VHYS: When assigning the correct ICD-10-PCS or CPT hysterectomy
procedure codes, a medical record coder must determine what structures were detached
and how they were detached based on the medical record documentation.
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Data Analyses: The Standardized Infection Ratio (SIR) is calculated by dividing the number 
of observed infections by the number of predicted (expected) infections. The number of 
predicted infections is calculated using SSI probabilities estimated from multivariate logistic 
regression models constructed from NHSN data during a baseline time period, which 
represents a standard population’s SSI experience4. The procedures/SSI occurring in adults are 
modeled separately from those occurring in pediatrics.  
There are three main SSI SIR Models available from NHSN, each briefly described in the table 
below. The first two models, the All SSI SIR and the Complex A/R SSI SIR models, are 
available for procedures/SSI occurring in both adults and pediatric patients, while the third 
model, the Complex 30-day SSI SIR is available for procedures/SSI occurring in adults only. 
All SSI SIR 
Model 
 Includes only inpatient procedures (under the 2015 baselilne)
 Includes Superficial, Deep & Organ/Space SSIs
 Superficial & Deep incisional SSIs limited to primary incisional SSIs only
 Includes SSIs identified on admission, readmission & via post-discharge
surveillance
Complex 
A/R SSI 
Model 
 Includes only Deep incisional primary SSIs & Organ/Space SSIs
 Includes only SSIs identified on Admission/Readmission to facility where
procedure was performed
 Includes only inpatient procedures
 Used for the HAI Progress Report, published annually by CDC
Complex 
30-day SSI
model (used
for CMS
IPPS)
 Includes only in-plan, inpatient COLO and HYST procedures in adult
patients (i.e., ≥ 18 years of age)
 Includes only deep incisional primary SSIs and organ/space SSIs with an
event date within 30 days of the procedure
 Includes SSIs identified on admission, readmission & via post-discharge
surveillance
 Uses Diabetes, ASA score, gender, age, BMI, oncology hospital and
closure technique to determine risk for COLO (under the 2015
baseline, BS2)
Diabetes, ASA score, age, BMI and oncology hospital to determine
risk for HYST (under the 2015 baseline, BS2)
 NOTE: The Complex 30-day SSI model, under the 2006-2008 baseline,
BS1, uses only age and ASA to determine risk for both COLO and HYST
(BS1 applies to data up to 2016)
 Used only for CMS IPPS reporting and for public reporting on Hospital
Compare
While the SSI SIR can be calculated for single procedure categories and for specific surgeons, 
the measure also allows you to summarize your data across multiple procedure categories 
while adjusting for differences in the estimated probability of infection among the patients 
included across the procedure categories. For example, you will be able to obtain one SSI SIR 
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adjusting for all procedures reported. Alternatively, you can obtain one SSI SIR for all colon 
surgeries (COLO) only within your facility. 
Additional Notes about SSI SIRS: 
1. Rebaseline of NHSN data: The new baseline, termed BS2, and updated risk-
adjustments of HAI data using the 2015 NHSN data is available in the application as of
January 2017. The new baseline can be applied to 2015 data and forward. The older
baseline, termed BS1, which used the 2006-2008 NHSN data, will also be available in
the application and may be applied to only the 2016 data and older.
2. Closure technique: All of the SSI SIRs that use the 2006-2008 SSI baseline data will
include only those procedures that were reported with a primary closure method.3  All
of the SSI SIRs that use the 2015 baseline data will include all procedures that were
reported with primary or other than primary closure methods.
3. Infection present at time of surgery (PATOS): All of the SSI SIR reports that use the
2006-2008 SSI baseline will include SSIs that are reported as present at time of
surgery. Meaning the PATOS event is included in the numerator of the SIR and the
procedure from which the event occurred is included in the denominator of the SIR. All
of the SSI SIR reports that use the new 2015 SSI baseline will exclude SSIs that are
reported as present at time of surgery from both the numerator and denominator.
Meaning the PATOS event is excluded in the numerator of the SIR and the procedure
from which the event occurred is excluded in the denominator of the SIR.
4. SIRs based on Procedure Date: SSIs will be included in the numerator of an SIR
based on the date of procedure, not the date of event. This is because the procedure
carries the risk for the infection/SSI.
5. Calculation of the SIR: The SIR will be calculated only if the number of predicted
HAIs (“numPred” in the NHSN application, previously known as the number of
expected HAIs, “numExp”) is ≥ 1 to help enforce a minimum precision criterion.
SIR = Observed (O) HAIs 
          Predicted (P) HAIs 
SSI rates per 100 operative procedures are calculated by dividing the number of SSIs by the 
number of specific operative procedures and multiplying the results by 100. SSIs will be 
included in the numerator of a rate based on the date of procedure, not the date of event. Using 
the advanced analysis feature of the NHSN application, SSI rate calculations can be performed 
separately for the different types of operative procedures and stratified by the basic risk index.  
Descriptive analysis options of numerator and denominator data are available in the NHSN 
application, such as line listings, frequency tables, and bar and pie charts. SIRs and SSI rates 
and run charts are also available. Guides on using NHSN analysis features are available from: 
www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html 
January 2018 9-25
Procedure-associated Module 
SSI 
APPENDIX.  SSI specific event types attributed to each NHSN procedure category. 
Procedure code Specific Event Code 
AAA - Abdominal aortic aneurysm repair DIP - Deep Incisional Primary 
ENDO - Endocarditis 
GIT - Gastrointestinal tract 
IAB - Intraabdominal, not specified elsewhere 
SIP - Superficial Incisional Primary 
VASC - Arterial or venous infection 
AMP - Limb amputation BONE - Osteomyelitis 
DIP - Deep Incisional Primary 
JNT - Joint or bursa 
SIP - Superficial Incisional Primary 
APPY - Appendix surgery DIP - Deep Incisional Primary 
GIT - Gastrointestinal tract 
IAB - Intraabdominal, not specified elsewhere 
SIP - Superficial Incisional Primary 
AVSD - AV shunt for dialysis DIP - Deep Incisional Primary 
SIP - Superficial Incisional Primary 
VASC - Arterial or venous infection 
BILI - Bile duct, liver or pancreatic surgery DIP - Deep Incisional Primary 
GIT - Gastrointestinal tract 
IAB - Intraabdominal, not specified elsewhere 
SIP - Superficial Incisional Primary 
BRST - Breast surgery BRST - Breast abscess or mastitis 
DIP - Deep Incisional Primary 
DIS - Deep Incisional Secondary 
SIP - Superficial Incisional Primary 
SIS - Superficial Incisional Secondary 
CARD - Cardiac surgery BONE - Osteomyelitis 
CARD - Myocarditis or pericarditis 
DIP - Deep Incisional Primary 
ENDO - Endocarditis 
IAB - Intraabdominal, not specified elsewhere 
LUNG - Other infections of the lower respiratory tract 
MED - Mediastinitis 
SIP - Superficial Incisional Primary 
VASC - Arterial or venous infection 
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Procedure code Specific Event Code 
CBGB - Coronary bypass with chest & donor 
incisions 
BONE - Osteomyelitis 
CARD - Myocarditis or pericarditis 
DIP - Deep Incisional Primary 
DIS - Deep Incisional Secondary 
ENDO - Endocarditis 
IAB - Intraabdominal, not specified elsewhere 
LUNG - Other infections of the lower respiratory tract 
MED - Mediastinitis 
SIP - Superficial Incisional Primary 
SIS - Superficial Incisional Secondary  
VASC - Arterial or venous infection 
CBGC - Coronary bypass graft with chest 
incision 
BONE - Osteomyelitis 
CARD - Myocarditis or pericarditis 
DIP - Deep Incisional Primary 
ENDO - Endocarditis 
IAB - Intraabdominal, not specified elsewhere 
LUNG - Other infections of the lower respiratory tract 
MED - Mediastinitis 
SIP - Superficial Incisional Primary 
VASC - Arterial or venous infection 
CEA - Carotid endarterectomy DIP - Deep Incisional Primary 
DIS - Deep Incisional Secondary 
SIP - Superficial Incisional Primary 
SIS - Superficial Incisional Secondary 
VASC - Arterial or venous infection 
CHOL - Gallbladder surgery DIP - Deep Incisional Primary 
GIT - Gastrointestinal tract 
IAB - Intraabdominal, not specified elsewhere 
SIP - Superficial Incisional Primary 
COLO - Colon surgery DIP - Deep Incisional Primary 
GIT - Gastrointestinal tract 
IAB - Intraabdominal, not specified elsewhere 
OREP - Other infection of the male or female 
reproductive tract 
SIP - Superficial Incisional Primary 
USI - Urinary System Infection 
CRAN - Craniotomy BONE - Osteomyelitis 
DIP - Deep Incisional Primary 
IC - Intracranial infection 
MEN - Meningitis or ventriculitis  
SINU - Sinusitis 
SIP - Superficial Incisional Primary 
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Procedure code Specific Event Code 
CSEC - Cesarean section 
  
 
DIP - Deep Incisional Primary 
EMET - Endometritis 
GIT - Gastrointestinal tract 
IAB - Intraabdominal, not specified elsewhere 
OREP - Other infection of the male or female 
reproductive tract 
SIP - Superficial Incisional Primary 
USI - Urinary System Infection 
FUSN - Spinal fusion 
  
 
BONE - Osteomyelitis 
DIP - Deep Incisional Primary 
DIS - Deep Incisional Secondary 
DISC - Disc space infection 
IAB - Intraabdominal, not specified elsewhere 
IC - Intracranial infection 
LUNG - Other infections of the lower respiratory tract 
MEN - Meningitis or ventriculitis  
SA - Spinal abscess without meningitis 
SIP - Superficial Incisional Primary 
SIS - Superficial Incisional Secondary  
FX - Open reduction of fracture 
  
 
BONE - Osteomyelitis 
DIP - Deep Incisional Primary 
JNT - Joint or bursa 
SIP - Superficial Incisional Primary 
GAST - Gastric surgery 
  
  
 
DIP - Deep Incisional Primary 
GIT - Gastrointestinal tract 
IAB - Intraabdominal, not specified elsewhere 
LUNG - Other infections of the lower respiratory tract 
SIP - Superficial Incisional Primary 
HER - Herniorrhaphy 
  
  
DIP - Deep Incisional Primary 
IAB - Intraabdominal, not specified elsewhere 
SIP - Superficial Incisional Primary 
HPRO - Hip prosthesis 
  
  
  
BONE - Osteomyelitis 
DIP - Deep Incisional Primary 
PJI - Prosthetic joint infection 
SIP - Superficial Incisional Primary 
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Procedure code Specific Event Code 
HTP - Heart transplant BONE - Osteomyelitis 
CARD - Myocarditis or pericarditis 
DIP - Deep Incisional Primary 
ENDO - Endocarditis 
IAB - Intraabdominal, not specified elsewhere 
LUNG - Other infections of the lower respiratory tract 
MED - Mediastinitis 
SIP - Superficial Incisional Primary 
VASC - Arterial or venous infection 
HYST - Abdominal hysterectomy DIP - Deep Incisional Primary 
IAB - Intraabdominal, not specified elsewhere 
OREP - Other infection of the male or female 
reproductive tract 
SIP - Superficial Incisional Primary 
VCUF - Vaginal cuff infection 
KPRO - Knee prosthesis BONE - Osteomyelitis 
DIP - Deep Incisional Primary 
PJI - Prosthetic joint infection  
SIP - Superficial Incisional Primary 
KTP - Kidney transplant DIP - Deep Incisional Primary 
IAB - Intraabdominal, not specified elsewhere 
OREP - Other infection of the male or female 
reproductive tract 
SIP - Superficial Incisional Primary 
USI - Urinary System Infection 
VASC - Arterial or venous infection 
LAM - Laminectomy BONE - Osteomyelitis 
DIP - Deep Incisional Primary 
DISC - Disc space infection 
IAB - Intraabdominal, not specified elsewhere 
IC - Intracranial infection 
MEN - Meningitis or ventriculitis  
SA - Spinal abscess without meningitis 
SIP - Superficial Incisional Primary 
LTP - Liver transplant DIP - Deep Incisional Primary 
GIT - Gastrointestinal tract 
IAB - Intraabdominal, not specified elsewhere 
SIP - Superficial Incisional Primary 
VASC - Arterial or venous infection 
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Procedure code Specific Event Code 
NECK - Neck surgery DIP - Deep Incisional Primary 
EAR - Ear, mastoid infection 
ORAL - Oral cavity infection (mouth, tongue, or gums) 
SIP - Superficial Incisional Primary 
UR - Upper respiratory tract infection, pharyngitis, 
laryngitis, epiglottitis 
NEPH - Kidney surgery DIP - Deep Incisional Primary 
IAB - Intraabdominal, not specified elsewhere 
OREP - Other infection of the male or female 
reproductive tract 
SIP - Superficial Incisional Primary 
USI - Urinary System Infection 
OVRY - Ovarian surgery DIP - Deep Incisional Primary 
IAB - Intraabdominal, not specified elsewhere 
OREP - Other infection of the male or female 
reproductive tract 
SIP - Superficial Incisional Primary 
USI - Urinary System Infection 
PACE - Pacemaker surgery CARD - Myocarditis or pericarditis 
DIP - Deep Incisional Primary 
ENDO - Endocarditis 
IAB - Intraabdominal, not specified elsewhere 
SIP - Superficial Incisional Primary 
VASC - Arterial or venous infection 
PRST - Prostate surgery DIP - Deep Incisional Primary 
IAB - Intraabdominal, not specified elsewhere 
OREP - Other infection of the male or female 
reproductive tract 
SIP - Superficial Incisional Primary 
USI - Urinary System Infection 
PVBY - Peripheral vascular bypass surgery DIP - Deep Incisional Primary 
DIS - Deep Incisional Secondary 
SIP - Superficial Incisional Primary 
SIS - Superficial Incisional Secondary 
VASC - Arterial or venous infection 
REC - Rectal surgery DIP - Deep Incisional Primary 
DIS - Deep Incisional Secondary 
GIT - Gastrointestinal tract 
IAB - Intraabdominal, not specified elsewhere 
OREP - Other infection of the male or female 
reproductive tract 
SIP - Superficial Incisional Primary 
SIS - Superficial Incisional Secondary  
USI - Urinary System Infection 
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Procedure code Specific Event Code 
SB - Small bowel surgery DIP - Deep Incisional Primary 
GIT - Gastrointestinal tract 
IAB - Intraabdominal, not specified elsewhere 
OREP - Other infection of the male or female 
reproductive tract 
SIP - Superficial Incisional Primary 
USI - Urinary System Infection 
SPLE - Spleen surgery DIP - Deep Incisional Primary 
IAB - Intraabdominal, not specified elsewhere 
SIP - Superficial Incisional Primary 
THOR - Thoracic surgery BONE - Osteomyelitis 
BRST - Breast abscess or mastitis 
DIP - Deep Incisional Primary 
IAB - Intraabdominal, not specified elsewhere 
LUNG - Other infections of the lower respiratory tract 
SIP - Superficial Incisional Primary 
THYR - Thyroid and/or parathyroid surgery DIP - Deep Incisional Primary 
EAR - Ear, mastoid infection 
GIT - Gastrointestinal tract 
SIP - Superficial Incisional Primary 
UR - Upper respiratory tract infection, pharyngitis, 
laryngitis, epiglottitis 
VHYS - Vaginal hysterectomy DIP - Deep Incisional Primary 
IAB - Intraabdominal, not specified elsewhere 
OREP - Other infection of the male or female 
reproductive tract 
SIP - Superficial Incisional Primary 
USI - Urinary System Infection 
VCUF - Vaginal cuff infection 
VSHN - Ventricular shunt BONE - Osteomyelitis 
DIP - Deep Incisional Primary 
DIS - Deep Incisional Secondary 
IAB - Intraabdominal, not specified elsewhere 
IC - Intracranial infection 
LUNG – Other infections of the lower respiratory tract 
MEN - Meningitis or ventriculitis  
SA - Spinal abscess without meningitis 
SIP - Superficial Incisional Primary 
SIS - Superficial Incisional Secondary  
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Procedure code Specific Event Code 
XLAP - Exploratory laparotomy DIP - Deep Incisional Primary 
EMET - Endometritis 
GIT - Gastrointestinal tract 
IAB - Intraabdominal, not specified elsewhere 
OREP - Other infection of the male or female 
reproductive tract 
SIP - Superficial Incisional Primary 
USI - Urinary System Infection 
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Introduction:  Mechanical ventilation is an essential, life-saving therapy for patients with 
critical illness and respiratory failure. Studies have estimated that more than 300,000 patients 
receive mechanical ventilation in the United States each year [1-3]. These patients are at high 
risk for complications and poor outcomes, including death [1-5]. Ventilator-associated 
pneumonia (VAP), sepsis, Acute Respiratory Distress Syndrome (ARDS), pulmonary embolism, 
barotrauma, and pulmonary edema are among the complications that can occur in patients 
receiving mechanical ventilation; such complications can lead to longer duration of mechanical 
ventilation, longer stays in the ICU and hospital, increased healthcare costs, and increased risk of 
disability and death. Mortality in patients with acute lung injury on mechanical ventilation has 
been estimated to range from 24% in persons 15-19 years of age to 60% for patients 85 years and 
older [4]. 
 
Surveillance for ventilator-associated events in the National Healthcare Safety Network (NHSN) 
prior to 2013 was limited to VAP. For the year 2012, VAP incidence for various types of 
hospital units ranged from 0.0-4.4 per 1,000 ventilator days [6]. However, there is currently no 
valid, reliable definition for VAP, and even the most widely-used VAP criteria and definitions 
are neither sensitive nor specific [7-10].  
 
A particular difficulty with many commonly-used VAP definitions, including the NHSN PNEU 
definitions (revised in 2002), is that they require radiographic findings of pneumonia. Evidence 
suggests that chest radiograph findings do not accurately identify VAP. The subjectivity and  
variability inherent in chest radiograph technique, interpretation, and reporting make chest 
imaging ill-suited for inclusion in a definition algorithm to be used for the potential purposes of 
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public reporting, inter-facility comparisons, and pay-for-reporting and pay-for-performance 
programs. Another major difficulty with available VAP definitions is their reliance on specific 
clinical signs or symptoms, which are subjective and may be poorly or inconsistently 
documented in the medical record. The NHSN PNEU protocol includes multiple definition 
pathways and special criteria for selected patient populations (for example, children, 
immunocompromised patients), increasing its complexity.  
 
The limitations of VAP surveillance definitions have implications for prevention. Valid and 
reliable surveillance data are necessary for assessing the effectiveness of prevention strategies. It 
is notable that some of the most effective measures for improving outcomes of patients on 
mechanical ventilation do not specifically target pneumonia prevention [11-14].  
 
In 2011, CDC convened a Working Group composed of members of several stakeholder 
organizations to address the limitations of the NHSN PNEU definitions and propose a new 
approach to surveillance for Ventilator-Associated Events (VAE) for NHSN [15]. The 
organizations represented in the Working Group include: the Critical Care Societies 
Collaborative (the American Association of Critical-Care Nurses, the American College of Chest 
Physicians, the American Thoracic Society, and the Society for Critical Care Medicine); the 
American Association for Respiratory Care; the Association of Professionals in Infection Control 
and Epidemiology; the Council of State and Territorial Epidemiologists; the Healthcare Infection 
Control Practices Advisory Committee’s Surveillance Working Group; the Infectious Diseases 
Society of America; and the Society for Healthcare Epidemiology of America.  
 
The VAE surveillance definition algorithm developed by the Working Group and implemented 
in the NHSN in January 2013 is based on objective, streamlined, and potentially automatable 
criteria that identify a broad range of conditions and complications occurring in mechanically-
ventilated adult patients [16]. Several modifications to the VAE definitions have been made 
since January 2013. These modifications address issues raised by NHSN users and discussed 
with the Working Group. There are three definition tiers within the VAE algorithm: 1) 
Ventilator-Associated Condition (VAC); 2) Infection-related Ventilator-Associated 
Complication (IVAC); and 3) Possible VAP (PVAP). Data indicate that streamlined, objective 
algorithms to detect ventilator-associated complications (similar to the VAC tier of the VAE 
algorithm) are easily implemented, can make use of electronic health record systems to automate 
event detection, and identify events that are clinically important and associated with outcomes 
such as ICU and hospital length of stay and mortality [16,17]. Research suggests that most VACs 
are due to pneumonia, ARDS, atelectasis, and pulmonary edema [16]. These are significant 
clinical conditions that may be preventable. VAE rates and event characteristics in 2014 in adult 
inpatient locations reporting data to NHSN have been published [18]. 
 
NOTE: The VAE definition algorithm is for use in surveillance; it is not a clinical definition 
algorithm and is not intended for use in the clinical management of patients. Examples provided 
throughout this protocol and in the VAE “Frequently-Asked Questions” are for illustration 
purposes only and are not intended to represent actual clinical scenarios.  
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Settings:  Inpatient locations eligible to participate in VAE surveillance are those adult locations 
in acute care hospitals, long term acute care hospitals, and inpatient rehabilitation facilities where 
denominator data (ventilator and patient days) can be collected for patients. Such locations may 
include critical/intensive care units (ICU), specialty care areas (SCA), step-down units and 
wards. A complete listing of adult inpatient locations can be found in Chapter 15.  
 
NOTE: Non-acute care locations in acute care facilities are not eligible to participate in VAE 
surveillance.  
 
NOTE: It is not required to monitor for VAEs after discharge if a patient is transferred to another 
facility while still on mechanical ventilation.  However, VAEs discovered within 2 calendar days 
of discharge (where the day of discharge is day 1) should be reported to NHSN. No additional 
ventilator days are reported. 
 
Definitions:  
 
VAE: VAEs are identified by using a combination of objective criteria: deterioration in 
respiratory status after a period of stability or improvement on the ventilator, evidence of 
infection or inflammation, and laboratory evidence of respiratory infection. The following pages 
outline the criteria that must be used for meeting the VAE surveillance definitions (Figure 1).  To 
report VAEs, use the Ventilator-Associated Event form (CDC 57.112) and Instructions for 
Completion. 
 
NOTE: Patients must be mechanically ventilated for at least 4 calendar days to fulfill 
VAE criteria (where the day of intubation and initiation of mechanical ventilation is day 
1). The earliest date of event for VAE (the date of onset of worsening oxygenation) is day 
3 of mechanical ventilation. Line lists of VAE data elements demonstrating scenarios that 
meet and do not meet the VAE definitions are presented in “Frequently-Asked Questions 
(FAQs)” number (no.) 2 at the end of this chapter. 
 
NOTE: The baseline period of stability or improvement on the ventilator is defined as the 
2 calendar days immediately preceding the first day of increased daily minimum PEEP or 
FiO2, and must be characterized by ≥ 2 calendar days of stable or decreasing daily 
minimum FiO2 or PEEP values (specifically the daily minimum PEEP or FiO2 on the 
second day of the baseline period of stability or improvement must be equal to or less 
than the daily minimum PEEP or FiO2 on the first day of the baseline period of stability 
or improvement). The definitions of “daily minimum PEEP” and “daily minimum FiO2” 
are included below. Note that the minimum daily PEEP or FiO2 used for VAE 
surveillance is the lowest setting during a calendar day that was maintained for > 1 hour 
(see daily minimum PEEP and FiO2 definitions for exception to 1 hour requirement).  
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For the purposes of VAE surveillance, PEEP values between 0 cmH2O and 5 cmH2O will 
be considered equivalent. This means that patients with daily minimum PEEP values 
from 0 to 5 cmH2O must then have an increase in the daily minimum PEEP to at least 8 
cmH2O, sustained for at least 2 calendar days, to meet the VAC definition.  
 
EXAMPLE: In the example below, the baseline period is defined by mechanical 
ventilation (MV) days 1 through 4 (shaded in light gray), and the period of worsening 
oxygenation by MV days 5 and 6 (shaded in darker gray), where the daily minimum 
PEEP is ≥ 3 cmH2O greater than the daily minimum PEEP of the first day in the  baseline 
period. Note that there is no VAC on MV day 3, because PEEP values 0-5 cmH2O are 
considered equivalent for the purposes of this surveillance. 
 
 
 
  
 
 
  
 
 
EXAMPLE: In the example below, the baseline period is defined by mechanical 
ventilation (MV) days 1 through 4 (shaded in light gray), and the period of worsening 
oxygenation by MV days 5 and 6 (shaded in darker gray), where the daily minimum 
PEEP is ≥ 3 cmH2O greater than the daily minimum PEEP of the first day  in the baseline 
period. In this example, note that MV days 1-4 are considered a baseline period even 
though the daily minimum PEEP increases from 0 to 3 to 5 cmH2O during this time 
period—because PEEP values from 0-5 cmH2O are considered equivalent for the 
purposes of this surveillance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MV Day 
Daily minimum 
PEEP (cmH2O) 
Daily minimum 
FiO2 (oxygen concentration, %) 
VAE 
1     0 (5) 1.00 (100%) - 
2     0 (5) 0.50 (50%) - 
3 5  0.50 (50%) - 
4 5 0.50 (50%) - 
5 8 0.50 (50%) VAC 
6 8 0.50 (50%) - 
MV Day 
Daily minimum 
PEEP (cmH2O) 
Daily minimum 
FiO2 (oxygen concentration, %) 
VAE 
1      0 (5) 1.00 (100%) - 
2      0 (5) 0.50 (50%) - 
3      3 (5) 0.50 (50%) - 
4 5 0.50 (50%) - 
5 8 0.50 (50%) VAC 
6 8 0.50 (50%) - 
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EXAMPLE: In the example below, the baseline period is defined by mechanical 
ventilation (MV) days 3 and 4 (shaded in light gray), and the period of worsening 
oxygenation by MV days 5 and 6 (shaded in darker gray), where the daily minimum FiO2 
is ≥ 0.20 (20 points) over the daily minimum FiO2 of the first day in the baseline period. 
 
 
 
  
 
 
 
 
EXAMPLE: In the example below, there is no VAC, because the FiO2 on MV day 4 is 
higher than the FiO2 on MV day 3 (and therefore not stable or decreasing) – even though 
the FiO2 on MV days 3 and 4 meets the 20-point threshold when compared with the daily 
minimum FiO2 on MV days 5 and 6.  
 
 
 
 
 
 
 
 
 
NOTE: Patients on high frequency ventilation or extracorporeal life support are 
EXCLUDED from VAE surveillance.  
 
NOTE: Patients who are receiving a conventional mode of mechanical ventilation while 
in the prone position and patients who are receiving a conventional mode of mechanical 
ventilation while receiving nitric oxide therapy, helium-oxygen mixtures (heliox) or 
epoprostenol therapy are INCLUDED in VAE surveillance. 
 
NOTE: Patients on Airway Pressure Release Ventilation (APRV) or related modes (see 
FAQ nos. 22 and 23), are INCLUDED, but the VAE period of stability or improvement 
on the ventilator and the period of worsening oxygenation should be determined by 
changes in FiO2 only, since changes in PEEP as indicated in this surveillance algorithm 
may not be applicable to APRV. In addition, patients with VAE who are on APRV or 
related modes of mechanical ventilation can optionally be  indicated as such on the VAE 
Form (CDC 57.112). 
 
NOTE: VAEs are defined by a 14-day period, starting on the day of onset of worsening 
oxygenation (the event date, day 1). A new VAE cannot be identified or reported until 
this 14-day period has elapsed. See FAQ no. 4. 
MV Day 
Daily minimum 
PEEP (cmH2O) 
Daily minimum 
FiO2 (oxygen concentration, %) 
VAE 
1 8 1.00 (100%) - 
2 6 0.50 (50%) - 
3 5 0.40 (40%) - 
4 5 0.40 (40%) - 
5 6 0.70 (70%) VAC 
6 6 0.70 (70%) - 
MV Day 
Daily minimum 
PEEP (cmH2O) 
Daily minimum 
FiO2 (oxygen concentration, %) 
VAE 
1 8 1.0 (100%)  
2 6 0.50 (50%)  
3 5 0.35 (35%)  
4 5 0.40 (40%)  
5 6 0.70 (70%) No event 
6 6 0.70 (70%)  
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Date of event: The date of onset of worsening oxygenation. This is defined as the first calendar 
day in which the daily minimum PEEP or FiO2 increases above the thresholds outlined in the 
VAE definition algorithm (specifically day 1 of the required ≥ 2-day period of worsening 
oxygenation following a ≥ 2-day period of stability or improvement on the ventilator). 
 
EXAMPLE: A patient is intubated in the Emergency Room for severe community-
acquired pneumonia and admitted to the MICU (day 1). The patient stabilizes and 
improves on days 2-5, with a daily minimum FiO2 of 0.35 (35%) on days 4 and 5. On day 
6, the patient experiences respiratory deterioration, and requires a minimum FiO2 of 0.60 
(60%) on days 6 and 7, meeting the criteria for a VAC. The date of the VAC event is day 
6. 
 
NOTE: The “date of event” is NOT the date on which all VAE criteria have been met. It 
is the first day (of a ≥ 2-day period) on which either of the worsening oxygenation 
thresholds (for PEEP or FiO2) is met. 
 
VAE Window Period: This is the period of days around the event date (specifically the day of 
onset of worsening oxygenation) within which other VAE criteria must be met. It is usually a 5-
day period and includes the 2 days before, the day of, and the 2 days after the VAE event date 
(specifically the first day of worsening oxygenation, the day of VAE onset). There is an 
exception, however, in which the VAE Window Period is only 3 or 4 days, as follows: 
 
In cases where the VAE event date corresponds to MV day 3 or day 4, the window period 
described above may only be a 3-day or a 4-day window, because it can NOT include any 
days before the 3rd day of MV. For example, if the VAE event date is MV day 3, then the 
window period includes only the day of VAE onset and the 2 days after VAE onset 
(because the 2 days before VAE onset are before the 3rd day of MV). 
 
Positive End-Expiratory Pressure (PEEP): “A technique used in respiratory therapy in which 
airway pressure greater than atmospheric pressure is achieved at the end of exhalation by the 
introduction of a mechanical impedance to exhalation” [19]. In patients on mechanical 
ventilation, PEEP is one of the key parameters that can be adjusted depending on the patient’s 
oxygenation needs, and is typically in the range of 0 to 15 cmH2O. A sustained increase (defined 
later in this protocol) in the daily minimum PEEP of ≥ 3 cmH2O following a period of stability 
or improvement on the ventilator is one of two criteria that can be used in meeting the VAC 
definition. For the purposes of this surveillance, PEEP values from 0 to 5 cmH2O are considered 
equivalent.  
 
Fraction of inspired oxygen (FiO2): The fraction of oxygen in inspired gas. For example, the 
FiO2 of ambient air is 0.21; the oxygen concentration of ambient air is 21%. In patients on 
mechanical ventilation, the FiO2 is one of the key parameters that can be adjusted depending on 
the patient’s oxygenation needs, and is typically in the range of 0.30 (oxygen concentration of 
30%) to 1.0 (oxygen concentration of 100%). A sustained increase (defined later in this protocol) 
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in the daily minimum FiO2 of ≥ 0.20 (20%) following a period of stability or improvement on the 
ventilator is the second of the two criteria that can be used in meeting the VAC definition. 
 
Daily minimum PEEP: The lowest value of PEEP during a calendar day that is set on the 
ventilator and maintained for > 1 hour. This requirement that the daily minimum PEEP be the 
lowest setting maintained for > 1 hour will ensure that units monitoring and recording PEEP 
settings hourly or more frequently than once per hour are able to apply the VAE surveillance 
PEEP criterion in a standardized way. In the event that ventilator settings are monitored and 
recorded less frequently than once per hour, the daily minimum PEEP is simply the lowest value 
of PEEP set on the ventilator during the calendar day. In circumstances where there is no value 
that is documented to have been maintained for > one hour (for example., the lowest value of 
PEEP is set late in the calendar day, mechanical ventilation is discontinued early in the calendar 
day, PEEP settings are changed very frequently throughout the calendar day) the daily minimum 
PEEP should default to the lowest PEEP setting during the calendar day (regardless of how long 
that setting was maintained). For example, a patient who is intubated and started on mechanical 
ventilation at 11:30 pm on June 1, with a PEEP setting of 10 cmH2O from 11:30 pm to midnight, 
would have a daily minimum PEEP of 10 cmH2O on June 1 for the purposes of VAE 
surveillance.   
 
NOTE: In units tracking PEEP settings every hour or more frequently than every hour, 
there must be sufficient consecutive recordings of a specific PEEP setting to meet the 
minimum required duration of > 1 hour. For example, in units tracking PEEP every 15 
minutes, 5 consecutive recordings of PEEP at a certain level would be needed to meet the 
required >1 hour minimum duration (for example., at 09:00, 09:15, 09:30, 09:45 and 
10:00). In units tracking PEEP every 30 minutes, 3 consecutive recordings of PEEP at a 
certain level would be needed to meet the required >1 hour minimum duration (for 
example, at 09:00, 09:30, and 10:00). In units tracking PEEP every hour, 2 consecutive 
recordings of PEEP at a certain level would be needed to meet the required >1 hour 
minimum duration (for example, at 09:00 and 10:00). 
 
EXAMPLE: The patient is intubated at 6 pm. PEEP is set at the following values through 
the remainder of the calendar day: 
 
Time 6 pm 7 pm 8 pm 9 pm 10 pm 11 pm 
PEEP 
(cmH2O) 
10 8 5 5 8 8 
 
In this example, the daily minimum PEEP for the purposes of VAE surveillance is 5 
cmH2O. PEEP settings are being monitored and recorded every hour. There are two 
consecutive hours where the PEEP setting is noted to be 5 cmH2O (8 pm and 9 pm), and 
therefore required minimum duration of >1 hour is met. 
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EXAMPLE: The patient is intubated at 6 pm. PEEP is set at the following values through 
the remainder of the calendar day: 
 
Time 6 pm 7 pm 8 pm 9 pm 10 pm 11 pm 
PEEP 
(cmH2O) 
8 8 5 8 5 8 
 
In this example, the daily minimum PEEP for the purposes of VAE surveillance is 8 
cmH2O. PEEP settings are being monitored and recorded every hour. Although the 
lowest PEEP is 5 cmH2O, it is recorded at two non-consecutive time points only (8 pm, 
then 10 pm), and so the required >1 hour minimum duration is not met. There are two 
consecutive hours where the PEEP setting is noted to be 8 cmH2O (6 pm and 7 pm), and 
therefore the required minimum duration of >1 hour is met to allow use of this setting as 
the daily minimum value for VAE surveillance.  
 
EXAMPLE: PEEP is set at the following values through the course of a calendar day: 
 
Time 12 am 4 am 8 am 12 pm 4 pm 8 pm 
PEEP 
(cmH2O) 
5 8 5 8 8 10 
 
In this example, the daily minimum PEEP is 5 cmH2O. PEEP settings are being 
monitored and recorded every 4 hours; therefore the lowest recorded PEEP setting for the 
calendar day is the value used in VAE surveillance. 
 
EXAMPLE: You are reviewing a patient’s ventilator settings on Wednesday morning to 
determine the daily minimum PEEP values for Monday and Tuesday. The MICU 
monitors and records PEEP settings for mechanically ventilated patients every 30 
minutes. You see that the lowest PEEP setting on Monday (5 cmH2O) was recorded at 
11:30 pm when the episode of mechanical ventilation was initiated for this patient. The 
patient remained at this PEEP setting for an additional 30 minutes on Tuesday morning, 
and was then maintained on PEEP 10 cmH2O for the rest of the day on Tuesday. What do 
you record as the daily minimum PEEP for Monday and for Tuesday? In this example, 
the only PEEP setting recorded on Monday was 5 cmH2O.  Because there is no value on 
Monday that has been maintained for > one hour, the lowest (and only) setting of 5 
cmH20 is recorded as the daily minimum PEEP for that calendar day. On Tuesday, the 
daily minimum PEEP should be recorded as 10 cmH2O, which is the lowest PEEP setting 
maintained for > 1 hour on Tuesday. 
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Day Time PEEP (cmH2O) 
Monday 23:30 5 
Tuesday 00:00  5 
Tuesday 00:30 5 
Tuesday 01:00 10 
Tuesday 01:30 10 
Tuesday 02:00 through 23:30 10 
 
 
Daily minimum FiO2: The lowest value of FiO2 during a calendar day that is set on the ventilator 
and maintained for > 1 hour. This requirement that the daily minimum FiO2 be the lowest setting 
maintained for > 1 hour will ensure that units monitoring and recording FiO2 settings hourly or 
more frequently than once per hour are able to apply the VAE surveillance FiO2 criterion in a 
standardized way. In the event that ventilator settings are monitored and recorded less frequently 
than once per hour, the daily minimum FiO2 is simply the lowest value of FiO2 set on the 
ventilator during the calendar day. Similarly, in circumstances where there is no value that has 
been maintained for > 1 hour (for example , the lowest value of FiO2 is set late in the calendar 
day, mechanical ventilation is discontinued early in the calendar day) the daily minimum FiO2 is 
the lowest value of FiO2 set on the ventilator during the calendar day. 
 
NOTE: In units tracking FiO2 settings every hour or more frequently than every hour, 
there must be sufficient consecutive recordings of a specific FiO2 setting to meet the 
minimum required duration of >1 hour. For example, in units tracking FiO2 every 15 
minutes, 5 consecutive recordings of FiO2 at a certain level would be needed to meet the 
required >1 hour minimum duration (for example, 09:00, 09:15, 09:30, 09:45 and 10:00). 
In units tracking FiO2 every 30 minutes, 3 consecutive recordings of FiO2 at a certain 
level would be needed to meet the required >1 hour minimum duration (for example, 
09:00, 09:30, and 10:00). In units tracking FiO2 every hour, 2 consecutive recordings of 
FiO2 at a certain level would be needed to meet the required >1 hour minimum duration 
(for example, 09:00 and 10:00). 
 
EXAMPLE: The patient is intubated at 6 pm. FiO2 is set at the following values through 
the remainder of the calendar day: 
 
Time 6 pm 7 pm 8 pm 9 pm 10 pm 11 pm 
FiO2 1.0 0.8 0.5 0.5 0.8 0.8 
 
In this example, the daily minimum FiO2 for the purposes of VAE surveillance is 0.5. 
FiO2 settings are being monitored and recorded every hour. There are two consecutive 
hours where the FiO2 setting is noted to be 0.5 (8 pm and 9 pm), and therefore required 
minimum duration of >1 hour is met.  
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EXAMPLE: The patient is intubated at 6 pm. FiO2 is set at the following values through 
the remainder of the calendar day: 
 
Time 6 pm 7 pm 8 pm 9 pm 10 pm 11 pm 
FiO2 0.8 0.8 0.5 0.8 0.5 0.8 
 
In this example, the daily minimum FiO2 for the purposes of VAE surveillance is 0.8. 
FiO2 settings are being monitored and recorded every hour. Although the lowest FiO2 is 
0.5, it is recorded at two non-consecutive time points only (8 pm, and then 10 pm), and so 
the required 1 hour minimum duration is not met. There are two consecutive hours where 
the FiO2 setting is noted to be 0.8 (6 pm and 7 pm), and therefore the required minimum 
duration of >1 hour is met to allow use of this setting as the daily minimum value for 
VAE surveillance.  
 
EXAMPLE: FiO2 is set at the following values through the course of a calendar day: 
 
Time 2 pm 4 pm 6 pm 8 pm 10 pm 12 am 
FiO2 1.0 0.60 0.40 0.50 0.55 0.60 
 
In this example, the patient was intubated at 2 pm. The daily minimum FiO2 is 0.40. FiO2 
settings are being monitored and recorded every 2 hours; therefore, the lowest recorded 
FiO2 setting for the calendar day is the value used in VAE surveillance.  
 
EXAMPLE: You are reviewing a patient’s ventilator settings on Friday morning to 
determine the daily minimum FiO2 value for Thursday. The patient was intubated and 
initiated on mechanical ventilation at 21:45 hours on Thursday. The ICU monitored and 
recorded FiO2 settings for the patient every 15 minutes during the remainder of the day 
on Thursday. Based on the information recorded in the table below, what should you 
record as the daily minimum FiO2 for Thursday? In this example, since there is no setting 
that is maintained for > 1 hour during the calendar day, the daily minimum FiO2 for 
Thursday is 0.70 (70%). This is the lowest value of FiO2 set on the ventilator during the 
calendar day. 
 
Day Time FiO2 
Thursday 21:45 Intubated; 1.0 
 22:00 1.0 
 22:15         0.90 
 22:30 0.90 
 22:45 0.70 
 23:00 0.80 
 23:15 0.85 
 23:30 0.85 
 23:45 0.85 
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Ventilator: a device used to support, assist or control respiration (inclusive of the weaning 
period) through the application of positive pressure to the airway when delivered via an artificial 
airway, specifically oral/nasal endotracheal or tracheostomy tube. 
 
Note: Ventilation and lung expansion devices that deliver positive pressure to the airway (for 
example: CPAP, Bipap, bi-level, IPPB and PEEP) via non-invasive means (for example: nasal 
prongs, nasal mask, full face mask, total mask, etc.) are not considered ventilators unless positive 
pressure is delivered via an artificial airway (oral/nasal endotracheal or tracheostomy tube). 
 
Episode of mechanical ventilation: Defined as a period of days during which the patient was 
mechanically ventilated for some portion of each consecutive day.  
 
NOTE: A break in mechanical ventilation of at least one full calendar day, followed by 
reintubation and/or reinitiation of mechanical ventilation during the same hospitalization, 
defines a new episode of mechanical ventilation.  
 
EXAMPLE: A patient is intubated and mechanical ventilation is initiated at 11 pm on 
hospital day 1. The patient remains intubated and mechanically ventilated from hospital 
days 2-10. The patient is extubated at 9 am on hospital day 11, and remains extubated on 
hospital day 12. The patient is reintubated and mechanical ventilation is reinitiated on 
hospital day 13. The patient remains intubated and mechanically ventilated from hospital 
day 14-18. This patient has had two episodes of mechanical ventilation (days 1-11 and 
days 13-18), separated by at least one full calendar day off of mechanical ventilation. 
 
New antimicrobial agent: Defined as any agent listed in the Appendix that is initiated on or after 
the third calendar day of mechanical ventilation AND in the VAE Window Period (specifically, 
the period typically defined by the 2 calendar days before, the day of, and the 2 calendar days 
after the onset date of the VAE).  The agent is considered new for the purposes of this definition 
if it was NOT given to the patient on either of the 2 days preceding the current start date.  
 
EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1 in the 
MSICU.  Ceftriaxone and azithromycin are started on day 1 and administered daily. After 
3 days of improving respiratory status, the patient’s oxygenation deteriorates on days 4 
and 5, with a daily minimum PEEP that is 4 cmH2O higher than it was on days 2 and 3. 
Criteria for the VAC definition are met; the date of the event is hospital day 4. 
Ceftriaxone is discontinued and meropenem is begun on day 5. Azithromycin is 
continued. In this case, meropenem is a new antimicrobial agent: 1) it was begun on day 
5 of mechanical ventilation, and 2) within the VAE Window Period (on the day after 
VAE onset), and 3) it was not given to the patient on either of the 2 days preceding the 
current start date. By contrast, ceftriaxone and azithromycin would not be considered new 
antimicrobial agents, since they were begun on day 1 of mechanical ventilation and 
continued daily into the VAE Window Period. 
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The antimicrobial agent(s) must have been given by one of the routes of administration outlined 
in Table 1, and therapy with one or more new antimicrobial agents must be continued for at least 
4 calendar days (referred to as 4 “qualifying antimicrobial days” or “QADs”). For further 
guidance on identification of new antimicrobial agents and on how to determine whether the 
requirement for 4 QADs is met, refer to FAQs nos. 6-10 at the end of this chapter. 
 
Table 1: Definitions of routes of administration 
 
Route of Administrationa  Definitionb 
Intravenous  An intravascular route that begins with a vein.  
Intramuscular  A route that begins within a muscle.  
Digestive Tract  A route that begins anywhere in the digestive tract extending 
from the mouth through rectum.  
Respiratory Tract  A route that begins within the respiratory tract, including the 
oropharynx and nasopharynx.  
aOther routes of administration are excluded (for example, antibiotic locks, intraperitoneal, intraventricular, irrigation, 
topical).  
bDefinitions per SNOMED Reference Terminology  
 
Qualifying Antimicrobial Day (QAD): A day on which the patient was administered an 
antimicrobial agent that was determined to be “new” within the VAE Window Period.  Four 
consecutive QADs are needed to meet the IVAC antimicrobial criterion—starting within the 
VAE Window Period. Days on which a new antimicrobial agent is administered count as QADs. 
Days between administrations of a new antimicrobial agent also count as QADs as long as there 
is a gap of no more than 1 calendar day between administrations. For example, if levofloxacin is 
given on VAE Day 1, has not been given in the 2 preceding calendar days, and is given again on 
VAE Days 3, 5 and 7, there are 7 QADs—because the days between levofloxacin doses also 
count as QADs. By contrast, days between administrations of different antimicrobial agents do 
NOT count as QADs; for example, if levofloxacin is given to the patient on VAE Days -2 and -1 
only, no antimicrobials are given on VAE Day 1, and meropenem is given only on VAE Day 2 
(remember there is no VAE Day 0), then there are not 4 consecutive QADs. VAE Days -2 and -1 
count as 2 consecutive QADs, but VAE Day 1 cannot be counted as a QAD because it is a day 
between different antimicrobial agents.  
 
Purulent Respiratory Secretions: Defined as secretions from the lungs, bronchi, or trachea that 
contain >25 neutrophils and <10 squamous epithelial cells per low power field [lpf, x100].  
 
NOTE: Some clinical laboratories may use different results reporting formats for direct 
examinations of respiratory secretions. Additional instructions for using the purulent 
respiratory secretions criterion are provided in Table 2, below (see also FAQ no. 19).  
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Table 2: Instructions for using the purulent respiratory secretions criterion, based on 
laboratory reporting of respiratory secretion direct examination results. 
 
How do I use the purulent respiratory 
secretions criterion if … 
Instruction 
My laboratory reports counts of “white blood 
cells” or “polymorphonuclear leukocytes” or 
“leukocytes” rather than counts of 
“neutrophils”? 
Assume that counts of cells identified by 
these other descriptors (for example, “white 
blood cells”) are equivalent to counts of 
neutrophils, unless the laboratory tells you 
this is not the case. 
My laboratory reports semi-quantitative 
results (not quantitative results) for numbers 
of neutrophils and squamous epithelial cells? 
Check with the laboratory to get information 
about what quantitative ranges the semi-
quantitative reports correspond to. 
My laboratory cannot provide additional 
information on how its semi-quantitative 
reporting corresponds to quantitative 
reporting ranges for neutrophils and 
squamous epithelial cells? 
Use the following direct examination results 
to meet the purulent respiratory secretions 
criterion: heavy, 4+, or ≥25 neutrophils per 
low power field (lpf) [x100], AND rare, 
occasional, few, 1+ or 2+, or ≤10 squamous 
epithelial cells per lpf [x100] [20]. 
My laboratory reports only the numbers of 
neutrophils present, without reporting the 
number of squamous epithelial cells? 
In this situation, the purulent secretions 
criterion may be met using the specified 
quantitative and semi-quantitative thresholds 
for neutrophils alone (specifically heavy, 4+, 
or ≥25 neutrophils per lpf [x100]). 
My laboratory uses different reporting 
thresholds for neutrophils and squamous 
epithelial cells (for example, maximum 
report of ≥ 20 neutrophils per low power 
field [x100], or minimum report of ≤ 15 
squamous epithelial cells per low power field 
[x100])? 
In this situation, the purulent secretions 
criterion may be met using the laboratory’s 
specified maximum quantitative threshold for 
neutrophils, and/or minimum quantitative 
threshold for squamous epithelial cells. 
My laboratory processes respiratory 
specimens such as bronchoalveolar lavage 
fluid using a centrifugation procedure (for 
example, “cytospin”), and there is no 
quantitation or semi-quantitation of 
neutrophils or white blood cells in the direct 
examination report? 
In this situation, a report indicating the 
presence of white blood cells, without 
quantitation, is sufficient to meet the purulent 
secretions criterion. 
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Location of attribution: The inpatient location where the patient was assigned on the date of the 
VAE, which is further defined as the date of onset of worsening oxygenation.   
 
EXAMPLE: Patient is intubated and ventilated in the Operating Room on hospital day 1, 
and then is admitted post-operatively to the SICU on hospital day 1, still on the 
ventilator.  On hospital day 3, the patient experiences the onset of worsening 
oxygenation, manifested by an increase in the daily minimum FiO2 of ≥ 0.20 (20%).  On 
day 4 (also the 4th day of mechanical ventilation) the patient meets criteria for a VAC. 
This is reported to NHSN as a VAC for the SICU. 
 
EXCEPTION: 
Transfer Rule:  If a VAE develops on the day of transfer or the day following transfer 
from one inpatient location to another in the same facility or to a new facility (where the 
day of transfer is day 1), the event is attributed to the transferring location.  This is called 
the Transfer Rule, and examples are shown below: 
 
EXAMPLE: Patient on a ventilator in the SICU who has had improving oxygenation for 
3 days is transferred to the MICU, still on the ventilator. On the day of transfer, after the 
patient has arrived in the MICU, the patient experiences an acute decompensation, 
requiring an increase of 0.30 (30 points) in FiO2 that persists during the following 
calendar day. VAC criteria are met on calendar day 2 in the MICU. Because the onset of 
worsening oxygenation occurred on the day of transfer to the MICU, the VAC event is 
attributed to the SICU.  
 
EXAMPLE: Patient is extubated in the MICU and transferred to the medical stepdown 
unit on hospital day 6. The next day, while in the stepdown unit (day 7), the patient 
experiences worsening oxygenation and is reintubated and transferred back to the MICU. 
Criteria for VAC are met the next day (day 8). In this case, the day prior to extubation 
and the day of extubation (hospital days 5 and 6) count as the required 2-day period of 
stability or improvement. The day of reintubation (day 7) and the following day (day 8) 
count as the required 2-day period of worsening oxygenation. Because the onset of 
worsening oxygenation occurred on the day following transfer out of the MICU, the 
event is reported to NHSN as a VAC for the MICU. 
 
EXAMPLE: Patient intubated and mechanically ventilated for 8 days in the MSICU of 
Hospital A is transferred for further care on day 8 to the MSICU of Hospital B. The 
patient was stable on the ventilator in Hospital A from days 3-8. On the day of transfer to 
Hospital B (day 1 in Hospital B), the patient’s respiratory status deteriorates. The 
patient’s respiratory status continues to worsen on the day after transfer (day 2 in 
Hospital B), the patient meets criteria for VAC on hospital day 3. The date of the event is 
day 2in Hospital B, the first day of the period of worsening oxygenation meeting VAE 
PEEP or FiO2 thresholds. The infection preventionist (IP) from Hospital B calls the 
Hospital A IP to report that this patient was admitted to Hospital B with a VAC.  This 
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VAC should be reported to NHSN for and by Hospital A, and attributed to the Hospital A 
MSICU. Date of event was day following transfer. No additional ventilator days are 
reported by Hospital A. 
 
REPORTING INSTRUCTIONS (additional guidance may be found in the FAQs at the end of 
this chapter):  
 Conducting in-plan VAE surveillance means assessing patients for the presence of ALL 
events included in the algorithm—from VAC to IVAC to PVAP. At this time, a unit 
conducting in-plan VAE surveillance cannot decide, for example, that only surveillance 
for VAC (and not for IVAC or PVAP) will be performed.  
 There is a hierarchy of definitions within VAE: 
o If a patient meets criteria for VAC and IVAC, report as IVAC. 
o If a patient meets criteria for VAC, IVAC and PVAP, report PVAP. 
 Do not upgrade an event using findings that occur outside the VAE Window period.  
 If the date of event (date of onset of worsening oxygenation) is on or after the date of 
documentation of evidence of consent AND the patient is being supported for organ 
donation purposes, the event should not be reported as a VAE.  
 Pathogens are not reported for VAC or IVAC events. 
 Secondary BSIs are not reported for VAC or IVAC events (see FAQ no.11).  
 Pathogens may be reported for PVAP events, provided they are isolated or identified 
from appropriate specimen types according to the requirements of the algorithm and are 
NOT on the list of excluded organisms and culture or non-culture based microbiologic 
testing method results: 
o Excluded organisms and culture or non-culture based microbiologic testing method 
results that cannot be used to meet the PVAP definition are as follows: “Normal 
respiratory flora,” “normal oral flora,” “mixed respiratory flora,” “mixed oral flora,” 
“altered oral flora” or other similar results indicating isolation of commensal flora of 
the oral cavity or upper respiratory tract; Candida species or yeast not otherwise 
specified; coagulase-negative Staphylococcus species; and Enterococcus species, 
when identified from sputum, endotracheal aspirates, bronchoalveolar lavage, or 
protected specimen brushings specimens. These organisms can be reported as PVAP 
pathogens if identified from lung tissue or pleural fluid specimens. 
o Additionally, because organisms belonging to the following genera are typically 
causes of community-associated respiratory infections and are rarely or are not 
known to be causes of healthcare-associated infections, they are also excluded, and 
cannot be used to meet the PVAP definition when isolated from any eligible 
specimen type (to include lung and pleural fluid):  Blastomyces, Histoplasma, 
Coccidioides, Paracoccidioides, Cryptococcus and Pneumocystis. 
 There are three criteria that can be used to meet the PVAP definition (Figure 1): 
o Criterion 1: Positive culture meeting specific quantitative or semi-quantitative 
threshold (Table 3);  
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o Criterion 2: Purulent respiratory secretions AND identification of organisms  
NOT meeting the quantitative or semi-quantitative thresholds specified in Table 
3; 
o Criterion 3: Organisms identified from pleural fluid specimen, positive lung 
histopathology, lower respiratory specimen cytology findings suggestive of 
infection and positive diagnostic test for Legionella species or selected 
respiratory viruses.  
 See Table 3 for the required quantitative culture thresholds meeting the PVAP definition 
(Criterion 1). Note that if your laboratory reports semi-quantitative culture results, you 
should check with your laboratory to confirm that semi-quantitative results match the 
quantitative thresholds noted in Table 3 (see also FAQ no. 24). 
 
Table 3:  Threshold values for cultured specimens used in the PVAP definition 
 
Specimen collection/technique Values 
Lung tissue ≥ 104 cfu/g tissue*  
Bronchoscopically (B) obtained specimens  
Bronchoalveolar lavage (B-BAL) ≥ 104 cfu/ml*  
Protected BAL (B-PBAL) ≥ 104 cfu/ml* 
Protected specimen brushing (B-PSB) ≥ 103 cfu/ml* 
Nonbronchoscopically (NB) obtained (blind) 
specimens 
 
NB-BAL ≥104 cfu/ml*  
NB-PSB ≥ 103 cfu/ml*  
Endotracheal aspirate (ETA) ≥ 105 cfu/ml* 
   cfu = colony forming units, g = gram, ml = milliliter  
  *Or corresponding semi-quantitative result.  
 
 Secondary BSIs may be reported for PVAP events, provided that at least one organism 
identified from the blood matches an organism isolated from an appropriate respiratory 
tract specimen (including respiratory secretions, pleural fluid and lung tissue). The 
respiratory tract specimen must have been collected on or after the 3rd day of mechanical 
ventilation and within 2 calendar days before or after the day of onset of worsening 
oxygenation to be considered as a criterion for meeting the PVAP definition. In addition, 
the organisms identified from blood must have been collected during the 14-day event 
period, where day 1 is the day of onset of worsening oxygenation (See FAQ no.13). 
o In cases where PVAP is met with only the histopathology criterion and no culture or 
non-culture based testing is performed on an eligible respiratory specimen, and there 
is also a positive blood specimen a secondary BSI is not reported.  
o In cases where a culture or non-culture based testing of respiratory secretions, pleural 
fluid or lung tissue is performed and does not identify an organism that matches an 
organism identified from blood, a secondary BSI is not reported. 
o A matching organism is defined as one of the following: 
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1. If genus and species are identified in both specimens, they must be the same. 
 
a. Example: A blood specimen resulted with Enterobacter cloacae and a 
BAL specimen resulted with Enterobacter cloacae are matching 
organisms. 
b. Example: A blood specimen resulted with Enterobacter cloacae and a 
BAL specimen resulted with Enterobacter aerogenes are NOT matching 
organisms as the species are different. 
 
2. If the organism is less definitively identified in one specimen than the other, the 
lesser identified organism must be identified to at least the genus level and at that 
level the organisms must be the same.  
 
a. Example: A BAL resulted with Pseudomonas spp. and a blood specimen 
resulted with Pseudomonas aeruginosa are considered a match at the 
genus level and therefore the BSI can be reported as secondary BSI to 
VAE 
 
Exception: In cases where an organism is identified only as “yeast” or 
“yeast not otherwise specified”, the organism can be considered a match to 
other yeasts, when collected during the required timeframe, whether more 
fully identified or not.   
 
Example: A blood specimen reported as Candida albicans and a lung 
tissue resulted with yeast not otherwise specified are considered to have 
matching organisms. In this example the two organisms are considered 
matching organisms because the organisms are complementary 
(specifically Candida is a type of yeast).  NOTE: This exception is limited 
to yeast. It does not apply to identification of organisms as Gram positive 
cocci, Gram negative rods, etc. 
 
NOTE: Candida species or yeast not otherwise specified, coagulase-
negative Staphylococcus species, and Enterococcus species identified 
from blood cannot be deemed secondary to a PVAP, unless the organism 
was also identified from pleural fluid or lung tissue.  
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Figure 1: Ventilator-Associated Events (VAE) Surveillance Algorithm 
 
 
 
Ventilator-Associated Condition (VAC) 
After a period of stability or improvement on the ventilator, the patient has at least one of the following indicators of worsening oxygenation: 
1) Increase in daily minimum* FiO2 of ≥ 0.20 (20 points) over the daily minimum FiO2 of the first day in the baseline period, sustained for ≥ 2
calendar days.
2) Increase in daily minimum* PEEP values of ≥ 3 cmH2O over the daily minimum PEEP of the first day in the baseline period†, sustained for ≥ 2
calendar days.
*Daily minimum defined by lowest value of FiO2 or PEEP during a calendar day that is maintained for > 1 hour.
†Daily minimum PEEP values of 0-5 cmH2O are considered equivalent for the purposes of VAE surveillance. 
On or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after the onset of worsening oxygenation, the patient 
meets both of the following criteria: 
1) Temperature > 38 °C or < 36°C, OR white blood cell count ≥ 12,000 cells/mm3 or ≤ 4,000 cells/mm3.
AND
2) A new antimicrobial agent(s) (see Appendix for eligible antimicrobial agents) is started, and is continued for ≥ 4 calendar days.
 
 
Infection-related Ventilator-Associated Complication (IVAC) 
On or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after the onset of worsening oxygenation, ONE of the 
following criteria is met (taking into account organism exclusions specified in the protocol):  
1) Criterion 1: Positive culture of one of the following specimens, meeting quantitative or semi-quantitative thresholds as outlined in
protocol, without requirement for purulent respiratory secretions:
 Endotracheal aspirate, ≥ 105 CFU/ml or corresponding semi-quantitative result
 Bronchoalveolar lavage, ≥ 104 CFU/ml or corresponding semi-quantitative result
 Lung tissue, ≥ 104 CFU/g or corresponding semi-quantitative result
 Protected specimen brush, ≥ 103 CFU/ml or corresponding semi-quantitative result
2) Criterion 2: Purulent respiratory secretions (defined as secretions from the lungs, bronchi, or trachea that contain >25 neutrophils and
<10 squamous epithelial cells per low power field [lpf, x100])† PLUS organism identified from one of the following specimens (to include
qualitative culture, or quantitative/semi-quantitative culture without sufficient growth to meet criterion #1):
 Sputum
 Endotracheal aspirate
 Bronchoalveolar lavage
 Lung tissue
 Protected specimen brush
† If the laboratory reports semi-quantitative results, those results must correspond to the above quantitative thresholds. See
additional instructions for using the purulent respiratory secretions criterion in the VAE Protocol.
3) Criterion 3: One of the following positive tests:
 Organism identified from pleural fluid (where specimen was obtained during thoracentesis or initial placement of chest tube
and NOT from an indwelling chest tube)
 Lung histopathology, defined as: 1) abscess formation or foci of consolidation with intense neutrophil accumulation in
bronchioles and alveoli; 2) evidence of lung parenchyma invasion by fungi (hyphae, pseudohyphae or yeast forms); 3) evidence
of infection with the viral pathogens listed below based on results of immunohistochemical assays, cytology, or microscopy
performed on lung tissue
 Diagnostic test for Legionella species
 Diagnostic test on respiratory secretions for influenza virus, respiratory syncytial virus, adenovirus, parainfluenza virus,
rhinovirus, human metapneumovirus, coronavirus
 
*Excludes the following: 
Possible Ventilator-Associated Pneumonia (PVAP) 
Patient has a baseline period of stability or improvement on the ventilator, defined by ≥ 2 calendar days of stable or decreasing daily minimum* 
FiO2 or PEEP values. The baseline period is defined as the 2 calendar days immediately preceding the first day of increased daily minimum PEEP or 
FiO2. 
*Daily minimum defined by lowest value of FiO2 or PEEP during a calendar day that is maintained for > 1 hour.
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Numerator Data:  The Ventilator-Associated Event form (CDC 57.112) is used to collect and 
report each VAE that is identified during the month selected for surveillance.  The Instructions 
for Completion of Ventilator-Associated Event Form  includes brief instructions for collection 
and entry of each data element on the form.  The VAE form includes patient demographic 
information and information on the start date and location of initiation of mechanical ventilation.  
Additional data include the specific criteria met for identifying VAE, whether the patient 
developed a secondary bloodstream infection, whether the patient died, and, where applicable, 
the organisms detected and their antimicrobial susceptibilities.  
 
Reporting Instruction: If no VAEs are identified during the month of surveillance, the “Report 
No Events” box must be checked on the appropriate denominator summary screen, for example, 
Denominators for Intensive Care Unit (ICU)/other locations (Not NICU or SCA), etc.   
 
Denominator Data: Device days and patient days are used for denominators (see Chapter 16 
Key Terms). Ventilator days, which are the numbers of patients managed with ventilatory 
devices, are collected daily, at the same time each day, according to the chosen location using the 
appropriate form (CDC 57.117 and 57.118). These daily counts are summed and only the total 
for the month is entered into NHSN. Ventilator and patient days are collected for each of the 
locations monitored. When denominator data are available from electronic sources (for example, 
ventilator days from respiratory therapy), these sources may be used as long as the counts are not 
substantially different (+/- 5%) from manually-collected counts, pre-validated for a minimum of 
3 months.  
 
NOTE: All ventilator days are counted, including ventilator days for patients on mechanical 
ventilation for < 3 days, and patients on high frequency ventilation and other therapies excluded 
from VAE surveillance. Patients with tracheostomies who are undergoing weaning from 
mechanical ventilation using tracheostomy collar trials are included in ventilator day counts as 
long as they spend some portion of the day on mechanical ventilation at a time that overlaps with 
the daily time during which ventilator day counts are performed. 
 
NOTE: In addition to the total number of patients on ventilators on each day of surveillance, the 
number of patients on ventilators who are on the APRV mode of mechanical ventilation or 
related modes (which is a subset of all patients on ventilators) can optionally  be indicated on the 
appropriate form (CDC 57.117 and 57.118). See FAQ nos. 22 and 23. 
 
Collection of an additional denominator, episodes of mechanical ventilation (EMV), is optionally 
available for VAE surveillance. The EMV denominator represents the sum of the number of 
episodes of mechanical ventilation that occurred in that location during the month. A single 
episode of mechanical ventilation for each patient is to be counted only once per month.  Do 
note, it is possible for a patient to have more than one episode of ventilation occur during a 
month (for example, discontinuation of mechanical ventilation for greater than 1 calendar day 
followed by re-initiation of mechanical ventilation). The EMV denominator is determined by 
counting all, patients in the location who are on mechanical ventilation on the first day of the 
month regardless of eligibility for inclusion in VAE surveillance. Then, on each subsequent day 
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of the month, count each additional patient that is started on mechanical ventilation. This would 
include those that are admitted to the location already on mechanical ventilation, those that are 
newly ventilated, and any previously ventilated patients who have new episodes of mechanical 
ventilation occurring during the same month. The sum of the count for the first day and each 
subsequent day of the month is entered in NHSN.    
 
EXAMPLE: On January 1, there are 5 patients on mechanical ventilation in the MICU               
(2 patients were started on mechanical ventilation on December 24, 2 patients on December 31, 
and 1 patient on January 1). During the rest of the month, the following are noted: 1 patient is 
started on mechanical ventilation on January 8; 2 patients are transferred to the MICU on 
mechanical ventilation on January 15, and 1 patient who was previously ventilated (from January 
1 through January 12) goes back on mechanical ventilation on January 20. No other patients are 
on mechanical ventilation during the month of January. The number of EMV for January is nine. 
This is calculated as follows: 5 patients (on mechanical ventilation on the first day of the month) 
+ 4 patients who were either started on mechanical ventilation, transferred into the MICU on 
mechanical ventilation, or re-initiated on mechanical ventilation after being off of the vent for at 
least 1 calendar day  = 9 EMV. 
 
Data Analyses: The VAE rate per 1000 ventilator days is calculated by dividing the number of 
VAEs by the number of ventilator days and multiplying the result by 1000 (ventilator days). The 
rate per 100 episodes of mechanical ventilation is calculated by dividing the number of VAEs by 
the number of episodes of mechanical ventilation and multiplying the result by 100 (episodes of 
mechanical ventilation). Rates and SIRs that may be appropriate for use in public reporting, 
inter-facility comparisons, and pay-for-reporting/pay-for-performance programs are the overall 
VAE rate (where the numerator consists of all events meeting at least the VAC definition). Rates 
and SIRs that may be appropriate for internal use within an individual unit or facility include the 
“IVAC-plus” rate (where the numerator consists of all events meeting at least the IVAC 
definition) rates of specific event types (e.g., events meeting only the VAC definition, events 
meeting only the IVAC definition, events meeting only the PVAP definition). The Ventilator 
Utilization Ratio is calculated by dividing the number of ventilator days by the number of patient 
days. These calculations will be performed separately for the different types of ICUs, SCAs, and 
other locations in the institution. 
 
The Standardized Infection Ratio (SIR) is calculated by dividing the number of observed events 
by the number predicted events. The number of predicted events, in the context of statistical 
prediction, is calculated using VAE rates from a standard population during a baseline time 
period as reported in the NHSN Report.  
 
NOTE: The SIR should be calculated only if the number of predicted VAEs is ≥ 1. 
 
SIR = Observed (O) VAEs /  Predicted (O)VAEs 
 
While the VAE SIR can be calculated for single locations, the measure also allows you to 
summarize your data by multiple locations, adjusting for differences in the incidence of VAEs 
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among the location types. For example, you can calculate one VAE SIR adjusting for all locations 
reported. Similarly, you can calculate one VAE SIR for all specialty care areas in your facility.  
 
Descriptive analysis options of numerator and denominator data are available in the NHSN 
application, such as line listings, frequency tables, and bar and pie charts. VAE rates and run 
charts are also available. Guides on using NHSN analysis features are available from: 
www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html.  
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Appendix. List of Antimicrobials Agents Eligible for IVAC, PVAP 
Antimicrobial Agent 
AMIKACIN 
AMPHOTERICIN B  
AMPHOTERICIN B LIPOSOMAL 
AMPICILLIN 
AMPICILLIN/SULBACTAM 
ANIDULAFUNGIN 
AZITHROMYCIN 
AZTREONAM 
CASPOFUNGIN 
CEFAZOLIN 
CEFEPIME 
CEFOTAXIME 
CEFOTETAN 
CEFOXITIN 
CEFTAROLINE 
CEFTAZIDIME 
CEFTAZIDIME/AVIBACTAM 
CEFTIZOXIME 
CEFTOLOZANE/TAZOBACTAM 
CEFTRIAXONE 
CEFUROXIME 
CIPROFLOXACIN 
CLARITHROMYCIN 
CLINDAMYCIN 
COLISTIMETHATE 
DALBAVANCIN 
DELAFLOXACIN 
DORIPENEM 
DOXYCYCLINE 
ERTAPENEM 
FLUCONAZOLE 
FOSFOMYCIN 
GEMIFLOXACIN 
GENTAMICIN 
IMIPENEM/CILASTATIN 
ISAVUCONAZONIUM 
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ITRACONAZOLE 
LEVOFLOXACIN 
LINEZOLID 
MEROPENEM 
METRONIDAZOLE 
MICAFUNGIN 
MINOCYCLINE 
MOXIFLOXACIN 
NAFCILLIN 
ORITAVANCIN 
OSELTAMIVIR 
OXACILLIN 
PENICILLIN G 
PERAMIVIR 
PIPERACILLIN 
PIPERACILLIN/TAZOBACTAM 
POLYMYXIN B 
POSACONAZOLE 
QUINUPRISTIN/DALFOPRISTIN 
RIFAMPIN 
SULFAMETHOXAZOLE/TRIMETHOPRIM 
SULFISOXAZOLE 
TEDIZOLID 
TELAVANCIN  
TELITHROMYCIN 
TETRACYCLINE 
TICARCILLIN/CLAVULANATE 
TIGECYCLINE 
TOBRAMYCIN 
VANCOMYIN, intravenous only 
VORICONAZOLE 
ZANAMIVIR 
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VAE Frequently Asked Questions (FAQs) 
 
1) When should I use VAE? Are there circumstances in which I should still use PNEU? 
 VAE surveillance is location based, and restricted to adult inpatient units only. 
 Pediatric and neonatal units are excluded from VAE surveillance (even in 
circumstances where a pediatric unit may occasionally care for patients who are 18 
years of age and older).  
 Locations mapped to mixed age CDC location codes are excluded from VAE 
surveillance. 
 Ventilated patients who are 18 years of age and older and who are cared for in 
pediatric units should be included in any in-plan PedVAP surveillance for that 
location. 
 
NOTE: It is NOT recommended to include in VAE surveillance young children 
housed in adult ICU locations who are not thought to be physiologically similar to the 
location’s adult patient population. Facilities may want to evaluate their location 
mapping to be sure that locations are mapped appropriately to the correct CDC 
location codes. In circumstances where the populations of adults and children cared 
for in the same physical location is more mixed (for example, 50% adult patients and 
50% pediatric patients), it is recommended that facilities weigh the possibility of 
establishing a virtual pediatric location for the purposes of surveillance. More 
information on virtual locations and location mapping can be found here: 
www.cdc.gov/nhsn/PDFs/pscManual/15LocationsDescriptions_current.pdf 
 
 While on high frequency ventilation or extracorporeal life support, patients are 
EXCLUDED from VAE surveillance.  
 
NOTE: Patients who are receiving a conventional mode of mechanical ventilation 
while in the prone position and patients who are receiving a conventional mode of 
mechanical ventilation while receiving nitric oxide therapy, helium-oxygen mixtures 
(heliox), or epoprostenol therapy are INCLUDED. 
 
NOTE: Patients on Airway Pressure Release Ventilation (APRV) and related modes 
of mechanical ventilation (see FAQ nos. 22 and 23) are INCLUDED; however, 
during periods of time while the patient is on APRV, the VAE period of stability or 
improvement on the ventilator and the period of worsening oxygenation should be 
determined by changes in FiO2 only, since changes in PEEP as indicated in this 
surveillance algorithm may not be applicable to APRV. In addition, patients with 
VAE who are on APRV or a related mode of mechanical ventilation at the time of 
VAE onset can be optionally  indicated as such on the VAE Form (CDC 57.112). 
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 In-plan surveillance for ventilator-associated PNEU may still be conducted for 
pediatric patients ONLY (“PedVAP” surveillance). 
 The PNEU definitions are still available for those units seeking to conduct off-plan 
PNEU/VAP surveillance for patients of any age and for assignment of a secondary 
BSI. 
2) I am having difficulty visualizing how to arrange the VAE data elements to facilitate easy 
identification of events. Can you provide some additional guidance? 
 For units in which VAE surveillance will be conducted manually, we recommend that 
you organize the necessary data elements in a table or spreadsheet to assist in 
identifying VAEs. There are a number of different ways in which to organize the data 
– you may consider limiting your spreadsheet to just include the daily minimum 
PEEP and FiO2 values, and then, if a VAC event is identified, utilize other data 
sources to gather information on the data elements included in the IVAC and PVAP 
definitions. Alternatively, you may choose to include columns for all data elements 
(from VAC through PVAP) in a single spreadsheet. 
 
NOTE: For most patients under surveillance for VAE, the only data elements you will 
need to record are the ventilator days, minimum daily PEEP, and minimum daily 
FiO2. The maximum and minimum daily temperatures and white blood cell counts 
only need to be recorded for those patients who are identified as having met criteria 
for VAC. The antimicrobial criterion only needs to be assessed for those patients with 
VAC and with an abnormal temperature or white blood cell count that meets the 
criteria within the IVAC definition. Microbiology and related data elements included 
as criteria in the PVAP definition only need to be assessed for those patients who 
have met the IVAC definition. 
 
NOTE: Keep in mind that the baseline period of stability or improvement on the 
ventilator is defined as the 2 calendar days immediately preceding the first day of 
increased daily minimum PEEP or FiO2, and must be characterized by ≥ 2 calendar 
days of stable or decreasing daily minimum FiO2 or PEEP values (specifically the 
daily minimum PEEP or FiO2 on the second day of the baseline period of stability or 
improvement must be equal to or less than the daily minimum PEEP or FiO2 on the 
first day of the baseline period of stability or improvement). Keep in mind, too, that 
PEEP values of 0 to 5 cmH2O are considered equivalent for the purposes of VAE 
surveillance. This means that any daily minimum value of 0 to 5 cmH2O will be 
evaluated as if it were 5 cmH2O when determining whether a VAC has occurred or 
not. Also, the daily minimum PEEP or FiO2 is defined as the lowest setting during a 
calendar day that is maintained for > 1 hour. 
 
EXAMPLE: In the table below, the data elements used to meet VAC, IVAC and 
PVAP definition are organized in a fashion that facilitates identification of an event, 
highlighted in the shaded region. In this example, MV days 3 and 4 constitute the 
baseline period, with stable minimum PEEP of 5 cmH2O on each day. On MV days 5 
and 6, the daily minimum PEEP is 8 cmH2O, which meets the VAC criterion for 
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worsening oxygenation. If we scan across the table, we can see that the IVAC 
temperature/white blood cell count criterion is not met (there are no temperatures < 
36°C or > 38°C, and no white blood cell counts ≤ 4,000 cells/mm3 or ≥ 12,000 
cells/mm3) – so even though the patient was started on a new antimicrobial agent and 
continued on that agent for 4 calendar days, IVAC is not met. Therefore, this event 
would be reported as a VAC, with the date of event being MV day 5. 
Patient MV Day PEEPmin FiO2min Tempmin Tempmax WBCmin WBCmax Abx Specimen Polys / Epis Organism VAE 
1 1 10 1.0 37.1 37.6 4.3 4.3 None -- -- -- -- 
1 2 5 0.60 36.8 37.2 4.6 4.6 None -- -- -- -- 
1 3 5 0.40 37.0 37.9 5.4 5.4 None -- -- -- -- 
1 4 5 0.40 36.5 37.3 9.2 9.2 Yes -- -- -- -- 
1 5 8 0.50 36.3 36.9 8.4 8.4 Yes ETA ≥ 25 / ≤ 10 S.aureus VAC 
1 6 8 0.40 37.2 37.5 8.5 8.8 Yes -- -- -- - 
1 7 5 0.40 37.8 37.9 7.6 7.6 Yes -- -- -- - 
MV = mechanical ventilation. PEEPmin = Daily minimum PEEP. FiO2min = Daily minimum FiO2. Tempmin = Daily minimum temperature. Tempmax = Daily 
maximum temperature. WBCmin = Daily minimum white blood cell count. WBCmax = Daily maximum white blood cell count. Abx = antimicrobial agents. 
Polys / epis = Polymorphonuclear leukocytes and squamous epithelial cells from respiratory specimen. 
EXAMPLE: In the table below, by scanning across the data elements, you can see 
that there are no periods in which there is a stable, 2-day baseline period followed by 
a 2-day period where the PEEP or FiO2 are increased 3 cmH2O or 20 points over the 
first day in the baseline period. On MV days 2 and 3, the PEEP values are 7 cmH2O 
and 6 cmH2O respectively, and then increase to 9 cmH2O on MV days 4 and 5 – but 
the difference between day 4 or day 5 and day 2 is only 2 cmH2O, rather than the 
required 3 cmH2O. Also, the gradual increase in FiO2 from the time of initiation of 
mechanical ventilation means that there are not two days on which the FiO2 is at least 
20 points higher than on the 2 previous days. Therefore, although the temperature and 
white blood cell counts exceed the required thresholds for IVAC on several 
occasions, and the patient appears to have received a new antimicrobial agent for 
several days in the setting of a positive blood culture, the VAC definition is not met, 
and so no VAE is reported. 
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3) Is there a hierarchy of reporting for VAE? How do I know whether to report a VAC, an
IVAC or a PVAP?
 Conducting in-plan VAE surveillance means assessing patients for the presence of
ALL events included in the algorithm—from VAC to IVAC to PVAP. At this time, a
unit participating in in-plan VAE surveillance cannot decide, for example, that only
surveillance for VAC (and not for IVAC or PVAP) will be performed.
 There is a hierarchy of definitions within VAE:
o If a patient meets criteria for VAC and IVAC, report as IVAC.
o If a patient meets criteria for VAC, IVAC and PVAP, report PVAP.
4) How do I determine the duration of a VAE? Can a patient have more than one VAE
during a hospitalization?
 Patients may have multiple VAEs during a single hospitalization. The event period is
defined by the 14-day period that starts on the date of onset of worsening
oxygenation. VAE criteria met during that 14-day period are attributed to the current
VAE.
EXAMPLE: Patient is intubated and mechanical ventilation is initiated in the MICU 
(day 1). The patient is stable during the following 4 calendar days (days 2 through 5). 
On days 6 and 7 the patient’s minimum daily FiO2 is increased more than 0.20 (20 
points) over the first day in the  baseline period, therefore meeting the VAC FiO2 
threshold. The VAC episode is defined by the period encompassing days 6 through 19 
(14 days, starting on day 1 of worsening oxygenation, which in this case is day 6). If 
the patient were to experience a period of stability or improvement on the ventilator 
on days 18 and 19, followed by another 2-day period of worsening on days 20 and 21, 
a new VAE would be reported, since the second period of worsening oxygenation has 
occurred more than 14 days after the start of the initial period of worsening 
oxygenation. 
Patient 
MV 
Day 
PEEPmin FiO2min Tempmin 
Tempma
x
WBCmin 
WBCma
x
Abx 
Specime
n 
Polys / 
Epis 
Organis
m 
VAE 
2 1 5 0.30 37.1 37.6 4.3 4.3 None -- -- -- -- 
2 2 7 0.30 36.8 37.2 4.6 4.6 None -- -- -- -- 
2 3 6 0.45 37.0 37.9 5.4 5.4 None -- -- -- -- 
2 4 9 0.45 36.5 37.3 9.2 9.2 None -- -- -- -- 
2 5 9 0.60 36.3 36.9 8.4 8.4 None ETA ≥ 25 / ≤ 10 S.aureus -- 
2 6 8 0.60 37.2 37.5 8.5 8.8 None -- -- -- -- 
2 7 6 0.75 37.8 37.9 7.6 7.6 None -- -- -- -- 
2 8 6 0.75 38.2 38.4 10.5 11.9 Yes Blood -- S. aureus -- 
2 9 5 0.80 38.5 38.9 12.7 12.7 Yes -- -- -- -- 
2 10 5 0.75 37.4 38.1 12.9 12.9 Yes -- -- -- -- 
2 11 5 0.70 37.2 37.9 9.4 9.4 Yes -- -- -- -- 
2 12 5 0.60 37.3 37.5 9.5 9.5 Yes -- -- -- -- 
2 13 7 0.60 37.2 37.8 8.2 8.2 Yes -- -- -- -- 
2 14 8 0.60 37.0 37.7 8.6 8.6 Yes -- -- -- -- 
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5) Sometimes patients are intubated, extubated, and reintubated several times during a
single hospitalization. How do I define an episode of mechanical ventilation, and can a
VAE occur in a patient who has recently been extubated?
 An episode of mechanical ventilation is defined as a period of days during which the
patient was mechanically ventilated for some portion of each consecutive day during
the period.
EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1. The 
patient remains on mechanical ventilation from hospital day 2 through 12 noon on 
hospital day 6. At noon on hospital day 6, the patient is extubated. The patient 
remains extubated on hospital day 7, and is then reintubated on hospital day 8. In this 
case, the first episode of mechanical ventilation is defined by days 1 through 6. Since 
the patient was extubated on day 6 and remained extubated for a full calendar day on 
day 7, the re-intubation of the patient on day 8 defines the start of a second episode of 
mechanical ventilation. See figure, below. 
Hosp Day No. 1 2 3 4 5 6 7 8 9 10 
MV Episode 1 1 1 1 1 1 -- 2 2 2 
MV Day No. 1 2 3 4 5 
6—extubated 
at noon 
-- 1--reintubated 2 3 
EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1. The 
patient remains on mechanical ventilation from hospital day 2 through hospital day 6 
at 12 noon. At noon on hospital day 6, the patient is extubated. The patient is 
reintubated at 9 pm on hospital day 7, and remains intubated and mechanically 
ventilated till 2 pm on day 10. The patient is extubated at 2 pm on day 10 and remains 
extubated until hospital discharge on day 15. In this case, there is only a single 
episode of mechanical ventilation, defined by days 1 through 10, because the patient 
was extubated on day 6 but reintubated the next calendar day (day 7). See figure, 
below. 
Hosp Day No. 1 2 3 4 5 6 7 8 9 10 
MV Episode 1 1 1 1 1 1 1 1 1 1 
MV Day No. 1 2 3 4 5 
6—extubated at 
noon 
7—reintubated 
at 9 pm 
8 9 
10—extubated 
at 2 pm 
 A VAE can occur in a patient who has been extubated and is then reintubated, subject to the
amount of time the patient was off the ventilator, as noted in the examples below.
1 full calendar day off mechanical ventilation, followed by reintubation, 
defines a new episode of mechanical ventilation. 
Patient was reintubated on the calendar day following extubation (days 6-7). Because there is not 1 
calendar day off mechanical ventilation, there is only 1 episode of mechanical ventilation.  
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EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1. The 
patient remains on mechanical ventilation from hospital day 2 through 12 noon on 
hospital day 6. At noon on hospital day 6, the patient is extubated. The patient remains 
extubated on hospital day 7, and is then reintubated on hospital day 8. In this case, 
because the patient has been extubated for 1 full calendar day (day 7), the “VAE clock” 
starts over with reintubation on hospital day 8. To meet VAE during this second episode 
of mechanical ventilation, the patient would have to have at least 2 days of stability or 
improvement and at least 2 days of worsening oxygenation on the ventilator; therefore, 
the earliest date on which the patient could meet VAE criteria would be hospital day 11 
(stable or improving settings on days 8 and 9, increased ventilator settings on days 10 and 
11). The VAE event date would be reported as day 10—the first day of worsening 
oxygenation meeting VAE criteria. See figure, below. 
EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1. The 
patient remains on mechanical ventilation from hospital day 2 through 12 noon on 
hospital day 6, when the patient is extubated. The patient is reintubated at 9 pm on 
hospital day 7. In this case, there is no “new” episode of mechanical ventilation, since 
there was not a full, ventilator-free calendar day. Therefore, the period of worsening 
oxygenation may be determined to have started on day 7, the day of reintubation, as 
long as PEEP or FiO2 criteria are met. PEEP and FiO2 data from hospital days 5 and 6 
(through the time of extubation) may be used to determine whether a period of 
stability and improvement occurred, and these data may be compared to PEEP and 
FiO2 data obtained from the time of reintubation on day 7 and beyond to determine 
whether at least 2 days of worsening oxygenation occurred. The earliest that the 
patient could meet VAE criteria would be day 8 (assuming stable or improving 
ventilator settings on days 5 and 6, and two days of worsening oxygenation meeting 
criteria on days 7 and 8). The VAE event date would be reported as day 7—the first 
day of worsening oxygenation meeting VAE criteria. See figure, below. 
Hosp Day No. 1 2 3 4 5 6 7 8 9 10 
MV Episode 1 1 1 1 1 1 1 1 1 1 
MV Day No. 1 2 3 4 5 
6—extubated 
at noon 
7—reintubated 
at 9 pm 
8 9 10 
VAE Criterion 
Day 1 of 
stability or 
improvement 
Day 2 of 
stability or 
improvement 
Day 1 of 
worsening 
oxygenation 
Day 2 of 
worsening 
oxygenation 
 A patient may also meet criteria for VAC while intubated, and then meet criteria for
IVAC (or PVAP) following extubation.
Hosp Day No. 1 2 3 4 5 6 7 8 9 10 11 
MV Episode 1 1 1 1 1 1 -- 2 2 2 2 
MV Day No. 1 2 3 4 5 
6—extubated 
at noon 
-- 
1--
reintubated 
2 3 4 
VAE Criterion -- -- -- -- -- -- -- 
Day 1 of 
stability or 
improvement 
Day 2 of 
stability or 
improvement 
Day 1 of 
worsening 
oxygenation 
Day 2 of 
worsening 
oxygenation 
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EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1. The 
patient remains on mechanical ventilation till 11 am on hospital day 10, when the 
patient is extubated. Criteria for VAC are met during the episode of mechanical 
ventilation, based on 2 days of stability or improvement (MV days 5 and 6) followed 
by 2 days of worsening oxygenation (MV days 7 and 8). The date of the event is MV 
day 7, the day of onset of worsening oxygenation. Within the 2 days before and 2 
days after the day of onset of worsening oxygenation, the patient has a temperature of 
38.4°C, and a new antimicrobial agent is started (meropenem, on MV day 9—see 
FAQ no. 6-10). The new antimicrobial agent is continued for at least 4 days (hospital 
days 8 through 11). Therefore, even though the patient was extubated on hospital day 
10 and remained extubated on hospital day 11 (the day on which all IVAC criteria 
were fulfilled), the event should be reported as an IVAC. See figure, below. 
Hosp Day No. 4 5 6 7 8 9 10 11 
MV Day No. 4 5 6 7 8 9 Extubated 
at 11 am 
-- 
VAE Criterion 
-- 
Day 1 of 
stability or 
improvement 
Day 2 of 
stability or 
improvement 
Day 1 of 
worsening 
oxygenation 
Day 2 of 
worsening 
oxygenation 
Temp 
38.4°C 
-- -- 
Antimicrobial 
agent 
Ceftriaxone Ceftriaxone Ceftriaxone Ceftriaxone Meropenem Meropenem Meropenem Meropenem 
6) What antimicrobial agents are included in the IVAC definition?
 See the Appendix for a list of the antimicrobial agents eligible for consideration in the
IVAC definition (as well as the PVAP definition).
 See Table 1 for eligible routes of administration.
7) How do I figure out if an antimicrobial agent is “new” for the IVAC definition?
 A new antimicrobial agent is defined as any agent listed in the Appendix that is
initiated on or after 3 days of mechanical ventilation AND in the VAE Window
Period (defined by the two days before, the day of, and the two days after the onset
date of the VAE—as long as all of these days are on or after the 3rd day of mechanical
ventilation).  The agent is considered new for the purposes of this definition if it was
NOT given to the patient on either of the 2 days preceding the current start date. The
agent must be administered via one of the routes listed in Table 1.
See the example in the figure below:
Patient has fulfilled all IVAC criteria, and 
IVAC should be reported. Date of the 
IVAC event is hospital day/MV day 7. 
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MV Day No. 4 5 6 7 8 9 10 11 
VAE Criterion - - - Onset (day 1) of worsening 
oxygenation meeting VAE PEEP 
or FiO2 thresholds 
Day 2 of worsening oxygenation 
meeting VAE PEEP or FiO2 
thresholds 
- - - 
EXAMPLE: A single dose of intravenous vancomycin is given to a patient on 
the VAE onset date (which is the day of onset of worsening oxygenation 
meeting VAE criteria, in this case MV day 7), and was not given to the patient 
during the 2 previous days (MV days 5 and 6). Vancomycin is therefore 
considered a new antimicrobial agent (see figure below).  
MV Day No. 4 5 6 7 8 9 10 
VAE Criterion 
-- 
Day 1 of 
stability or 
improvement 
Day 2 of 
stability or 
improvement 
Day 1 of 
worsening 
oxygenation 
Day 2 of 
worsening 
oxygenation 
- - 
Antimicrobial 
agent 
None None None 
Single dose of 
vancomycin 
ordered and 
administered 
None None 
Single dose of 
vancomycin 
ordered and 
administered 
EXAMPLE: If meropenem is given to a patient on the VAE onset date (which 
is the day of onset of worsening oxygenation meeting VAE criteria, in this 
case MV day 7), and was not given to the patient during the 2 previous days 
(MV days 5 and 6), then meropenem is considered a new antimicrobial agent 
(see figure below). Note that the patient is also receiving ceftriaxone, and 
receives doses during the 5-day period around the onset of worsening 
oxygenation (first dose during the 5-day period was on MV day 5). However, 
because ceftriaxone was given to the patient the day before the 5-day period 
(on MV day 4), ceftriaxone does not count as a new antimicrobial agent for 
the purposes of the IVAC definition. 
MV Day No. 4 5 6 7 8 9 10 
VAE Criterion 
-- 
Day 1 of 
stability or 
improvement 
Day 2 of 
stability or 
improvement 
Day 1 of 
worsening 
oxygenation 
Day 2 of 
worsening 
oxygenation 
- - 
Antimicrobial 
agent 
Ceftriaxone Ceftriaxone Ceftriaxone Meropenem Meropenem Meropenem Meropenem 
First dose of meropenem during the 5-day period around the onset of worsening 
oxygenation. Note that no meropenem was given in the 2 preceding days, and so 
meropenem is a “new” antimicrobial agent for the purposes of the VAE definition. 
Example of the 5-day period during which the first dose of a new antimicrobial 
agent must be given to meet requirements of IVAC definition 
A single dose of vancomycin is ordered and administered to the patient within the 
period defined by the two days before, the day of, and the two days after the VAE onset 
date. Note that no vancomycin was given in the 2 preceding days, and so vancomycin is 
a “new” antimicrobial agent for the purposes of the VAE definition. 
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8) I have figured out that a new antimicrobial agent was given to the patient. How do I
determine whether it was continued for 4 days?
 Make sure you are using the Medication Administration Record. You need to know
which antimicrobial agents were actually administered to the patient. Antimicrobial
orders or dispensing information is not sufficient.
 You do not need to know the dose or frequency of administration.
 Four consecutive Qualifying Antimicrobial Days (QADs)—starting within the VAE
Window Period—are needed to meet the IVAC criterion. A QAD is a day on which
the patient was administered an antimicrobial agent that was determined to be “new”
within the VAE Window Period. Days between administrations of a new
antimicrobial agent also count as QADs as long as there is a gap of no more than 1
calendar day between administrations of the same antimicrobial agent. For example,
if levofloxacin is given on VAE Day 1, has not been given in the 2 preceding
calendar days, and is given again on VAE Days 3, 5 and 7, there are 7 QADs—
because the days between levofloxacin doses also count as QADs.
 The requirement for 4 consecutive QADs can be met with 4 days of therapy with the
same antimicrobial (with a gap of no more than 1 calendar day between
administrations of that antimicrobial)—or it can be met with 4 days of therapy with
multiple antimicrobial agents, as long as each antimicrobial was started within the
VAE Window Period.
EXAMPLE: In the figure below, meropenem would meet the antimicrobial 
criterion of the IVAC definition because at least one dose was given on 4 
consecutive days. 
MV Day No. 1 2 3 4 5 6 7 
VAE Criterion -- Day 1 of 
Stability or 
improvement 
Day 2 of 
stability or 
improvement 
Day 1 of 
worsening 
oxygenation 
Day 2 of 
worsening 
oxygenation 
- - 
Antimicrobial 
agent 
Ceftriaxone Ceftriaxone Ceftriaxone Meropenem Meropenem Meropenem Meropenem 
QAD No No No Yes Yes Yes Yes 
EXAMPLE: In the figure below, the 3 drugs shown in bold lettering all 
qualify as new antimicrobial agents, and therefore the antimicrobial criterion 
of IVAC is met, since the patient is given 4 consecutive days of new 
antimicrobial agents. 
MV Day No. 1 2 3 4 5 6 7 
VAE Criterion -- Day 1 of 
Stability or 
improvement 
Day 2 of 
stability or 
improvement 
Day 1 of 
worsening 
oxygenation 
Day 2 of 
worsening 
oxygenation 
- - 
Antimicrobial 
agent 
Ceftriaxone Ceftriaxone Ceftriaxone Meropenem Imipenem Piperacillin/ 
Tazobactam 
Piperacillin/ 
Tazobactam 
QAD No No No Yes Yes Yes Yes 
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EXAMPLE: In the figure below, levofloxacin is a new antimicrobial agent (it 
was started during the VAE Window Period, on MV day 3, and was not given 
in the 2 days preceding the first day of administration). There are gaps of no 
more than 1 calendar days between days on which levofloxacin is given, and 
so the intervening days also count as QADs. In this example, there are 5 
QADs (MV days 3-7); therefore the antimicrobial criterion of IVAC is met. 
MV Day No. 1 2 3 4 5 6 7 
VAE Criterion -- Day 1 of 
Stability or 
improvement 
Day 2 of 
stability or 
improvement 
Day 1 of 
worsening 
oxygenation 
Day 2 of 
worsening 
oxygenation 
- - 
Antimicrobial 
agent 
Levofloxacin Levofloxacin Levofloxacin 
QAD No No Yes Yes Yes Yes Yes 
9) There are many patients in my ICU with renal insufficiency and/or who are receiving
hemodialysis. These patients may receive certain antimicrobial agents on an infrequent
dosing schedule (for example, every 48 hours). How do I determine whether they have
received 4 consecutive days of new antimicrobial therapy?
 See above. You do not need to know the patient’s renal function, the dose of the
antimicrobial agent, or the frequency of administration. The antimicrobial criterion
rules remain the same, regardless of whether patients have renal dysfunction or not.
10) What if the patient is being given one-time doses of intravenous vancomycin? How do I
take that into account when using the IVAC surveillance definition?
 The rules for determining whether the antimicrobial criterion is met do not require
that you know the dose or frequency of administration.
 Make sure that vancomycin qualifies as a new antimicrobial agent—that it was not
given in the 2 days preceding the day on which vancomycin was given during the
VAE Window Period.
 Check to see whether there are 4 consecutive QADs with vancomycin; if there are
gaps of no more than 1 calendar day between days on which vancomycin is given, the
intervening days may be counted as QADs. If there are gaps of longer than 1 calendar
day between days of vancomycin therapy, the requirement for 4 consecutive QADs
cannot be met using vancomycin alone—but make sure to check whether the 4
consecutive QAD requirement is met by considering any other antimicrobials being
administered to the patient.
EXAMPLE: A patient is given a single dose of vancomycin 1 gram IV on MV 
day 5. Since vancomycin was started on or after day 3 of mechanical 
ventilation, and no vancomycin was administered on MV days 2, 3 or 4, 
vancomycin qualifies as a new antimicrobial agent. A second, single dose of 
vancomycin 1 gram IV is administered on MV day 8. Because there is a gap 
of more than 1 calendar day between days of vancomycin administration 
(there is a gap of 2 days in this example), the requirement for 4 consecutive 
QADs is not met, and therefore the IVAC antimicrobial criterion is not met.   
- - - - 
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MV Day No. 2 3 4 5 6 7 8 9 
VAE Criterion -- -- Day 1 of 
Stability or 
improvement 
Day 2 of 
stability or 
improvement 
Day 1 of 
worsening 
oxygenation 
Day 2 of 
worsening 
oxygenation 
- - 
Antimicrobial 
agent 
None None None Vancomycin 
1 gram IV x 1 
dose 
None None Vancomycin 
1 gram IV x 1 
dose 
None 
QAD No No No Yes No No Yes No 
 
 
11) Can I report pathogens or secondary BSIs for VAC and IVAC?  
 Pathogens are NOT reported for VAC or IVAC events. 
 Secondary BSIs are NOT reported for VAC or IVAC events.  
 
EXAMPLE: A patient hospitalized and mechanically-ventilated in the MICU 
for 14 days develops worsening oxygenation following a 7-day period of 
stability on the ventilator. VAC criteria are met on hospital day 15 (stable 
ventilator settings on days 12 and 13, increased ventilator settings on days 14 
and 15). The onset date is day 14. The white blood cell count is noted to be 
15,500 cells/mm3 on day 14. Meropenem and intravenous vancomycin are 
begun on day 15, administered through the patient’s right-sided central line, 
which was inserted on ICU admission. The antibiotics continue to be 
administered on day 18, meeting IVAC criteria. Endotracheal aspirate cultures 
done on days 15 and 16 grow scant upper respiratory flora. A blood culture 
collected on day 15 is positive for Klebsiella oxytoca. There are no other signs 
or symptoms of infection. This patient should be reported as having an IVAC 
and a central line-associated BSI if the BSI cannot be attributed as secondary 
to another primary site of infection. The BSI cannot be reported as secondary 
to the IVAC event. 
 
12) Can I report pathogens for PVAP? 
 Pathogens may be reported for PVAP events, provided they are isolated or identified 
from appropriate specimen types according to the requirements of the algorithm and 
are NOT on the list of excluded organisms and culture results: 
o Excluded organisms and culture results that cannot be used to meet the 
PVAP definition are as follows: “Normal respiratory flora,” “normal oral 
flora,” “mixed respiratory flora,” “mixed oral flora,” “altered oral flora” or 
other similar results indicating isolation of commensal flora of the oral 
cavity or upper respiratory tract; Candida species or yeast not otherwise 
specified; coagulase-negative Staphylococcus species; and Enterococcus 
species, when identified from sputum, endotracheal aspirates, 
bronchoalveolar lavage, or protected specimen brushings. Only eligible 
pathogens identified from eligible specimens with a collection date 
occurring in the infection window period can be reported.   
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NOTE: When Candida species or yeast not otherwise specified, coagulase-negative 
Staphylococcus species or Enterococcus species are identified from lung tissue or 
pleural fluid, these organisms may be reported as PVAP pathogens. 
 
Additionally, because organisms belonging to the following genera are usually causes 
of community-associated respiratory infections and rarely or are not known to be 
causes of healthcare-associated infections, they are also excluded, and cannot be used 
to meet the PVAP definition when isolated from any eligible specimen type (to 
include lung and pleural fluid):  Blastomyces, Histoplasma, Coccidioides, 
Paracoccidioides, Cryptococcus and Pneumocystis. 
 
 See Table 3 for the required quantitative culture thresholds associated with various 
specimen types in the PVAP definition. Note that if your laboratory reports semi-
quantitative culture results, you should check with your laboratory to confirm that 
semi-quantitative results match the quantitative thresholds noted in Table 3. 
 
13) Can I report secondary BSIs for PVAP? 
 Secondary BSIs may be reported for PVAP events, provided that the organism 
identified from blood specimen matches an organism identified from an appropriate 
respiratory tract specimen (including respiratory secretions, pleural fluid and lung 
tissue). The respiratory tract specimen must have been collected within 2 calendar 
days before or after the day of onset of worsening oxygenation to be considered as a 
criterion for meeting the PVAP definition. In addition, the positive blood specimen 
must have been collected during the 14-day event period, where day 1 is the day of 
onset of worsening oxygenation. 
o In cases where PVAP is met with only the histopathology criterion and no 
culture or non-culture based test is performed on an eligible respiratory 
specimen, and there is also a positive blood specimen, a secondary BSI for 
VAE is not reported.  
o In cases where a culture or non-culture based test of respiratory secretions, 
pleural fluid or lung tissue is performed and does not identify an organism that 
matches an organism identified from blood, a secondary BSI for VAE is not 
reported. 
 
NOTE: Candida species or yeast not otherwise specified, coagulase-negative 
Staphylococcus species, and Enterococcus species identified from blood cannot 
be deemed secondary to a PVAP, unless the organism was also identified from 
pleural fluid or lung tissue. 
 
EXAMPLE: Patient hospitalized and mechanically ventilated in the MICU for 14 
days develops worsening oxygenation following a 7-day period of stability on the 
ventilator. VAC criteria are met on hospital day 15 (stable ventilator settings on 
days 12 and 13, increased ventilator settings on days 14 and 15). The onset date is 
day 14. The white blood cell count is noted to be 15,500 cells/mm3 on day 14. 
Meropenem and vancomycin are begun on day 15, administered through the 
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patient’s right-sided central line (inserted on ICU admission). The antibiotics 
continue to be administered on day 18, meeting IVAC criteria. Endotracheal 
aspirate specimens collected on days 15 and 16 grow ≥ 105 CFU/ml Klebsiella 
oxytoca. A blood culture collected on day 15 is positive for K. oxytoca. This 
patient should be reported as having a PVAP with a secondary BSI due to K. 
oxytoca. 
 
EXAMPLE: Patient hospitalized and mechanically ventilated in the MICU for 14 
days develops worsening oxygenation following a 7-day period of stability on the 
ventilator. VAC criteria are met on hospital day 15 (stable ventilator settings on 
days 12 and 13, increased ventilator settings on days 14 and 15). The onset date is 
day 14. The white blood cell count is noted to be 15,500 cells/mm3 on day 14. 
Meropenem and vancomycin are begun on day 15, administered through the 
patient’s right-sided central line (inserted on ICU admission). The antibiotics 
continue to be administered on day 18, meeting IVAC criteria. A thoracentesis is 
performed on day 15 at the patient’s bedside using aseptic technique. Pleural fluid 
is sent for culture and grows Candida albicans. A blood culture collected on day 
16 is positive for C. albicans. This patient should be reported as having a PVAP 
with a secondary BSI due to C. albicans. 
 
EXAMPLE: Patient hospitalized and mechanically ventilated in the MICU for 14 
days develops worsening oxygenation following a 7-day period of stability on the 
ventilator. VAC criteria are met on hospital day 15 (stable ventilator settings on 
days 12 and 13, increased ventilator settings on days 14 and 15). The onset date is 
day 14. The white blood cell count is noted to be 15,500 cells/mm3 on day 14. 
Meropenem and vancomycin are begun on day 15, administered through the 
patient’s right-sided central line (inserted on ICU admission). The antibiotics 
continue to be administered on day 18, meeting IVAC criteria. An endotracheal 
aspirate collected on day 15 is a good quality specimen, with ≥ 25 neutrophils and 
≤ 10 squamous epithelial cells per low power field, and grows Staphylococcus 
aureus (qualitative result). A blood culture collected on day 24 is positive for S. 
aureus and for coagulase-negative staphylococci (CoNS). This patient should be 
reported as having a PVAP, with S. aureus reported as the pathogen. A secondary 
BSI should also be reported for the PVAP, since the positive blood culture was 
collected within the 14-day period of the VAE, and an organism isolated from 
blood (S. aureus) matched an organism isolated from culture of the endotracheal 
aspirate. The CoNS also isolated from the blood culture on day 24 is not reported 
as a pathogen for the PVAP because it is an excluded organism.  
 
14) Can I only report pathogens if they are isolated in cultures of appropriate specimens? 
What about pathogens identified by non-culture-based diagnostic testing? 
 PVAP incorporates results of non-culture-based microbiological diagnostic testing. 
For PVAP, pathogens that are grown in culture OR selected pathogens that are 
identified as a result of other laboratory testing (for example, antigen testing, PCR, 
immunohistochemistry, etc.) should be reported. Do not limit reporting to just those 
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organisms isolated in culture. For example, influenza A identified by polymerase 
chain reaction (PCR) in a patient meeting PVAP criteria should be reported as a 
pathogen for that event. 
 
15) The “PVAP” criterion 3 includes “positive diagnostic tests” for Legionella species, and 
selected viruses. What kinds of diagnostic tests can be used to meet the definition? 
 Diagnostic testing practices may vary from facility to facility and change over time as 
better tests are developed. Listed here are some examples of diagnostic tests for 
specific pathogens included in the PVAP definition. Positive results of these tests 
may be used in meeting the PVAP definition. Your facility may use other testing 
methods; positive results obtained using these methods may also be appropriate for 
use in meeting the PVAP definition. If you have a question regarding a diagnostic test 
method, check with your laboratory. 
 For Legionella species, positive results of any of the following, performed on the 
appropriate specimen: urinary antigen, Legionella-specific respiratory culture, paired 
serology (4-fold rise in titer between acute and convalescent specimens), direct 
fluorescent antibody stain, immunohistochemistry stain, or nucleic acid detection 
assays (such as PCR) performed on a respiratory specimen. 
 For respiratory viruses (influenza, respiratory syncytial virus [RSV], parainfluenza 
viruses, human metapneumovirus, coronaviruses, rhinoviruses and adenovirus), 
positive results for any of the following:   
o Performed on an appropriate respiratory specimens – PCR or other viral 
nucleic acid detection methods, antigen detection methods, including rapid 
tests, viral cell culture, or 
o Performed on appropriate pathologic specimens – immunohistochemical 
assays, cytology, microscopy, or 
o Performed on appropriately timed paired sera (acute and convalescent) – 
serological assays demonstrating seroconversion or a significant rise in 
antibody titer.  
 
16) What about pneumonitis that occurs in a mechanically-ventilated patient and is 
determined to be due to herpes simplex virus (HSV) or cytomegalovirus (CMV)? Can 
these infections be reported as VAEs? 
 In most cases pneumonitis due to HSV and CMV represents reactivation of a latent 
infection, and therefore would not be considered healthcare-associated, according to 
the NHSN definition of a healthcare-associated infection.  
 
17) Are there any culture results or microorganisms that CANNOT be used to meet the 
PVAP definition? 
 The following pathogens and culture results may NOT be used to meet the definition 
and may NOT be reported as causes of PVAP when they are identified from sputum, 
endotracheal aspirates, bronchoalveolar lavages or protected specimen brushings:  
o Culture results reported as “Normal respiratory flora,” “normal oral flora,” 
“mixed respiratory flora,” “mixed oral flora,” “altered oral flora” or other 
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similar results indicating isolation of commensal flora of the oral cavity or 
upper respiratory tract. 
o Candida species or yeast not otherwise specified 
o Coagulase-negative Staphylococcus species 
o Enterococcus species 
 
NOTE: These organisms are excluded because they are common upper respiratory 
tract commensals, colonizers or contaminants, and are unusual causes of VAP. Their 
exclusion from the surveillance definitions should NOT be used in clinical decision-
making regarding patient treatment. Providers must independently determine the 
clinical significance of these organisms identified from respiratory specimens and the 
need for treatment. 
 
NOTE: When Candida species or yeast not otherwise specified, coagulase-negative 
Staphylococcus species or Enterococcus species are identified from lung tissue or 
pleural fluid, these organisms may be reported as PVAP pathogens. 
 
Additionally, because organisms belonging to the following genera are typically 
causes of community-associated respiratory infections and are rarely or are not 
known to be causes of healthcare-associated infections, they are also excluded, and 
cannot be used to meet the PVAP definition when isolated from any eligible 
specimen type (to include lung and pleural fluid):  Blastomyces, Histoplasma, 
Coccidioides, Paracoccidioides, Cryptococcus and Pneumocystis. 
 
 When sputum, endotracheal aspirate, bronchoalveolar lavage or protected specimen 
brushing culture or non-culture based testing results are mixed and contain one or 
more of the excluded pathogens in addition to one or more non-excluded pathogens, 
the culture may be used to meet the PVAP definition (depending on whether a 
qualitative, semi-quantitative or quantitative culture was performed, and whether the 
semi-quantitative or quantitative cfu/ml thresholds were met) BUT only the non-
excluded pathogen(s) should be reported. 
 
EXAMPLE: Patient intubated and mechanically ventilated in the MSICU meets 
IVAC criteria on day 8 of mechanical ventilation. On the day after the onset of 
worsening oxygenation, an endotracheal aspirate is collected. The Gram stain shows 
≥ 25 neutrophils and ≤ 10 squamous epithelial cells per low power field, and the 
culture grows “heavy Staphylococcus aureus” and “heavy Candida albicans.” This 
patient should be reported as having a PVAP (criterion1) due to Staphylococcus 
aureus – as long as the semi-quantitative result “heavy” is equivalent to the 
quantitative threshold of ≥ 105 cfu/ml for endotracheal aspirates. If the semi-
quantitative result is not equivalent to the quantitative threshold of ≥ 105 cfu/ml for 
endotracheal aspirates, the patient should still be reported as PVAP (criterion 2). 
Candida albicans from the endotracheal aspirate culture is not reported, because it is 
an excluded result. 
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18) What about organisms identified from pleural fluid and lung tissue specimens? Can I 
report any pathogen identified from a lung tissue, or from a pleural fluid specimen, 
assuming the specimen was obtained during thoracentesis or at the time of chest tube 
insertion? 
 Any pathogen identified from lung tissue, when that lung tissue was obtained during 
an open lung biopsy, video-assisted thoracoscopic surgery, or via other transthoracic 
or transbronchial biopsy approach, may be reported with the exception of the 
excluded pathogens belonging to the following genera: Blastomyces, Histoplasma, 
Coccidioides, Paracoccidioides, Cryptococcus and Pneumocystis. 
 Any pathogen identified from pleural fluid, when that fluid was obtained during 
thoracentesis or at the time of initial chest tube insertion, may be reported with the 
exception of the excluded pathogens belonging to the following genera: Blastomyces, 
Histoplasma, Coccidioides, Paracoccidioides, Cryptococcus and Pneumocystis. 
 
19) How are “purulent respiratory secretions” defined? 
 Purulent respiratory secretions used to meet Criterion #2 of the PVAP definition are 
defined as: 
o Secretions from the lungs, bronchi, or trachea with ≥ 25 neutrophils and ≤ 
10 squamous epithelial cells per low power field [lpf, x100].   
o If the laboratory reports semi-quantitative results, you should check with 
your laboratory to be certain that the semi-quantitative results match the 
quantitative thresholds noted above. 
 If your laboratory is not able to provide additional information on how a semi-
quantitative reporting system corresponds to quantitative reporting ranges for 
neutrophils and squamous epithelial cells, here is some guidance from the Clinical 
Microbiology Procedures Handbook (3rd ed., 2010)*: 
 
1+ = occasional or rare = <1 cell per low power field [lpf, x100] 
2+ = few = 1-9 cells per low power field [lpf, x100] 
3+ = moderate = 10-25 cells per low power field [lpf, x100] 
4+ = heavy = >25 cells per low power field [lpf, x100] 
 
*Reference: Garcia, LS (Ed.). (2010). Clinical Microbiology Procedures Handbook. Herndon, VA: ASM Press, page 
3.2.1.16. 
o With this range in mind, and in the absence of additional information from 
your laboratory, “purulent respiratory secretions” are defined as secretions 
that contain heavy, 4+ or ≥25 neutrophils per low power field [lpf, x100] 
AND rare, occasional, few, 1+ or 2+, or ≤10 squamous epithelial cells per 
low power field [lpf, x100]. 
 
 If your laboratory uses a different reporting format for results of direct 
examination of respiratory secretions, you may still be able to use the purulent 
respiratory secretions in meeting the PVAP definition. See the instructions 
available in the VAE Protocol, Table 2.  
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20) What is the definition of “positive lung histopathology” that can be used to meet the 
PVAP definition? 
 If the lung tissue specimen was obtained via open lung biopsy, video-assisted 
thoracoscopic surgery, or via other transthoracic or transbronchial biopsy approach, it 
is eligible for consideration in meeting the PVAP definition (Criterion 3).  
 Histopathological findings that can be used to meet the PVAP definition include: 
o Abscess formation or foci of consolidation with intense neutrophil 
accumulation in bronchioles and alveoli; 
o Evidence of lung parenchyma invasion by fungi (hyphae, pseudohyphae or 
yeast forms); 
o Evidence of infection with the viral pathogens listed in FAQ no. 14 based 
on results of immunohistochemical assays, cytology, or microscopy 
performed on lung tissue. 
 Additionally, lower respiratory specimen cytology findings suggestive of infection 
are eligible for consideration in meeting the PVAP definition (Criterion 3). 
 
21) I am still having trouble understanding the time frame that defines a VAE. Can you 
explain what is meant by this statement that appears in the algorithm: “On or after 
calendar day 3 of mechanical ventilation and within 2 calendar days before or after the 
onset of worsening oxygenation”? 
 The intent of these criteria is to determine whether a VAC is due to an infectious 
process (IVAC) and/or pneumonia (PVAP) by looking for corroborating 
inflammatory and infectious signs at the time of VAC onset.  The criterion, “on or 
after calendar day 3” is intended to exclude inflammatory and infectious signs present 
on the first two days of mechanical ventilation because they are more likely to be due 
to pre-existing conditions than ventilator-acquired complications. The criterion, 
“within 2 calendar days before or after the onset of worsening oxygenation,” is 
intended to identify infectious and inflammatory signs that arise at the same time as 
VAC and may therefore point to the cause of the VAC.  + 
 The figures below illustrate the time frame that defines a VAE. The event date is the 
first day of worsening oxygenation, defined by the PEEP and FiO2 thresholds 
outlined in the algorithm. The event date defines the time frame within which all 
other criteria must be met. In the examples below, the shaded area defines the VAE 
Window Period in which IVAC criteria (temperature or white count abnormalities, 
plus a new antimicrobial agent started and continued for at least 4 days) must be met, 
and in which a PVAP criterion must be met. 
 
NOTE: Keep in mind that VAE criteria must be met based on specimens collected or 
antimicrobial agents started after day 2 of mechanical ventilation. 
 
EXAMPLE 1: When the onset date of the VAE occurs early in the course of 
mechanical ventilation (for example, day 3 or 4 of mechanical ventilation), the period 
in which certain inflammatory and infectious criteria are sought for IVAC and PVAP 
is shorter, because the first 2 days of mechanical ventilation are excluded from the 
normal 5 day window surrounding the day of increased ventilator support. 
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MV Day No. 1 2 3 4 5 6 7 
Worsening oxygenation  -- Day 1 of 
Stability or 
improvement 
Day 2 of 
stability or 
improvement 
Day 1 of 
worsening 
oxygenation 
Day 2 of 
worsening 
oxygenation 
- - 
Temperature abnormality or 
white blood cell count 
abnormality 
- 
- 
An abnormal temperature or white blood cell count, according 
to the algorithm parameters, must be documented within this 
shaded period 
- 
Antimicrobial agent - 
- 
New agent must be started on any day within this shaded 
period, and then continued for at least 4 days 
- 
Purulent respiratory secretions, 
positive culture, positive 
histopathology 
- 
- 
Specimen must be collected on any day within this shaded 
period 
- 
 
 
EXAMPLE 2: When the onset date of the VAE occurs later in the course of 
mechanical ventilation, the period in which certain criteria must be met is a day 
longer, because the patient has already been on mechanical ventilation for more than 
3 days and therefore inflammatory and infectious signs arising anywhere in the full 5-
day window surrounding the day of increased ventilator settings can count towards 
IVAC and PVAP. 
 
MV Day No. 10 11 12 13 14 15 16 
Worsening oxygenation  -- Day 1 of 
Stability or 
improvement 
Day 2 of 
stability or 
improvement 
Day 1 of 
worsening 
oxygenation 
Day 2 of 
worsening 
oxygenation 
- - 
Temperature abnormality or 
white blood cell count 
abnormality 
- 
An abnormal temperature or white blood cell count, according to the algorithm 
parameters, must be documented within this shaded period 
- 
Antimicrobial agent - New agent must be started on any day within this shaded period, and then 
continued for at least 4 days 
- 
Purulent respiratory secretions, 
positive culture, positive 
histopathology 
- 
Specimen must be collected on any day within this shaded period 
- 
 
22) Providers in my ICU use different types of mechanical ventilation for different patients. 
Can you explain the circumstances in which mechanically-ventilated patients are to be 
excluded from VAE surveillance, and the circumstances in which mechanically-
ventilated patients should be included in VAE surveillance? 
 VAE surveillance is restricted to adult inpatient locations. Patients on mechanical 
ventilation who are in adult inpatient locations in acute care and long-term acute care 
hospitals and inpatient rehabilitation facilities are eligible for inclusion in VAE 
surveillance.  
 Patients are excluded from VAE surveillance during periods of time when they are 
receiving high frequency ventilation, or if they are receiving extracorporeal life 
support (extracorporeal membrane oxygenation). 
 Patients are included in surveillance if they are on a ventilator (as defined in the VAE 
surveillance protocol), and are being mechanically ventilated through an endotracheal 
or tracheostomy tube using a conventional mode of mechanical ventilation (such as 
volume controlled, pressure controlled, or pressure support mechanical ventilation). 
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o Patients on conventional mechanical ventilation who are receiving nitric 
oxide, helium-oxygen mixtures (heliox) or epoprostenol therapy are 
included in surveillance. 
o Patients on conventional mechanical ventilation who are being ventilated 
in the prone position are included in surveillance. 
 Patients are also included in surveillance if they are on a ventilator (as defined in the 
VAE surveillance protocol), and are being mechanically ventilated through an 
endotracheal or tracheostomy tube using Airway Pressure Release Ventilation 
(APRV) or related modes. Some terms that are used to indicate APRV or a related 
mode of mechanical ventilation include (but may not be limited to): BiLevel, Bi Vent, 
BiPhasic, PCV+, and DuoPAP. 
o For patients on APRV or related modes, the period of worsening 
oxygenation following a period of stability or improvement on the 
ventilator that is required for identification of a VAE will be defined by 
the FiO2 criterion within the VAE surveillance definition algorithm. The 
PEEP criterion may not be applicable in patients on APRV or related 
modes of mechanical ventilation.  
 If you have questions about mechanical ventilation, you should check with the 
Respiratory Care or Respiratory Therapy and/or Critical Care departments in your 
facility. 
 
23) Do I need to indicate if a patient was on APRV at the time of VAE onset, and do I need 
to indicate the number of patients on APRV in my ICU for each day of VAE 
surveillance? 
 If the VAE occurred in a patient on Airway Pressure Release Ventilation (APRV) or a 
related mode of mechanical ventilation (for example, BiLevel, Bi Vent, BiPhasic, 
PCV+, DuoPAP) at the time of VAE onset, responding “Yes”.in the “APRV” field is 
optional on the VAE Form (CDC 57.112). Otherwise, indicate “No.” 
 On the appropriate denominator form (CDC 57.117 or 57.118); in the column for 
“Number of patients on a ventilator,” you will see that there are two sub-columns. In 
the sub-column, “Total patients,” enter the total number of patients on a ventilator on 
that day. It is optional to provide,the “Number on APRV,” in the sub-column . If 
provided, enter the number for the subset of patients on a ventilator on that day who 
are on the APRV mode of mechanical ventilation or related modes (for example, 
BiLevel, Bi Vent, BiPhasic, PCV+, DuoPAP) at the time the count is performed. If 
there are no patients on APRV or a related mode of mechanical ventilation, enter “0” 
(zero).  
 
 
24) My laboratory only performs semi-quantitative cultures of lower respiratory tract 
specimens, and cannot provide me with additional guidance to help me know what semi-
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quantitative culture result corresponds to the quantitative thresholds specified in 
Criterion1 of the PVAP definition. Can you provide more information? 
 For the purposes of this surveillance, and in the absence of additional information 
available from your laboratory, a semi-quantitative result of “moderate” or “heavy” 
growth, or 2+, 3+ or 4+ growth, meets the PVAP definition (Criterion 1). 
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Background: Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
Enterococcus spp. (VRE), and certain gram-negative bacilli have increased in prevalence in 
U.S. hospitals over the last three decades, and have important implications for patient safety. 
There is concern about these multidrug-resistant organisms (MDROs) as options for treating 
patients with these infections are often extremely limited, and MDRO infections are associated 
with increased lengths of stay, costs, and mortality. Many of these traits have also been 
observed for Clostridium difficile infection (CDI). The Healthcare Infection Control Practices 
Advisory Committee (HICPAC) has approved guidelines for the control of MDROs.1 These 
guidelines are available at 
https://www.cdc.gov/infectioncontrol/guidelines/MDRO/index.html).  The MDRO and CDI 
module of the NHSN can provide a tool to assist facilities in meeting some of the criteria 
outlined in the guidelines.  In addition, many of the metrics used in this module are consistent 
with “Recommendations for Metrics for Multidrug-Resistant Organisms in Healthcare Settings: 
SHEA/HICPAC Position Paper.”2  
 
Clostridium difficile (C. difficile) is responsible for a spectrum of C. difficile infections (CDI), 
including uncomplicated diarrhea, pseudomembranous colitis, and toxic megacolon, which can, 
in some instances, lead to sepsis and even death.  Although CDI represents a subset of 
gastrointestinal tract infections in the current CDC definitions for HAIs, specific standard 
definitions for CDI 3 should be incorporated to obtain a more complete understanding of how 
C. difficile is being transmitted in a healthcare facility.  
  
As outlined in the HICPAC guideline1, these MDRO and C. difficile pathogens may require 
specialized monitoring to evaluate if intensified infection control efforts are required to reduce 
the occurrence of these organisms and related infections. The goal of this module is to provide 
a mechanism for facilities to report and analyze these data that will inform infection prevention 
professionals of the impact of targeted prevention efforts.  
 
This module contains two core reporting options for MDRO and C. difficile – Laboratory 
Identified (LabID) Event reporting and Infection Surveillance reporting.  These reporting 
options function as two separate and independent reporting methods - one focused on 
laboratory based reporting and the second on infection criteria based surveillance reporting. 
Reporting options are summarized in Table 1. Participants may choose either one or both of 
these reporting options and then may also choose to participate in any of the supplemental 
monitoring methods described in Table 1.  
 
See Appendix 3: Differentiating Between LabID Event and Infection Surveillance for key 
differences between the two options.  
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Table 1.  Core and Supplemental Reporting Choices for MDRO and CDI Module 
 
 MDRO  CDI 
Reporting Choices 
MRSA  or 
MRSA/MSSA 
VRE 
CephR-Klebsiella, CRE 
(E. coli, Enterobacter, 
Klebsiella), 
Acinetobacter spp. (MDR) 
C. difficile 
Core Method Method Method Method 
Proxy Infection 
Measures 
LabID Event 
Choose ≥1 organism 
A, B, C, D A, B, C, D A, B, C, D ±A, B, C 
AND/OR     
Infection 
Surveillance 
Choose ≥1 organism 
 
A, B 
 
A, B 
 
A, B 
 
±A, B 
Supplemental Method Method Method Method 
Prevention Process 
Measures 
Options: 
 Hand Hygiene 
Adherence 
 Gown and 
Gloves Use 
Adherence 
 Active 
Surveillance 
Testing (AST) 
Adherence 
 
 
 
B 
 
 
B 
 
 
 
B 
 
 
 
B 
 
 
B 
 
 
 
B 
 
 
 
B 
 
 
B 
 
 
 
N/A 
 
 
 
B 
 
 
B 
 
 
 
N/A 
AST Outcome 
Measures 
 Incident and 
Prevalent Cases 
using AST 
 
B 
 
B 
 
N/A 
 
N/A 
N/A – not available or contraindicated 
 
±No surveillance for CDI will be performed in Neonatal Intensive Care Units (NICU), 
Specialty Care Nurseries (SCN), babies in LDRP (Labor, Delivery, Recovery, and Post-
partum), well-baby nurseries, or well-baby clinics.  And, if conducting facility-wide monitoring 
(Method C) the denominator counts (admissions, patient-days, encounters) for these locations 
must be removed.  
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Reporting Method (must choose to monitor by LabID Event or Infection Surveillance reporting 
before supplemental methods can also be used for monitoring): 
 
A: Facility-wide by location. Report for each location separately and cover all locations in  
a facility. This reporting method requires the most effort, but provides the most detail 
for local and national statistical data.  
 
B: Selected locations within the facility (1 or more). Report separately for one or more 
specific locations within a facility. This includes reporting individual Events and 
denominator data for each of the selected locations. This reporting method is ideal for 
use during targeted prevention programs.  
Note: MDRO “Blood Specimens Only” monitoring is the only MDRO LabID event 
reporting option for IRF, ED and 24-hr Observation locations. For Inpatient locations 
other than IRF, ED and 24-hr Observation (examples: IPF, Medical, Surgical, etc.) ‘All 
Specimens” monitoring is the only MDRO LabID event reporting option.  
C: Overall facility-wide. Report individual LabID events from each inpatient location and 
total denominator counts for the entire facility. Options include:  
(1) Overall Facility-wide Inpatient (FacWideIN) to cover all inpatient locations. When 
using FacWideIN reporting, facilities must also include location specific reporting 
for outpatient emergency department (adult and pediatric) and 24-hr Observation 
location(s).  
Note: When following FacWideIN, facilities must enter denominators for all inpatient 
locations physically located in the hospital, as well as denominators for all inpatient 
locations minus any inpatient rehabilitation facility (IRF) and inpatient psychiatric 
facility (IPF) locations with separate CCNs. Totals reported should not include 
facilities affiliated with the hospital that are enrolled separately. Additionally, separate 
denominator data will be required to capture encounters for each mapped emergency 
department and 24-hr observation location.  
(2) Overall Facility-wide Outpatient (FacWideOUT) to cover all outpatient locations 
affiliated with the facility. Facilities may choose to monitor FacWideOUT in 
addition to FacWideIN monitoring.  
D: Overall facility-wide: Blood Specimens Only. This method is available for MDRO 
LabID Events only and targets the most invasive events. Report individual LabID 
events from each inpatient location and total denominator counts for the entire facility. 
Options include: 
(1) Overall Facility-wide Inpatient (FacWideIN) to cover all inpatient locations. Using 
this option, facilities must also include location specific reporting for outpatient 
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emergency department (specifically, adult and pediatric) and 24-hr observation 
location(s). 
Note: When following FacWideIN, facilities must enter denominators for all inpatient 
locations physically located in the hospital, as well as denominators for all inpatient 
locations minus any inpatient rehabilitation facility (IRF) and inpatient psychiatric 
facility (IPF) locations with separate CCNs.  Totals reported should not include 
facilities affiliated with the hospital that are enrolled separately. Additionally, separate 
denominator data will be required to capture encounters for each mapped emergency 
department and 24-hr observation location.  
(2) Overall Facility-wide Outpatient (FacWideOUT) to cover all outpatient locations 
affiliated with the facility. Facilities may choose to monitor FacWideOUT in 
addition to FacWideIN monitoring.  
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Core Reporting 
Option 1: Laboratory-Identified (LabID) Event Reporting 
 
Introduction: LabID Event reporting option allows laboratory testing data to be used without 
clinical evaluation of the patient, and therefore is a much less labor-intensive method to track 
MDROs and C. difficile. These provide proxy infection measures of MDRO and/or C. difficile 
healthcare acquisition, exposure burden, and infection burden based almost exclusively on 
laboratory data and limited admission date data, including patient care location. LabID Event 
reporting is ONLY for collecting and tracking positive laboratory results (for example, positive 
cultures) that are collected for “clinical” purposes (specifically, specifically for diagnosis and 
treatment). This means that the results of laboratory specimens collected for active surveillance 
testing (AST) purposes only should not be reported as LabID Events.  
 
Key points for LabID Event Reporting: 
 LabID Events can be monitored at the overall facility-wide level for inpatient areas 
(FacWideIN), and/or at the overall facility-wide level for outpatient areas (FacWideOUT).  
 At the Overall facility-wide levels and for IRF, ED, and 24-hour observation, MDROs can 
be monitored for All Specimen types or for Blood Specimens Only.  All other locations can 
only monitor for All Specimen types. 
 LabID Events can be monitored for specific locations and require unique denominator data 
from each of the specific locations (specifically, facility-wide locations monitored 
separately [Method A] allowing for both facility-wide and location-specific data, or by 
selected locations only [Method B]).  
 A facility choosing to conduct FacWideIN surveillance for LabID Events must also follow 
location-specific surveillance for that same organism in each outpatient emergency 
department (pediatric and adult) and 24-hour observation location. 
 
Laboratory and admission data can be used to calculate a variety of distinct proxy measures 
including: admission prevalence rate and overall patient prevalence rate (measures of exposure 
burden), MDRO bloodstream infection incidence rate (measure of infection burden and 
healthcare acquisition), overall MDRO infection/colonization incidence rate (measure of 
healthcare acquisition), and CDI incidence rate (measure of infection burden and healthcare 
acquisition).   
 
Use NHSN forms to collect all required data, using the definitions of each data field as 
indicated in the Tables of Instructions.  When denominator data are available from electronic 
databases, these sources may be used as long as the counts are not substantially different (+ or – 
5%) from manually collected counts.  
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MDRO LabID Event Reporting 
Methodology: Facilities may choose to monitor one or more of the following MDROs: MRSA, 
MRSA and MSSA, VRE, CephR- Klebsiella, CRE, and/or multidrug-resistant Acinetobacter 
spp. (see definitions below). For S. aureus, both the resistant (MRSA) and the susceptible 
(MSSA) phenotypes can be tracked to provide concurrent measures of the susceptible 
pathogens as a comparison to those of the resistant pathogens in a setting of active MRSA 
prevention efforts.   
Note:  No Active Surveillance Culture/Testing (ASC/AST) results are to be included in this 
reporting of individual results (See General Key Terms chapter).  Do NOT enter surveillance 
nasal swabs or other surveillance cultures as reports of LabID Events.  AST tracking should be 
recorded under Process & Outcome Measures. 
MDRO Definitions: MDROs included in this module are defined below. 
MRSA: 
MSSA: 
VRE: 
CephR-
Klebsiella: 
CRE: 
Includes S. aureus cultured from any specimen that tests oxacillin-resistant, 
cefoxitin-resistant, or methicillin-resistant by standard susceptibility testing 
methods, or by a laboratory test for  MRSA detection from isolated 
colonies; these methods may also include a positive result by any FDA-
approved test for MRSA detection from specific sources. 
S. aureus cultured from any specimen testing intermediate or susceptible to 
oxacillin, cefoxitin, or methicillin by standard susceptibility testing 
methods, or by a negative result from a test that is FDA-approved for 
MRSA detection from isolated colonies; these methods may also include a 
positive result from test for MSSA detection from specific specimen sources
Enterococcus faecalis, Enterococcus faecium, or Enterococcus species 
unspecified (only those not identified to the species level) that is resistant to 
vancomycin, by standard susceptibility testing methods or by results from 
any FDA-approved test for VRE detection from specific specimen sources.  
Klebsiella oxytoca or Klebsiella pneumoniae testing non-susceptible 
(specifically, either resistant or intermediate) to ceftazidime, cefotaxime, 
ceftriaxone, or cefepime.  
Any Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, or 
Enterobacter spp. testing resistant to imipenem, meropenem, doripenem, or 
ertapenem by standard susceptibility testing methods (specifically,  
minimum inhibitory concentrations of ≥4 mcg/mL for doripenem, imipenem 
and meropenem or ≥2 mcg/mL for ertapenem) OR by production of a 
carbapenemase (specifically, KPC, NDM, VIM, IMP, OXA-48) 
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MDR-
Acinetobacter: 
demonstrated using a recognized test (examples: polymerase chain reaction, 
metallo-β-lactamase test, modified-Hodge test, Carba-NP). Note: For in-
plan CRE surveillance, facilities must conduct surveillance for all three 
organisms CRE-E.coli, CRE-Enterobacter, and CRE-Klebsiella (Klebsiella 
oxytoca and Klebsiella pneumoniae). 
Any Acinetobacter spp. testing non-susceptible (specifically, either resistant 
or intermediate) to at least one agent in at least 3 antimicrobial classes of the 
following 6 antimicrobial classes: 
Class Antimicrobial Class Antimicrobial 
Aminoglycosides: Amikacin 
Gentamicin 
Tobramycin 
β-lactam/β-lactam       
β-lactamase 
inhibitor 
combination: 
Piperacillin 
Piperacillin/tazobactam 
Carbapenems: Imipenem 
Meropenem 
Doripenem 
Cephalosporins: Cefepime 
Ceftazidime 
Fluoroquinolones: Ciprofloxacin 
Levofloxacin 
Sulbactam: Ampicillin/sulbactam 
Settings:  MDRO LabID Event reporting can occur in any location: inpatient or outpatient.  
Requirements: Facilities choose at least one of the reporting methods listed below and report 
data accordingly: 
Note: Facilities must indicate each reporting choice chosen for the calendar month on the 
Patient Safety Monthly Reporting Plan (CDC 57.106).     
For each MDRO being monitored, all MDRO test results are evaluated using either the 
algorithm in Figure 1 (All Specimens) or Figure 2 (Blood Specimens only) to determine 
reportable LabID events for each calendar month, for each facility location as determined by 
the reporting method chosen. If monitoring all specimens, all first MDRO isolates 
(chronologically) per patient, per month, per location are reported as a LabID event regardless 
of specimen source [EXCLUDES tests related to active surveillance testing] (Figure 1); if a 
duplicate MDRO isolate is from blood, or if monitoring blood specimens only, it is reported as 
a LabID event only if it represents a unique blood source [specifically, no prior isolation of the 
MDRO in blood from the same patient and location in ≤2 weeks, even across calendar months] 
(Figures 1 & 2). As a general rule, at a maximum, there should be no more than 3 blood isolates 
reported, which would be very rare. If monitoring all specimens and a blood isolate is entered 
as the first specimen of the month, then no non-blood specimens can be entered that month for 
that patient and location. Report each LabID Event individually on a separate form.  
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Table 2: Reporting Options for the MDRO Module 
Method 
Numerator Data Reporting by 
Location 
Denominator Data Reporting 
Facility-wide by location 
Note: Must monitor All 
Specimen sources 
Enter each MDRO LabID Event 
reported by location 
Report separate denominators for each 
location in the facility as specified in the 
NHSN Monthly Reporting Plan 
Selected locations 
Note: Must monitor All 
Specimen sources with the 
exception of IRF units, 24-
hour observation, and 
emergency department 
Enter each MDRO LabID Event 
reported by selected locations 
Report separate denominators for each 
Selected location(s) monitored as specified 
in the NHSN Monthly Reporting Plan 
Overall Facility-wide 
Inpatient (FacWideIN), 
All Specimen  
Enter each MDRO LabID 
Specimen Event from all inpatient 
locations AND separately for 
outpatient emergency department, 
and 24-hour observation 
location(s) 
Report total denominator data for all 
inpatient locations physically located in 
the hospital (for example, total number of 
admissions and total number of patient 
days), as well as denominators for all 
inpatient locations minus inpatient 
rehabilitation facility and inpatient 
psychiatric facility locations with separate 
CCNs 
 Separate denominators should be entered
for each mapped outpatient emergency
department and 24-hour observation
location(s)
Overall Facility-wide 
Outpatient (FacWideOUT), 
All Specimen 
Enter each MDRO LabID Event 
from all affiliated outpatient 
locations separately 
Report total denominator data for all 
outpatient locations (for example, total 
number of encounters, including ED and 
OBS encounters in addition to other 
outpatient locations) 
Overall Facility-wide 
Inpatient (FacWideIN), 
Blood Specimen Only 
Enter each MDRO LabID Blood 
Specimen Event from all inpatient 
locations AND separately for 
outpatient emergency department, 
and 24-hour observation 
location(s) 
Report total  denominator data for all 
inpatient locations physically located in 
the hospital (for example, total number of 
admissions and total number of patient 
days), as well as denominators for all 
locations minus inpatient rehabilitation 
facility and inpatient psychiatric facility 
locations with separate CCNs 
 Separate denominators should be entered
for each mapped outpatient emergency
department and 24-hour observation
location(s)
Overall Facility-wide 
Outpatient (FacWideOUT), 
Blood Specimen Only 
Each MDRO LabID Blood 
Specimen Event from all affiliated 
outpatient locations by location 
Total denominator data for all outpatient 
locations (for example, total number of 
encounters) 
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Definitions: 
MDRO Isolate:  Any specimen, obtained for clinical decision making, testing positive for an 
MDRO (as defined above). Note: Excludes tests related to active surveillance testing. 
Duplicate MDRO Isolate:  If monitoring all specimens, any subsequent MDRO isolate from the 
same patient and location after the first isolate of the specific MDRO during a calendar month, 
regardless of specimen source, except unique blood source (Figure 1). 
EXAMPLE: On January 2, a newly admitted ICU patient has a positive MRSA urine 
culture. The following week, while still in the ICU, the same patient has MRSA 
cultured from an infected decubitus ulcer. The MRSA wound culture is considered a 
duplicate MDRO isolate, since it is the second non-blood MRSA isolate collected from 
the same patient and location during the same calendar month. 
Unique Blood Source: A MDRO isolate from blood in a patient with no prior positive blood 
culture for the same MDRO and location in ≤14 days, even across calendar months and 
different facility admissions (Figure 2).  There should be 14 days with no positive blood culture 
result for the patient, MDRO, and location before another Blood LabID Event is entered into 
NHSN for the patient, MDRO, and location. Additionally, if following all specimens, the first 
MDRO for the patient, month, and location should be reported. The date of specimen collection 
is considered Day 1.  
Note: NHSN recommends that facilities keep an internal line listing log of all positive isolates 
for reference in LabID event reporting. 
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EXAMPLE:  
Monitoring Blood 
Specimens only 
with multiple 
isolates from 
same location 
On January 1, an ICU patient has a positive MRSA urine culture which is 
not entered into NHSN because blood specimens only are being 
monitored. On January 2, while in the same location (ICU), the same 
patient has a positive MRSA blood culture which is entered into NHSN. 
This starts the 14 day count.  On January 5, while in the same location 
(ICU), the same patient has another positive MRSA blood culture which is 
not entered into NHSN because it has not been 14 days since the original 
positive MRSA blood culture while in the same location. The January 5 
positive blood culture starts a new 14 day count.  On January 19, while in 
the same location (ICU), the same patient has another positive MRSA 
blood culture.  The January 19 MRSA blood culture is entered into NHSN 
because it has been > 14 days since the patient’s most recent positive blood 
culture (January 5) while in the same location (January 19 is day 15).   
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EXAMPLE: 
Monitoring All 
Specimens with 
multiple isolates 
from same 
location 
On January 1, an ICU patient has positive MRSA urine culture which is 
entered into NHSN because it is the first MDRO isolate of the month for 
this patient. On January 2, while in the same location (ICU), the same 
patient has a positive MRSA blood culture which is entered into NHSN 
because it is the first positive MRSA blood isolate for the month. No other 
non-blood MRSA isolates should be reported for the month for this patient 
and location as these would represent duplicate isolates. Any additional 
MRSA positive blood isolates for the month should be reported following 
the same 14-day rule as when reporting Blood Specimens only. Subsequent 
months should be reported in the same manner.   
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Laboratory-Identified (LabID) Event: All non-duplicate MDRO isolates from any specimen 
source and unique blood source MDRO isolates. [EXCLUDES tests related to active 
surveillance testing]. Even if reporting at the FacWide level, all reporting must follow rules by 
location for reporting. 
Notes: A LabID Event calculator is available on the NHSN website to help with data entry 
decision making around the 14-day rule.  
EXAMPLE #1:  
Monitoring Blood 
Specimens only 
with isolates from 
ED & inpatient 
location  
If monitoring blood specimens for FacWideIN (which requires 
surveillance in the emergency department and 24-hour observation 
locations), a patient has a positive MRSA laboratory isolate while in the 
emergency department (ED). This specimen represents an MRSA LabID 
Event and should be entered for the outpatient emergency department. 
The next calendar day, the same patient is admitted to ICU and three days 
later, has a second positive MRSA blood specimen. This specimen also 
represents a unique LabID Event, because it is the first positive blood 
specimen in this location (ICU). Note:  while this patient has two LabID 
Events, the second specimen taken from the ICU will be removed from 
most analysis reports. 
EXAMPLE #2: 
Monitoring All 
Specimens 
If monitoring all specimens, on January 2, a newly admitted ICU patient 
with no previous positive laboratory isolates during this admission has a 
positive MRSA urine culture. This specimen represents a LabID Event 
since it is the first MRSA isolate for the patient, the location, and the 
calendar month. 
EXAMPLE #3: 
Monitoring All 
Specimens with 
isolates from ED 
& inpatient 
location 
If monitoring all specimens for FacWideIN surveillance, on January 2, a 
VRE wound culture is collected from the facility’s own ED.  The patient 
is then admitted to 4W the next calendar day. The ED culture result must 
be entered as an outpatient LabID event for the ED location for January 2, 
as the ED location is included in FacWideIN surveillance and reporting.   
EXAMPLE #4: 
Monitoring Blood 
Specimens only 
with multiple 
blood isolates  
If monitoring blood specimens only, on January 26, a newly admitted ICU 
patient with no previous positive laboratory isolates during this admission 
has a positive MRSA urine culture which is not entered as a LabID Event 
since blood specimens only are being monitored. The following day, 
while in the same location, the same patient has a positive MRSA blood 
culture. This specimen represents a LabID Event since it is a unique blood 
source (the first MRSA blood isolate for the same patient and same 
location). While remaining in ICU, the same patient has another positive 
blood culture on February 5. This does not represent a new LabID Event 
since it has not been >14 days since the most recent MRSA positive blood 
isolate for this patient and location.  
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Reporting Instructions: 
 All LabID Events must be reported by location
 LabID event reporting is separate and independent of events reported through MDRO
Infection Surveillance reporting and/or HAIs reported through the Device-associated
and/or Procedure-associated Modules.
 For instructions on unique reporting scenarios, see Appendix 1. Guidance for Handling
MDRO and CDI Module Infection Surveillance and LabID Event Reporting When Also
Following Other NHSN Modules
 For additional reporting information, see Appendix 3. Differentiating Between LabID
Event and Infection Surveillance
Note: When determining a patient’s admission dates to both the facility and specific 
inpatient location, the NHSN user must take into account any days spent in an 
inpatient location as an “observation” patient before being officially admitted as 
an inpatient to the facility, as these days contribute to exposure risk.  Therefore, 
all days spent in an inpatient unit, regardless of admission and/or billing status 
are included in the counts of admissions and inpatient days for the facility and 
specific location; for NHSN reporting purposes, the date admitted to the facility 
is the calendar date that the patient physically locates to an inpatient location.  
Numerator Data:  Data will be reported using the Laboratory-identified MDRO or CDI Event 
form (CDC 57.128). 
Denominator Data:  Patient days, admissions (for inpatient locations), and encounters for 
emergency department, observation units, and other affiliated outpatient locations are reported 
using the MDRO and CDI Prevention Process and Outcome Measures Monthly Monitoring 
form (CDC 57.127). 
FacWideIN reporting: Summary denominator data- facilities will enter total patient days and 
total patient admissions to reflect all inpatient locations physically located in the hospital. 
Additionally, for MDRO patient days/admissions (second row of denominator data entry), 
denominator data must reflect all inpatient locations minus inpatient rehabilitation facility and 
inpatient psychiatric facility locations with a separate CCN.  Lastly, CDI patient 
days/admissions denominator data (third row of denominator data entry) should reflect all 
inpatient location minus inpatient rehabilitation facility and inpatient psychiatric facility 
locations with a separate CCN minus baby-based locations (for example, NICU, well baby 
nursery, etc.). The totals should not include other facility types within the hospital that are 
enrolled and reporting separately (for example, LTAC). See Table of Instructions for 
completion instructions.  
FacWideOUT and ED/24-hour Observation locations reporting:  Denominator data is provided 
using encounters.  An encounter is defined as any patient visit to an outpatient location.  
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For further information on counting patient days and admissions, see Appendix 
2: Determining Patient Days for Summary Data Collection: Observation vs. 
Inpatients.  
` 
 
Data Analysis: Based on data provided on the LabID Event form, each event will be 
categorized by NHSN to populate different measures.  By classifying positive specimens 
obtained on day 1 (admission date), day 2, and day 3 of admission as community-onset (CO) 
LabID Events and positive specimens obtained on or after day 4 as healthcare facility-onset 
(HO) LabID Events, all HO LabID Events will have occurred more than 48 hours after 
admission. 
 
The following categorizations and prevalence and incidence calculations are built into the 
analysis capabilities of NHSN, and are based on timing of admission to a facility and/or 
location, specimen collection, location where specimen was collected, and monthly 
denominators.  Descriptions are provided to explain how the categories and metrics are defined 
in NHSN. 
 
Categorizing MDRO LabID Events – Based on Date Admitted to Facility and Date 
Specimen Collected: 
 
Community-Onset (CO): LabID Event specimen collected in an outpatient location or an 
inpatient location ≤3 days after admission to the facility (specifically, days 1, 2, or 3 of 
admission).  
 
Healthcare Facility-Onset (HO): LabID Event specimen collected >3 days after admission to 
the facility (specifically, on or after day 4).  
 
The following section describes the various measures calculated for MDRO LabID event 
surveillance.  
 
Note: FacWideIN MDRO rate and SIR calculations utilize the FacWideIN denominators 
(patient days and admissions) reported for the facility minus admissions and patient days from 
inpatient rehabilitation facility (IRF) and inpatient psychiatric facility (IPF) locations with 
unique CCNs. For NHSN reporting purposes, IRF/IPFs located within an acute care hospital 
(ACH)  are recognized as an inpatient location for the ACH; therefore, admissions/ discharges 
from ACH to IRF/IPF and vice versa are considered ‘transfers’, specifically, the hospitalization 
is considered a ‘continuous’ stay for event reporting.   
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Proxy Measures for Exposure Burden of MDROs – All specimens: 
 
Inpatient Reporting: 
 Admission Prevalence Rate = Number of 1st LabID Events per patient per month 
identified ≤3 days after admission to the location (if monitoring by inpatient location), 
or the facility (if monitoring by overall facility-wide inpatient=FacWideIN) / Number of 
patient admissions to the location or facility x 100 
 
 Location Percent Admission Prevalence that is Community-Onset = Number of 
Admission Prevalent LabID Events to a location that are CO / Total number Admission 
Prevalent LabID Events x 100 
 
 Location Percent Admission Prevalence that is Healthcare Facility-Onset = Number of 
Admission Prevalent LabID Events to a location that are HO / Total number of 
Admission Prevalent LabID Events x 100 
 
 Overall Patient Prevalence Rate = Number of 1st LabID Events per patient per month 
regardless of time spent in location (specifically prevalent + incident, if monitoring by 
inpatient location), or facility (specifically, CO + HO, if monitoring by overall facility-
wide inpatient=FacWideIN) / Number of patient admissions to the location or facility x 
100 
 
Outpatient Reporting: 
 Outpatient Prevalence Rate = Number of 1st LabID Events per patient per month for the 
location (if monitoring by outpatient location), or the facility (if monitoring by overall 
facility-wide outpatient = FacWideOUT) / Number of patient encounters for the 
location or facility x 100 
 
Measures for MDRO Bloodstream Infection: Calculated when monitoring either all 
specimens or blood specimens only. Note:  except for certain locations (specifically inpatient 
rehabilitation facilities, emergency department, and 24-hour observation locations), the Blood 
specimens only option can only be used at the FacWideIN and FacWideOUT levels. 
 
MRSA Bloodstream Infection Standardized Infection Ratio (SIR): 
The SIR is calculated by dividing the number of observed events by the number of predicted 
events. The number of predicted events is calculated using LabID probabilities estimated from 
negative binomial models constructed from 2015 NHSN data, which represents a standard 
population. For most settings, MRSA Bloodstream Infection SIRs are calculated for 
FacWideIN surveillance only.  
 
Note: In the NHSN application, the number of predicted events is referred to as “numPred”.  
The SIR will be calculated only if the number of predicted events (numPred) is ≥1 to help 
enforce a minimum precision criterion. 
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Inpatient Reporting: 
 
 MRSA Bloodstream Infection SIR =  Number of all unique blood source MRSA LabID 
Events identified in a non-IRF/IPF inpatient location >3 days after admission to the 
facility (specifically, HO MRSA blood events with no prior MRSA blood event for that 
patient in the previous 14 days) / Number of predicted HO MRSA blood LabID Events 
 MDRO Bloodstream Infection Admission Prevalence Rate =  Number of all unique 
blood source LabID Events per patient per month identified ≤3 days after admission to 
the location (if monitoring by inpatient location), or facility  (if monitoring by overall 
FacWideIN)/ Number of patient admissions to the location or facility x 100 
o Note: For MRSA Bacteremia FacWideIN surveillance, this is the CO rate that is 
used in the risk adjustment calculations of the MRSA bacteremia SIR. The 
numerator excludes any event in which the patient had a prior positive event in 
the previous 14 days.  
 
 MDRO Bloodstream Infection Incidence Rate = Number of all unique blood source 
LabID Events per patient per month identified >3 days after admission to the location 
(if monitoring by inpatient location), or facility (if monitoring by overall facility-wide 
inpatient=FacWideIN) / Number of patient admissions to the location or facility x 100  
 
 MDRO Bloodstream Infection Incidence Density Rate = Number of all unique blood 
source LabID Events per patient per month identified >3 days after admission to the 
location (if monitoring by inpatient location), or facility (if monitoring by overall 
facility-wide inpatient=FacWideIN) / Number of patient days for the location or facility 
x 1,000  
 
 MDRO Bloodstream Infection Overall Patient Prevalence Rate = Number of 1st Blood 
LabID Events per patient per month regardless of time spent in location (specifically, 
prevalent + incident, if monitoring by inpatient location), or facility (specifically, CO + 
HO, if monitoring by overall facility-wide inpatient=FacWideIN) / Number of patient 
admissions to the location or facility x 100 
 
MRSA Bloodstream Reporting for CMS-certified Inpatient Rehabilitation 
Facilities (IRFs) mapped as units within a hospital: 
   
IRF units within a hospital that participate in the CMS Inpatient Rehabilitation Facility 
Quality Reporting Program will be given an MRSA bacteremia SIR separate from the 
FacWideIN SIR for the acute care hospital. The IRF SIR will be sent to CMS on behalf 
of IRF units participating in the CMS IRF Quality Reporting Program. In addition, an 
incidence density rate is also available for IRF units. 
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 MRSA Bloodstream Infection SIR for IRF units =  Number of all unique blood 
source MRSA LabID Events identified >3 days after location admission to the 
IRF unit and where the patient had no positive MRSA bacteremia LabID Event 
in the prior 14 days in any CMS-certified IRF unit / Number of predicted HO 
MRSA blood LabID Events in the IRF unit 
 Inpatient MRSA Bacteremia Incidence Density Rate for IRF units: Number of 
all incident blood source MRSA LabID events identified > 3 days after location 
admission to an IRF unit and where the patient had no positive MRSA 
bacteremia LabID Events in the prior 14 days in any CMS-certified IRF unit / 
Total number of patient days for IRF unit (s) x  1,000 
 
Outpatient Reporting: 
 Combined MRSA Bloodstream Infection Outpatient Prevalence Rate for ED and 
24 hour Observation Locations = Number of unique blood source MRSA LabID 
events identified in an ED or 24 hour observation location / Total patient 
encounters in ED and 24 hour observation location(s) x 100 
o Note: For MRSA Bacteremia FacWideIN surveillance, this outpatient 
rate is used in the risk adjustment calculations of the MRSA bacteremia 
SIR. The numerator excludes any event in which the patient had a prior 
positive event in the previous 14 days in an ED or 24-hour observation 
location.  
 
 MDRO Bloodstream Infection Outpatient Prevalence Rate = Number of all 
unique blood source LabID Events per patient per month for the location (if 
monitoring by outpatient location), or the facility (if monitoring by overall 
facility-wide outpatient=FacWideOUT) / Number of patient encounters for the 
location or facility x 100 
 
Measures for MDRO-CRE surveillance: the above incidence and prevalence rates are 
calculated separately for each species of CRE (specifically, Klebsiella, E.coli, and 
Enterobacter) as well as for all species combined. The following additional metric is available 
for CRE LabID event reporting:  
 
Percent Positive for Carbapenemase: number CRE positive for carbapenemase / number CRE 
tested for carbapenemase x 100 
 
 
Proxy Measures for MDRO Healthcare Acquisition: 
 Overall MDRO Infection/Colonization Incidence Rate = Number of 1st LabID Events 
per patient per month among those with no documented prior evidence of previous 
infection or colonization with this specific organism type from a previously reported 
LabID Event, and identified >3 days after admission to the location (if monitoring by 
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inpatient location), or facility (if monitoring by overall facility-wide 
inpatient=FacWideIN) / Number of patient admissions to the location or facility x 100 
 Overall MDRO Infection/Colonization Incidence Density Rate = Number of 1st LabID
Events per patient per month among those with no documented prior evidence of
previous infection or colonization with this specific organism type from a previously
reported LabID Event, and identified >3 days after admission to the location (if
monitoring by inpatient location), or facility (if monitoring by overall facility-wide
inpatient=FacWideIN) / Number of patient days for the location or facility x 1,000
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Clostridium difficile (C. difficile) LabID Event Reporting 
Methodology: Facilities may choose to monitor C. difficile where C. difficile testing in the 
laboratory is performed routinely only on unformed (specifically, conforming to the shape of 
the container) stool samples.   C. difficile LabID events may be monitored from all available 
inpatient locations, emergency departments and 24 hour observation locations as well as all 
available affiliated outpatient locations where care is provided to patients post discharge or 
prior to admission (for example, outpatient clinics and/or physician offices that submit samples 
to the facility’s laboratory).  
Settings:  C. difficile LabID Event reporting can occur in any location: inpatient or outpatient. 
Surveillance will NOT be performed in NICU, SCN, babies in LDRP, well-baby nurseries, or 
well-baby clinics. If LDRP locations are being monitored, baby counts must be removed. 
Requirements: Facilities must choose one or more of the reporting choices listed in Table 3 
below and report data accordingly: 
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Table 3: Reporting Options for the CDI Module 
Note: Facilities must indicate each reporting choice chosen for the calendar month on the 
Patient Safety Monthly Reporting Plan (CDC 57.106).   
Definitions: 
CDI-positive laboratory assay:
A positive laboratory test result for C. difficile toxin A and/or B, (includes molecular assays
[PCR] and/or toxin assays) tested on an unformed stool specimen (must conform to the
container)
OR
A toxin-producing C. difficile organism detected by culture or other laboratory means
performed on an unformed stool sample (must conform to the container).
Note: 
• When using a multi-testing methodology for CD identification, the final result of the last 
test finding which is placed onto the patient medical record will determine if the CDI 
positive laboratory assay definition is met. 
Method 
Numerator Data Reporting 
by Location 
Denominator Data Reporting 
Facility-wide by 
location 
Enter each CDI LabID Event 
reported by location 
Report separate denominators for each 
location in the facility as specified in the 
NHSN Monthly Reporting Plan 
Selected locations 
Enter each CDI LabID Event 
reported by selected locations 
Report separate denominators for selected 
locations monitored as specified in the 
NHSN Monthly Reporting Plan 
Overall Facility-wide 
Inpatient 
(FacWideIN) 
Enter each CDI LabID Event 
from all inpatient locations 
AND separately for outpatient 
emergency department and 24-
hour observation location(s) 
Report total denominator data for all 
inpatient locations physically located in the 
hospital (for example, total number of 
admissions and total number of patient days), 
minus inpatient rehabilitation facility and 
inpatient psychiatric facility locations with 
unique CCNs  
 Separate denominators should be entered to
capture encounters for each mapped
outpatient emergency department and 24-
hour observation location(s)
Overall Facility-wide 
Outpatient 
(FacWideOUT) 
Enter each CDI LabID Event 
from all affiliated outpatient  
locations separately 
Report total denominator data for all 
outpatient locations (for example, total 
number of encounters including ED and OBS 
encounters in addition to other outpatient 
locations) 
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Duplicate C. difficile-positive test:  Any C. difficile toxin-positive laboratory result from the 
same patient and location, following a previous C. difficile toxin-positive laboratory result 
within the past two weeks [14 days] (even across calendar months and readmissions to the 
same facility).  There should be 14 days with no C. difficile toxin-positive laboratory result for 
the patient and location before another C. difficile LabID Event is entered into NHSN for the 
patient and location. The date of specimen collection is considered Day 1. 
Note: NHSN recommends each facility keep an internal line listing log of all positive toxin 
tests as a reference in LabID event reporting to ensure the 14-day rule is applied correctly. 
EXAMPLE: On January 1, an ICU patient has a C. difficile toxin-positive laboratory result 
which is entered into NHSN. On January 4, while in the same location (ICU), the same patient 
has another positive C. difficile toxin-positive laboratory result which is not entered into NHSN 
because it is a duplicate for the patient and location (has not been >14 days since the original C. 
difficile toxin-positive laboratory result while in the same location). On January 16, while in the 
same location (ICU), the same patient has another C. difficile toxin-positive laboratory result. 
While it has been more than 14 days since the initial positive C. difficile toxin-positive 
laboratory result was entered into NHSN (January 1) for the same patient and same location, it 
has not been >14 days since the patient’s most recent C. difficile toxin-positive laboratory result 
(January 4) while in the same location. Therefore, the C. difficile toxin-positive laboratory 
result for January 16 is not entered into NHSN. On January 31, the patient has another C. 
difficile toxin-positive laboratory result while in the same location (ICU). Since it has been >14 
days since the patient’s most recent C. difficile toxin-positive laboratory result (January 16) 
while in the same location, this event is entered into NHSN. 
Laboratory-Identified (LabID) Event:  All non-duplicate C. difficile toxin-positive laboratory 
results.  Even if reporting at the FacWide level, all reporting must follow rules by location for 
reporting.  
Notes: 
 A LabID Event calculator is available on the NHSN website to help with data entry
decision making around the 14-day rule.
 If a facility is participating in FacWideIN surveillance and reporting, the facility must also
conduct separate location-specific surveillance in all outpatient emergency department and
24-hour observation locations.  This means LabID Events for the same organism and LabID
Event type must be reported from these locations even if the patient is not subsequently
admitted to an inpatient location during the same encounter.
 All emergency department and 24-hour observation locations must be identified and
mapped as outpatient locations within NHSN. For more information about mapping
locations, see Chapter 15 in the NHSN manual.
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Reporting Instructions: All C. difficile LabID Events must be reported by location and 
separately and independently of Events reported using the C. difficile Infection Surveillance 
reporting option and/or HAI reporting.  
Numerator:  Data will be reported using the Laboratory-Identified MDRO or CDI Event form 
(CDC 57.128).   
Denominator Data:  Patient days, admissions (for inpatient locations), and encounters for 
emergency department, observation units, and other affiliated outpatient locations are reported 
using the MDRO and CDI Prevention Process and Outcome Measures Monthly Monitoring 
form (CDC 57.127).   
FacWideIN reporting: Summary denominator data- facilities will enter total patient days and 
total patient admissions to reflect all inpatient locations physically located in the hospital. 
Additionally, for MDRO patient days/admissions (second row of denominator data entry), 
denominator data must reflect all inpatient locations minus inpatient rehabilitation facility and 
inpatient psychiatric facility locations with a separate CCN.  Lastly, CDI patient 
days/admissions denominator data (third row of denominator data entry) should reflect all 
inpatient location minus inpatient rehabilitation facility and inpatient psychiatric facility 
locations with a separate CCN minus baby-based locations, for example such as NICU and well 
baby nursery. The totals should not include other facility types within the hospital that are 
enrolled and reporting separately (for example, LTAC and/or NH). See Table of Instructions 
for completion instructions (CDC 57.127).  
Note: For Acute Care Hospitals completing FacWideIN surveillance, additional guidance on 
denominator reporting is available here: https://www.cdc.gov/nhsn/pdfs/cms/acutecare-mrsa-
cdi-labiddenominator-reporting.pdf  
FacWideOUT and ED/24-hour Observation locations reporting:  Denominator data is 
provided using encounters.  An encounter is defined as a patient visit to an outpatient location 
for care. When determining a patient’s admission dates to both the facility and specific 
inpatient location, the NHSN user must take into account all days, including any days spent in 
an inpatient location as an “observation” patient before being officially admitted as an inpatient 
to the facility, as these days contribute to exposure risk.  Therefore, all days spent in an 
inpatient unit, regardless of admission and/or billing status are included in the counts of 
admissions and inpatient days for the facility and specific location.  For NHSN reporting 
purposes, the facility and specific location admission date is the first day spent in the inpatient 
location. For further information on counting patient days and admissions, see Appendix 2: 
Determining Patient Days for Summary Data Collection: Observation vs. Inpatients  
CDI Data Analysis: 
The following categorizations and prevalence and incidence calculations are built into the 
analysis capabilities of NHSN, and are based on timing of admission to a facility and/or 
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location, specimen collection, location where specimen was collected, and monthly 
denominators.  Descriptions are provided to explain how the categories and metrics are defined 
in NHSN. 
Categorization Based on Current Date Specimen Collected and Prior Date Specimen 
Collected of a previous CDI LabID Event (refer to “cdiAssay” variable in NHSN): 
 Incident CDI LabID Event:  Any CDI LabID Event from a specimen obtained > 56 days
after the most recent CDI LabID Event (or with no previous CDI LabID Event
documented) for that patient. Note: the date of first specimen collection is considered
day 1.
 Recurrent CDI LabID Event:  Any CDI LabID Event from a specimen obtained > 14
days and ≤ 56 days after the most recent CDI LabID Event for that patient.
Notes: 
o the date of first specimen collection is considered day 1.
o cdiAssay will be unassigned, or “blank”, for any CDI LabID event from a
specimen obtained ≤ 14 days after the most recent CDI LabID event for that
patient.
Note: Beginning in 2015, for FacWideIN surveillance, CDI Assay is assigned based on Events 
from inpatient locations, emergency departments, and 24-hour observation locations. For data 
reported prior to 2015, CDI Assay was assigned based on events from within the same setting 
only. For example, in 2014, if performing both FacWideIN and FacWideOUT surveillance, 
CDI Assay of inpatient CDI LabID Events was determined by a review of previously-entered 
CDI LabID Events from inpatient locations only.  
The incident and recurrent CDI LabID Events are further categorized within NHSN.  The 
following categorizations, as well as prevalence and incidence calculations are built into the 
analysis capabilities of NHSN, and are based on timing of admission to facility and/or location, 
specimen collection, location where specimen was collected, and previous discharge.  
Descriptions are provided to explain how the categories and metrics are defined in NHSN. 
Categorizing CDI LabID Events – Based on Date Admitted to Facility and Date Specimen 
Collected: 
• Community-Onset (CO): LabID Event meeting one of the following criteria:
o A) collected in an outpatient location in which the patient was not previously 
discharged from an inpatient location within the same facility ≤ 28 days prior to 
current date of specimen collection
o B) collected in an inpatient location ≤3 days after admission to the facility
(specifically, days 1, 2, or 3 of admission). 
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The following section describes the various measures calculated for CDI LabID event 
surveillance.  
Note: Beginning with 2015 data, the number of FacWideIN admissions and number of 
FacWideIN patient days used in the various CDI rate and SIR calculations will represent those 
reported for the facility minus admissions and patient days from the following: IRF and IPF 
locations with unique CCNs separate from the reporting facility, neonatal ICUs, special care 
nurseries, and well-baby locations.  
Calculated CDI Prevalence Rates: 
Inpatient Reporting: 
 Admission Prevalence Rate = Number of non-duplicate CDI LabID Events per patient
per month identified ≤3 days after admission to the location (if monitoring by inpatient
location), or facility (if monitoring by overall facility-wide inpatient=FacWideIN)
(includes CO and CO-HCFA events) / Number of patient admissions to the location or
facility x 100
 Community-Onset Admission Prevalence Rate = Number of CDI LabID events that are
CO, per month, in the facility / Number of patient admissions to the facility x 100 (this
calculation is only accurate for Overall Facility-wide Inpatient reporting)
o Note: For CDI FacWideIN surveillance, this is the CO rate that is used in the
risk adjustment calculations of the CDI SIR.
 Location Percent Admission Prevalence that is Community-Onset = Number of
Admission Prevalent LabID Events to a location that are CO / Total number Admission
Prevalent LabID Events x 100 (Note:  The numerator in this formula does not include
Admission Prevalent LabID Events that are CO-HCFA.)
 Location Percent Admission Prevalence that is Community-Onset Healthcare Facility-
Associated = Number of Admission Prevalent LabID Events to a location that are CO-
HCFA / Total number Admission Prevalent LabID Events x 100
 Community-Onset Healthcare Facility-Associated (CO-HCFA): CO LabID Event
collected from an inpatient our outpatient location from a patient who was discharged
from the facility ≤ 28 days prior to current date of stool specimen collection. The
previous discharge must have been from an inpatient location (in other words, an
outpatient visit does not qualify as “admitted”, and therefore is not used to set the
timeline for CO-HCFA).
 Healthcare Facility-Onset (HO): LabID Event collected from an inpatient location >3
days after admission to the facility (specifically, on or after day 4).
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 Location Percent Admission Prevalence that is Healthcare Facility-Onset = Number of 
Admission Prevalent LabID Events to a location that are HO / Total number of 
Admission Prevalent LabID Events x 100 
 Overall Patient Prevalence Rate = Number of 1st CDI LabID Events per patient per 
month regardless of time spent in location (specifically, prevalent + incident, if 
monitoring by inpatient location), or facility (specifically, CO + CO-HCFA + HO, if 
monitoring by overall facility-wide inpatient=FacWideIN) / Number of patient 
admissions to the location or facility x 100 
 
Outpatient Reporting: 
 
 Outpatient Prevalence Rate = Number of all non-duplicate CDI LabID Events per 
patient per month for the location (if monitoring by outpatient location), or the facility 
(if monitoring by overall facility-wide outpatient=FacWideOUT) / Number of patient 
encounters for the location or facility x 100 
 
Measures of CDI Incidence: (see categorization of Incident, HO, and CO-HCFA above). 
 CDI Standardized Infection Ratio (SIR): 
The SIR is calculated by dividing the number of observed events by the number of predicted 
events. The number of predicted events is calculated using LabID probabilities estimated from 
negative binomial models constructed from 2015 NHSN data, which represents a standard 
population. For most settings, CDI SIRs are calculated for FacWideIN surveillance only. 
 
Note: In the NHSN application, the number of predicted events is referred to as “numPred“.  
The SIR will be calculated only if the number of predicted events (numPred) is ≥1, to help 
enforce a minimum precision criterion. For acute care hospitals, the CDI SIRs are only 
calculated at the quarter level or higher in order to account for the quarterly-reporting of CDI 
test type. Note that SIRs will not be calculated for a quarter until the CDI test type has been 
reported. When the “MDRO/CDI Prevention Process and Outcome Measures Monthly 
Reporting” form is completed for the last month of each quarter, users are asked to report the 
primary type of test that was used to identify CDI in the hospital for that quarter.  That test type 
is then used in the calculation of the CDI SIR for that quarter.  The test type selected should 
reflect the testing methodology used for clinical decision making. 
 
 Facility CDI Incidence SIR = Number of all Incident CDI LabID Events identified in a 
non-IRF/IPF location >3 days after admission to the facility (specifically, HO events 
with no prior positive events for that patient in the previous 14 days) / Number of 
predicted Incident HO CDI LabID Events 
 Location CDI Incidence Rate = Number of Incident CDI LabID Events per month 
identified >3 days after admission to the location / Number of patient days for the 
location x 10,000 
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 Facility CDI Healthcare Facility-Onset Incidence Rate = Number of all Incident HO
CDI LabID Events per month in the facility/ Number of patient days for the facility x
10,000 (this calculation is only accurate for Overall Facility-wide Inpatient reporting)
 Facility CDI Combined Incidence Rate = Number of all Incident HO and CO-HCFA
CDI LabID Events per month in the facility / Number of patient days for the facility x
10,000 (this calculation is only accurate for Overall Facility-wide Inpatient reporting)
C. difficile Reporting for CMS-certified Inpatient Rehabilitation Facilities (IRFs) mapped
as units within a hospital: 
 IRF units within a hospital that participate in the CMS Inpatient Rehabilitation Facility Quality 
Reporting Program will be given a CDI SIR separate from the FacWideIN SIR for the acute 
care hospital. The SIR will be sent to CMS on behalf of IRF units participating in the CMS IRF 
Quality Reporting Program. In addition, a CDI LabID Event incidence rate is available for IRF 
units.  
 Inpatient CDI SIR for IRF units: Number of all incident CDI LabID events identified >
3 days after location admission to an IRF unit and where the patient had no positive
CDI LabID events in the prior 14 days in any CMS-certified IRF unit / Number of
predicted incident CDI LabID events in the IRF unit(s)
 Inpatient CDI Incidence Density Rate for IRF units: Number of all incident CDI LabID
events identified > 3 days after location admission to an IRF unit and where the patient
had no positive CDI LabID events in the prior 14 days in any CMS-certified IRF unit /
Total number of patient days for IRF units  x  10,000
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Figure 1. MDRO Test Result Algorithm for All Specimens Laboratory-Identified (LabID) Events 
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Yes 
MDRO isolate from any specimen (except AST 
specimens) per patient and location 
1st in calendar 
month per 
patient, per 
location, per 
MDRO 
LabID Event (Non-
duplicate isolate) 
No 
LabID Event (Unique blood 
source MDRO) 
Yes 
Duplicate MDRO 
isolate 
Source 
= Blood 
for 
patient 
and 
Not a 
LabID 
Event 
Prior (+) same 
MDRO from 
blood in ≤14 days 
from same 
location   
(including across 
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** NOTE:  If the first MDRO isolate for calendar month is a blood isolate, the specimen is reported as a LabID event, even if a 
previous MDRO blood isolate was reported in the previous 14 days (across calendar months). 
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Figure 2. MDRO Test Result Algorithm for Blood Specimens Only Laboratory-Identified (LabID) Events 
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Figure 3.  C. difficile Test Result Algorithm for Laboratory Identified (LabID) Events 
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Table 4.  Measures Delivered to CMS For Facilities Participating in Quality Reporting Programs:  
MRSA Bloodstream Infection and C. difficile LabID Events 
 
Facility Type 
 
CMS Quality 
Reporting Program 
MRSA Bloodstream 
Infection LabID Event 
Measure Sent to CMS 
C. difficile LabID 
Event Measure Sent 
to CMS 
General Acute Care Hospitals 
Inpatient Quality 
Reporting Program 
MRSA Bloodstream 
Infection SIR (FacWideIN) 
CDI Incidence SIR 
(FacWideIN) 
Long Term Care Hospitals 
(referred to as Long Term 
Acute Care Hospitals in 
NHSN) 
Long Term Care 
Hospital Quality 
Reporting Program 
MRSA Bloodstream 
Infection SIR (FacWideIN) 
CDI Incidence SIR 
(FacWideIN) 
 
 
 
Inpatient Rehabilitation 
Facilities (IRFs) 
 
 
Inpatient Rehabilitation 
Facility Quality 
Reporting Program 
IRF units within a 
hospital: MRSA 
Bloodstream Infection SIR 
for IRF Units  
IRF units within a 
hospital: CDI Incidence 
SIR for IRF Units  
Free-standing IRFs: MRSA 
Bloodstream Infection SIR 
(FacWideIN)  
Free-standing IRFs: 
CDI Incidence SIR 
(FacWideIN) 
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Option 2: Infection Surveillance Reporting 
 
Introduction: The Infection Surveillance reporting option for MDRO and C. difficile infections enables 
users to utilize the CDC/NHSN healthcare-associated infections definitions for identifying and reporting 
infections associated with MDROs and/or C. difficile. Surveillance must occur from at least one patient care 
area and requires active, patient-based, prospective surveillance of the chosen MDRO(s) and/or C. difficile 
infections (CDIs) by a trained Infection Preventionist (IP).  This means that the IP shall seek to confirm and 
classify infections caused by the chosen MDRO(s) and/or C. difficile for monitoring during a patient’s stay 
in at least one patient care location during the surveillance period. These data will enhance the ability of 
NHSN to aggregate national data on MDROs and CDIs.   
 
A. MDRO Infection Surveillance Reporting 
 
Methodology: Facilities may choose to monitor one or more of the following MDROs:  MRSA, MRSA and 
MSSA, VRE, CephR- Klebsiella, CRE (CRE-Klebsiella, CRE-E. coli, and CRE-Enterobacter), and 
multidrug-resistant Acinetobacter spp. (See definitions in Section I, Option 1A).  For S. aureus, both the 
resistant (MRSA) and the susceptible (MSSA) phenotypes can be tracked to provide concurrent measures of 
the susceptible pathogens as a comparison to those of the resistant pathogens in a setting of active MRSA 
prevention efforts. Note: No Active Surveillance Culture/Testing (ASC/AST) results are to be included in 
this reporting of individual results.   
 
Settings:  Infection Surveillance can occur in any inpatient location where such infections may be identified 
and where denominator data can be collected, which may include critical/intensive care units (ICU), 
specialty care areas (SCA), neonatal units, step-down units, wards, and chronic care units. In Labor, 
Delivery, Recovery, & Post-partum (LDRP) locations, where mom and babies are housed together, users 
must count both mom and baby in the denominator. If moms only are being counted, then multiply moms 
times two to include both mom and baby in denominators. 
 
Requirements: Surveillance for all types of NHSN-defined healthcare-associated infections (HAIs), 
regardless if HAI is included in “in-plan” or “off- plan” surveillance, of the MDRO selected for monitoring 
in at least one location in the healthcare facility as indicated in the Patient Safety Monthly Reporting Plan 
(CDC 57.106).  
 
Definitions: MDROs included in this module are defined in Section I, Option 1A. Refer to CDC/NHSN 
Surveillance Definitions for Specific Types of Infections  for infection site criteria.  
 
Location of Attribution and Transfer Rule applies – See Identifying HAIs in NHSN chapter (Chapter 2). 
 
Reporting Instructions: If participating in MDRO/CDI Infection Surveillance and/or LabID Event 
Reporting, along with the reporting of HAIs through the Device-Associated and/or Procedure-Associated 
Modules, see Appendix 1: Guidance for Handling MDRO/CDI Module Infection Surveillance and LabID 
Event Reporting When Also Following Other NHSN Modules, for instructions on unique reporting scenarios. 
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Numerator Data:  Number of healthcare-associated infections, by MDRO type.   Infections are reported on 
the appropriate NHSN forms:  Primary Bloodstream Infection, Pneumonia, Ventilator-Associated Event, 
Urinary Tract Infection, Surgical Site Infection, or MDRO or CDI Infection Event (CDC 57.108, 57.111, 
57.112, 57.114, 57.120, and 57.126, respectively.).  See the Table of Instructions, located in each of the 
applicable chapters, for completion instructions. 
 
Denominator Data:  Number of patient days and admissions. Patient days and admissions are reported by 
location using the MDRO and CDI Prevention Process and Outcome Measures Monthly Monitoring form 
(CDC 57.127).  See Table of Instructions for completion instructions. 
 
Data Analysis:  Data are stratified by time (for example, month, quarter, etc.) and patient care location.   
MDRO Infection Incidence Rate = Number of HAIs by MDRO type/ Number of patient days x 1000 
 
B. Clostridium difficile Infection Surveillance Reporting 
 
Methodology: C. difficile Infection (CDI) Surveillance, reporting on all NHSN-defined healthcare-
associated CDIs from at least one patient care area, is one reporting option for C. difficile (part of your 
facility’s Monthly Reporting Plan).  These data will enhance the ability of NHSN to aggregate national data 
on CDIs.   
 
Settings: Infection Surveillance will occur in any inpatient location where denominator data can be 
collected, which may include critical/intensive care units (ICU), specialty care areas (SCA), step-down 
units, wards, and chronic care units.  Surveillance will NOT be performed in Neonatal Intensive Care Units 
(NICU), Specialty Care Nurseries (SCN), babies in LDRP, or well-baby nurseries. If LDRP locations are 
being monitored, baby counts must be removed. 
 
Requirements: Surveillance for CDI must be performed in at least one location in the healthcare institution 
as indicated in the Patient Safety Monthly Reporting Plan (CDC 57.106).    
 
Definitions: Report all healthcare-associated infections where C. difficile, identified by a positive toxin 
result including toxin producing gene [PCR]), is the associated pathogen, according to the Repeat Infection 
Timeframe (RIT) rule for HAIs (See Identifying HAIs in NHSN chapter).  Refer to specific definitions in 
CDC/NHSN Surveillance Definitions for Specific Types of Infections chapter for C. difficile gastrointestinal 
system infection (GI-CDI).  
 
HAI cases of CDI that meet criteria for a healthcare-associated infection should be reported as Clostridium 
difficile gastrointestinal system infection (GI-CDI). Report the pathogen as C. difficile on the MDRO or CDI 
Infection Event form (CDC 57.126). If the patient develops GI-CDI, and GI-GE or GI-GIT, report the GI-
CDI and the GI-GE or GI-GIT only if additional enteric organisms are identified and applicable criteria are 
met.  Note: CDI laboratory-identified event (LabID Event) categorizations (for example, recurrent CDI 
assay, incident CDI assay, healthcare facility-onset, community-onset, community-onset healthcare facility-
associated) do not apply to HAIs; including C. difficile associated gastrointestinal system infections (GI-
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CDI). Each new GI-CDI must be reported according to the HAI rules outlined in Identifying HAIs in NHSN 
chapter.    
CDI Complications:  CDI in a case patient within 30 days after CDI symptom onset with at least one of the 
following: 
1. Admission to an intensive care unit for complications associated with CDI (for example, example:
for shock that requires vasopressor therapy);
2. Surgery (for example, colectomy) for toxic megacolon, perforation, or refractory colitis
AND/OR
3. Death caused by CDI within 30 days after symptom onset and occurring during the hospital
admission.
Location of Attribution and Transfer Rule apply to Infection Surveillance – See Identifying HAIs in NHSN 
chapter. 
Numerator Data: Number of healthcare-associated C. difficile infections. Infections are reported on the 
MDRO or CDI Infection Event form (CDC 57.126). See Tables of Instructions for completion instructions.   
Denominator Data:  Number of patient days and admissions by location are reported using the MDRO and 
CDI Prevention Process and Outcome Measures Monthly Monitoring form (CDC 57.127).  See Tables of 
Instructions for completion instructions. 
C. difficile Infections:
Numerator:  The total number of HAI CDI cases identified during the surveillance month for a 
location. 
Denominator:  The total number of patient days and admissions during the surveillance month for a 
location.   
Data Analysis:  Data are stratified by time (for example, month, quarter, etc.) and by patient care location.  
C. difficile Infection Incidence Rate = Number of HAI CDI cases / Number of patient days x 10,000
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II. Supplemental Reporting 
 
1. Prevention Process Measures Surveillance 
 
a. Monitoring Adherence to Hand Hygiene 
 
Introduction: This option will allow facilities to monitor adherence to hand hygiene after a healthcare 
worker (HCW) has contact with a patient or inanimate objects in the immediate vicinity of the patient. 
Research studies have reported data suggesting that improved after-contact hand hygiene is associated with 
reduced MDRO transmission. While there are multiple opportunities for hand hygiene during patient care, 
for the purpose of this option, only hand hygiene after contact with a patient or inanimate objects in the 
immediate vicinity of the patient will be observed and reported.  (http://www.cdc.gov/handhygiene/) 
 
Settings:  Surveillance will occur in any location:  inpatient or outpatient.  
 
Requirements: Surveillance for adherence to hand hygiene in at least one location in the healthcare 
institution for at least one calendar month as indicated in the Patient Safety Monthly Reporting Plan (CDC 
57.106).  This should be done in patient care locations also selected for Infection Surveillance or LabID 
Event reporting. 
 
In participating patient care locations, perform at least 30 different unannounced observations after contact 
with patients for as many individual HCWs as possible.  For example, try to observe all types of HCWs 
performing a variety of patient care tasks during the course of the month, not only nurses, or not only during 
catheter or wound care.  No personal identifiers will be collected or reported.  
Definitions:  
 
Antiseptic handwash:   Washing hands with water and soap or other detergents containing an antiseptic 
agent. 
 
Antiseptic hand-rub:  Applying an antiseptic hand-rub product to all surfaces of the hands to reduce the 
number of microorganisms present. 
 
Hand hygiene:  A general term that applies to either:  handwashing, antiseptic hand wash, antiseptic hand 
rub, or surgical hand antisepsis. 
 
Handwashing:  Washing hands with plain (specifically, non-antimicrobial) soap and water. 
 
Numerator:  Hand Hygiene Performed = Total number of observed contacts during which a HCW touched 
either the patient or inanimate objects in the immediate vicinity of the patient and appropriate hand hygiene 
was performed. 
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Denominator:  Hand Hygiene Indicated = Total number of observed contacts during which a HCW touched 
either the patient or inanimate objects in the immediate vicinity of the patient and therefore, appropriate 
hand hygiene was indicated. 
Hand hygiene process measure data are reported using the MDRO and CDI Prevention Process and 
Outcome Measures Monthly Monitoring form (CDC 57. 127). See Tables of Instructions for completion 
instructions. 
 
Data Analysis:  Data are stratified by time (for example, month, quarter, etc.) and patient care location.  
 
Hand Hygiene Percent Adherence = Number of contacts for which hand hygiene was performed / Number 
of contacts for which hand hygiene was indicated x 100 
 
b. Monitoring Adherence to Gown and Gloves Use as Part of Contact Precautions 
 
Introduction:  This option will allow facilities to monitor adherence to gown and gloves use when a HCW 
has contact with a patient or inanimate objects in the immediate vicinity of the patient, when that patient is 
on Transmission-based Contact Precautions.  While numerous aspects of adherence to Contact Precautions 
could be monitored, this surveillance option is only focused on the use of gown and gloves. 
(http://www.cdc.gov/ncidod/dhqp/gl_isolation_contact.html) 
 
Settings:  Surveillance can occur in any of 4 types of inpatient locations:  (1) intensive care units (ICU), (2) 
specialty care areas, (3) neonatal intensive care units (NICU), and (4) any other inpatient care location in the 
institution (for example, surgical wards). 
 
Requirements: Surveillance for adherence to gown and gloves use in at least one location in the healthcare 
institution for at least 1 calendar month as indicated in the Patient Safety Monthly Reporting Plan (CDC 
57.106).  Ideally, this should be done in patient care locations also selected for Infection Surveillance or 
LabID Event reporting.   
 
Among patients on Transmission-based Contact Precautions in participating patient care locations, perform 
at least 30 unannounced observations. A total of thirty different contacts must be observed monthly among 
HCWs of varied occupation types.   For example, try to observe all types of HCWs performing a variety of 
patient care tasks during the course of the month, not only nurses, or not only during catheter or wound care.  
Both gown and gloves must be donned appropriately prior to contact for compliance.  No personal 
identifiers will be collected or reported. 
 
Definitions:  
 
Gown and gloves use:  In the context of Transmission-based Contact Precautions, the donning of both a 
gown and gloves prior to contact with a patient or inanimate objects in the immediate vicinity of the patient.  
Both a gown and gloves must be donned appropriately prior to contact for compliance.  
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Numerator:  Gown and Gloves Used = Total number of observed contacts between a HCW and a patient or 
inanimate objects in the immediate vicinity of a patient on Transmission-based Contact Precautions for 
which gown and gloves had been donned appropriately prior to the contact. 
 
Denominator: Gown and Gloves Indicated = Total number of observed contacts between a HCW and a 
patient on Transmission-based Contact Precautions or inanimate objects in the immediate vicinity of the 
patient and therefore, gown and gloves were indicated. 
 
Gown and gloves use process measure data are reported using the MDRO and CDI Prevention Process and 
Outcome Measures Monthly Monitoring form (CDC 57.127). See Tables of Instructions for completion 
instructions. 
 
Data Analysis:  Data are stratified by time (for example, month, quarter, etc.) and patient care location.   
Gown and Glove Use Percent Adherence = Number of contacts for which gown and gloves were used 
appropriately / Number of contacts for which gown and gloves were indicated x 100   
 
 c. Monitoring Adherence to Active Surveillance Testing 
 
Introduction: This option will allow facilities to monitor adherence to active surveillance testing (AST) of 
MRSA and/or VRE, using culturing or other methods.  
 
Settings:  Surveillance will occur in any of 4 types of inpatient locations:  (1) intensive care units (ICU),  
(2) specialty care areas, (3) neonatal intensive care units (NICU), and (4) any other inpatient care location in 
the institution (for example, surgical wards). 
 
Requirements: Surveillance of AST adherence in at least one location in the healthcare facility for at least 
one calendar month as indicated in the Patient Safety Monthly Reporting Plan (CDC 57.106). A facility may 
choose to report AST for MRSA and/or VRE in one or multiple patient care locations, as the facility deems 
appropriate. Ideally, this should be done in patient care locations also selected for Infection Surveillance or 
LabID Event reporting.  To improve standardization of timing rules for AST specimen collection, classify 
admission specimens as those obtained on day 1 (admission date), day 2, or day 3 (specifically, ≤3 days).  
Classify discharge/transfer AST specimens as those collected on or after day 4 (specifically, >3 days). 
 
Definitions: 
 
AST Eligible Patients:  Choose one of two methods for identifying patients that are eligible for AST:   
All = All patients in the selected patient care area regardless of history of MRSA or VRE infection 
or colonization. 
OR 
NHx = All patients in the selected patient care area who have NO documented positive MRSA or 
VRE infection or colonization during the previous 12 months (as ascertained by either a facility’s 
laboratory records or information provided by referring facilities); and no evidence of MRSA or 
VRE during stay in the patient care location (specifically, they are not in Contact Precautions). 
  
 
January 2018 12 - 38 
 
MDRO and CDI Module 
 
Timing of AST:  Choose one of two methods for reporting the timing of AST: 
Adm = Specimens for AST obtained ≤3 days after admission,  
OR 
Both = Specimens for AST obtained ≤3 days after admission and, for patients’ stays of >3 days, at 
the time of discharge/transfer.  Discharge/transfer AST should include all discharges (including 
discharges from the facility or to other wards or deaths) and can include the most recent weekly AST 
if performed >3 days after admission to the patient care location.  Discharge/transfer AST should not 
be performed on patients who tested positive on AST admission. 
 
 
Numerator and Denominator Data: Use the MDRO and CDI Prevention Process and Outcome Measures 
Monthly Monitoring form (CDC 57.127) to indicate: 1) AST was performed during the month for MRSA 
and/or VRE, 2) AST-eligible patients, and 3) the timing of AST.  No personal identifiers will be collected or 
reported. See Tables of Instructions for completion instructions. 
 
Numerator: For each month during which AST is performed: 
Admission AST Performed = Number of patients eligible for admission AST who had a specimen 
obtained for testing ≤3 days after admission, 
AND/OR 
Discharge/Transfer AST Performed = For patients’ stays >3 days, the number of discharged or 
transferred patients eligible for AST who had a specimen obtained for testing prior to discharge, not 
including the admission AST. 
  
 Denominator: For each month during which AST is performed: 
Admission AST Eligible = Number of patients eligible for admission AST (All or NHx), 
AND/OR 
Discharge/Transfer AST Eligible = Number of patients eligible for discharge/transfer AST (All or 
NHx) AND in the facility location >3 days AND negative if tested on admission. 
 
Data Analysis:  Data are stratified by patient care location and time (for example, month, quarter, etc.), 
according to AST-eligible patients monitored and the timing of AST. 
 
Admission AST Percent Adherence = Number of patients with admission AST Performed / Number of 
patients admission AST eligible x 100 
 
Discharge/transfer AST Percent Adherence = Number of patients with discharge/transfer AST performed / 
Number of patients discharge/transfer AST eligible x 100 
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2. Active Surveillance Testing Outcome Measures 
 
Introduction: This option will allow facilities to use the results of AST to monitor the prevalent and 
incident rates of MRSA and/or VRE colonization or infection.  This information will assist facilities in 
assessing the impact of intervention programs on MRSA or VRE transmission. 
 
Settings:  Surveillance will occur in any of 4 types of inpatient locations:  (1) intensive care units (ICU), (2) 
specialty care, (3) neonatal intensive care units (NICU), and (4) any other inpatient care location in the 
institution (for example, surgical wards). 
 
Requirements: Surveillance for prevalent and/or incident MRSA or VRE cases in at least one location in 
the healthcare facility for at least one calendar month as indicated in the Patient Safety Monthly Reporting 
Plan (CDC 57.106).  This can be done ONLY in locations where AST adherence is being performed.  A 
minimum AST adherence level will be required for the system to calculate prevalence and incidence.  A 
facility may choose to report AST for MRSA and/or VRE in one or multiple patient care locations, as the 
facility deems appropriate.  Ideally, this should be done in patient care locations also selected for Infection 
Surveillance or LabID Event reporting. To improve standardization of timing rules for AST specimen 
collection, classify admission specimens as those obtained on day 1 (admission date), day 2, or day 3 
(specifically, ≤3 days).  Classify discharge/transfer AST specimens as those collected on or after day 4 
(specifically, >3 days). Only the first specimen positive for MRSA or VRE from a given patient in the 
patient care location is counted, whether obtained for AST or as part of clinical care.  If an Admission AST 
specimen is not collected from an eligible patient, assume the patient has no MRSA or VRE colonization. 
 
Definitions: 
 
AST Admission Prevalent case:   
Known Positive = A patient with documentation on admission of MRSA or VRE colonization or 
infection in the previous 12 months (specifically, patient is known to be colonized or infected as 
ascertained by either a facility’s laboratory records or information provided by referring facilities).  
(All MRSA or VRE colonized patients currently in a location during the month of surveillance 
should be considered “Known Positive”), 
OR 
Admission AST or Clinical Positive = A patient with MRSA or VRE isolated from a specimen 
collected for AST ≤3 days after admission or from clinical specimen obtained ≤3 days after 
admission (specifically, MRSA or VRE cannot be attributed to this patient care location). 
 
AST Incident case:  A patient with a stay >3 days: 
With no documentation on admission of MRSA or VRE colonization or infection during the 
previous 12 months (as ascertained either by the facility’s laboratory records or information 
provided by referring facilities); including admission AST or clinical culture obtained ≤3 days after 
admission (specifically, patient without positive specimen), 
AND 
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With MRSA or VRE isolated from a specimen collected for AST or clinical reasons > 3 days after 
admission to the patient care location or at the time of discharge/transfer from the patient care 
location (including discharges from the facility or to other locations or deaths). 
 
MRSA colonization:  Carriage of MRSA without evidence of infection (for example, nasal swab test 
positive for MRSA, without signs or symptoms of infection). 
 
AST Eligible Patients: Choose one of two methods for identifying patients’ eligible for AST:   
All = All patients in the selected patient care area regardless of history of MRSA or VRE infection 
or colonization, 
OR 
NHx = All patients in the selected patient care area who have NO documented positive MRSA or 
VRE infection or colonization during the previous 12 months (as ascertained either by the facility’s 
laboratory records or information provided by referring facilities); and no evidence of MRSA or 
VRE during stay in the patient care location.   
 
Timing of AST:  Choose one of two methods for reporting the timing of AST: 
Adm = Specimens for AST obtained ≤3 days after admission, 
OR 
Both = Specimens for AST obtained ≤3 days after admission and, for patients’ stays of >3 days, at 
the time of discharge/transfer.  Discharge/transfer AST should include all discharges (including 
discharges from the facility or to other wards or deaths) and can include the most recent weekly AST 
if performed >3 days after admission to the patient care location.  Discharge/transfer AST should not 
be performed on patients who tested positive on AST admission. 
 
Numerator and Denominator Data: Use the MDRO and CDI Prevention Process and Outcome Measures 
Monthly Monitoring form (CDC 57.127) to indicate: 1) AST outcomes monitoring and adherence was 
performed during the month for MRSA and/or VRE, 2) AST eligible patients, and 3) the timing of AST. No 
personal identifiers will be collected or reported. See Tables of Instructions for completion instructions. 
 
If only admission AST is performed, only prevalent cases of MRSA or VRE can be detected in that patient 
care location.  If both admission and discharge/transfer AST are performed, both prevalent and incident 
cases can be detected.  No personal identifiers will be collected or reported.   
 
Admission Prevalent Case:  
Numerator Sources:  (1) Known Positive; (2) Admission AST or Clinical Positive = Cases ≤3 days after 
admission 
Denominator Source:  Total number of admissions 
 
Incident Case: 
Numerator:  Discharge/transfer AST or Clinical Positive = Cases >3 days after admission and without 
positive test result(s) on admission 
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Denominator:  Total number of patient days 
Note:  For research purposes calculating patient-days at risk (specifically, excluding patient-days in which 
patients were known to be MRSA or VRE colonized or infected) may be a preferable denominator, but for 
surveillance purposes and ease of aggregating, total number of patient days is required for this module. 
Data Analysis:  Data are stratified by patient care location and time (for example, month, quarter, etc.) 
according to the eligible patients monitored and timing of AST. 
AST Admission Prevalence rate =  
For Eligible patients = All:  
Number of admission AST or clinical positive / Number of admissions x 100 
For Eligible patients = NHx: 
Number of admission AST or clinical positive + Number of known positive / Number of admissions x 100   
AST Incidence rate =  
Number of discharge/transfer AST or clinical positive / Number of patient days x 1000 
1HICPAC, Management of Multidrug-Resistant Organisms in Healthcare Settings. 
<http://www.cdc.gov/NCIDOD/DHQP/hicpac_pubs.html>. 
2Cohen AL, et al. Infection Control and Hospital Epidemiology. Oct 2008; 29:901-913. 
3McDonald LC, Coignard B, Dubberke E, Song X. Horan T, Kutty PK. Recommendations for surveillance of Clostridium 
difficile-associated disease. Infection Control Hospital Epidemiology 2007; 28:140-5. 
4Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium 
difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious 
Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology 2010; 31:431-455. 
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Appendix 1. Guidance for Handling MDRO and CDI Module Infection Surveillance and LabID 
Event Reporting When Also Following Other NHSN Modules 
 
If a facility is monitoring CLABSIs, CAUTIs, VAPs, or VAEs within the Device-Associated Module and/or 
SSIs within the Procedure-Associated Module and is also monitoring MDROs (for example, MRSA) in the 
MDRO and CDI Module, then there are a few situations where reporting the infection or LabID event may 
be confusing.  The following scenarios provide guidance to keep the counts and rates consistent throughout 
your facility and between all of the NHSN Modules.  These rules apply to the reporting of “Big 5” 
infections (BSI, UTI, PNEU, VAE, and SSI) caused by an MDRO selected for monitoring. 
 
Device-Associated Module with MDRO and CDI Module 
 
Scenario 1:  Facility is following CLABSI, CAUTI, VAP, or VAE along with MDRO Infection Surveillance 
and possibly LabID Event Reporting in the same location: 
Healthcare-associated Infection identified for this location.  
1. Report the infection (BSI, UTI, PNEU, or VAE). 
2. Answer “Yes” to the MDRO infection question. 
This fulfills the infection reporting requirements of both modules in one entry and lets the NHSN reporting 
tool know that this infection should be included in both the Device-Associated and the MDRO infection 
datasets and rates. 
3. If following LabID event reporting in the same location, report also (separately) as a LabID Event (if 
meets the MDRO protocol criteria for LabID event). 
 
 
Scenario 2: Facility is following BSI (CLABSI), UTI (CAUTI), PNEU/VAP, or VAE along with MDRO 
Infection Surveillance and possibly LabID Event Reporting in multiple locations: 
The event date for the infection is the day of patient transfer from one location (the transferring location) to 
another location (the new location), or the next day. 
1. Report the infection (BSI, UTI, PNEU and VAE) and attribute to the transferring location, if 
transferring location was following that Event Type (BSI, UTI, PNEU, VAE) on the day of Event, 
which occurred on the date of transfer, or the following day. 
2. Answer “Yes” to the MDRO infection question, if the transferring location was following that 
MDRO on the day of Event, which occurred on the date of transfer, or the following day. 
3. If, on the date of culture collection, the new location is following LabID event reporting, report also 
(separately) as a LabID Event and attribute to the new location (if meets the MDRO protocol criteria 
for LabID event). 
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Procedure-Associated Module with MDRO and CDI Module 
 
Note: SSIs are associated with a procedure and not a patient location, but MDROs are connected with the 
patient location. 
 
Scenario 3:  Facility is following SSI along with MDRO Infection Surveillance and possibly LabID Event 
Reporting: 
Patient has surgery, is transferred to a single unit for the remainder of the stay, and during the current stay 
acquires an SSI.  
1. Report the infection (SSI) and attribute to the post-op location. 
2. Answer “Yes” to the MDRO infection question, if the post-op location is following that MDRO 
during the month of the date of event. 
3. If following LabID event reporting in the post-op location, report also (separately) as a LabID Event 
(if meets the MDRO protocol criteria for LabID event). 
 
Scenario 4: Facility is following SSI along with MDRO Infection Surveillance and possibly LabID Event 
Reporting: 
Patient has surgery, is either discharged immediately (outpatient) or transferred to a unit (inpatient), is 
discharged, and subsequently is readmitted with an SSI. 
1. Report the infection (SSI) and attribute to the discharging (post-op) location (not the readmission 
location). 
2. Answer “Yes” to the MDRO infection question, if the discharging (post-op) location was following 
that MDRO during the Date of Event. 
3. If following LabID event reporting in the readmitting location or outpatient clinic where the 
specimen was collected, report also (separately) as a LabID Event (if meets the MDRO protocol 
criteria for LabID event). 
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Appendix 2: Counts Involving Observation Patients  
 
In response to questions regarding counting “observation” patients, the following guidance is offered.  
 
For the purpose of NHSN surveillance and reporting, an “observation” location (for example, 24-hour 
observation area) is considered an outpatient unit, and time spent in this type of unit does not ever contribute 
to any inpatient counts (specifically, patient days, device days, admissions). Stays in such outpatient units 
represent “encounters” for the purposes of outpatient surveillance for LabID Event monitoring in the 
MDRO/CDI module.  
 
The NHSN instructions for recording the number of patients in an inpatient unit state that for each day of 
the month selected, at the same time each day, the number of patients on the unit should be recorded. This 
procedure should be followed regardless of the patient’s admission status as an observation patient or an 
inpatient.  
 
Key point -- it is the patient’s physical location and NOT the patient’s admission status as an “observation” 
patient that determines whether the patient counts for an inpatient location or the 24 hour observation 
location  
 
1. Observation patient in observation location:  
When an observation patient is housed in a location that is mapped as a 24-hr Observation area, they 
should not be included in any inpatient counts.  These areas are considered outpatient locations.  
2. Observation patient in inpatient location:  
a. If an observation patient is transferred to an inpatient location: 
 LabID event reporting -- Only patient days in the inpatient location are to be included in patient 
day counts for the location or FacWideIN. 
 
 Device-associated surveillance -- Device days accrue beginning when the patient arrives in any 
inpatient location where surveillance is occurring, in accordance with the location’s device-count 
methods.  
 
b. If an observation patient is admitted to an inpatient location, the patient must be included in all 
surveillance events designated in the monthly reporting plan and included in patient and device day 
counts.  The patient is being housed, monitored, and cared for in an inpatient location and therefore 
is at risk for acquisition of an HAI.  The facility assignment of the patient as an observation patient 
or an inpatient has no bearing for the purpose of counting.  
 
Below is an example of attributing patient days to a patient admitted to an inpatient location, regardless of 
whether the facility considers the patient an observation patient or an inpatient.  
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The examples show counts taken at: A) 12:00 am and B) 11:00 pm. 
 
A. Count at 12:00 am (midnight):  
 
Date Mr X Pt Day Mr Y Pt Day 
01/01 Mr X admitted at 8:00 pm 
 
Mr X not counted because the count for 
01/01/10 was taken at 12:00 am on 01/01 10 
and he was not yet admitted 
 
X 
Mr Y admitted at 12:00 am 
 
Mr Y is counted because the count for 01/01 
was taken at 12:00 am and that is when he 
was admitted 
 
1 
01/02 1 2 
01/03 2 3 
01/04 3 4 
01/05 Mr X discharged at 5:00 pm 
4 
Counted for 01/05 because he was in the 
hospital at 12:00 am on 01/05 when the 
count for that day was taken 
Mr Y discharged at 12:01 am 
5 
Counted for 01/05 because he was in the 
hospital at 12:00 am on 01/05 when the 
count for that day was taken 
Total 4 patient days 5 patient days 
 
 
If we use the same admission dates and times for Mr. X, but a different time is selected for the patient day 
count, say 11:00 pm, the total number of days in the count will be the same; they will simply be coming 
from different dates. 
 
B. Count at 11:00 pm: 
 
Date Mr X Pt Day 
01/01 Mr X admitted at 8:00 am Counted because the count for 01/01 is taken 
at 11:00 pm on 01/01 and he is in the hospital 
at that time 
1 
01/02 - 2 
01/03 - 3 
01/04 - 4 
01/05 MR X discharged at 5:00 pm Not counted for 01/05 because he was not in 
the hospital at 11:00 pm on 01/05 when the 
count for that day was taken 
X 
Total  4 patient days 
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Determining Admission Counts for Summary Data Collection: 
 
In response to questions regarding how to count number of admissions, the following guidance is offered. 
How you operationalize this guidance will depend on how you are obtaining the data for your counts. 
 
Recognizing that there are a variety of ways in which patient day and admission counts are obtained for a 
facility and for specific locations, this guidance is offered to assist with standardization within and across 
facilities. It is most important that whatever method is used by a facility, it should be used each and every 
month for consistency of data and metrics. 
 
If admissions are calculated electronically, the data must be checked to ensure that all appropriate patients 
are included or excluded from those counts and that your electronic data are within +/- 5% of the number 
obtained if doing the calculations manually. If these counts are more than 5% discrepant, then you will need 
to evaluate and discuss with your IT staff to determine the cause of the discrepancies and methods to 
address them. The main goal is to accurately count patients in the denominators that are at risk for 
potentially contributing to the numerator. 
 
See below for specific examples: 
 
1. Facility-Wide Inpatient Admission Count: Include any new patients that are assigned to a bed in any 
inpatient location within the facility regardless of billing status. Qualification as a new patient means 
that the patient was not present on the previous calendar day. The daily admission counts are summed at 
the end of the calendar month for a monthly facility-wide inpatient admission count. 
 
2. Inpatient Location-Specific Admission Count: Include any new patients that are assigned to a bed in the 
specific inpatient location. Qualification as a new patient means that the patient was not present on the 
specific inpatient location on the previous calendar day. The daily admission counts are summed at the 
end of the calendar month for a monthly inpatient location-specific admission count. 
 
Any patient who meets criteria for new inclusion should be counted, regardless of whether they are coded 
by the facility as an inpatient or as an observation patient. 
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Below is an example of manually counting location-specific and facility-wide  admission counts related to a 
patient admitted to an inpatient location and transferred to multiple patient locations during his hospital stay. 
The example show counts taken at 11:00 pm.  
Example: Counts at 11:00 pm:  
Unit Date/Time Mr. X 
Placed on 
Inpatient Unit 
Date/Time Mr. X 
Transferred Out 
of Inpatient Unit 
Inpatient 
Location-Specific 
Admission Count 
Inpatient Facility-
Wide Admission 
Count 
SICU 10/08 – 10:00am 
(facility admission) 
10/13 – 9:00am 1 Adm for SICU 1 Adm for 
FacWideIN 
MICU  10/13 – 9:15am 10/13 – 11:00am Not present and so 
not counted 
Same Adm, and 
also not present so 
not counted 
Surgical Ward 10/13 – 11:30am 10/25 – 1:00pm 1 Adm for Surgical 
Ward 
Same Adm so not 
counted 
Medical Ward  10/25 – 1:30pm 10/26 – 10:00am 
(facility discharge) 
1 Adm for Medical 
Ward 
Same Adm so not 
counted 
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Appendix 3: Differentiating Between LabID Event and Infection Surveillance 
- LabID Event Infection Surveillance (using HAI 
surveillance definitions) 
Protocol LabID Event protocol in Chapter 12 of 
NHSN manual 
Infection Surveillance protocol in Chapter 12 of 
NHSN manual and HAI site-specific definitions 
in NHSN manual (for example, BSI, UTI, SSI, 
PNEU, VAE, and GI-CDI and other HAI 
definitions) 
Signs & 
Symptoms 
NONE.  Laboratory and admission data, 
without clinical evaluation of patient 
Combination of laboratory data and clinical 
evaluation of patient (signs/symptoms) 
Surveillance 
Rules 
• HAI and POA do NOT apply 
• Transfer Rule does NOT apply 
• Location = location of patient at time 
of specimen collection 
• Event date = specimen collection 
date 
• HAI and POA do apply 
• Transfer Rule applies 
• See NHSN protocol for details regarding 
location and date of event 
Denominator 
Reporting 
• Number of patient days and 
admissions 
• Can be reported by specific location 
or facility-wide, depending on 
reporting option(s) selected 
• Inpatient and/or outpatient 
• Device days and patient days must be 
collected separately for each monitored 
location 
• Inpatient reporting only 
Categorization 
of Infections 
• Events categorized based on 
inpatient or outpatient and admission 
and specimen collection dates 
• Healthcare Facility-Onset 
(HO)  
• Community-Onset (CO) 
• Community-Onset 
Healthcare Facility-
Associated (CO-HCFA) for 
C. difficile only 
• HO,CO, and CO-HCFA (if 
applicable) LabID Events must be 
reported to NHSN 
• Additional categorizations are 
applied to C. difficile, which include 
Incident CDI event and Recurrent 
CDI event. Both must be reported to 
NHSN.  
• HAI protocols used 
• Events are either HAI or not, therefore 
LabID Event categorizations do not apply 
• Only HAIs are reported to NHSN 
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Instructions for Mapping Patient Care Locations in NHSN 
NHSN requires that facilities map each patient care area in their facility to one or more locations as 
defined by NHSN in order to report surveillance data collected from these areas. This document functions 
as a decision-making tool when determining the appropriate CDC location for NHSN surveillance, as 
defined in the NHSN Manual. This process should be followed when adding any new unit to NHSN for 
surveillance and should be repeated for any unit when there has been a significant change in patient mix 
(e.g., merging of units, taking on a new service). 
Step 1: Define the acuity level for the location 
 
  
Is this patient care area comprised of at least 80% of 
patients that are of the same acuity level? 1 
Proceed to Step 2 and map to a location type 
of that acuity level using the NHSN 80% Rule 
for that specific type.2 
Can this patient care area be split into 2 or 
more locations in NHSN for the purposes of 
surveillance – also referred to as “virtual 
locations”? 3 
Proceed to Step 2 and create 
locations in NHSN for each of 
the acuity levels, using the 
NHSN 80% Rule.2 
Map to a CDC Mixed 
Acuity location.4 
YES 
NO 
YES 
NO 
List of Acuity Levels: 
Adult Critical Care Units  Mixed Acuity Units  
Pediatric Critical Care Units  Operating Rooms 
Neonatal Critical Care Units  Chronic Care 
Specialty Care Areas (SCA)/Oncology Long Term Acute Care 
Adult Wards    Rehabilitation 
Pediatric Wards    Outpatient (ACUTE) Locations 
Neonatal Wards   Clinic (Nonacute) Settings 
Step Down Units    
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Step 2: Define the type of service for the location 
 
  
Is this patient care area a general medical, 
surgical, or medical/surgical unit? Or is it 
comprised of patients from a specific service 
type (e.g., burn, cardiac)? 1 
If general medical or surgical, are 
more than 60% of patients either 
medical or surgical? 
If the unit is comprised of 
patients of a specific service type, 
does this unit meet the NHSN 
80% Rule for locations2?  
Create a 
location in 
NHSN that is 
mapped to the 
majority type 
(i.e., medical or 
surgical) 
The mix of 
patients should 
then be a 50/50 
to 60/40 mix of 
medical and 
surgical patients 
 Create a 
location in 
NHSN that is 
mapped to a 
combined 
medical/surgical 
CDC location 
General Specific 
Create a location 
in NHSN that is 
mapped to that 
CDC location 
type 
Can this single unit be 
split into 2 or more 
units in NHSN for the 
purposes of surveillance 
– also referred to as 
“virtual locations3”? 
YES 
NO 
Create locations 
in NHSN for 
each of these 
specific service 
virtual locations 
Is the mix of patients in 
this unit approximately 
a 50/50 to 60/40 mix of 
combined medical and 
surgical? 
Create a location in NHSN 
that is mapped to a combined 
medical/surgical unit 
YES 
YES 
NO 
NO 
Create a location in 
NHSN that is mapped to 
the location of the 
majority type (i.e., 
greater than 60%) - 
either medical or surgical 
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Please see the CDC Location descriptions for definitions of each CDC Location used for NHSN 
surveillance in this chapter.  
 
1. Patient mix: When determining the appropriate CDC Location mapping for a unit, facilities should 
review the patient mix in that unit for the last full calendar year. If a full year is not available, facilities 
should review patient mix based on the data they have available for that unit. When determining the acuity 
level, as well as the specific service type of a location, acuity billing data or admission/transfer diagnosis 
should be used when determining the appropriate location mapping.  Acuity billing data is considered the 
most accurate depiction of the patient’s illness and reason for being admitted to a particular unit. Facilities 
should consistently use the same method to determine patient mix across all location mapping in NHSN. 
2. NHSN 80% Rule: Each patient care area in a facility that is monitored in NHSN is “mapped” to one 
CDC Location.  The specific CDC Location code is determined by the type of patients cared for in that 
area according to the 80% Rule.  That is, if 80% of patients are of a certain type (e.g., pediatric patients 
with orthopedic problems) then that area is designated as that type of location (in this case, an Inpatient 
Pediatric Orthopedic Ward). 
 
3. Virtual locations: Virtual locations are created in NHSN when a facility is unable to meet the 80% rule 
for location designation in a single physical unit but would like to report their NHSN surveillance data for 
each of the major, specific patient types in that unit. The use of virtual locations is recommended only for 
those physical units that are geographically split by patient service or those in which beds are designated 
by service.  For example, a facility has an ICU – called 5 West – that is comprised of approximately 50% 
neurology patients and 50% neurosurgery patients. Additionally, the neurology patients are housed in beds 
1 thru 10 and the neurosurgery patients are housed in beds 11 thru 20. Rather than map as a 
medical/surgical critical care unit, the facility decides to create 2 new locations in NHSN: 
 5WEST_N: Neurologic Critical Care (10 beds) 
 5WEST_NS: Neurosurgical Critical Care (10 beds) 
This facility will collect and enter data for 5WEST_N and 5WEST_NS separately. The facility will also be 
able to obtain rates and standardized infection ratios (SIRs) for each location separately.  Note that the data 
collected and reported for each virtual location will be limited to the designated 10 beds assigned (i.e., 
overflow from 5WEST_N into 5WEST_NS will be counted with 5WEST_NS). For those facilities that 
use an electronic source for collecting their data, we recommend that you discuss compatibility of virtual 
locations in NHSN with your facility’s EHR contact prior to reporting data for these locations. 
 
4. Mixed Acuity Unit: This location is intended for those units comprised of patients with varying levels 
of acuity.  
 
NOTE: Mapping a location in NHSN to the CDC “Mixed Acuity” designation may have implications on 
data that your facility reports for the CMS Hospital Inpatient Quality Reporting Program and/or your 
state’s reporting mandate(s). Although a Mixed Acuity location may have ICU beds and ICU patients, it is 
not considered an ICU location type for the purposes of NHSN reporting and therefore, would not be 
included in any ICU-specific reporting requirements. Mixed Acuity units are also excluded from ward-
specific reporting requirements. For information about how this location designation may impact your 
facility’s compliance with CMS HAI reporting measures, please contact your Quality Improvement 
Organization (QIO). For information about how this location designation may impact your facility’s 
compliance with your state mandate (if applicable), please contact your state HAI coordinator: 
www.cdc.gov/HAI/state-based/index.html. 
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Examples 
Example 1: An ICU that is 85% Burn patients, 15% Trauma 
CDC Location: Burn Critical Care (IN:ACUTE:CC:B) 
Why? Meets 80% rule for critical care acuity level and 80% rule for specific service 
(burn) 
Example 2: An ICU that is 55% medical and 45% surgical 
CDC Location: Medical/Surgical Critical Care (IN:ACUTE:CC:MS) 
Why? Meets 80% rule for critical care acuity level and does not meet the 60% rule for 
designation as either medical or surgical service level alone, therefore, use combined 
medical/surgical designation 
Example 3: A unit that is comprised of 60% medical inpatients and 40% general observation patients 
CDC Location: Medical Ward (IN:ACUTE:WARD:M) 
Why? This is a special scenario due to the mix of inpatients and outpatients in this unit.  A 
location where at least 51% of the patients have been formally admitted to the facility 
should be mapped as in inpatient unit, rather than an outpatient observation unit. The 60% 
rule for general service and the 80% rule for specific service still apply when deciding on 
the specific type of inpatient location to use; this location met the 60% rule for medical 
service. All patients housed in this unit should be included in the surveillance efforts for 
this location.  
Example 4: An ICU that is 40% Neurosurgical, 40% Surgical, and 20% Medical 
 Option 1 - Single CDC Location: Surgical Critical Care 
Why? Meets 80% rule for critical care acuity level and does not meet the 80% rule for a 
specific service level alone, but when surgical patients are combined, that total does equal 
80%.  
Option 2 - Multiple CDC Virtual Locations: Neurosurgical Critical Care and Surgical Critical 
Care, with the medical patients reported with the Surgical Critical Care location since the general 
surgical designation is the least specific of the two 
Why? By splitting this unit into 2 virtual locations, each meets the 80% rule for critical 
care acuity level and one meets the 80% rule for designation as Neurosurgical Critical 
Care, while the other meets the 60% rule as general surgical service (when combining 
surgical and medical patients). 
Example 5: A unit that is comprised of 60% Medical ICU and 40% Step Down patients 
 Option 1 - Single CDC Location: Mixed Acuity Unit 
Why? This location is not comprised of at least 80% of the patients of the same acuity 
level and therefore meets the single location definition of a mixed acuity unit. Note that 
this location is not considered an ICU location type for the purposes of NHSN reporting 
and therefore, would not be included in any ICU-specific reporting requirements. 
 Option 2 - Multiple CDC Virtual Locations: Medical Critical Care and Step Down Unit 
Why? By splitting this unit into 2 virtual locations, each meets the 80% rule for the 
appropriate acuity level and each meets the 80% rule for type of service. 
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Example 6: A pediatric ward that is comprised of 70% neurosurgical patients and 30% orthopedic patients 
 Option 1 - Single CDC Location: Pediatric Surgical Ward 
Why? Meets 80% rule for ward-level acuity and does not meet the 80% rule for a specific 
service level alone, but meets the 60% rule for general surgical service. 
Option 2 - Multiple CDC Virtual Locations: Pediatric Neurosurgical Ward and Pediatric 
Orthopedic Ward 
Why? By splitting this unit into 2 virtual locations, each meets the 80% rule for the 
appropriate acuity level and each meets the 80% rule for type of service. 
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Appendix: Creation and Management of Locations in NHSN 
Create New Locations: 
If there are any operational locations in your hospital that are not already set-up in NHSN, you will need to 
create these locations for the purposes of NHSN surveillance and reporting.  
Locations can be set up by following these steps:  
1. Go to Facility > Locations. 
2. On the Locations screen, enter a location code (“Your Code”) and location label (“Your Label”).  
3. Select a CDC Location Description from the drop-down menu. NOTE: When selecting a CDC 
Location Description, your location must meet the 80% Rule in order to be assigned as that CDC 
Location Description.  
4. Make sure the Status is set to “Active” and then enter the number of beds that are set up and 
staffed in that location.  
5. Once all information for this new location is entered, click ‘Add’. 
Manage Existing Locations: 
Facilities should make sure that the only locations with an “Active” status in NHSN are those that are 
operational units within the facility. The number of beds indicated for each location should also be 
checked for accuracy and, if necessary, updated to reflect the current number of beds set up and staffed. 
Location information can be updated by following these steps:  
1. Go to Facility > Locations. 
2. On the Locations screen, click ‘Find’. 
3. Review the information that appears in the Location Table at the bottom of the screen. Review the 
Status of each location, as well as Bed size.  
4. If a location’s information needs to be updated, click the location code under the “Your Code” 
column; the location’s information will auto-fill in the fields above the Location Table.  
5. Make any modifications to the Status and/or Bed size, then click ‘Save’. 
Set Active Location to Inactive 
If a facility adds a new unit to replace an existing location, they must take steps to ensure that the old 
location is inactivated and the new location is added to all applicable Monthly Reporting Plans. 
Setting an Active Location to Inactive can be done by following these steps: 
1. Go to Facility > Locations. 
2. Select “Find” on the Locations page. 
3. Locate the unit to inactivate in the populated list on the screen. 
4. Select the value of “Your Code” for the location that you wish to inactivate. The location fields 
will now populate and the “Save” button appears. 
5. Change “Status” to “Inactive”. Click “Save”. 
Manage Physically Moved Locations 
Units within a facility may physically move to another area of the same facility, and be given a different 
name. If the staff are moving with these locations, and the type of patients remains the same (i.e., the only 
difference is the geographical location and/or Bed size), then it's recommended to change “Your Code” 
and "Your Label" (and Bed size, if appropriate) on the existing location records. These fields can be 
updated by following the instructions for “Manage Existing Locations” above. Updating the value of 
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“Your Code” will also update all previously-entered records for these locations, allowing for continuous 
analysis and reporting. 
Inaccurate CDC Location Description 
Please note that the CDC Location Description cannot be edited after a location is mapped in NHSN. If 
you believe that the CDC Location Description assigned to your existing location is incorrect, there are 
additional steps you will need to follow, depending on the scenario:  
Scenario 1: The patient population in this unit has changed such that the current CDC Location 
Description, using the 80% rule, is inaccurate.  
Solution: Because the patient population has changed, a new location should be created in NHSN 
and should be mapped to a CDC Location Description that most accurately reflects the type of 
patients receiving care in that location, using the 80% rule. The old location should be put into 
“Inactive” status. When creating a new location, you will need to use a different “Your Code” and 
“Your Label” value. Note that data that have been reported from inactive locations can continue to 
be analyzed within NHSN for the months during which they appear in the Monthly Reporting 
Plans. Please note that these inactive locations will not be linked to new, active locations.  
Scenario 2: The CDC Location Description initially assigned has been inaccurate for much, if not all, of 
the reporting to NHSN, based on the updated location guidance for 2017.  
Solution: Users cannot change the CDC Location Description on existing locations within NHSN. 
Facilities should ensure that the locations set up in NHSN are accurate for 2017 reporting per the 
updated guidance. If a new CDC Location Description is needed, users must create a new location 
in NHSN and inactivate the old location, per the instructions above. Note that data for the old 
location can still be analyzed, but these data will not be connected to data reported under the new 
location. To connect data to the new location, facility administrators must edit the older location 
event and summary records to the newly created locations. This must be done before the old 
location is put into “Inactive” status. Once the new location is active, facilities need to change their 
monthly reporting plan to record the change and capture the new location data.
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Master CDC Locations and Descriptions 
CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
INPATIENT LOCATIONS 
ACUTE CARE FACILITIES GENERAL 
Adult Critical Care Units 
Burn Critical Care 1026-4 IN:ACUTE:CC:B Critical care area specializing in the care of patients with 
significant/major burns. 
Medical Cardiac Critical Care 1028-0 IN:ACUTE:CC:C Critical care area specializing in the care of patients with 
serious heart problems that do not require heart surgery. 
Medical Critical Care 1027-2 IN:ACUTE:CC:M Critical care area for patients who are being treated for 
nonsurgical conditions. 
Medical/Surgical Critical Care 1029-8 IN:ACUTE:CC:MS An area where critically ill patients with medical and/or 
surgical conditions are managed. 
Neurologic Critical Care  1035-5 IN:ACUTE:CC:N Critical care area for the care of patients with life-
threatening neurologic diseases. 
Neurosurgical Critical Care 1031-4 IN:ACUTE:CC:NS Critical care area for the surgical management of patients 
with severe neurologic diseases or those at risk for 
neurologic injury as a result of surgery. 
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
ONC Medical Critical Care 1223-7 IN:ACUTE:CC:ONC_M Critical care area for the care of oncology patients who 
are being treated for nonsurgical conditions related to 
their malignancy. 
ONC Surgical Critical Care 1224-5 IN:ACUTE:CC:ONC_S Critical care area for the evaluation and management of 
oncology patients with serious illness before and/or after 
cancer-related surgery. 
ONC Medical-Surgical Critical 
Care 
1225-2 IN:ACUTE:CC:ONC_MS Critical care area for the care of oncology patients with 
medical and/or surgical conditions related to their 
malignancy. 
Prenatal Critical Care 1034-8 IN:ACUTE:CC:PNATL Critical care area for the care of pregnant patients with 
complex medical or obstetric problems requiring a high 
level of care to prevent the loss of the fetus and to protect 
the life of the mother. 
Respiratory Critical Care 1033-0 IN:ACUTE:CC:R Critical care area for the evaluation and treatment of 
patients with severe respiratory conditions. 
Surgical Cardiothoracic 
Critical Care 
1032-2 IN:ACUTE:CC:CT Critical care area specializing in the care of patients 
following cardiac and thoracic surgery. 
Surgical Critical Care 1030-6 IN:ACUTE:CC:S Critical care area for the evaluation and management of 
patients with serious illness before and/or after surgery. 
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Trauma Critical Care 1025-6 IN:ACUTE:CC:T Critical care area specializing in the care of patients who 
require a high level of monitoring and/or intervention 
following trauma or during critical illness related to 
trauma. 
Pediatric Critical Care Units 
ONC Pediatric Critical Care 1233-6 IN:ACUTE:CC:ONC_PED Critical care area for the care of oncology patients ≤18 
years old who are being treated for surgical or 
nonsurgical conditions related to their malignancy. 
Pediatric Burn Critical Care 1042-1 IN:ACUTE:CC:B_PED Critical care area specializing in the care of patients ≤18 
years old with significant/major burns.  
Pediatric Cardiothoracic 
Critical Care 
1043-9 IN:ACUTE:CC:CT_PED Critical care area specializing in the care of patients ≤18 
years old following cardiac and thoracic surgery. 
Pediatric Medical Critical Care 1044-7 IN:ACUTE:CC:M_PED Critical care area for patients ≤18 years old who are 
being treated for nonsurgical conditions.  In the NNIS 
system, this was called Pediatric ICU (PICU). 
Pediatric Medical/Surgical 
Critical Care  
1045-4 IN:ACUTE:CC:MS_PED An area where critically ill patients ≤18 years old with 
medical and/or surgical conditions are managed. 
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Pediatric Neurosurgical 
Critical Care 
1046-2 IN:ACUTE:CC:NS_PED Critical care area specializing in the surgical management 
of patients ≤18 years old with severe neurological 
diseases or those at risk for neurological injury as a result 
of surgery. 
Pediatric Respiratory Critical 
Care 
1047-0 IN:ACUTE:CC:R_PED Critical care area for the evaluation and treatment of the 
patients ≤18 years old with severe respiratory conditions. 
Pediatric Surgical Critical Care 1048-8 IN:ACUTE:CC:S_PED Critical care area for the evaluation and management of 
patients ≤18 years old with serious illness before and/or 
after surgery. 
Pediatric Trauma Critical Care 1049-6 IN:ACUTE:CC:T_PED Critical care area specializing in the care of patients ≤18 
years old who require a high level of monitoring and/or 
intervention following trauma or during critical illness 
related to trauma. 
Neonatal Units 
Well Baby Nursery (Level I) 1038-9 IN:ACUTE:WARD:NURS Hospital area for evaluation and postnatal care of healthy 
newborns. May include neonatal resuscitation and 
stabilization of ill newborns until transfer to a facility at 
which specialty neonatal care is provided. 
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Step down Neonatal Nursery 
(Level II) 
 
 
1041-3 IN:ACUTE:STEP:NURS The capabilities of Level II, listed below, are from the 
American Academy of Pediatrics definitions of levels of 
neonatal care.1  
Level II special care nursery 
Level I capabilities plus:  
 Provide care for infants born ≥32 wks. 
gestation and weighing ≥1500 g who have 
physiologic immaturity or who are 
moderately ill with problems that are 
expected to resolve rapidly and are not 
anticipated to need subspecialty services on 
an urgent basis 
 Provide care for infants convalescing after 
intensive care 
 Provide mechanical ventilation for brief 
duration (<24 h) or continuous positive 
airway pressure or both 
 Stabilize infants born before 32 wks. 
gestation and weighing less than 1500 g 
until transfer to a neonatal intensive care 
facility 
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Neonatal Critical Care 
(Level II/III) 
1039-7 IN:ACUTE:CC_STEP: NURS Combined nursery housing both Level II and III 
newborns and infants, as per the NHSN level definitions 
above and below. This is analogous to a mixed acuity 
unit specifically for Neonatal Critical Care patients. 
Neonatal Critical Care  
(Level III) 
1040-5 IN:ACUTE:CC:NURS A hospital neonatal intensive care unit (NICU) organized 
with personnel and equipment to provide continuous life 
support and comprehensive care for extremely high-risk 
newborn infants and those with complex and critical 
illness.  
The capabilities of Level III and Level IV, listed below, 
are from the American Academy of Pediatrics definitions 
of levels of neonatal care.1 NOTE: These classifications 
are all considered Level III NICUs in NHSN. 
Level III NICU 
Level II capabilities plus: 
 Provide sustained life support
 Provide comprehensive care for infants born < 32
wks. gestation and weighing <1500 g and infants
born at all gestational ages and birth weights
with critical illness
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
 Provide prompt and readily available access to a
full range of pediatric medical subspecialists,
pediatric surgical specialists, pediatric
anesthesiologists, and pediatric ophthalmologists
 Provide a full range of respiratory support that
may include conventional and/or high-frequency
ventilation and inhaled nitric oxide
 Perform advanced imaging, with interpretation
on an urgent basis, including computed
tomography, MRI, and echocardiography
Level IV Regional NICU
Level III capabilities plus:
 Located within an institution with the
capability to provide surgical repair of
complex congenital or acquired conditions
 Maintain a full range of pediatric medical
subspecialists, pediatric surgical
subspecialists, and pediatric subspecialists at
the site
 Facilitate transport and provide outreach
education
- - -
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Specialty Care Areas (SCA) 
Inpatient Dialysis SCA 1198-1 IN:ACUTE:SCA:DIAL Hospital specialty care area for patients who require 
dialysis as part of their care. These patients may be 
chronic or acute dialysis patients. 
Pediatric Dialysis SCA 1091-8 IN:ACUTE:SCA:DIAL_PED Hospital specialty care area for patients ≤18 years old 
who require acute dialysis as part of their care. These 
patients may be chronic or acute dialysis patients. 
Pediatric Solid Organ 
Transplant SCA 
1093-4 IN:ACUTE:SCA:SOTP_PED Hospital specialty area for the postoperative care of 
patients ≤18 years old who have had a solid organ 
transplant (e.g., heart/lung, kidney, liver, pancreas). 
Solid Organ Transplant SCA 1092-6 IN:ACUTE:SCA:SOTP Hospital specialty area for the postoperative care of 
patients who have had a solid organ transplant (e.g., 
heart/lung, kidney, liver, pancreas). 
Adult Wards 
Antenatal Care Ward 1205-4 IN:ACUTE:WARD: 
ANTENAT 
Hospital area for observation, evaluation, treatment or 
surgery of high risk pregnancy patients. 
Behavioral Health/Psych Ward 1051-2 IN:ACUTE:WARD:BHV Area for the evaluation and treatment of patients with 
acute psychiatric or behavioral disorders. This may 
include those units identified as chemical dependency 
units. 
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Burn Ward 1052-0 IN:ACUTE:WARD:B Hospital area for evaluation and treatment of patients 
who have burns. 
Ear/Nose/Throat Ward 1053-8 IN:ACUTE:WARD:ENT Hospital area for the evaluation, treatment, or surgery of 
patients with ear, nose, or throat disorders. 
Gastrointestinal Ward 1054-6 IN:ACUTE:WARD:GI Hospital area for evaluation, treatment or surgery of 
patients with disorders of the gastrointestinal tract. 
Genitourinary Ward 1055-3 IN:ACUTE:WARD:GU Hospital area for the evaluation, treatment or surgery of 
patients with disorders of the genitourinary system. 
Gerontology Ward 1056-1 IN:ACUTE:WARD:GNT Hospital area for the evaluation, treatment or surgery of 
patients with age-related diseases. 
Gynecology Ward 1057-9 IN:ACUTE:WARD:GYN Hospital area for the evaluation, treatment, or surgery of 
female patients with reproductive tract disorders. 
Jail Unit 1171-8 IN:ACUTE:WARD:JAL Overnight stay patient care area of a hospital or 
correctional facility used only for those who are in 
custody of law enforcement during their treatment. 
Labor and Delivery Ward 1058-7 IN:ACUTE:WARD:LD Hospital area where women labor and give birth. 
Labor, Delivery, Recovery, 
Postpartum Suite (LDRP) 
1059-5 IN:ACUTE:WARD:LD_PP Hospital suite used for labor, delivery, recovery and post-
partum (LDRP) -- all within the same suite. 
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Medical Ward 1060-3 IN:ACUTE:WARD:M Hospital area for the evaluation and treatment of patients 
with medical conditions or disorders. 
Medical/Surgical Ward 1061-1 IN:ACUTE:WARD:MS Hospital area for the evaluation of patients with medical 
and/or surgical conditions.  
Neurology Ward 1062-9 IN:ACUTE:WARD:N Hospital area where patients with neurological disorders 
are evaluated and treated. 
Neurosurgical Ward 1063-7 IN:ACUTE:WARD:NS Hospital area for care of patients whose primary reason 
for admission is to have neurosurgery or to be cared for 
by a neurosurgeon after head or spinal trauma. 
ONC Leukemia Ward 1226-0 IN:ACUTE:WARD: 
ONC_LEUK 
Area for the evaluation and treatment of patients with 
leukemia. 
ONC Lymphoma Ward 1228-6 IN:ACUTE:WARD:ONC_ 
LYMPH 
Area for the evaluation and treatment of patients with 
lymphoma. 
ONC Leukemia/Lymphoma 
Ward 
1229-4 IN:ACUTE:WARD: ONC_LL Area for the evaluation and treatment of patients with 
leukemia and/or lymphoma. 
ONC Solid Tumor Ward 1230-2 IN:ACUTE:WARD:ONC_ST Area for the evaluation and treatment of oncology 
patients with solid tumors. 
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
ONC Hematopoietic Stem Cell 
Transplant Ward 
1231-0 IN:ACUTE:WARD: 
ONC_HSCT 
Area for the care of patients who undergo stem cell 
transplant for the treatment of cancers and/or blood or 
immune system disorders. 
ONC General 
Hematology/Oncology Ward 
1232-8 IN:ACUTE:WARD: 
ONC_HONC 
Area for the evaluation and treatment of patients with 
cancer and/or blood disorders. 
Ophthalmology Ward 1064-5 IN:ACUTE:WARD:OPH Hospital area for care of patients whose primary reason 
for admission is to have eye surgery or to be cared for by 
an ophthalmologist after eye trauma. 
Orthopedic Ward 1065-2 IN:ACUTE:WARD:ORT Hospital area for evaluation, treatment or surgery on 
bones, joints, and associated structures by an orthopedist. 
Orthopedic Trauma Ward 1066-0 IN:ACUTE:WARD:T_ORT Hospital area where patients with orthopedic injuries or 
disorders are evaluated and treated. 
Plastic Surgery Ward 1067-8 IN:ACUTE:WARD:PLS Hospital area for the care of patients who have 
reconstructive surgery performed by a plastic surgeon. 
Postpartum Ward 1068-6 IN:ACUTE:WARD:PP Hospital area for the patient who is recovering from 
childbirth. 
Pulmonary Ward 1069-4 IN:ACUTE:WARD:PULM Hospital area where patients with respiratory system 
conditions or disorders are evaluated and treated. 
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Rehabilitation Ward – within 
ACH 
1070-2 IN:ACUTE:WARD:REHAB Hospital area for evaluation and restoration of function to 
patients who have lost function due to acute or chronic 
pain, musculoskeletal problems, stroke, or catastrophic 
events resulting in complete or partial paralysis. 
School Infirmary 1172-6 IN:ACUTE:WARD:IFM Overnight stay patient care area of a school infirmary or 
health center (e.g., private residential school or college 
campus). 
Stroke (Acute) Ward 1071-0 IN:ACUTE:WARD:STRK Hospital area for evaluation, stabilization and treatment 
of patients who have experienced an acute stroke. 
Surgical Ward 1072-8 IN:ACUTE:WARD:S Hospital area for evaluation and treatment of patients 
who have undergone a surgical procedure. 
Telemetry Ward 1208-8 IN:ACUTE:WARD:TEL Hospital area dedicated specifically to provide evaluation 
and treatment of patients requiring continuous cardiac 
monitoring. 
Vascular Surgery Ward 1073-6 IN:ACUTE:WARD:VS Hospital area for evaluation and treatment of patients 
who have undergone vascular surgery. 
Pediatric Wards 
Adolescent Behavioral Health 
Ward 
1075-1 IN:ACUTE:WARD: 
BHV_ADOL 
Hospital area for evaluation and treatment of patients 
between the ages of 13 and 18 with acute psychiatric or 
behavioral disorders.  
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
ONC Pediatric Hematopoietic 
Stem Cell Transplant Ward 
1234-4 IN:ACUTE:WARD: 
ONC_HSCT_PED 
Area for the care of patients ≤18 years old who undergo 
stem cell transplant for the treatment of cancers and/or 
blood or immune system disorders. 
ONC Pediatric General 
Hematology/Oncology Ward 
1235-1 IN:ACUTE:WARD: 
ONC_HONC_PED 
Area for the evaluation and treatment of patients ≤18 
years old with cancer and/or blood disorders. 
Pediatric Behavioral Health 
Ward 
1077-7 IN:ACUTE:WARD:BHV_PED Hospital area for evaluation and management of patients 
≤18 years old with acute psychiatric or behavioral 
disorders. 
Pediatric Burn Ward 1078-5 IN:ACUTE:WARD:B_PED Hospital area specializing in the evaluation and treatment 
of patients ≤18 years old who have tissue injury caused 
by burns. 
Pediatric Ear, Nose, Throat 
Ward 
1079-3 IN:ACUTE:WARD: ENT_PED Hospital area for evaluation and management of patients 
≤18 years old with disorders of the ear, nose and/or 
throat. 
Pediatric Genitourinary Ward 1080-1 IN:ACUTE:WARD: GU_PED Hospital area where patients ≤18 years old with disorders 
of the genitourinary system are evaluated and treated. 
Pediatric Medical Ward 1076-9 IN:ACUTE:WARD:M_PED Area for the evaluation and treatment of patients ≤18 
years of old with medical conditions or disorders. 
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Pediatric Medical/Surgical 
Ward 
1081-9 IN:ACUTE:WARD: MS_PED Hospital area where patients ≤18 years old with medical 
and/or surgical conditions are managed. 
Pediatric Neurology Ward 1082-7 IN:ACUTE:WARD:N_PED Area for the evaluation and treatment of patients ≤18 
years old with neurologic disorders. 
Pediatric Neurosurgical Ward 1083-5 IN:ACUTE:WARD:NS_PED Hospital area for care of patients ≤18 years old whose 
primary reason for admission is to have neurosurgery or 
to be cared for by a neurosurgeon after head or spinal 
trauma. 
Pediatric Orthopedic Ward 1084-3 IN:ACUTE:WARD: ORT_PED Hospital area where patients ≤18 years old with 
orthopedic injuries or disorders are evaluated and treated. 
Pediatric Rehabilitation Ward 1085-0 IN:ACUTE:WARD: 
REHAB_PED 
Hospital area for evaluation and restoration of function to 
patients ≤18 years old  who have lost function due to 
acute or chronic pain, musculoskeletal problems, stroke, 
or catastrophic events resulting in complete or partial 
paralysis. 
Pediatric Surgical Ward 1086-8 IN:ACUTE:WARD:S_PED Hospital area for evaluation and treatment of patients ≤18 
years old that have undergone a surgical procedure. 
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Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Step Down Units 
Adult Step Down Unit     (e.g., 
post-critical care) 
1099-1 IN:ACUTE:STEP Hospital area for adult patients that are hemodynamically 
stable who can benefit from close supervision and 
monitoring, such as frequent pulmonary toilet, vital 
signs, and/or neurological and neurovascular checks. 
ONC Step Down Unit 
(all ages) (e.g., post-critical 
care) 
1227-8 IN:ACUTE:STEP:ONC Area for oncology patients who are hemodynamically 
stable and can benefit from close supervision and 
monitoring, such as frequent pulmonary toilet, vital 
signs, and/or neurologic and neurovascular checks.  
Pediatric Step Down Unit (e.g., 
post-critical care) 
1100-7 IN:ACUTE:STEP:PED Patients ≤18 years old that are hemodynamically stable 
who can benefit from close supervision and monitoring, 
such as frequent pulmonary toilet, vital signs, and/or 
neurological and neurovascular checks. 
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CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Mixed Acuity Units 
Adult Mixed Acuity Unit 1210-4 IN:ACUTE:MIXED: 
ALL_ADULT 
Hospital area for the evaluation and treatment of adult 
patients whose conditions are varying levels of acuity 
(e.g., critical care, ward-level care, step down type care, 
etc.). Such a care area may be comprised of patients 
followed by different hospital services (e.g., coronary, 
medical, surgical, etc.). This care area may or may not 
include “acuity adaptable” or “universal” beds (i.e., this 
model of patient care allows a patient to stay in the same 
bed during all phases of his care, from critical care 
through lower levels of care).  
Pediatric Mixed Acuity Unit 1211-2 IN:ACUTE:MIXED: 
ALL_PEDS 
Hospital area for the evaluation and treatment of 
pediatric patients (≤18 years old) whose conditions are of 
varying levels of acuity (e.g., critical care, etc.). Such a 
care area may be comprised of patients followed by 
different hospital services (e.g., coronary, medical, 
surgical, etc.). This care area may or may not include 
“acuity adaptable” or “universal” beds (i.e., this model of 
patient care allows a patient to stay in the same bed 
during all phases of his care, from critical care through 
lower levels of care). 
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Healthcare 
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Mixed Age Mixed Acuity Unit 1212-0 IN:ACUTE:MIXED:ALL Hospital area for the evaluation and treatment of a 
mixture of adult and pediatric patients whose conditions 
are of varying levels of acuity (e.g., critical care, ward-
level care, step down type care, etc.). Such a care area 
may be comprised of patients followed by different 
hospital services (e.g., coronary, medical, surgical, etc.). 
This care area may or may not include “acuity adaptable” 
or “universal” beds (i.e., this model of patient care allows 
a patient to stay in the same bed during all phases of his 
care, from critical care through lower levels of care). 
ONC Mixed Acuity Unit 
(all ages) 
1236-9 IN:ACUTE:MIXED:ONC 
Operating Rooms 
Cardiac Catheterization 
Room/Suite 
1005-8 IN:ACUTE:OR:CATH A room or rooms in a hospital equipped for the 
performance of heart catheterizations for diagnostic or 
therapeutic purposes.  Operating Room requirements for 
air changes, temperature, humidity and surfaces must be 
met. 
- 
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Healthcare 
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Cesarean Section Room/Suite 1095-9 IN:ACUTE:OR:LD A room or suite in a hospital equipped for the 
performance of obstetric and gynecologic surgeries and 
for the care of the neonate immediately after birth. 
Operating Room requirements for air changes, 
temperature, humidity and surfaces must be met. 
Interventional Radiology   
 
1203-9 IN:ACUTE:OR:RAD A room or suite in a hospital where diagnostic or 
therapeutic radiologic procedures on outpatients and/or 
inpatients occurs.  Operating Room requirements for air 
changes, temperature, humidity and surfaces must be 
met. 
Operating Room/Suite 1096-7 IN:ACUTE:OR A room or suite in a hospital equipped for the 
performance of surgical operations. Requirements for air 
changes, temperature, humidity and surfaces must be 
met. (For outpatient operating room, use Ambulatory 
Surgery Center designation or other specialty OR shown 
in Outpatient Locations section of this chapter). 
Post Anesthesia Care 
Unit/Recovery Room 
1097-5 IN:ACUTE:OR_STEP Hospital area designated for monitoring patients for 
immediate effects of anesthesia before either going home 
or on to an in-patient care area. May also be used for pre 
surgical prep. 
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Chronic Care Units (Previously named Long Term Care) 
NOTE: These location descriptions should only be used to define chronic care units that share a CCN with the affiliated acute care hospital. NHSN does not 
specifically define “extended periods of time”, which is used to describe many of the chronic care units. NHSN leaves this to the facility’s discretion. Chronic care 
units are traditionally non-medical wards where dedicated care is given towards those patients with pre-existing or long term illness, as opposed to acute care 
which is concerned with short term or severe illness.  Skilled nursing facility (SNF) units located within a hospital that have a CCN that is different from the acute 
care hospital should be enrolled as a separate NHSN facility within the NHSN Long Term Care Facility Component, and use the long term care locations defined 
on pages 28-29. 
Inpatient Hospice 1165-0 IN:NONACUTE:LTC:HSP Area where palliative care is provided to the dying 
patient. 
Chronic Alzheimer's Unit 
 
1103-1 IN:NONACUTE:LTC:ALZ Area where care is provided to patients diagnosed with 
Alzheimer's syndrome for extended periods of time. 
Formerly called Long Term Care Alzheimer’s Unit. 
Chronic Behavioral 
Health/Psych Unit 
 
1104-9 IN:NONACUTE:LTC:BHV Area where care is provided to patients with psychiatric 
or behavioral-disorder diagnoses for extended periods of 
time. Formerly called Long Term Care Behavioral 
Health/Psych Unit. 
Chronic Rehabilitation Unit 
 
1105-6 IN:NONACUTE:LTC: REHAB Area where evaluation and restoration of function is 
provided to patients who have lost function due to acute 
or chronic pain, musculoskeletal problems, stroke, or 
catastrophic events resulting in complete or partial 
paralysis. Formerly called Long Term Care 
Rehabilitation Unit. 
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Chronic Care Unit 
 
1102-3 IN:NONACUTE:LTC Area where care provided for patients with chronic 
disease or disabilities for extended periods of time. 
Formerly called Long Term Care Unit. 
Ventilator Dependent Unit 1164-3 IN:NONACUTE:LTC:R Area where care is provided to patients whose 
respirations depend on the use of a ventilator for 
extended periods of time. 
LONG TERM CARE FACILITIES   
LTCF Inpatient Hospice Unit 1254-2 IN:NONACUTE:LTCF:HSP A unit or designed area which provides palliative and 
supportive care services to individuals diagnosed with 
life limiting (terminal) conditions. 
LTCF Dementia Unit 1255-9 IN:NONACUTE:LTCF:DEM A unit or designed area which provides specialized care 
for individuals diagnosed with dementia or related 
conditions, including Alzheimer’s disease. 
LTCF Psychiatric Unit 1256-7 IN:NONACUTE:LTCF:PSY Unit or designated area which provides specialized care 
for individuals diagnosed with psychiatric or behavioral 
disorders. 
LTCF Skilled Nursing/Short 
Term Rehabilitation 
1257-5 IN:NONACUTE:LTCF: 
REHAB 
A unit or designated area which primarily provides short 
term (˂90 days), medical, skilled nursing or rehabilitation 
services to individuals requiring restorative care 
following recent hospitalization. 
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LTCF General Nursing Unit 1258-3 IN:NONACUTE:LTCF:GEN A unit or designated area which primarily provides 
nursing, rehabilitative or custodial services to individuals 
with varying levels of chronic conditions or disability 
requiring long term (˃90 days) support. 
LTCF Ventilator Dependent 
Unit 
1259-1 IN:NONACUTE:LTCF:VEN A unit or designated area which provides nursing and 
respiratory care to individuals who require mechanical 
ventilation. 
LTCF Bariatric Unit 1260-9 IN:NONACUTE:LTCF:BAR A unit or designated area which provides specializing 
care for individuals who are preparing for or have 
undergone bariatric surgery. 
LONG TERM ACUTE CARE FACILITIES  
LTAC ICU 1220-3 IN:ACUTE:CC:LTAC Critical care area specializing in the evaluation, 
treatment, and management of patients that require high 
observance/acuity and/or special care that are suffering 
medically complex conditions or who have suffered 
recent catastrophic illness or injury and require and 
extended stay in an acute care environment. 
LTAC Ward 1221-1 IN:ACUTE:WARD:LTAC Hospital area for the evaluation and treatment of patients 
suffering medically complex conditions or who have 
suffered recent catastrophic illness or injury, and require 
an extended stay in an acute care environment. 
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LTAC Pediatric ICU 1222-9 IN:ACUTE:CC:LTAC_PED Critical care area specializing in the evaluation, 
treatment, and management  of patients ≤18 years old, 
that require high observation/acuity and/or special care 
that are suffering medically complex conditions or who 
have suffered recent catastrophic illness or injury, and 
require an extended stay in an acute care environment. 
LTAC Pediatric Ward 1214-6 IN:ACUTE:WARD:LTAC_PE
D 
Hospital area for the evaluation and treatment of patients 
≤18 years old, suffering medically complex conditions or 
who have suffered recent catastrophic illness or injury, 
and require an extended stay in an acute care 
environment. 
INPATIENT REHABILITATION FACILITIES 
Rehabilitation Ward – 
Freestanding IRF 
1217-9 IN:ACUTE:IRF Hospital area for evaluation, treatment, and restoration of 
function to patients have lost function due to acute or 
chronic pain, musculoskeletal problems, stroke, brain or 
spinal cord dysfunction, or catastrophic events resulting 
in complete or partial paralysis. 
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Rehabilitation Pediatric Ward 1218-7 IN:ACUTE:IRF:PED Hospital area for evaluation, treatment, and restoration of 
function to patients ≤18 years old who have lost function 
due to acute or chronic pain, musculoskeletal problems, 
stroke, brain or spinal cord dysfunction, or catastrophic 
events results in complete or partial paralysis. 
ONCOLOGY FACILITIES 
ONC Medical Critical Care 1223-7 IN:ACUTE:CC:ONC_M Critical care area for the care of oncology patients who 
are being treated for nonsurgical conditions related to 
their malignancy. 
ONC Surgical Critical Care 1224-5 IN:ACUTE:CC:ONC_S Critical care area for the evaluation and management of 
oncology patients with serious illness before and/or after 
cancer-related surgery. 
ONC Medical-Surgical Critical 
Care 
1225-2 IN:ACUTE:CC:ONC_MS Critical care area for the care of oncology patients with 
medical and/or surgical conditions related to their 
malignancy. 
ONC Pediatric Critical Care 1233-6 IN:ACUTE:CC:ONC_PED Critical care area for the care of oncology patients ≤18 
years old who are being treated for surgical or 
nonsurgical conditions related to their malignancy. 
ONC Leukemia Ward 1226-0 IN:ACUTE:WARD: 
ONC_LEUK 
Area for the evaluation and treatment of patients with 
leukemia. 
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ONC Lymphoma Ward 1228-6 IN:ACUTE:WARD:ONC_ 
LYMPH 
Area for the evaluation and treatment of patients with 
lymphoma. 
ONC Leukemia/Lymphoma 
Ward 
1229-4 IN:ACUTE:WARD: ONC_LL Area for the evaluation and treatment of patients with 
leukemia and/or lymphoma. 
ONC Solid Tumor Ward 1230-2 IN:ACUTE:WARD:ONC_ST Area for the evaluation and treatment of oncology 
patients with solid tumors. 
ONC Hematopoietic Stem Cell 
Transplant Ward 
1231-0 IN:ACUTE:WARD: 
ONC_HSCT 
Area for the care of patients who undergo stem cell 
transplant for the treatment of cancers and/or blood or 
immune system disorders. 
ONC General 
Hematology/Oncology Ward 
1232-8 IN:ACUTE:WARD: 
ONC_HONC 
Area for the evaluation and treatment of patients with 
cancer and/or blood disorders. 
ONC Pediatric Hematopoietic 
Stem Cell Transplant Ward 
1234-4 IN:ACUTE:WARD: 
ONC_HSCT_PED 
Area for the care of patients ≤18 years old who undergo 
stem cell transplant for the treatment of cancers and/or 
blood or immune system disorders. 
ONC Pediatric General 
Hematology/Oncology Ward 
1235-1 IN:ACUTE:WARD: 
ONC_HONC_PED 
Area for the evaluation and treatment of patients ≤18 
years old with cancer and/or blood disorders. 
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ONC Step Down Unit 1227-8 IN:ACUTE:STEP:ONC Area for oncology patients who are hemodynamically 
stable and can benefit from close supervision and 
monitoring, such as frequent pulmonary toilet, vital 
signs, and/or neurologic and neurovascular checks.  
ONC Mixed Acuity Unit 
(all ages) 
1236-9 IN:ACUTE:MIXED:ONC Area for the evaluation and treatment of a mixture of 
adult and pediatric oncology patients whose conditions 
are of varying levels of acuity (e.g., critical care, ward-
level care, step down type care, etc.).  This care area may 
or may not include ''acuity adaptable'' or ''universal'' beds 
(i.e., this model of patient care allows a patient to stay in 
same bed during all phases of care, from critical care 
through lower levels of care). 
In addition to the 14 ONC specific locations, HOSP-ONC facilities can also use the following locations within NHSN (Location codes and 
descriptions can be found in the appropriate section of the master location table): 
Inpatient Locations 
 Operating Rooms: 
 Cardiac Catheterization Room/Suite 
 Interventional Radiology 
 Inpatient Operating Room/Suite 
 Post-Anesthesia Care Unit/Recovery Room 
 Facility-wide Areas: 
 FACWIDEIN 
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 Miscellaneous Areas: 
 Pulmonary Function Testing 
 Treatment Room 
 Transport Service 
 Float 
Outpatient Locations 
 Acute Care 
 24-Hour Observation Area 
 Ambulatory Surgery Center  
 Emergency Department 
 Outpatient Pediatric Surgery Center 
 Outpatient Plastic Surgery Center  
 Outpatient Surgery Recovery Room/Post-Anesthesia Care Unit 
 Pediatric Emergency Department 
 Clinic (Nonacute) Settings 
 Infusion Center  
 Occupational Health Clinic 
 Outpatient Hematology/Oncology Clinic 
 Pediatric Hematology/Oncology Clinic 
 Radiology (includes Nuclear Medicine) 
 Specimen Collection Area (Healthcare) 
 Community Locations 
 Home Care 
 Home-based Hospice 
 Location outside facility 
 All Non-Patient Care Locations as designated on page 51 in the location table 
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INPATIENT PSYCHIATRIC FACILITIES 
HOSP-PSYCH facilities can use the following locations within NHSN (Location codes and descriptions can be found in the appropriate section of 
the master location table): 
Inpatient Locations 
 Adult Wards 
 Behavioral Health /Psych Ward 
 Jail Unit 
 Medical Ward 
 Medical/Surgical Ward 
 Pediatric Wards 
 Adolescent Behavioral Health/Psych Ward 
 Pediatric Behavioral Health/Psych Ward 
 Mixed Acuity Locations 
 Adult Mixed Acuity 
 Pediatric Mixed Acuity 
 Chronic Care Units 
 Chronic Alzheimer’s Unit 
 Chronic Behavioral Health/Psych Unit 
 Facility-wide Areas: 
 FACWIDEIN 
 FACWIDEOUT 
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OUTPATIENT LOCATIONS 
OUTPATIENT AMBULATORY SURGERY CENTERS  
 
Outpatient Ambulatory 
Surgery Center 
 
 
1243-5 OUT:ASC:OR Area that is equipped for the performance of surgical 
operations; can be attached to an ACH or free-standing 
and has a separate ASC CCN. Operating Room 
requirements for air changes, temperature, humidity and 
surfaces must be met.  
Ambulatory Surgery Recovery 
Room 
1245-0 OUT:ASC:OR_STEP Area designated in an ASC for monitoring patients for 
the immediate effects of anesthesia. 
 
Outpatient Ambulatory 
Pediatric Surgery Center 
1246-8  OUT:ASC:OR:PED Area, in an ASC, that is equipped for the performance of 
surgical operations for patients ≤18 years old; may be 
free-standing or part of a hospital. Operating Room 
requirements for air changes, temperature, humidity and 
surfaces must be met. Patients do not stay overnight. 
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Outpatient Ambulatory Plastic 
Surgery Center 
1247-8  OUT:ASC:OR:PED Area, in an ASC, that is equipped for the performance of 
plastic surgery operations; may be free-standing or part 
of a hospital.  Operating Room requirements for air 
changes, temperature, humidity and surfaces must be 
met. Patients do not stay overnight.  
ACUTE CARE FACILITIES GENERAL 
Acute Settings 
24-Hour Observation Area 1162-7 OUT:ACUTE:WARD Area where patients are monitored for suspected or non-
life threatening conditions for 24 hours or less. More than 
50% of patients in this location must be outpatients who 
are not expected to be admitted to an inpatient unit. 
Emergency Department 1108-0 OUT:ACUTE:ED Area that provides emergency medical services; top 
priority is given to those with life-threatening illness or 
injury. 
Mobile Emergency 
Services/EMS 
1174-2 OUT:ACUTE:MOBILE:UE Mobile unit that provides clinical and emergency medical 
services to patients who require them in the pre-hospital 
setting. 
Post Anesthesia Care Unit 1169-2 OUT:ACUTE:OR_STEP Area designated for monitoring patients for the 
immediate effects of anesthesia before being sent home. 
May also be used for pre surgical prep. 
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Outpatient Operating 
Room/Suite_ Attached 
1242-7 OUT:ACUTE:OR:HOPD_A A room or suite equipped for the performance of surgical 
operations that is physically within the walls of the 
affiliated ACH. It is considered a hospital outpatient 
department used for outpatient surgical 
procedures.  Requirements for air changes, temperature, 
humidity, and surfaces must be met. 
Outpatient Operating 
Room/Suite_ Detached 
1244-3 OUT:ACUTE:OR:HOPD_D A room or suite equipped for the performance of surgical 
operations that is not physically attached to the affiliated 
ACH (could be on the same campus or miles away). It is 
considered a hospital outpatient department used for 
outpatient surgical procedures.   Requirements for air 
changes, temperature, humidity, and surfaces must be 
met. 
Pediatric Emergency 
Department 
1109-8 OUT:ACUTE:ED:PED Area that provides emergency medical services to 
patients ≤18 years old; top priority is given to those with 
life-threatening illness or injury. 
Urgent Care Center 1160-1 OUT:ACUTE:CLINIC:UE Area that provides medical care services for illnesses and 
injuries that are not life-threatening. 
Clinic (non-acute) Settings 
Allergy Clinic 1110-6 OUT:NONACUTE:CLINIC: 
ALRG 
An outpatient setting for the purpose of providing 
services to patients with allergies. 
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Behavioral Health Clinic 1145-2 OUT:NONACUTE:CLINIC: 
BHV 
An outpatient setting for the purpose of providing 
services to patients with psychiatric or behavior-
disorders. 
Blood Collection Center 1147-8 OUT:NONACUTE:CLINIC: 
BLOOD 
An outpatient setting where blood is collected from 
donors. This does not include donation centers that are 
temporarily set up in non-clinical settings (e.g., schools, 
churches) or mobile blood collection centers. 
Cardiac Rehabilitation Center 1112-2 OUT:NONACUTE:CLINIC: 
C_REHAB 
An outpatient setting where patients with cardiac disease, 
in partnership with a multidisciplinary team of health 
professionals, are encouraged and supported to achieve 
and maintain optimal physical health through exercise, 
nutritional  and psychological counseling. 
Cardiology Clinic 1113-0 OUT:NONACUTE:CLINIC:C An outpatient setting for the evaluation and management 
of patients with cardiac problems. 
Continence Clinic 1148-6 OUT:NONACUTE:CLINIC: 
CON 
An outpatient setting for the evaluation and management 
of patients with incontinence problems. 
Dermatology Clinic 1115-5 OUT:NONACUTE:CLINIC: 
DERM 
An outpatient setting for the evaluation and management 
of dermatologic conditions by a dermatologist. 
Diabetes/Endocrinology Clinic 1116-3 OUT:NONACUTE:CLINIC: 
DIAB 
An outpatient setting for the evaluation, education and 
management of patients with diabetes. 
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Ear, Nose, Throat Clinic 1126-2 OUT:NONACUTE:CLINIC: 
ENT 
An outpatient setting for the evaluation and management 
of conditions related to the ear, nose and/or throat. 
Endoscopy Suite 1007-4 OUT:NONACUTE:DIAG:GI An area where endoscopic procedures (e.g., upper 
gastrointestinal endoscopies, bronchoscopy) are 
performed on outpatients and/or inpatients. Patient care 
and processing of equipment may take place in this 
location. 
Family Medicine Clinic 1117-1 OUT:NONACUTE:CLINIC: 
FAM 
An outpatient setting for patients who are managed by a 
family practice physician or group of physicians. Does 
not include private physician practice. 
Genetics Clinic 1122-1 OUT:NONACUTE:CLINIC: 
GEN 
An outpatient setting for testing and counseling of 
patients may have genetic or hereditary disorders. 
Gynecology Clinic 1121-3 OUT:NONACUTE:CLINIC: 
GYN 
An outpatient setting for women for the evaluation and 
management of female reproductive tract conditions. 
Holistic Medicine Center 1161-9 OUT:NONACUTE:CLINIC: 
HOL 
An outpatient setting where alternative healthcare 
practices are used, focusing on the physical, mental, 
emotional, social and spiritual aspects of health. 
Hyperbaric Oxygen Center 1017-3 OUT:NONACUTE:CLINIC: 
HBO 
An outpatient setting where therapeutic hyperbaric 
oxygen is administered. 
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Infusion Center 1018-1 OUT:NONACUTE:CLINIC: 
FUS 
An outpatient setting for the administration of fluids, 
blood products and medications. 
Mobile Blood Collection 
Center 
1176-7 OUT:NONACUTE:MOBILE: 
BLOOD 
A self-contained mobile unit such as a bus or trailer that 
is specifically designed and equipped for the collection of 
blood and blood products from public donors. This unit 
typically moves from location to location. 
Mobile MRI/CT 1175-9 OUT:NONACUTE: 
MOBILE_DIAG:RAD 
A self-contained mobile unit such as a bus or trailer that 
is equipped with MRI or CT radiologic equipment and 
that may be moved between healthcare locations (e.g., 
hospitals, clinics). 
Neurology Clinic 1123-9 OUT:NONACUTE:CLINIC:N An outpatient setting for the diagnosis, evaluation, and 
treatment of patients with neurologic disorders. 
Occupational Health Clinic 1151-0 OUT:NONACUTE:CLINIC: 
OCC 
An outpatient setting where workplace physicals, 
workplace injury management and immunological 
evaluations take place 
Occupational Therapy Clinic 1152-8 OUT:NONACUTE:CLINIC: 
OT_REHAB 
An outpatient setting where patients with injury or 
disability are helped to resume activities of daily living 
with exercise, massage and other therapies. 
Ophthalmology Clinic 1124-7 OUT:NONACUTE:CLINIC: 
OPH 
An outpatient setting for the diagnosis, evaluation and 
treatment of ophthalmologic disorders. 
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Orthopedic Clinic 1125-4 OUT:NONACUTE:CLINIC: 
ORT 
An outpatient setting for the diagnosis, evaluation and 
treatment of orthopedic disorders. 
Ostomy Clinic 1149-4 OUT:NONACUTE:CLINIC: 
OST 
An outpatient setting for the management of patients who 
have had surgical procedure for removing normal bodily 
wastes through a surgical opening (stoma) on the 
abdominal wall. 
Dental Clinic 1150-2 OUT:NONACUTE:CLINIC: 
DENT 
An outpatient setting that provides dental services, 
including preventive teeth cleaning, emergency 
treatment, and comprehensive oral care. This may be a 
private or group practice or a teaching facility for dentists 
and/or dental hygienists. 
Gastrointestinal (GI) Clinic 1118-9 OUT:NONACUTE:CLINIC:GI An outpatient setting for the diagnosis, evaluation and 
management of conditions related to the gastrointestinal 
tract.  Usually includes an endoscopy suite.  
Hematology/Oncology Clinic 1200-5 OUT:NONACUTE:CLINIC: 
HONC 
An outpatient setting for the diagnosis, evaluation and 
treatment of patients with hematologic and/or oncologic 
disorders. This may include chemotherapy or 
blood/blood products infusion services. 
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Hemodialysis Clinic 1153-6 OUT:NONACUTE:CLINIC: 
HD  
An outpatient setting for chronic maintenance 
hemodialysis patients where they are evaluated and 
dialyzed. (Available only for use in the Biovigilance 
Component) 
HIV Clinic 1154-4 OUT:NONACUTE:CLINIC: 
HIV 
An outpatient setting for the diagnosis, evaluation and 
treatment of patients who are HIV positive or who have 
AIDS. 
Medical Clinic 1120-5 OUT:NONACUTE:CLINIC:M An outpatient setting for the diagnosis, evaluation and 
treatment of medical disorders. 
Rehabilitation Clinic 1151-1 OUT:NONACUTE:CLINIC: 
REHAB 
An outpatient setting where patients with injury or 
disability are evaluated and treated to resume activities of 
daily living, speech and language skills and maximum 
physical function.  This may include social and 
psychological evaluation and treatment. 
Pain Clinic 1127-0 OUT:NONACUTE:CLINIC: 
PAIN 
An outpatient setting for the evaluation and treatment of 
patients with chronic or intractable pain. 
Pediatric Behavioral Health 
Clinic 
1146-0 OUT:NONACUTE:CLINIC: 
BHV_PED 
An outpatient setting for the evaluation and management 
of patients ≤18 years old with psychiatric or behavior 
disorders. 
 January 2018 15-44 
Master CDC Locations and Descriptions 
CDC Location Label NHSN 
Healthcare 
Service 
Location Code 
CDC Location Code Location Description 
Pediatric Cardiology Center 1129-6 OUT:NONACUTE:CLINIC: 
PED_C 
An outpatient setting for the evaluation and management 
of patients ≤18 years old with cardiac disorders. 
Pediatric Clinic 1128-8 OUT:NONACUTE:CLINIC: 
PED 
An outpatient setting for the evaluation and treatment of 
patients ≤18 years old. 
Pediatric Dental Clinic 1130-4 OUT:NONACUTE:CLINIC: 
DENT_PED 
An outpatient setting that provides dental services, 
including preventive teeth cleaning, emergency 
treatment, and comprehensive oral care to patients ≤18 
years old. This may be a private or group practice or a 
teaching facility for dentists and/or dental hygienists. 
Pediatric Dermatology Clinic 1131-2 OUT:NONACUTE:CLINIC: 
DERM_PED 
An outpatient setting for the evaluation and management 
of patients ≤18 years old with dermatologic disorders. 
Pediatric 
Diabetes/Endocrinology Clinic 
1132-0 OUT:NONACUTE:CLINIC: 
DIAB_PED 
An outpatient setting for the evaluation and management 
of patients ≤18 years old with diabetes or other endocrine 
disorders. 
Pediatric Gastrointestinal 
Clinic 
1119-7 OUT:NONACUTE:CLINIC: 
GI_PED 
An outpatient setting for the evaluation and treatment of 
patients ≤18 years old with gastrointestinal disorders. 
Pediatric 
Hematology/Oncology Clinic 
1136-1 OUT:NONACUTE:CLINIC: 
HONC_PED 
An outpatient setting for the evaluation and treatment of 
patients ≤18 years old with cancer and/or blood 
disorders. 
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Pediatric Nephrology Clinic 1137-9 OUT:NONACUTE:CLINIC: 
PGU_PED 
An outpatient setting for the evaluation and treatment of 
patients ≤18 years old with disorders of the genitourinary 
tract. 
Pediatric Orthopedic Clinic 1133-8 OUT:NONACUTE:CLINIC: 
ORT_PED 
An outpatient setting for the evaluation and treatment of 
patients ≤18 years old with fractures or other orthopedic 
disorders. 
Pediatric Rheumatology Clinic 1138-7 OUT:NONACUTE:CLINIC: 
RHEUM_PED 
An outpatient setting for the evaluation and treatment of 
patients ≤18 years old with rheumatology disorders. 
Pediatric Scoliosis Clinic 1134-6 OUT:NONACUTE:CLINIC: 
SCOL_PED 
An outpatient setting for the evaluation and treatment of 
patients ≤18 years old with scoliosis or other growth 
disorders of the spine. 
Physical Therapy Clinic 1202-1 OUT:NONACUTE:CLINIC: 
PT_REHAB 
An outpatient setting where patients with injury or 
disability are helped to obtain maximum physical 
function. 
Physician's Office 1141-1 OUT:NONACUTE:CLINIC A physician's office practice. 
Podiatry Clinic 1140-3 OUT:NONACUTE:CLINIC: 
POD 
An outpatient setting for the evaluation and treatment of 
patients with conditions or disorders of the feet. 
Prenatal Clinic 1156-9 OUT:NONACUTE:CLINIC: 
PNATL 
An outpatient setting for the evaluation and treatment of 
pregnant women. 
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Pulmonary Clinic 1157-7 OUT:NONACUTE:CLINIC: 
PULM 
An outpatient setting for the evaluation and treatment of 
patients with disorders of the respiratory tract. 
Pulmonary Function Testing 1009-0 OUT:NONACUTE:DIAG: 
PULM 
Area where the evaluation of a patient's respiratory status 
takes place. 
Radiology (includes Nuclear 
Medicine) 
1008-2 OUT:NONACUTE:DIAG: 
RAD 
An area where diagnostic or therapeutic radiologic 
procedures are done on outpatients and/or inpatients. 
Operating room requirements for air changes, 
temperature, humidity, and surfaces are NOT met. 
Rheumatology Clinic 1142-9 OUT:NONACUTE:CLINIC: 
RHEUM 
An outpatient setting for the evaluation and treatment of 
patients with autoimmune disorders, primarily 
rheumatoid arthritis. 
School or Prison Infirmary 1170-0 OUT:NONCUTE:CLINIC: 
IFM 
Area in a school or correctional facility that provides 
medical care to students/inmates.  This area is not staffed 
or equipped for overnight stay patients. 
Speech Therapy Clinic 1158-5 OUT:NONACUTE:CLINIC: 
ST_REHAB 
An outpatient setting for the evaluation and treatment of 
patients with brain injury to maximize their speech, 
swallow and language functions. 
Surgical Services Clinic 1143-7 OUT:NONACUTE:CLINIC:S An outpatient setting for the pre-operative evaluation and 
the postoperative management of patients undergoing a 
surgical procedure. 
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Well Baby Clinic 1139-5 OUT:NONACUTE:CLINC: 
NURS 
An outpatient setting for the examination and treatment 
of normal newborns. 
Wound Center 1144-5 OUT:NONACUTE:CLINIC: 
WND 
An outpatient setting for the evaluation and treatment of 
patients with acute or chronic wounds. 
Wound Ostomy Continence 
Clinic 
1159-3 OUT:NONACUTE:CLINIC: 
WND_OST_CONT 
An outpatient area which provides acute and 
rehabilitative care for patients with selective disorders of 
the gastrointestinal, genitourinary and integumentary 
(skin) systems. 
Therapeutic Apheresis Clinic 1207-0 OUT:NONACUTE:CLINIC: 
THERAPHERSIS 
Outpatient setting where blood is collected from patients 
and therapeutic apheresis procedures are performed. 
Miscellaneous Outpatient Settings 
Specimen Collection Area  1019-9 OUT:NA:LAB:SPEC An area within a healthcare facility where procedures are 
performed to collect blood, tissue, or other specimens for 
diagnostic purposes. 
Transport Service 1178-3 OUT:NONACUTE:MOBILE Mobile unit used to transport patients to their home or 
from one healthcare setting to another non-emergently. 
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OUTPATIENT DIALYSIS FACILITIES  
(Available for use in outpatient ambulatory hemodialysis facilities only) 
Outpatient Hemodialysis 
Clinic 
1153-6 OUT:NONACUTE:CLINIC: 
DIAL 
An outpatient setting for maintenance hemodialysis 
patients where they are evaluated and dialyzed in-center. 
Home Hemodialysis 1262-1 COMM:NONACUTE: 
HOME:DIAL 
Hemodialysis performed by a patient (and the patient’s 
caregiver) and at home. 
MISCELLANEOUS AREAS  
(Mainly used for Healthcare Personnel Safety component) 
Float  1206-2 IN:ACUTE:FLOAT For HCWs who do not work at least 75% of the time at a 
single location, the work location code for ‘float’ should 
be entered. (This location is available only for Healthcare 
Personnel Safety Component use only.) 
Morgue/Autopsy Room        1189-0 NONPTC:NA:LAB: 
PATH_MORG 
An area within a facility that is used for the storage 
and/or postmortem examination of deceased persons. 
Sleep Studies (for in and out 
patients) 
1020-7 IN:NONACUTE:CLINIC: 
SLEEP 
Area where patients stay overnight and are evaluated for 
sleep disorders. 
Treatment Room 1209-6 IN:ACUTE:SUPPORT: 
TREAT 
A room in a patient care unit, in which various treatments 
or procedures requiring special equipment are performed, 
such as removing sutures, draining a hematoma, packing 
a wound, or performing an examination. 
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FACILITY-WIDE LOCATIONS 
(Available only for Laboratory Identified Event Reporting [LABID] and Antimicrobial Use and Resistance [AUR] Module) 
Facility-wide Inpatient  
FacWideIN 
1250-0 FACWIDEIN This location represents all inpatient locations for the 
facility, where appropriate numerator and denominator 
counts can be collected. All of the facility’s inpatient 
locations with an overnight stay must be represented for 
full inpatient facility coverage, where denominators can 
be accurately collected and there is the possibility of the 
MDRO to present, transmitted, and identified in that 
specific location. Currently, it is available for use in the 
MDRO/CDI Module for LabID Event reporting and in 
the AUR Module. 
Facility-wide Outpatient 
FacWideOUT 
1251-8 FACWIDEOUT This location represents all outpatient locations for the 
facility, where appropriate numerator and accurate 
denominator counts can be collected. All of the facility’s 
outpatient locations must be represented for full 
outpatient facility coverage, where denominators can be 
accurately collected and there is the possibility of the 
MDRO to be present, transmitted, and identified in that 
specific location. Currently, it is available for use in the 
MDRO/CDI Module for LabID Event reporting.   
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COMMUNITY LOCATIONS 
Blood Collection (Blood Drive 
Campaign) 
1195-7 COMM:NONACUTE:CLINIC:
BLOOD 
A location not designated or equipped to perform 
healthcare functions (e.g., school gym or shopping mall) 
that have been set up specifically to collect donations of 
blood and blood products from the public. 
Home Care 1192-4 COMM:NONACUTE: HOME A patient’s home location where medical services 
including routine noninvasive and other noninvasive 
procedures (e.g., insertion of indwelling urinary catheter, 
insertion of IV line) are performed by healthcare workers 
and family members under the supervision of a licensed 
independent practitioner (e.g., MD, CNP, PA). 
Home-based Hospice 1194-0 COMM:NONACUTE:HOME:
HSP 
A patient’s home location where end-of-life services are 
performed by healthcare workers, family members, and 
volunteers. 
Location outside facility 1204-7 COMM:NOTFAC A location outside this facility, including unknown 
outside location. 
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Specimen Collection Area 
(Community) 
1196-5 COMM:NA:LAB:SPEC A location not designated or equipped to perform 
healthcare functions (e.g., school gym or shopping mall) 
that have been set up specifically to collect body fluids 
for healthcare testing. Examples would be blood sugar or 
cholesterol screening clinics. 
NON-PATIENT CARE LOCATIONS 
 (Non-Patient Care Areas available for use in Biovigilance or Healthcare Personnel Safety Components only) 
Administrative Areas 1184-1 NONPTC:NA:SUPPORT: 
ADMIN 
Areas within a healthcare facility where administrative 
functions take place. No patient care takes place in these 
areas. 
Assisted Living Area 1106-4 NONPTC:NA:HOME A location where persons live and have available to them 
housekeeping, meal preparation, transportation, and other 
non-medical services. Patient care is not done in this 
area. 
Blood Bank 1185-8 NONPTC:NA:LAB:BLOOD An area within a healthcare facility that may collect, 
store, and distribute blood and blood products, and 
performs diagnostic tests on blood/components to 
determine compatibilities. 
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Central Sterile Supply 1186-6 NONPTC:NA:SUPPORT: CSS An area within a healthcare facility where durable 
medical equipment is cleaned/decontaminated, wrapped, 
sterilized, and stored in preparation for transport to a 
landfill or incineration. 
Central Trash Area 1187-4 NONPTC:NA:SUPPORT: 
SOILED  
 
An area adjacent to a healthcare facility where bio-
hazardous and non-bio-hazardous wastes are collected in 
preparation for transport to a landfill or incineration. 
Centralized Transfusion 
Service 
1261-7 NONPTC:NA:LAB:CTS A location outside the facility that stores, manipulates, 
issues, and/or performs compatibility testing on blood 
and blood products (e.g., a contracted transfusion service 
or a separate hospital that provides transfusion services 
for your facility). 
Clinical Chemistry Laboratory 1011-6 NONPTC:NA:LAB:CHEM An area within a diagnostic laboratory that performs 
general clinical chemistry analysis (clinical 
biochemistry), endocrinology, therapeutic substance 
monitoring, toxicology, blood pH and blood gas analysis, 
urinalysis and urine pregnancy testing. 
Facility Grounds 118-2 NONPTC:NA:SUPPORT: 
GRNDS 
Any outdoor area adjacent to a healthcare facility that 
belongs to the facility (e.g., sidewalks, parking ramps, 
lawns). 
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General Laboratory 1010-8 NONPTC:NA:LAB An area that encompasses all clinical divisions within a 
diagnostic laboratory. 
Hematology Laboratory 1012-4 NONPTC:NA:LAB:H An area within a diagnostic laboratory that determines 
the specific properties of blood (e.g., CBC, white blood 
count). 
Histology/Surgical Pathology 
Laboratory 
1013-2 NONPTC:NA:LAB: 
HIST_PATH 
An area within a diagnostic laboratory that uses high-
power microscopy to evaluate cells and tissues for the 
presence or absence of disease. 
Housekeeping/Environmental 
Services 
1182-5 NONPTC:NA:SUPPORT: 
HSKP 
An area within a healthcare facility where the activities 
of housekeeping/environmental services staff are 
coordinated and supplies are stored. 
Laundry Room 1183-3 NONPTC:NA:SUPPORT: 
LAUN 
An area within a healthcare facility where laundry is 
sorted, washed, dried, and prepared for transport and use. 
Microbiology Laboratory 1014-0 NONPTC:NA:LAB:MICRO An area within a laboratory that performs diagnostic tests 
to determine the presence or absence of bacteria and their 
related properties. 
Pharmacy 1179-1 NONPTC:NA:SUPPORT: 
PHARM 
An area within a healthcare facility where medications 
are prepared and labeled for patient use. 
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Physical Plant Operations 
Center 
1181-7 NONPTC:NA:SUPPORT: 
ENG 
An area within a healthcare facility where construction, 
renovation, and maintenance staff activities and supplies 
are coordinated. They may also include areas of 
machinery and equipment. 
Public Area in Facility 1180-9 NONPTC:NA:SUPPORT: PUB Any indoor area within a healthcare facility that is not 
used for patient care and that is available to the public 
(e.g., waiting rooms, cafeterias, hallways). 
Serology Laboratory 1015-7 NONPTC:NA:LAB:SER An area within a diagnostic laboratory that performs 
blood tests to determine the presence or absence of 
certain diseases or the levels of immunity. 
Soiled Utility Area 1190-8 IN:NA:SUPPORT:TRASH Area where used and/or soiled disposable or durable 
medical equipment is stored and/or cleaned in 
preparation for disposal or reprocessing/reuse. 
Virology Laboratory 1016-5 NONPTC:NA:LAB:VIR An area within a diagnostic laboratory that performs tests 
and/or culturing to determine the presence or absence of 
specific viruses. 
 
References 
1. American Academy of Pediatrics.  Policy Statement Levels of Neonatal Care.  Pediatrics 2012; 130 (3): 587-597. 
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Definitions specific to individual protocols are found in the respective protocol. 
 
Term Definition 
Active Surveillance 
Culture/Testing 
(ASC/AST) 
For purposes of NHSN surveillance, Active Surveillance Culture/Testing 
(ASC/AST) refers to testing that is intended to identify the 
presence/carriage of microorganisms for the purpose of instituting or 
discontinuing isolation precautions (for example, nasal swab for MRSA, 
rectal swab for VRE), or monitoring for eradication of a carrier state. 
ASC/AST does NOT include identification of microorganisms with cultures 
or tests performed for diagnosis and treatment purposes (for example, 
specimens collected from sterile body sites including blood specimens). 
Also, see Surveillance cultures. 
Apnea See Vital Signs.   
Aseptically 
obtained 
Obtained in a manner to prevent introduction of organisms from the 
surrounding tissues into the specimen being collected. 
Birthweight Birthweight is the weight of the infant at the time of birth and should not be 
changed as the infant gains weight. The birthweight categories are as 
follows: A = ≤750 g; B = 751-1000 g; C = 1001-1500 g; D = 1501-2500 g; 
E = >2500 g. 
CDC location A CDC-defined designation given to a patient care area housing patients 
who have similar disease conditions or who are receiving care for similar 
medical or surgical specialties. Each facility location that is monitored is 
“mapped” to one CDC Location. The specific CDC Location code is 
determined by the type of patients cared for in that area according to the 
80% Rule.  The 80% Rule is when 80% of the patients in a location are of a 
certain type (for example, if 80% of the patients in an area are pediatric 
patients receiving orthopedic care, this area should be designated as an 
Inpatient Pediatric Orthopedic Ward).   
 Acuity billing data (if available) is the most reliable and objective 
method of determining appropriate location mapping.  
 Admission/transfer diagnosis can also be used to determine location 
mapping if billing data is not available.  
 Facilities, when possible, should use 1 years’ worth of data to make this 
determination. If that is not available, a shorter period of at least 3 
months is acceptable, but every effort should be made to collect and 
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analyze greater periods of time in the future, consistently using the same 
method.  
Also, see Virtual Location in the Locations and Descriptions chapter. 
For detailed instructions on how to map locations, see “Instructions for 
Mapping Patient Care Locations in NHSN” in the Locations and 
Descriptions chapter.  
Clinical correlation Physician documentation of antimicrobial treatment for site-specific 
infection related to equivocal findings (not clearly identified) as infection on 
imaging test. 
For example, when applying intraabdominal infection (IAB) criterion 3b, 
the finding of ‘fluid collection seen in the lower abdominal cavity’ on an 
imaging test, may or may not represent an infection. This finding is not 
clearly identified as an infection and should be confirmed with clinical 
evidence that an infection is present. In the case of IAB criterion 3b, the 
clinical evidence required is physician documentation of antimicrobial 
therapy for treating the intraabdominal infection. 
Date of event The date of event is the date the first element used to meet an NHSN site-
specific infection criterion occurs for the first time within the seven-day 
infection window period or SSI surveillance period.  Synonyms: infection 
date, date of infection, event date. 
In the case of a process measure, the date the process or intervention was 
performed (for example, the day a central line was inserted is the date of 
CLIP event).  
This definition does not apply to LabID event, or VAE.  See Date of event 
for VAE, SSI, and LabID Event in respective protocols. 
Device-associated 
infection 
An infection meeting the HAI definition is considered a device-associated 
HAI (for example, associated with the use of a ventilator, central line, or 
indwelling urinary catheter) if the device was in place for >2 calendar days 
on the date of event and was also in place on the date of event or the day 
before.  
If the device was in place for >2 calendar days and then removed, the date 
of event must be the day of discontinuation or the next day to be device 
associated.  For a patient who has a central line in place on hospital 
admission, day of first inpatient access is considered Device Day 1.  For a 
patient who has a ventilator or urinary catheter in place on the day of 
admission, Device Day 1 is day of admission. 
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Device days A count of the number of patients with a specific device in a patient care 
location during a time period. This count can be determined electronically 
or manually by a daily count or weekly sampling. See Denominator Data 
section within individual protocols. 
Died The patient died during the current facility admission. 
Event contributed 
to death 
The event either directly caused death or exacerbated an existing disease 
condition that then led to death as evidenced by available documentation 
(for example, death/discharge note, autopsy report, etc.). 
Event date See Date of event. 
Fever See Vital signs. 
Gross anatomical 
exam 
Evidence of infection elicited or visualized on physical examination or 
observed during an invasive procedure.  This includes physical examination 
of a patient during admission and subsequent assessments of the patient. 
Additionally, it may include findings noted during a medical/invasive 
procedure and is dependent on the location of the infection as well as the 
NHSN infection criterion.   
Examples: 
 An intraabdominal abscess requires an invasive procedure to actually 
visualize the abscess.  
 Visualization of pus or purulent drainage from drains within an abscess 
is acceptable.  
 Abdominal pain elicited on physical exam post-CSEC or hysterectomy, 
is sufficient evidence of infection detected without an invasive 
procedure. 
Healthcare-
associated infection 
(HAI) 
An infection is considered a HAI if the date of event of the NHSN site-
specific infection criterion occurs on or after the 3rd calendar day of 
admission to an inpatient location where day of admission is calendar day 1. 
See Identifying HAIs chapter. Note: Rules for HAI should not be applied to 
SSI, VAE, or LabID Events.   
Hypotension See Vital signs. 
Infant A patient who is ≤ 1 year (≤ 365 days) of age. 
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Infection date See Date of Event. 
Infection window 
period (IWP) 
The Infection Window Period is defined as the 7 days during which all site-
specific infection criteria must be met. It includes the date the first positive 
diagnostic test that is used as an element of the site-specific infection 
criterion was obtained, the 3 calendar days before, and the 3 calendar days 
after. 
Inpatient location See Location. 
In-plan 
surveillance 
Facility has indicated in their monthly reporting plan that the NHSN 
surveillance protocol(s) will be utilized, in its entirety, for that particular 
event.  Only in-plan data are submitted to CMS in accordance with CMS’s 
Quality Reporting Programs. Only data that are entered into NHSN “in-
plan” are included in NHSN annual reports or other NHSN publications. 
Intensive care unit 
(ICU) 
Also known as, a Critical Care Unit, the ICU is a nursing care area that 
provides intensive observation, diagnostic and therapeutic procedures for 
adults and/or children who are critically ill. An ICU excludes nursing areas 
that provide step-down, intermediate care or telemetry only. Specialty care 
areas are also excluded (see definition).  
The type of ICU is determined by the kind of patients cared for in that unit 
according to the 80% Rule – that is 80% of the patients in a location are of a 
certain type. For example, if 80% of the patients in an area are patients 
receiving critical care for trauma, this area should be designated as an 
Inpatient Trauma Critical Care Unit. When an ICU houses roughly equal 
populations of medical and surgical patients (a 50/50 to 60/40 mix), it is 
called a medical/surgical ICU. 
Location The patient care area to which a patient is assigned while receiving care in 
the healthcare facility. Note: Only mapped inpatient locations where 
denominator data are collected can be used for reporting infection events 
via the Device-associated Module. Operating rooms (including cardiac 
catheter labs, C-section rooms, and interventional radiology), emergency 
departments and outpatient locations are not valid locations for these types 
of surveillance. Also, see CDC Location. 
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Location 
of attribution 
(LOA) 
The inpatient location where the patient was assigned on the date of event is 
the location of attribution (also, see Date of Event and Transfer Rule terms). 
Non-bedded patient locations, (for example, PACU or OR) are not eligible 
for assignment of location of attribution for HAI events. Location of 
attribution must be assigned to a location where denominator data can be 
collected. See individual HAI protocol(s) for additional details. 
Neonate A patient who is ≤ 30 days of age. 
Non-culture based 
microbiologic 
testing  
 
Non-culture based testing refers to identification of microorganisms using a 
method of testing other than a culture. Culturing requires that a specimen be 
inoculated to a culture media, incubated and observed for actual growth of 
microorganisms and, depending on the organism identified, can take several 
days to weeks for a final report. In contrast, non-culture based testing 
methods generally provide faster results, which can assist with early 
diagnosis and tailoring of antimicrobial therapy. Examples of non-culture 
based testing include PCR (polymerase chain reaction) and ELISA 
(Enzyme-linked immunosorbent assay).  
With the exception of Active Surveillance Culture/Testing (ASC/AST), any 
test methodology (culture or non-culture based), providing a final laboratory 
report in the medical record, that identifies an organism, is eligible for use 
in meeting an NHSN infection definition.  
Off-plan 
surveillance 
 
Facility has not indicated in their monthly reporting plan that the NHSN 
surveillance protocol(s) will be utilized, in its entirety, for that particular 
event.  Off-plan data are not submitted to CMS in accordance with CMS’s 
Quality Reporting Programs. Off-plan data are not included in NHSN 
annual reports or other NHSN publications. 
Patient days A count of the number of patients in the patient care location during a time 
period. This count can be determined electronically or manually by a daily 
count or weekly sampling. See Denominator Data section within individual 
protocols. 
Present on 
admission (POA) 
An infection is considered POA if the date of event of the NHSN site-
specific infection criterion occurs during the POA time period, which is 
defined as the day of admission to an inpatient location (calendar day 1), the 
2 days before admission, and the calendar day after admission. See 
Identifying HAIs chapter.  Note: Rules for POA should not be applied to 
SSI, VAE, or LabID Events.   
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Repeat infection 
timeframe (RIT) 
The RIT is a 14-day timeframe during which no new infections of the same 
type are reported. The RIT applies to both POA and HAI event 
determinations.   
 The date of event is Day 1 of the 14-day RIT.  
 If criteria for the same type of infection are met and the date of event is 
within the 14-day RIT, a new event is not identified or reported.  
 Additional pathogens recovered during the RIT from the same type of 
infection are added to the event and the original date of event is 
maintained as is the original 14-day RIT. 
 Device association determination and location of attribution are not 
amended.   
See Identifying HAIs chapter.  Note: Rules for RIT should not be applied to 
SSI, VAE, or LabID Events.   
Secondary BSI 
attribution period 
(SBAP) 
The Secondary BSI Attribution Period is the period in which a blood 
specimen must be collected for a secondary bloodstream infection to be 
attributed to a primary site infection. This period includes the Infection 
Window Period (IWP) combined with the Repeat Infection Timeframe 
(RIT). It is 14-17 days in length depending upon the date of event.  
Note: Rules for Secondary BSI Attribution Period should not be applied to 
VAE, or LabID Events; the Secondary BSI Attribution Period for SSIs is 
the 17-day period that includes the date of event, 3 days prior, and 13 days 
after the SSI date of event. 
Standardized 
Infection Ratio 
(SIR) 
Summary measure used to track HAIs over time. It compares the number of 
reported HAIs to the number of predicted HAIs, based on NHSN baseline 
data. The SIR adjusts for several factors that may impact the risk of 
acquiring an HAI. See the SIR Guide for more information. 
Surveillance 
cultures 
Those cultures reported as part of a facility’s infection prevention and 
control surveillance and are not used in patient diagnosis and treatment. 
Cultures include but not limited to stool cultures for vancomycin-resistant 
Enterococci (VRE) and/or nasal swabs for methicillin-resistant 
Staphylococcus aureus (MRSA) surveillance.  These cultures are also called 
active surveillance cultures or testing (ASC/AST).  
 
Note: Positive cultures collected from sterile body sites including blood 
specimens are not surveillance cultures and are eligible for use in meeting 
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NHSN HAI, LabID, VAE, and SSI event criteria.  Also, see Active 
Surveillance Culture/Testing (ASC/AST). 
Teaching hospital There are three types of teaching hospitals defined in NHSN: 
 Major: Facility has a program for medical students and post-graduate 
medical training. 
 Graduate: Facility has a program for post-graduate medical training 
(residency and/or fellowships). 
 Undergraduate: Facility has a program for medical / nursing students 
only. 
Temperature See Vital signs. 
Temperature 
instability 
See Vital signs. 
Transfer rule If the date of event is on the date of transfer or discharge, or the next day, 
the infection is attributed to the transferring/discharging location. This is 
called the Transfer Rule. If the patient was in multiple locations within the 
transfer rule time frame, attribute the infection to the first location in which 
the patient was housed the day before the infection’s date of event. 
Vital signs 
 
If a specific value for a vital sign is not stated in a CDC/NHSN HAI 
definition, criterion (for example, hypotension and temperature instability) 
the facility should use the vital sign parameter(s) as stated in its policies and 
procedures for clinical practices.  
 For fever, NHSN does have a stated value; the facility should use the 
temperature documented in the patient’s medical record. There is no 
conversion of temperature based on route of collection.  
 For apnea in ventilated patients < 1 year of age, apnea cannot be 
determined by changes /adjustments in ventilator settings or by 
worsening oxygenation.   
 
 
 
 
  
January 2018 17- 1   
Surveillance Definitions 
CDC/NHSN Surveillance Definitions for Specific Types of 
Infections  
 
INTRODUCTION 
 
This chapter contains the CDC/NHSN surveillance definitions and criteria for all specific types of 
infections. This chapter also provides additional required criteria for the specific infection types that 
constitute organ space surgical site infections (SSI) ( for example, mediastinitis [MED] that may follow 
a coronary artery bypass graft, intra-abdominal abscess [IAB] after colon surgery, etc.). Comments 
and reporting instructions that follow the site-specific criteria provide further explanation and 
are integral to the correct application of the criteria.  Refer to Chapter 2 (Identifying HAIs in 
NHSN) for specific guidance for making HAI determinations. 
 
Infection criteria contained in this chapter may be necessary for determining whether a positive blood 
specimen represents a primary bloodstream infection (BSI) or is secondary to a different type of 
infection (see Appendix B Secondary Bloodstream Infection (BSI) Guide). A BSI that is identified as 
secondary to another site of infection must meet one of the infection criteria detailed in this chapter and 
meet other requirements. Secondary BSIs are not reported as Laboratory Confirmed Bloodstream 
Infections in NHSN, nor can they be associated with the use of a central line. 
 
NOTES:  
 
  See individual protocol chapters for infection criteria for urinary tract infections  (UTI), 
bloodstream infections (BSI), pneumonia (PNEU), ventilator-associated infections (VAE), and 
surgical site infections (SSI).  
 
 Organisms belonging to the following genera cannot be used to meet any NHSN definition:  
Blastomyces, Histoplasma, Coccidioides, Paracoccidioides, Cryptococcus and Pneumocystis. 
These organisms are typically causes of community-associated infections and are rarely known 
to cause healthcare-associated infections, and therefore are excluded.   
 
 Antibiograms of the blood and isolates from potential primary sites of infection do not have to 
match for purposes of determining the source of BSIs (see “matching organisms” below).  
 
 A matching organism is defined as one of the following:  
  
1. If genus and species are identified in both specimens, they must be the same.  
a. Example: An intraabdominal specimen is used as an element to meet IAB 
definition and is growing Enterobacter cloacae. A blood specimen with a 
collection date in the IAB secondary BSI attribution period is reported to 
be growing Enterobacter cloacae. These are considered matching 
organisms.  
b. Example: An intraabdominal specimen is used as an element to meet IAB 
definition and is growing Enterobacter aerogenes. A blood specimen with 
a collection date in the IAB secondary BSI attribution period is reported to 
be growing Enterobacter cloacae. These are NOT considered matching 
organisms as the species are different.  
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2. If the organism is less definitively identified in one specimen than the other, the 
lesser identified organism must be identified to at least the genus level and at that level 
the organisms must be the same. 
a.    Example: A surgical wound growing Pseudomonas species is used to 
meet deep incisional SSI criteria and a blood specimen growing 
Pseudomonas aeruginosa is collected in the SSI secondary BSI attribution 
period. The organisms are considered matching at the genus level and 
therefore the BSI is secondary to the SSI. 
b.    Example: PCR identifying Enterococcus faecalis in CSF meets the MEN 
definition. A subsequent blood culture collected in the MEN secondary 
BSI attribution period is identified as Enterococcus species. The organisms 
are considered to be matching and therefore the BSI is secondary to MEN  
 3.  There are two exceptions to the definition:  
a. Infections meeting LCBI 2 criteria with staphylococcus or streptococcus 
Example-(staphylococcus): A patient has a fever and a previous chest 
tube site is reddened, swollen and a culture is collected from the soft 
tissue.  The chest tube site culture is reported positive for Staphylococcus 
species. SST/ST definition is met. The next day 2 blood culture sets are 
collected.  The blood cultures are both positive for coagulase negative 
Staphylococcus.  The organisms are NOT considered matching, because 
Staphylococcus species could represent a coagulase negative or a 
coagulase positive Staphylococcus. Therefore the BSI would not be 
considered secondary to SST/ST.   
Example-(streptococcus): A patient has a fever and a previous chest tube 
is reddened swollen and a culture is collected from the soft tissue.  The 
chest tube site culture is reported positive for Streptococcus species. 
SST/ST definition is met. The next day 2 blood culture sets are collected.  
The blood cultures are both positive for Streptococcus, viridans group.  
The organisms are NOT considered matching, because Streptococcus 
species could represent a Streptococcus, viridans group or non- 
Streptococcus, viridans group. Therefore the BSI would not be considered 
secondary to SST/ST.   
b. In cases where an organism is identified only as “yeast” or “yeast not 
otherwise specified”, the organism can be considered a match to other 
yeasts, when collected during the required timeframe, whether more fully 
identified or not.   
Example: A culture of tissue from ulcer margin of a decubiti reported 
positive for yeast is used as an element to meet DECU definition. A blood 
specimen collected in the secondary BSI attribution period of the DECU is 
reported as Candida albicans. In this example the two organisms are 
considered matching organisms as the organisms are complementary 
(specifically, Candida is a type of yeast) and because yeasts isolated from 
non-sterile sites are commonly not identified to the genus or genus and 
species level.  
NOTE: This exception is limited to yeast. It does not apply to 
identification of organisms as Gram positive cocci, Gram negative 
rods, etc.  
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Example: A culture of tissue from ulcer margin of a decubiti reported 
positive for Gram negative rod is used as an element to meet DECU 
definition. A blood specimen collected in the secondary BSI 
attribution period of the DECU is reported as E.coli. In this example 
the two organisms are NOT considered matching organisms.  
 
 
CRITERIA FOR SPECIFIC TYPES OF INFECTION 
 
Infection criteria used for NHSN healthcare-associated infection surveillance have been grouped into 
14 major types with some further categorized into specific infection types. For example, there are three 
specific types of central nervous system infections (intracranial infection, meningitis or ventriculitis, 
and spinal abscess without meningitis) that are grouped under the major type of CNS–Central Nervous 
System. 
 
Infection criteria are listed in alphabetical order, according to their (abbreviated) major codes, and the 
criteria for each of the specific types of infection follow it. 
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Table 1: CDC/NHSN Major and Specific Types of Infections 
 
Type 
Page 
BJ – Bone and Joint Infection 6 
BONE – Osteomyelitis 6 
DISC – Disc space infection 6 
JNT – Joint or bursa infection 7 
PJI – Prosthetic joint infection 7 
  
CNS – Central Nervous System  8 
IC – Intracranial infection 8 
MEN – Meningitis or ventriculitis 9 
SA – Spinal abscess without meningitis 10 
  
CVS – Cardiovascular System Infection 10 
CARD – Myocarditis or pericarditis 10 
ENDO – Endocarditis 11 
MED – Mediastinitis 14 
VASC – Arterial or venous infection 14 
  
EENT – Eye, Ear, Nose, Throat, or Mouth Infection 16 
CONJ – Conjunctivitis 16 
EAR – Ear, mastoid infection 16 
EYE – Eye infection, other than conjunctivitis 17 
ORAL – Oral cavity infection (mouth, tongue, or gums) 17 
SINU – Sinusitis 18 
UR – Upper respiratory tract infection, pharyngitis, laryngitis, epiglottitis 18 
  
GI – Gastrointestinal System Infection 19 
CDI-Clostridium difficile Infection 19 
GE – Gastroenteritis 20 
GIT – Gastrointestinal (GI) tract infection 20 
IAB – Intraabdominal infection, not specified elsewhere 21 
NEC – Necrotizing enterocolitis 22 
  
LRI – Lower Respiratory System Infection, Other Than Pneumonia 23 
LUNG – Other infection of the lower respiratory tract 23 
  
REPR – Reproductive Tract Infection 23 
EMET – Endometritis 23 
EPIS – Episiotomy infection 24 
OREP – Other infection of the male or female reproductive tract 24 
VCUF – Vaginal cuff infection 25 
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SST-Skin and Soft Tissue Infection 25 
BRST – Breast abscess or mastitis 25 
BURN – Burn Infection 25 
CIRC– Newborn circumcision infection 26 
DECU – Decubitus ulcer infection (also known as pressure injury infection) 26 
SKIN – Skin infection 26 
ST – Soft tissue infection 28 
UMB – Omphalitis 28 
  
USI – Urinary System Infection 28 
  
References 30 
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BJ-BONE AND JOINT INFECTION 
BONE-Osteomyelitis 
Osteomyelitis must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from bone by culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis and treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST). 
2.  Patient has evidence of osteomyelitis on gross anatomic or histopathologic exam. 
3. Patient has at least two of the following localized signs or symptoms: fever (>38.0°C),  swelling*,   
pain or  tenderness*, heat*, or drainage* 
And at least one of the following: 
a. organism(s) identified from blood by culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis and treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST)  
AND 
 imaging test evidence suggestive of infection (for example, x-ray, CT scan, MRI, radiolabel 
scan [gallium, technetium, etc.]), which if equivocal is supported by clinical correlation, 
specifically, physician documentation of antimicrobial treatment for osteomyelitis.  
b. imaging test evidence suggestive of infection (for example, x-ray, CT scan, MRI, radiolabel 
scan [gallium, technetium, etc.]), which if equivocal is supported by clinical correlation, 
specifically, physician documentation of antimicrobial treatment for osteomyelitis.  
 
* With no other recognized cause 
 
Reporting instructions 
 Report mediastinitis following cardiac surgery that is accompanied by osteomyelitis as SSI-
MED rather than SSI-BONE.  
 If a patient meets both organ space JNT and BONE report the SSI as BONE 
 After an HPRO or a KPRO if a patient meets both organ space PJI and BONE report the SSI as 
BONE 
 
DISC-Disc space infection 
Vertebral disc space infection must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from vertebral disc space by culture or non-culture based 
microbiologic testing method, which is performed for purposes of clinical diagnosis and treatment, 
for example, not Active Surveillance Culture/Testing (ASC/AST). 
2. Patient has evidence of vertebral disc space infection on gross anatomic or histopathologic exam. 
3. Patient has at least one of the following:  fever (>38.0°C) or pain* at the involved vertebral disc 
space 
And at least one of the following: 
a. organism(s) identified from blood by culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis and treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST)  
AND 
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 imaging test evidence suggestive of infection (for example, x-ray, CT scan, MRI, radiolabel 
scan [gallium, technetium, etc.]), which if equivocal is supported by clinical correlation, 
specifically, physician documentation of antimicrobial treatment for vertebral disc space 
infection. 
b. imaging test evidence suggestive of infection ( for example, x-ray, CT scan, MRI, radiolabel 
scan [gallium, technetium, etc.]), which if equivocal is supported by clinical correlation, 
specifically, physician documentation of antimicrobial treatment for vertebral disc space 
infection. 
* With no other recognized cause 
 
JNT-Joint or bursa infection (not for use as Organ/Space SSI after HPRO or KPRO procedures) 
 
Joint or bursa infections must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from joint fluid or synovial biopsy by culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis and treatment, 
for example, not Active Surveillance Culture/Testing (ASC/AST). 
2. Patient has evidence of joint or bursa infection on gross anatomic or histopathologic exam. 
3. Patient has at least two of the following: swelling*, pain* or tenderness*, heat*, evidence of 
effusion*, or limitation of motion*. 
And at least one of the following: 
a. elevated  joint fluid white blood cell count (per reporting laboratory’s reference range) OR 
positive leukocyte esterase test strip of joint fluid 
b. organism(s) and white blood cells seen on Gram stain of joint fluid  
c. organism(s) identified from blood by culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis and treatment ,for example, not 
Active Surveillance Culture/Testing (ASC/AST).  
d. imaging test evidence suggestive of infection (for example, x-ray, CT scan, MRI, radiolabel 
scan [gallium, technetium, etc.]), which if equivocal is supported by clinical correlation,  
specifically, physician documentation of antimicrobial treatment for joint or bursa infection. 
 
* With no other recognized cause 
 
Reporting instruction 
If a patient meets both organ space JNT and BONE report the SSI as BONE 
 
PJI – Periprosthetic Joint Infection (for use as Organ/Space SSI following HPRO and KPRO 
only) 
 
Joint or bursa infections must meet at least one of the following criteria: 
 
1. Two positive periprosthetic specimens (tissue or fluid) with at least one matching organism, 
identified by culture or non-culture based microbiologic testing method which is performed for 
purposes of clinical diagnosis and treatment, for example, not Active Surveillance Culture/Testing 
(ASC/AST). 
2. A sinus tract* communicating with the joint identified on gross anatomic exam. 
3. Having three of the following minor criteria: 
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a. elevated serum C-reactive protein (CRP; >100 mg/L) and erythrocyte sedimentation rate 
(ESR; >30 mm/hr.) 
b. elevated synovial fluid white blood cell (WBC; >10,000 cells/μL) count OR “++” (or 
greater) change on leukocyte esterase test strip of synovial fluid 
c. elevated synovial fluid polymorphonuclear neutrophil percentage (PMN% >90%) 
d. positive histological analysis of periprosthetic tissue (>5 neutrophils (PMNs) per high power 
field) 
e. organism(s) identified from a single positive periprosthetic specimen (tissue or fluid) by 
culture or non-culture based microbiologic testing method which is performed for purposes 
of clinical diagnosis and treatment ,for example, not Active Surveillance Culture/Testing 
(ASC/AST) 
* A sinus tract is defined as a narrow opening or passageway that can extend in any direction through 
soft tissue and results in dead space with potential for abscess formation. 
 
Comments: 
 
 A matching organism is defined on page 17 -1.Organism(s) identified from hip or knee 
hardware can be used to meet criterion 1. 
 The NHSN definition of PJI is closely adapted from the Musculoskeletal Infection Society’s 
(MSIS’s) definition of PJI (Proceedings of the International Consensus Meeting on 
Periprosthetic Joint Infection, 2013).  
 The standard laboratory cutoff values in criteria 3a - 3d are provided by NHSN for HPRO and 
KPRO SSI surveillance purposes only. The NHSN laboratory cutoffs are not intended to guide 
clinicians in the actual clinical diagnosis and management of acute or chronic PJI. Clinicians 
should refer to the MSIS consensus definition for clinical use. 
 
Reporting Instruction: 
After an HPRO or a KPRO if a patient meets both organ space PJI and BONE report the SSI as BONE 
 
 
CNS-CENTRAL NERVOUS SYSTEM INFECTION 
 
IC-Intracranial infection (brain abscess, subdural or epidural infection, encephalitis) 
 
Intracranial infection must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from brain tissue or dura by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or treatment ,for 
example, not Active Surveillance Culture/Testing (ASC/AST). 
2. Patient has an abscess or evidence of intracranial infection on gross anatomic or histopathologic 
exam 
3. Patient has at least two of the following signs or symptoms: headache*, dizziness*, fever 
(>38.0°C), localizing neurologic signs*, changing level of consciousness*, or confusion* 
And at least one of the following: 
a. organism(s) seen on microscopic examination of brain or abscess tissue obtained by needle 
aspiration or during an invasive procedure or autopsy. 
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b. imaging test evidence suggestive of infection (for example, ultrasound, CT scan MRI, 
radionuclide brain scan, or arteriogram), which if equivocal is supported by clinical correlation, 
specifically, physician documentation of antimicrobial treatment for intracranial infection. 
c. diagnostic single antibody titer (IgM) or 4-fold increase in paired sera (IgG) for organism 
4. Patient ≤1 year of age has at least two of the following signs or symptoms: fever (>38.0°C), 
hypothermia (<36.0°C), apnea*, bradycardia*, localizing neurologic signs*, or changing level of 
consciousness* ,for example, irritability, poor feeding, lethargy 
And at least one of the following: 
a. organism(s) seen on microscopic examination of brain or abscess tissue obtained by needle 
aspiration or during an invasive procedure or autopsy  
b. imaging test evidence suggestive of infection, (for example, ultrasound, CT scan, MRI, 
radionuclide brain scan, or arteriogram), which if equivocal is supported by clinical 
correlation ,specifically, physician documentation of antimicrobial treatment for intracranial 
infection. 
c. diagnostic single antibody titer (IgM) or 4-fold increase in paired sera (IgG) for organism 
 
* With no other recognized cause 
 
Reporting instructions 
 Report as MEN if meningitis (MEN) and encephalitis (IC) are present together.  
 Report as IC if meningitis (MEN) and a brain abscess (IC) are present together after operation. 
 Report as SA if meningitis (MEN) and spinal abscess (SA) are present together.  
 
MEN-Meningitis or ventriculitis 
 
Meningitis or ventriculitis must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from cerebrospinal fluid (CSF) by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or treatment for 
example, not Active Surveillance Culture/Testing (ASC/AST). 
2. Patient has at least two of the following:  
i. fever (>38.0°C) or headache (Note: Elements of “i” alone may not be used to meet the two 
required elements)  
ii. meningeal sign(s)* 
iii. cranial nerve sign(s)* 
And at least one of the following: 
a. increased white cells, elevated protein, and decreased glucose in CSF (per reporting 
laboratory’s reference range)   
b. organism(s) seen on Gram stain of CSF 
c. organism(s) identified from blood by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST) 
d. diagnostic single antibody titer (IgM) or 4-fold increase in paired sera (IgG) for organism 
3. Patient ≤1 year of age has at least two of the following elements:  
i. fever (>38.0°C), hypothermia (<36.0°C±), apnea*, bradycardia*, or irritability* (Note: 
Elements of “i” alone may not be used to meet the required two elements). 
ii. meningeal signs* 
iii. cranial nerve signs* 
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And at least one of the following: 
a. increased white cells, elevated protein, and decreased glucose in CSF (per reporting 
laboratory’s reference range) 
b. organism(s) seen on Gram stain of CSF 
c. organism(s) identified from blood by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST) 
d. diagnostic single antibody titer (IgM) or 4-fold increase in paired sera (IgG) for organism. 
 
* With no other recognized cause 
 
Reporting instructions 
 Report CSF shunt infection as SSI-MEN if it occurs within 90 days of placement; if later or 
after manipulation/access, it is considered CNS-MEN but is not reportable as an SSI 
 Report as MEN if meningitis (MEN) and encephalitis (IC) are present together  
 Report as IC if meningitis (MEN) and a brain abscess (IC) are present together after operation 
Report as SA if meningitis (MEN) and spinal abscess (SA) are present together  
 
SA-Spinal abscess  
 
An abscess of the spinal epidural or subdural space, without involvement of the cerebrospinal fluid or 
adjacent bone structures, must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from abscess in the spinal epidural or subdural space by a culture 
or non-culture based microbiologic testing method which is performed for purposes of clinical 
diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). 
2. Patient has an abscess in the spinal epidural or subdural space on gross anatomic or histopathologic 
exam.  
3. Patient has at least one of the following localized signs or symptoms: fever (>38.0°C), back pain* 
or tenderness*, radiculitis*, paraparesis*, or paraplegia* 
And at least one of the following: 
a. organism(s) identified from blood by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST)  
AND 
imaging test evidence of spinal abscess, which if equivocal is supported by clinical 
correlation, specifically, physician documentation of antimicrobial treatment for spinal 
abscess. 
b. imaging test evidence of a spinal abscess (for example, myelography, ultrasound, CT scan, 
MRI, or other scans [gallium, technetium, etc.]) which if equivocal is supported by clinical 
correlation ,specifically, physician documentation of antimicrobial treatment for spinal 
abscess. 
 
* With no other recognized cause 
 
Reporting instructions 
 Report as IC if meningitis (MEN) and a brain abscess (IC) are present together after operation.  
 Report as SA if meningitis (MEN) and spinal abscess (SA) are present together.  
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CVS-CARDIOVASCULAR SYSTEM INFECTION 
 
CARD-Myocarditis or pericarditis 
 
Myocarditis or pericarditis must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from pericardial tissue or fluid by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, 
for example, not Active Surveillance Culture/Testing (ASC/AST) 
2. Patient has at least two of the following signs or symptoms: fever (>38.0°C), chest pain*,       
paradoxical pulse*, or increased heart size* 
And at least one of the following: 
a. abnormal EKG consistent with myocarditis or pericarditis 
b. evidence of myocarditis or pericarditis on histologic exam of heart tissue 
c. 4-fold rise in paired sera from IgG  antibody titer 
d. pericardial effusion identified by echocardiogram, CT scan, MRI, or angiography. 
3. Patient ≤1 year of age has at least two of the following signs or symptoms: fever (>38.0°C), 
hypothermia (<36.0°C ), apnea*, bradycardia*, paradoxical pulse*, or increased heart size* 
And at least one of the following: 
a. abnormal EKG consistent with myocarditis or pericarditis 
b. histologic examination of heart tissue shows evidence of myocarditis or pericarditis. 
c. 4-fold rise in paired sera from IgG antibody titer 
d. pericardial effusion identified by echocardiogram, CT scan, MRI, or angiography 
 
* With no other recognized cause 
 
Comment:  
 Most cases of post cardiac surgery or post myocardial infarction pericarditis are not infectious. 
 
ENDO-Endocarditis 
 
When meeting the Endocarditis (ENDO) definition: 
 
 The ENDO Infection Window Period is defined as the 21 days during which all site-
specific infection criteria must be met. It includes the date the first positive diagnostic 
test that is used as an element of the ENDO criterion was obtained, the 10 calendars 
days before and the 10 calendar days after. The Infection Window Period is lengthened 
for this event to accommodate the extended diagnostic timeframe that is frequently 
required to reach a clinical determination of endocarditis. 
 The RIT for Endocarditis (ENDO) is extended to include the remainder of the patient’s 
current admission.   
 When meeting the Endocarditis (ENDO) definition, the secondary BSI attribution 
period includes the 21-day infection window period and all subsequent days of the 
patient’s current admission.  
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o As a result of this lengthy secondary BSI attribution period, secondary BSI 
pathogen assignment for ENDO, is limited to organism(s) identified in blood 
specimen that match the organism(s) used to meet the ENDO definition.  
Example: If the ENDO definition was met using a site-specific specimen (for example, 
cardiac vegetation) or using a blood specimen with S.aureus as the identified 
organism, if a blood specimen collected during the ENDO secondary BSI attribution 
period is positive for S. aureus and E.coli, while the S. aureus can be assigned to the 
ENDO event, it cannot be assumed the E.coli can be assigned as a secondary BSI 
pathogen. The blood organism (E.coli) does not match the organism (S.aureus) used to 
meet the ENDO definition.  If the blood specimen can be used to meet an ENDO 
definition criterion both organisms can be assigned. Otherwise the E.coli will need to 
be investigated as a separate BSI and identified as a secondary BSI to another site-
specific infection or determined to be a primary BSI. 
 
Endocarditis of a natural or prosthetic heart valve must meet at least one of the following criteria: 
 
1. Organism(s) identified from cardiac vegetation*, embolized vegetation ( for example, solid-organ 
abscess) documented as originating from cardiac source, or intracardiac abscess by a culture or 
non-culture based microbiologic testing method which is performed for purposes of clinical 
diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). 
2. Organism(s) seen on histopathologic examination of cardiac vegetation, embolized vegetation, for 
example, solid organ abscess, documented as originating from cardiac source, or intracardiac 
abscess. 
3. Endocarditis seen on histopathologic examination of cardiac vegetation or intracardiac abscess. 
4. At least one of the following echocardiographic evidence of endocarditis*†: 
i. vegetation on cardiac valve or supporting structures 
ii. intracardiac abscess 
iii. new partial dehiscence of prosthetic valve 
     And at least one of the following: 
a. typical infectious endocarditis organism(s) (specifically, Viridans group streptococci,  
Streptococcus bovis, Haemophilus spp., Actinobacillus actinomycetemcomitans, 
Cardiobacterium hominis, Eikenella corrodens, Kingella spp., Staphylococcus aureus, 
Enterococcus spp.) identified from ≥2 blood collections drawn on separate occasions  
with no more than 1 calendar day between specimens  by a culture or non-culture 
based microbiologic testing method which is performed for purposes of clinical 
diagnosis or treatment, for example, not Active Surveillance Culture/Testing 
(ASC/AST) 
b. Coxiella burnetii identified from blood by a culture or non-culture based microbiologic 
testing method which is performed for purposes of clinical diagnosis or treatment ,for 
example, not Active Surveillance Culture/Testing (ASC/AST) or identified by anti-
phase I IgG  antibody titer >1:800 
5. At least three of the following: 
i. prior endocarditis, prosthetic valve, uncorrected congenital heart disease, history of 
rheumatic heart disease, hypertrophic obstructive cardiomyopathy, or known IV drug use 
ii. fever (>38.0°C) 
iii. vascular phenomena: major arterial emboli ( specifically, embolic stroke, renal infarct, 
splenic infarct or abscess, digital ischemic/gangrene from embolic source), septic 
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pulmonary infarcts, mycotic aneurysm (documented by imaging, seen in surgery, or 
described in gross pathological specimen), intracranial hemorrhage, conjunctival 
hemorrhages, or Janeway’s lesions documented 
iv. immunologic phenomena: glomuleronephritis (documented or chart, or white cell or red 
blood cell casts on urinalysis), Osler’s nodes, Roth’s spots, or positive rheumatoid factor 
     And at least one of the following: 
a. typical infectious endocarditis organism(s) (specifically, Viridans group streptococci, 
Streptococcus bovis, Haemophilus spp., Actinobacillus actinomycetemcomitans, 
Cardiobacterium hominis, Eikenella corrodens, Kingella spp., Staphylococcus aureus, 
Enterococcus spp.) identified from  ≥2 blood collections drawn on separate occasions 
with no more than 1 calendar day between specimens  by a culture or non-culture 
based microbiologic testing method which is performed for purposes of clinical 
diagnosis or treatment, for example, not Active Surveillance Culture/Testing 
(ASC/AST) 
b. Coxiella burnetii identified from blood by a culture or non-culture based microbiologic 
testing method which is performed for purposes of clinical diagnosis or treatment ,for 
example, not Active Surveillance Culture/Testing (ASC/AST)or identified by anti-
phase I IgG antibody titer >1:800 
6.   At least one of the following*†: 
i. vegetation on cardiac valve or supporting structures seen on echocardiogram 
ii. intracardiac abscess seen on echocardiogram 
iii. new partial dehiscence of prosthetic valve seen on echocardiogram 
      And at least three of the following: 
a.    prior endocarditis, prosthetic valve, uncorrected congenital heart disease, history of 
rheumatic heart disease, hypertrophic obstructive cardiomyopathy, or known IV drug 
use 
b.   fever (>38.0°C) 
c.    vascular phenomena: major arterial emboli ( specifically, embolic stroke, renal infarct, 
splenic infarct or abscess, digital ischemic/gangrene from embolic source), septic 
pulmonary infarcts, mycotic aneurysm (documented by imaging, seen in surgery, or 
described in gross pathological specimen), intracranial hemorrhage, conjunctival 
hemorrhages, or Janeway’s lesions documented 
d. immunologic phenomena: glomuleronephritis (documented in chart, or white cell or 
red blood cell casts on urinalysis), Osler’s nodes, Roth’s spots, or positive rheumatoid 
factor 
e. identification of organism(s) from the blood by at least one of the following methods: 
 recognized pathogen(s) identified from blood by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis 
or treatment ,for example, not Active Surveillance Culture/Testing (ASC/AST) 
 same common commensal organism(s) identified from  ≥2 blood collections drawn 
on separate occasions on the same or consecutive days by a culture or non-culture 
based microbiologic testing method which is performed for purposes of clinical 
diagnosis or treatment ,for example, not Active Surveillance Culture/Testing 
(ASC/AST) 
7.  All of the following criteria: 
a. prior endocarditis, prosthetic valve, uncorrected congenital heart disease, history of rheumatic 
heart disease, hypertrophic obstructive cardiomyopathy, or known IV drug use 
b. fever (>38.0°C) 
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c. vascular phenomena: major arterial emboli ( specifically, embolic stroke, renal infarct, splenic 
infarct or abscess, digital ischemic/gangrene from embolic source), septic pulmonary infarcts, 
mycotic aneurysm (documented by imaging, seen in surgery, or described in gross pathological 
specimen), intracranial hemorrhage, conjunctival hemorrhages, or Janeway’s lesions 
documented 
d. immunologic phenomena: glomuleronephritis (documented or chart, or white cell or red blood 
cell casts on urinalysis), Osler’s nodes, Roth’s spots, or positive rheumatoid factor 
e. identification of organism(s) from the blood by at least one of the following methods: 
 recognized pathogen(s) identified from blood by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or 
treatment ,for example, not Active Surveillance Culture/Testing (ASC/AST). 
 same common commensal organism(s) identified from  ≥2 blood collections drawn on 
separate occasions on the same or consecutive days by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or 
treatment ,for example, not Active Surveillance Culture/Testing (ASC/AST). 
*“Cardiac vegetation” includes vegetation on a pacemaker/ defibrillator lead or ventricular assist 
devices (VAD) components within the heart 
† Which if equivocal is supported by clinical correlation (specifically, physician documentation of 
antimicrobial treatment for endocarditis). 
MED-Mediastinitis  
 
Mediastinitis must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from mediastinal tissue or fluid by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for 
example, not Active Surveillance Culture/Testing (ASC/AST)  
2. Patient has evidence of mediastinitis on gross anatomic or histopathologic exam. 
3. Patient has at least one of the following signs or symptoms: fever (>38.0°C),  chest pain*, or sternal 
instability* 
And at least one of the following: 
a. purulent drainage from mediastinal area 
b. mediastinal widening on imaging test 
4. Patient ≤1 year of age has at least one of the following signs or symptoms: fever (>38.0°C), 
hypothermia (<36.0°C ), apnea*, bradycardia*, or sternal instability* 
And at least one of the following: 
a. purulent drainage from mediastinal area 
b. mediastinal widening on imaging test 
 
* With no other recognized cause 
 
Comment: 
 The mediastinal space is the area under the sternum and in front of the vertebral column, 
containing the heart and its large vessels, trachea, esophagus, thymus, lymph nodes, and other 
structures and tissues. It is divided into anterior, middle, posterior, and superior regions. 
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Reporting instruction 
 Report mediastinitis (MED) following cardiac surgery that is accompanied by osteomyelitis as SSI-
MED rather than SSI-BONE. 
 
 
VASC-Arterial or venous infection  
 
Note: If a patient meets the criteria for an LCBI in the presence of an intravascular infection 
report as an LCBI not as a VASC. ** 
 
Arterial or venous infection must meet at least one of the following criteria: 
 
1. Patient has organism(s) from extracted arteries or veins identified by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for 
example, not Active Surveillance Culture/Testing (ASC/AST).  
2. Patient has evidence of arterial or venous infection on gross anatomic or histopathologic exam.  
3. Patient has at least one of the following signs or symptoms: fever (>38.0°C), pain*, erythema*, or 
heat at involved vascular site* 
AND 
 More than 15 colonies cultured from intravascular cannula tip using semi-quantitative culture 
method. 
4. Patient has purulent drainage at involved vascular site 
5. Patient ≤1 year of age has at least one of the following signs or symptoms: fever (>38.0°C), 
hypothermia (<36.0°C), apnea*, bradycardia*, lethargy*, pain*, erythema*, or heat at involved 
vascular site* 
AND 
More than 15 colonies cultured from intravascular cannula tip using semi-quantitative culture 
method 
 
* With no other recognized cause 
 
Reporting instructions 
 Report infections of an arteriovenous graft, shunt, fistula or intravascular cannulation site without 
organism(s) identified from blood as CVS-VASC. 
 Report Organ Space VASC infections as an SSI and not an LCBI when you have an SSI with 
secondary BSI. 
 
** Report intravascular infections with organism(s) identified from the blood and meeting the LCBI 
criteria, as BSI-LCBI.  However, if the BSI meets the CLABSI criteria and BOTH of the following are 
present within the infection window period, mark the data field for risk factor “Central line” as “No”: 
 Pus at the site 
AND 
 Specimen collected from the site of one of the following, has at least one matching organism to 
organism(s) identified in a blood specimen:  
o Arterial catheters 
o Arteriovenous fistula 
o Arteriovenous graft 
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o Atrial catheters (also known as transthoracic intra-cardiac catheters, those catheters 
inserted directly into the right or left atrium via the heart wall) 
o Hemodialysis reliable outflow (HERO) dialysis catheters 
o Intra-aortic balloon pump (IABP) devices 
o Non-accessed central line (not accessed nor inserted during the hospitalization) 
o Peripheral IV or Midlines 
 
 
EENT-EYE, EAR, NOSE THROAT, OR MOUTH INFECTION 
 
CONJ-Conjunctivitis 
 
Conjunctivitis must meet at least one of the following criteria: 
 
1. Patient has organism(s) or virus identified from conjunctival scraping or purulent exudate obtained 
from the conjunctiva or contiguous tissues, ( for example, eyelid, cornea, meibomian glands, or 
lacrimal glands) by a culture or non-culture based microbiologic testing method which is 
performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance 
Culture/Testing (ASC/AST).  
2. Patient has pain or redness of conjunctiva or around eye 
And at least one of the following: 
a. WBCs and organism(s) seen on Gram stain of exudate 
b. purulent exudate 
c. multinucleated giant cells seen on microscopic examination of conjunctival exudate or 
scrapings 
d. diagnostic single antibody titer (IgM) or 4-fold increase in paired sera (IgG) for organism  
 
Reporting instructions 
 Report other infections of the eye as EYE. 
 Do not report chemical conjunctivitis, caused by silver nitrate (AgNO3), as a healthcare–
associated infection. 
 Do not report a separate case of conjunctivitis (CONJ) that occurs as a part of another viral 
illness (for example, UR). 
 
EAR-Ear, mastoid infection 
 
Ear and mastoid infections must meet at least one of the following criteria: 
 
Otitis externa must meet at least one of the following criteria: 
1. Patient has organism(s) identified from purulent drainage from ear canal by a culture or non-
culture based microbiologic testing method which is performed for purposes of clinical diagnosis 
or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). 
2. Patient has at least one of the following: fever (>38.0°C), pain*, or erythema*  
AND 
organism(s) seen on Gram stain of purulent drainage from ear canal. 
 
Otitis media must meet at least one of the following criteria: 
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3. Patient has organism(s) identified from fluid from middle ear obtained during an invasive 
procedure ( for example, tympanocentesis) by a culture or non-culture based microbiologic 
testing method which is performed for purposes of clinical diagnosis or treatment, for example, 
not Active Surveillance Culture/Testing (ASC/AST). 
4. Patient has at least two of the following: fever (>38.0°C), pain *, inflammation*, retraction* or 
decreased mobility of eardrum*, or fluid behind eardrum*. 
 
Otitis interna must meet at least one of the following criteria: 
5. Patient has organism(s) identified from fluid from inner ear obtained during an invasive 
procedure by a culture or non-culture based microbiologic testing method which is performed 
for purposes of clinical diagnosis or treatment, for example, not Active Surveillance 
Culture/Testing (ASC/AST). 
6. Patient has a physician diagnosis of inner ear infection. 
 
Mastoiditis must meet at least one of the following criteria: 
7. Patient has organism(s) identified from fluid or tissue from mastoid by a culture or non-culture 
based microbiologic testing method which is performed for purposes of clinical diagnosis or 
treatment,for example not Active Surveillance Culture/Testing (ASC/AST). 
8. Patient has at least two of the following: fever (>38.0°C), pain or tenderness*, post auricular 
swelling*, erythema*, headache*, or facial paralysis* 
And at least one of the following: 
a. organism(s) seen on Gram stain of fluid or tissue from mastoid 
b. imaging test evidence suggestive of infection ( for example, CT scan), which if 
equivocal is supported by clinical correlation, specifically, physician documentation of 
antimicrobial treatment for mastoid infection. 
 
* With no other recognized cause 
 
EYE-Eye infection, other than conjunctivitis 
 
An infection of the eye, other than conjunctivitis, must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from anterior or posterior chamber or vitreous fluid by a culture or 
non-culture based microbiologic testing method which is performed for purposes of clinical 
diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). 
2. Patient has at least two of the following signs or symptoms with no other recognized cause: eye 
pain, visual disturbance, or hypopyon  
AND  
physician initiates antimicrobial therapy within two days of onset or worsening of symptoms  
 
ORAL-Oral cavity infection (mouth, tongue, or gums) 
 
Oral cavity infections must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from abscess or purulent material from tissues of oral cavity by a 
culture or non-culture based microbiologic testing method which is performed for purposes of 
clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). 
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2. Patient has an abscess or other evidence of oral cavity infection found on invasive procedure, gross 
anatomic exam, or histopathologic exam. 
3. Patient has at least one of the following signs or symptoms with no other recognized cause:  
ulceration, raised white patches on inflamed mucosa, or plaques on oral mucosa. 
 
And at least one of the following: 
a. virus identified from mucosal scrapings or exudate by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or 
treatment, for example, not Active Surveillance Culture/Testing (ASC/AST) 
b. multinucleated giant cells seen on microscopic examination of mucosal scrapings or exudate 
c. diagnostic single antibody titer (IgM) or 4-fold increase in paired sera (IgG) for organism. 
d. fungal elements seen on microscopic exam of mucosal scrapings or exudate (for example, 
Gram stain, KOH ) 
e. physician initiates antimicrobial therapy within 2 days of onset or worsening of symptoms. 
 
Reporting instruction 
 Report healthcare–associated primary herpes simplex infections of the oral cavity as ORAL; 
recurrent herpes infections are not healthcare associated. 
 
SINU-Sinusitis 
 
Sinusitis must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from fluid or tissue from the sinus cavity obtained during an 
invasive procedure by a culture or non-culture based microbiologic testing method which is 
performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance 
Culture/Testing (ASC/AST). 
2. Patient has at least one of the following signs or symptoms: fever (>38.0°C), pain or tenderness 
over the involved sinus*, headache*, purulent exudate*, or nasal obstruction* 
AND 
Imaging test evidence of sinusitis (for example, x-ray, CT scan) 
 
* With no other recognized cause 
 
UR-Upper respiratory tract infection, pharyngitis, laryngitis, epiglottitis  
 
Upper respiratory tract infections must meet at least one of the following criteria: 
 
1. Patient has at least two of the following signs or symptoms: fever (>38.0°C), erythema of pharynx*, 
sore throat*, cough*, hoarseness*, or purulent exudate in throat* 
And at least one of the following: 
a. organism(s) identified from upper respiratory site [ specifically: larynx, pharynx, and 
epiglottis] by a culture or non-culture based microbiologic testing method which is 
performed for purposes of clinical diagnosis or treatment, for example, not Active 
Surveillance Culture/Testing (ASC/AST). Note: excludes sputum and tracheal aspirate 
because these are not upper respiratory specimens 
b. diagnostic single antibody titer (IgM) or 4-fold increase in paired sera (IgG) for  organism 
c. physician diagnosis of an upper respiratory infection 
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2. Patient has an abscess on gross anatomical or histopathologic exam or imaging test. 
3. Patient ≤1 year of age has at least two of the following signs or symptoms: fever (>38.0°C), 
hypothermia (<36.0°C ), apnea*, bradycardia*, nasal discharge*, or purulent exudate in throat* 
And at least one of the following: 
a. organism(s) identified from upper respiratory site [ specifically larynx, pharynx, and 
epiglottis] by a culture or non-culture based microbiologic testing method which is 
performed for purposes of clinical diagnosis or treatment, for example, not Active 
Surveillance Culture/Testing (ASC/AST). Note: excludes sputum because sputum is not an 
upper respiratory specimen 
b. diagnostic single antibody titer (IgM) or 4-fold increase in paired sera (IgG) for organism 
c. physician diagnosis of an upper respiratory infection 
 
* With no other recognized cause 
 
 
GI-GASTROINTESTINAL SYSTEM INFECTION 
 
CDI-Clostridium difficile Infection 
 
Clostridium difficile infection must meet at least one of the following criteria: 
 
1. Positive test for toxin-producing C. difficile on an unformed stool specimen (conforms to the shape 
of the container). 1,2  
2. Patient has evidence of pseudomembranous colitis on gross anatomic (includes endoscopic exams) 
or histopathologic exam. 
 
Note: 
 When using a multi-testing methodology for CD identification, the result of the last test finding, 
which is placed onto the patient medical record, will determine if GI-CDI criterion 1 is met. 
Comments: 
 The date of event for CDI criterion 1, will always be the specimen collection date of the 
unformed stool, specifically, not the date of onset of unformed stool. 
 A positive test for toxin-producing C. difficile and an unformed stool specimen is a single 
element and both are required to meet criterion . 
 
Reporting instructions  
 Report the CDI and the GE or GIT if additional enteric organism(s) are identified and criteria 
are met for GE or GIT.  
 Report each new GI-CDI according to the Repeat Infection Timeframe (RIT) rule for HAIs 
(see NHSN HAI definitions in Chapter 2 for further details and guidance).  
 CDI laboratory-identified event (LabID Event) categorizations (for example, recurrent CDI 
assay, incident CDI assay, healthcare facility-onset, community-onset, community-onset 
healthcare facility-associated) do not apply to HAIs; including C. difficile associated 
gastrointestinal infections (GI-CDI).  
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GE-Gastroenteritis (excluding C. difficile infections) 
 
Gastroenteritis must meet at least one of the following criteria: 
 
1. Patient has an acute onset of diarrhea (liquid stools for > 12 hours) and no likely noninfectious cause 
(for example, diagnostic tests, therapeutic regimen other than antimicrobial agents, acute 
exacerbation of a chronic condition, or psychological stress information). 
2. Patient has at least two of the following signs or symptoms: nausea*, vomiting*, abdominal pain*, 
fever (>38.0°C), or headache* 
And at least one of the following: 
a. an enteric pathogen is identified from stool or rectal swab by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or 
treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). 
b. an enteric pathogen is detected by microscopy on stool  
c. diagnostic single antibody titer (IgM) or 4-fold increase in paired sera (IgG) for organism 
 
* With no other recognized cause 
 
Comment: 
 The reference to “enteric pathogens” describes pathogens that are not considered to be normal 
flora of the intestinal tract.  Enteric pathogens identified on culture or with the use of other 
diagnostic laboratory tests include Salmonella, Shigella, Yersinia, Campylobacter, Listeria, 
Vibrio, Enteropathogenic or Enterohemorrhagic E.coli or Giardia. 
 
Reporting instruction  
 Report only GI-GIT using the event date as that of GI-GIT if the patient meets criteria for both 
GI-GE and GI-GIT.  
 
GIT-Gastrointestinal tract infection (esophagus, stomach, small and large bowel, and rectum) 
excluding gastroenteritis, appendicitis, and C. difficile infection 
 
Gastrointestinal tract infections, excluding, gastroenteritis and appendicitis, must meet at least one of 
the following criteria: 
 
1. Patient has one of the following:  
a. an abscess or other evidence of gastrointestinal tract infection on gross anatomic or 
histopathologic exam.  
b. abscess or other evidence of gastrointestinal tract infection on gross anatomic or 
histopathologic exam  
                  AND  
     organism(s) identified from blood by a culture or non-culture based microbiologic testing    
     method, which is performed for purposes of clinical diagnosis or treatment, for example, not    
     Active Surveillance Culture/Testing (ASC/AST).  The organism(s) identified in the blood   
     must contain at least one MBI organism. (See Appendix A of the BSI protocol)  
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2. Patient has at least two of the following signs or symptoms compatible with infection of the organ 
or tissue involved: fever (>38.0°C), nausea*, vomiting*, pain*or tenderness*, odynophagia*, or 
dysphagia* 
And at least one of the following: 
a. organism(s) identified from drainage or tissue obtained during an invasive procedure                    
or from drainage from an aseptically-placed drain by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or 
treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).  
b. organism(s) seen on Gram stain or fungal elements seen on KOH stain or multinucleated 
giant cells seen on microscopic examination of drainage or tissue obtained during an invasive 
procedure or from drainage from an aseptically-placed drain 
c. organism(s) identified from blood by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST). The organism(s) identified in the blood 
must contain at least one MBI organism  (See Appendix A of the BSI protocol)  
AND 
       imaging test evidence suggestive of gastrointestinal infection ( for example, endoscopic       
       exam, MRI, CT scan), which if equivocal is supported by clinical correlation,  specifically,                                                       
       physician documentation of antimicrobial treatment for gastrointestinal tract infection.  
d. imaging test evidence suggestive of infection ( for example, endoscopic exam, MRI, CT 
scan), which if equivocal is supported by clinical correlation, specifically, physician 
documentation of antimicrobial treatment for gastrointestinal tract infection. 
 
* With no other recognized cause 
 
 Reporting instruction  
 Report only GI-GIT using the event date as that of GI-GIT if the patient meets criteria for both 
GI-GE and GI-GIT 
 
IAB-Intraabdominal infection, not specified elsewhere, including gallbladder, bile ducts, liver 
(excluding viral hepatitis), spleen, pancreas, peritoneum, retroperitoneal, subphrenic or 
subdiaphragmatic space, or other intraabdominal tissue or area not specified elsewhere 
 
Intraabdominal infections must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from an abscess or from purulent material from intraabdominal 
space by a culture or non-culture based microbiologic testing method which is performed for 
purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing 
(ASC/AST).  
2. Patient has at least one of the following: 
a. abscess or other evidence of intraabdominal infection on gross anatomic or histopathologic 
exam 
b. abscess or other evidence of intraabdominal infection on gross anatomic or histopathologic 
exam  
AND  
organism(s) identified from blood by a culture or non-culture based microbiologic testing 
method, which is performed for purposes of clinical diagnosis or treatment, for example, not 
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Active Surveillance Culture/Testing (ASC/AST).  The organism(s) identified in the blood 
must contain at least one MBI organism. See Appendix A of the BSI protocol  
3. Patient has at least two of the following: fever (>38.0°C), hypotension, nausea*, vomiting*, 
abdominal pain or tenderness*, elevated transaminase level(s), or jaundice*  
And at least one of the following: 
a. organism(s) seen on Gram stain and/or identified from intraabdominal fluid or tissue 
obtained during invasive procedure or from an aseptically-placed drain in the intraabdominal 
space (for example, closed suction drainage system, open drain, T-tube drain, CT guided 
drainage) by a culture or non-culture based microbiologic testing method which is performed 
for purposes of clinical diagnosis or treatment, for example, not Active Surveillance 
Culture/Testing (ASC/AST).  
b. organism(s) identified from blood by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST). The organism(s) identified in the blood 
must contain at least one MBI organism(See Appendix A of the BSI protocol)  
AND  
imaging test evidence suggestive of infection ( for example, ultrasound, CT scan, MRI, 
ERCP, radiolabel scans [gallium, technetium, etc.] or on abdominal x-ray), which if 
equivocal is supported by clinical correlation, specifically, physician documentation of 
antimicrobial treatment for intraabdominal infection † 
* With no other recognized cause 
Reporting instruction  
 †Biliary ductal dilatation is considered an equivocal finding for cholangitis.  
 Do not report pancreatitis (an inflammatory syndrome characterized by abdominal pain, 
nausea, and vomiting associated with high serum levels of pancreatic enzymes) unless it is 
determined to be infectious in origin. 
 
NEC-Necrotizing enterocolitis 
 
Necrotizing enterocolitis in infants (≤1 year of age) must meet one of the following criteria: 
 
1. Infant has at least one of the clinical and one of the imaging test findings from the lists below: 
At least one clinical sign: 
a. bilious aspirate** (see Note) 
b. vomiting  
c. abdominal distention 
d. occult or gross blood in stools (with no rectal fissure) 
 
And at least one imaging test finding which if equivocal is supported by clinical correlation 
(specifically, physician documentation of antimicrobial treatment for NEC): 
a. Pneumatosis intestinalis 
b. Portal venous gas (Hepatobiliary gas) 
c. Pneumoperitoneum 
**Note:  Bilious aspirate from a transpyloric feeding tube should be excluded 
 
2. Surgical NEC: Infant has at least one of the following surgical findings: 
a. surgical evidence of extensive bowel necrosis (>2 cm of bowel affected) 
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b. surgical evidence of pneumatosis intestinalis with or without intestinal perforation 
 
Reporting instruction 
 Necrotizing enterocolitis (NEC) criteria include neither a site-specific specimen nor organism 
identified from blood specimen, however an exception for assigning a BSI secondary to NEC 
is provided.  A BSI is considered secondary to NEC if the patient meets one of the two NEC 
criteria AND an organism identified from blood specimen collected during the secondary BSI 
attribution period is an LCBI pathogen, or the same common commensal is identified from two 
or more blood specimens drawn on separate occasions collected on the same or consecutive 
days. 
 
 
LRI- LOWER RESPIRATORY INFECTION, OTHER THAN PNEUMONIA 
 
LUNG-Other infection of the lower respiratory tract 
 
Other infections of the lower respiratory tract must meet at least one of the following criteria: 
 
1. Patient has organism(s) seen on Gram stain of lung tissue or pleural fluid or identified from lung 
tissue or pleural fluid (when pleural fluid was obtained during thoracentesis or initial placement of 
chest tube and NOT from an indwelling chest tube) by a culture or non-culture based microbiologic 
testing method which is performed for purposes of clinical diagnosis or treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST). 
2.  Patient has a lung abscess or other evidence of infection (for example, empyema) on gross 
anatomic or histopathologic exam. 
3. Patient has imaging test evidence of abscess or infection (excludes imaging test evidence of 
pneumonia) which if equivocal is supported by clinical correlation, specifically, physician 
documentation of antimicrobial treatment for lung infection).   
 
Reporting instruction 
 If patient meets LUNG and PNEU report as PNEU only, unless the LUNG is a surgical site 
organ/space infection, in which case, report both PNEU and SSI-LUNG. 
 
 
REPR-REPRODUCTIVE TRACT INFECTION 
 
EMET-Endometritis 
 
Endometritis must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from endometrial fluid or tissue by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or treatment,   
for example, not Active Surveillance Culture/Testing (ASC/AST).   
2. Patient has at least two of the following signs or symptoms: fever (>38.0°C), pain or tenderness 
(uterine or abdominal)*, or purulent drainage from uterus. 
 
* With no other recognized cause 
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Reporting instructions 
 Do not report an HAI chorioamnionitis as EMET (see OREP). 
 Do not report subsequent postpartum endometritis after a vaginal delivery as an HAI if a 
patient is admitted with POA chorioamnionitis (OREP). (See next bullet for endometritis 
following a C-section).  
 Report as an organ space SSI-EMET if a C-section was performed on a patient with 
chorioamnionitis, and the patient later develops endometriti.  
 
EPIS-Episiotomy infection 
 
Episiotomy infections must meet at least one of the following criteria: 
 
1. Postvaginal delivery patient has purulent drainage from the episiotomy 
2. Postvaginal delivery patient has an episiotomy abscess 
 
Comment: 
 Episiotomy is not considered an operative procedure in NHSN. 
 
OREP- Deep pelvic tissue infection or other infection of the male or female reproductive tract 
(epididymis, testes, prostate, vagina, ovaries, uterus) including chorioamnionitis, but excluding 
vaginitis, endometritis or vaginal cuff infections 
 
Other infections of the male or female reproductive tract must meet at least one of the following 
criteria: 
 
1. Patient has organism(s) identified from tissue or fluid from affected site (excludes urine and 
vaginal swabs) by a culture or non-culture based microbiologic testing method which is performed 
for purposes of clinical diagnosis or treatment, for example, not Active Surveillance 
Culture/Testing (ASC/AST).  
2. Patient has an abscess or other evidence of infection of affected site on gross anatomic or 
histopathologic exam. 
3. Patient has suspected infection of one of the listed OREP sites and two of the following localized 
signs or symptoms: fever (>38.0°C), nausea*, vomiting*, pain or tenderness*, or dysuria* 
And at least one of the following: 
a. organism(s) identified from blood by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST). 
b. physician initiates antimicrobial therapy within two days of onset or worsening of symptoms 
 
* With no other recognized cause 
  
Reporting instructions 
 Report endometritis as EMET. 
 Report vaginal cuff infections as VCUF. 
 If patient has epididymitis, prostatitis, or orchitis and meets OREP criteria, and they also meet 
UTI criteria, report UTI only, unless the OREP is a surgical site organ/space infection, in which 
case, only OREP should be reported. 
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VCUF-Vaginal cuff infection 
 
Vaginal cuff infections must meet at least one of the following criteria: 
 
1. Post hysterectomy patient has purulent drainage from the vaginal cuff on gross anatomic exam. 
2. Post hysterectomy patient has an abscess or other evidence of infection at the vaginal cuff on gross 
anatomic exam. 
3. Post hysterectomy patient has organism(s) identified from fluid or tissue obtained from the vaginal 
cuff by a culture or non-culture based microbiologic testing method which is performed for purposes 
of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). 
 
Reporting instruction  
 Report vaginal cuff infections as SSI-VCUF 
 
SST-SKIN AND SOFT TISSUE INFECTION 
 
BRST-Breast infection or mastitis 
  
A breast abscess or mastitis must meet at least one of the following criteria: 
 
1. Patient has organism(s) identified from affected breast tissue or fluid obtained by invasive 
procedure by a culture or non-culture based microbiologic testing method which is performed for 
purposes of clinical diagnosis or treatment  for example, not Active Surveillance Culture/Testing 
(ASC/AST). 
2. Patient has a breast abscess or other evidence of infection on gross anatomic or histopathologic 
exam. 
3. Patient has fever (>38.0°C) and local inflammation of the breast, 
AND 
Physician initiates antimicrobial therapy within 2 days of onset or worsening of symptoms  
 
Reporting instruction 
 For SSI after a BRST procedure: if the infection is in the subcutaneous region report as a 
superficial incisional SSI, and if the infection involves the muscle/fascial level report as a deep 
incisional SSI. 
 BRST Criterion 3, above, cannot meet organ/space Surgical Site Infections. 
 
BURN-Burn infection 
 
Burn infections must meet the following criteria: 
 
1. Patient has a change in burn wound appearance or character, such as rapid eschar separation, or dark 
brown, black, or violaceous discoloration of the eschar, 
AND 
Organism(s) identified from blood by a culture or non-culture based microbiologic testing method 
which is performed for purposes of clinical diagnosis or treatment, for example, not Active 
Surveillance Culture/Testing (ASC/AST).  
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CIRC-Newborn circumcision infection 
 
Circumcision infection in a newborn (≤30 days old) must meet at least one of the following criteria: 
 
1. Newborn has purulent drainage from circumcision site. 
2. Newborn has at least one of the following signs or symptoms at circumcision site: erythema*, 
swelling*, or tenderness*, 
AND 
Pathogen identified from circumcision site by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or treatment, for example, not Active 
Surveillance Culture/Testing (ASC/AST). 
3. Newborn has at least one of the following signs or symptoms at circumcision site: erythema*, 
swelling*, or tenderness*, 
AND 
Common commensal is identified from circumcision site by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for 
example, not Active Surveillance Culture/Testing (ASC/AST), 
AND 
 Physician initiates antimicrobial therapy within two days on onset or worsening of symptoms. 
 
* With no other recognized cause 
 
DECU-Decubitus ulcer infection (also known as pressure injury infection), including both 
superficial and deep infections 
 
Decubitus ulcer infections must meet the following criterion: 
 
1. Patient has at least two of the following signs or symptoms: erythema*, tenderness*, or swelling of 
decubitus wound edges*, 
AND 
Organism(s) identified from needle aspiration of fluid or biopsy of tissue from ulcer margin by a 
culture or non-culture based microbiologic testing method which is performed for purposes of 
clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). 
 
* With no other recognized cause 
 
SKIN-Skin infection (skin and /or subcutaneous) excludes decubitus ulcers and burns 
 
Skin infections must meet at least one of the following criteria: 
 
1. Patient has at least one of the following: 
 purulent drainage 
 pustules 
 vesicles  
 boils (excluding acne) 
2. Patient has at least two of the following localized signs or symptoms: pain* or tenderness*,  
swelling*, erythema*, or heat* 
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And at least one of the following: 
a. organism(s) identified from aspirate or drainage from affected site by a culture or non-culture 
based testing method which is performed for purposes of clinical diagnosis and treatment  for 
example, not Active Surveillance Culture/Testing (ASC/AST).  Identification of 2 or more 
common commensal organisms without a recognized pathogen is not eligible for use.  
Common Commensal organisms include, but not are not limited to, diphtheroids 
(Corynebacterium spp. not C. diphtheria), Bacillus spp. (not B. anthracis), Propionibacterium 
spp., coagulase-negative staphylococci (including S. epidermidis), viridans group streptococci, 
Aerococcus spp.  
b. Micrococcus spp, and Rhodococcus spp. For a full list of Common Commensals see the 
Common Commensal tab of the NHSN organisms list. 
c. multinucleated giant cells seen on microscopic examination of affected tissue 
d. diagnostic single antibody titer (IgM) or 4-fold increase in paired sera (IgG) for organism 
 
* With no other recognized cause 
 
Reporting instructions 
 Do not report acne as a skin/soft tissue HAI. 
 Apply the site specific definition (not SKIN) for the following:  
 Report omphalitis in infants as UMB 
 Report infections of the circumcision site in newborns as CIRC 
 For decubitus ulcers, apply the DECU infection. 
 Report infected burns as BURN 
 Report breast abscesses or mastitis as BRST 
 Report localized infection at a vascular access site as a VASC unless there is an 
organism identified from blood, meeting LCBI criteria, which should instead be 
reported as an LCBI (see VASC definition) 
 
ST-Soft tissue infection (muscle and/or fascia [for example, necrotizing fasciitis, infectious 
gangrene, necrotizing cellulitis, infectious myositis, lymphadenitis, lymphangitis, or parotitis] 
excluding decubitus ulcers and burns)  
 
Soft tissue infections must meet at least one of the following criteria: 
1. Patient has organism(s) identified from tissue or drainage from affected site by a culture or non-
culture based microbiologic testing method which is performed for purposes of clinical diagnosis 
or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST) 
2. Patient has purulent drainage at affected site. 
3. Patient has an abscess or other evidence of infection on gross anatomic or histopathologic exam 
 
Reporting instructions 
 Apply the site-specific definitions identified below (not ST) for the following: 
 Report infected decubitus ulcers as DECU. 
 Report infected burns as BURN. 
 Report infection of deep pelvic tissues as OREP. 
 Report localized infection at a vascular access site as a VASC unless there is an 
organism identified from blood, then it should be reported as an LCBI (see VASC 
definition). 
  
January 2018 17- 28   
Surveillance Definitions 
 
UMB-Omphalitis 
 
Omphalitis in a newborn (≤30 days old) must meet at least one of the following criteria: 
 
1. Patient has erythema or drainage from umbilicus  
And at least one of the following: 
a. organism(s) identified from drainage or needle aspirate by a culture or non-culture based 
microbiologic testing method which is performed for purposes of clinical diagnosis or 
treatment, for example, not Active Surveillance Culture/Testing (ASC/AST) 
b. organism(s) identified from blood by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or treatment, for example, not 
Active  Surveillance Culture/Testing (ASC/AST).  
2. Patient has erythema and purulence at the umbilicus 
 
Reporting instructions 
 Report infection of the umbilical artery or vein related to umbilical catheterization as VASC if 
there is no accompanying organism identified from blood specimen. 
 If the patient meets criteria for LCBI, report as a LCBI (see VASC). 
 
 
USI – Urinary System Infection [formerly OUTI] (kidney, ureter, bladder, urethra, or 
perinephric space) 
 
Urinary system infections must meet at least one of the following criteria: 
 
1. Patient has microorganism(s) identified from fluid (not urine) or tissue from affected site by a 
culture or non-culture based microbiologic testing method which is performed for purposes of 
clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST)  
2. Patient has an abscess or other evidence of infection on gross anatomical exam, during invasive 
procedure, or on histopathologic exam. 
3. Patient has one of the following signs or symptoms:  
 fever (>38.0°C)  
 localized pain or tenderness*                 
And at least one of the following: 
a. purulent drainage from affected site 
b. organism(s) identified from blood by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST).  
AND 
imaging test evidence suggestive of infection, for example,ultrasound, CT scan, magnetic 
resonance imaging [MRI], or radiolabel scan [gallium, technetium]), which if equivocal is 
supported by clinical correlation, specifically, physician documentation of antimicrobial 
treatment for urinary system infection. 
4. Patient <1 year of age has at least one of the following signs or symptoms:  
 fever (>38.0°C)  
 hypothermia (<36.0°C)  
 apnea* 
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 bradycardia* 
 lethargy* 
 vomiting* 
And at least one of the following: 
a. purulent drainage from affected site 
b. organism(s) identified from blood by a culture or non-culture based microbiologic testing 
method which is performed for purposes of clinical diagnosis or treatment, for example, not 
Active Surveillance Culture/Testing (ASC/AST) 
AND 
imaging test evidence suggestive of infection,  for example, ultrasound, CT scans, magnetic 
resonance imaging [MRI], or radiolabel scan [gallium, technetium]), which if equivocal is 
supported by clinical correlation, specifically, physician documentation of antimicrobial 
treatment for urinary system infection.  
 
* With no other recognized cause 
 
Reporting instructions 
 Report infections following circumcision in newborns as SST-CIRC. 
 If patient meets USI criteria and they also meet UTI criteria, report UTI only, unless the USI is 
a surgical site organ/space infection, in which case, only USI should be reported.  
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